<SEC-DOCUMENT>0001144204-12-013420.txt : 20120307
<SEC-HEADER>0001144204-12-013420.hdr.sgml : 20120307
<ACCEPTANCE-DATETIME>20120307104343
ACCESSION NUMBER:		0001144204-12-013420
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20111231
FILED AS OF DATE:		20120307
DATE AS OF CHANGE:		20120307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProPhase Labs, Inc.
		CENTRAL INDEX KEY:			0000868278
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				232577138
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21617
		FILM NUMBER:		12672958

	BUSINESS ADDRESS:	
		STREET 1:		621 N. SHADY RETREAT ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18901
		BUSINESS PHONE:		2153450919

	MAIL ADDRESS:	
		STREET 1:		621 N. SHADY RETREAT ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18901

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QUIGLEY CORP
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v303307_10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(Mark One)</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: center"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>ANNUAL
                                                                                                                                REPORT
                                                                                                                                PURSUANT
                                                                                                                                TO
                                                                                                                                SECTION
                                                                                                                                13
                                                                                                                                OR
                                                                                                                                15(d)
                                                                                                                                OF
                                                                                                                                THE
                                                                                                                                SECURITIES
                                                                                                                                EXCHANGE
                                                                                                                                ACT
                                                                                                                                OF
                                                                                                                                1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 24pt">For the fiscal year ended <U>December
31, 2011</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center"><B>OR</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: center"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD><B>TRANSITION
                                                                                                                                    REPORT
                                                                                                                                    PURSUANT
                                                                                                                                    TO
                                                                                                                                    SECTION
                                                                                                                                    13
                                                                                                                                    OR
                                                                                                                                    15(d)
                                                                                                                                    OF
                                                                                                                                    THE
                                                                                                                                    SECURITIES
                                                                                                                                    EXCHANGE
                                                                                                                                    ACT
                                                                                                                                    OF
                                                                                                                                    1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 24pt">For the transition period from ______
to ______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center"><B>Commission file number <U>01-21617</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">ProPhase Labs,
    Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Exact name of registrant as specified in its charter)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.75in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; border-bottom: Black 1pt solid; text-indent: 0.6in">Nevada</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: center; border-bottom: Black 1pt solid">23-2577138</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(State or other jurisdiction</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">of incorporation or organization)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">621 N. Shady Retreat Road, Doylestown, Pennsylvania</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">18901</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Registrant&rsquo;s telephone number, including area code
<U>(215) 345-0919</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Securities registered pursuant to Section 12(b) of the
Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center">Title of
    each class</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center">Name of
    each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common Stock,
    $0.0005 par value per share</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Nasdaq Global
    Market</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common Share
    Purchase Rights</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Nasdaq Global
    Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(g) of the Act: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 25pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT>
&#9;No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
</FONT>by<FONT STYLE="font-family: Times New Roman, Times, Serif"> check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. </FONT>Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT> &#9;No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. </FONT>Yes <FONT STYLE="font-family: Wingdings">x</FONT>
No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 25pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was
required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect;229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.</FONT> <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of
&ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 25pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Large
accelerated filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;Accelerated
filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &#9;Non-accelerated
filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;Smaller
reporting company </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </FONT>Yes <FONT STYLE="font-family: Wingdings">&uml;
</FONT>&#9;No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate market <FONT STYLE="font-family: Times New Roman, Times, Serif">value
</FONT>of the registrant&rsquo;s voting and non-voting common stock held by non-affiliates was $6,755,730 as of June 30, 2011,
based on the closing price of the common stock on The NASDAQ Global Market.<FONT STYLE="color: #E36C0A"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #E36C0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Number of shares of <FONT STYLE="font-family: Times New Roman, Times, Serif">each
</FONT>of the registrant&rsquo;s classes of securities outstanding on March 1, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Common stock, $0.0005 par value per share:</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;14,836,340</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Common share purchase rights:</TD>
    <TD STYLE="text-align: right">-</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: center"><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Information set forth in Part III
of this report is incorporated by reference to the registrant&rsquo;s proxy statement for the 2012 annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"></TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 70%; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-decoration: none; text-align: center; border-bottom: Black 1pt solid">Page</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Part I&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Item</TD>
    <TD STYLE="vertical-align: top">1.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Business</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">3</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">1A.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Risk Factors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">8</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">1B.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Unresolved Staff Comments</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">16</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">2.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Properties</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">16</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">3.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Legal Proceedings</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">16</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Part II</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">5.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Market for Registrant&rsquo;s Common Equity, Related
    Stockholder Matters and Issuer Purchases of Equity Securities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">6.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Selected Financial Data</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">7.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Management&rsquo;s Discussion and Analysis of Financial
    Condition and Results of Operations</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">7A.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Quantitative and Qualitative Disclosures About Market
    Risk</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">28</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">8.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Financial Statements and Supplementary Data</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">29</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">9.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Changes in and Disagreements with Accountants on
    &nbsp;Accounting and Financial Disclosure</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">9A</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Controls and Procedures</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">9B.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Other Information</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Part III</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">10.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Directors, Executive Officers and Corporate Governance</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">11.&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Executive Compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">12.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Security Ownership of Certain Beneficial Owners
    and Management and Related Stockholder Matters</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">13.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Certain Relationships and Related Transactions and
    Director Independence</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">14.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Principal Accountant Fees and Services</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Part IV</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">15.</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Exhibits and Financial Statement Schedules</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">56</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Signatures</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; color: red">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; color: red; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">59</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PART I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report on
Form 10-K (&ldquo;Report&rdquo;) contains &ldquo;forward looking statements&rdquo; within the meaning of Section 27A of the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;). These forward looking statements relate to future events or our future financial performance
and involve known and unknown risks, uncertainties and other factors that may cause our or our industry&rsquo;s actual results,
levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance
or achievements expressed or implied by the forward-looking statements. Many of these factors are beyond our ability to predict.
Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements.
Forward-looking statements typically are identified by use of terms such as &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;plan&rdquo;,
&ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;may&rdquo;, &ldquo;will&rdquo;, &ldquo;should&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;predict&rdquo;, &ldquo;potential&rdquo;, &ldquo;continue&rdquo; and similar words although some forward-looking statements
are expressed differently. This Report may contain forward-looking statements attributed to third parties relating to their estimates
regarding the growth of our markets. You are cautioned that such forward looking statements are not guarantees of future performance
and that all forward-looking statements address matters that involve risk and uncertainties, and there are many important risks,
uncertainties and other factors that could cause our actual results, levels of activity, performance, achievements and prospects,
as well as those of the markets we serve, to differ materially from the forward-looking statements contained in this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Such risks and uncertainties
include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                                                                                              ability of our management
                                                                                                              to successfully
                                                                                                              implement our business
                                                                                                              plan and strategy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                                                                                              ability to fund
                                                                                                              our operations including
                                                                                                              the cost and availability
                                                                                                              of capital and credit;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                                                                                              ability to compete
                                                                                                              effectively, including
                                                                                                              our ability to maintain
                                                                                                              and increase our
                                                                                                              markets and/or market
                                                                                                              share in the markets
                                                                                                              in which we do business;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                                                                                              dependence on sales
                                                                                                              from our principal
                                                                                                              product, Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;
                                                                                                              </SUP></FONT>Cold
                                                                                                              Remedy, and our
                                                                                                              ability to successfully
                                                                                                              develop and commercialize
                                                                                                              new products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                                                                                              uncertain length
                                                                                                              and severity of
                                                                                                              the current general
                                                                                                              financial and economic
                                                                                                              downturn, the timing
                                                                                                              and strength of
                                                                                                              an economic recovery,
                                                                                                              if any, and their
                                                                                                              impacts on our business
                                                                                                              including demand
                                                                                                              for our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                                                                                              ability to protect
                                                                                                              our proprietary
                                                                                                              rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                                                                                              continued ability
                                                                                                              to comply with regulations
                                                                                                              relating to our
                                                                                                              current products
                                                                                                              and any new products
                                                                                                              we develop, including
                                                                                                              our ability to effectively
                                                                                                              respond to changes
                                                                                                              in laws and regulations
                                                                                                              or the interpretation
                                                                                                              thereof including
                                                                                                              changing market
                                                                                                              rules and evolving
                                                                                                              federal, state and
                                                                                                              regional laws and
                                                                                                              regulations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Potential
                                                                                                              disruptions in our
                                                                                                              ability to manufacture
                                                                                                              our products or
                                                                                                              our access to raw
                                                                                                              materials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Seasonal
                                                                                                              fluctuations in
                                                                                                              demand for our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our
                                                                                                              ability to attract,
                                                                                                              retain and motivate
                                                                                                              key employees;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                                                                                              ability of Phusion
                                                                                                              Laboratories, LLC,
                                                                                                              a 50% owned joint
                                                                                                              venture (see below
                                                                                                              for further details),
                                                                                                              to successfully
                                                                                                              implement its business
                                                                                                              plan and strategy
                                                                                                              to develop and commercialize
                                                                                                              one or more non-prescription
                                                                                                              remedies using certain
                                                                                                              patented and proprietary
                                                                                                              technology; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Other
                                                                                                              risks identified
                                                                                                              in this Report.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should also consider
carefully the statements under other sections of this Report, including the Risk Factors included in Item 1A, which address additional
risks that could cause our actual results to differ from those set forth in any forward-looking statements. Our forward-looking
statements speak only as the date of this Report. We undertake no obligation to publicly update or review any forward-looking
statements, whether as a result of new information, future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Where You Can Find Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ProPhase Labs, Inc. (&ldquo;we&rdquo;,
&ldquo;us&rdquo; or the &ldquo;Company&rdquo;) files periodic and current reports, proxy statements and other information with
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). We make available on our website (<U>www.ProPhaseLabs.com</U>)
free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments
to or exhibits included in those reports as soon as reasonably practical after we electronically file such materials with or furnish
them to the SEC. Information appearing on our website is not part of this Annual Report on Form 10-K. You can also read and copy
any materials we file with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Washington D.C. 20549-1004. You
may request copies of these documents, upon payment of a duplication fee, by writing the SEC at its principal office at 100 F
Street, NE Room 1580, Washington, D.C. 20549-1004. In addition, the SEC maintains an Internet site (<U>www.sec.gov</U>) that contains
reports, proxy and information statements regarding issuers that file electronically with the SEC, including the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Item 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">General Development of Business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a manufacturer,
marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We
are also engaged in the research and development of potential over-the-counter (&ldquo;OTC&rdquo;) drug, natural base health products
along with supplements, personal care and cosmeceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our primary business is
currently the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through food, multi-outlet
pharmacy and chain drug stores, large wholesalers and mass merchandisers. Our flagship brand is Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;
</SUP></FONT>Cold Remedy and our principal product is Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> zinc
gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by nearly half.
Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> is an established product in the health care and cold remedy
market. For 2011, 2010 and 2009, our revenues have come principally from our OTC cold remedy products. For Fiscal 2011 and 2010,
our net sales for each period were related to markets in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use a December 31 year-end
for financial reporting purposes. References herein to the fiscal year ended December 31, 2011 shall be the term &ldquo;Fiscal
2011&rdquo; and references to other &ldquo;Fiscal&rdquo; years shall mean the year, which ended on December 31 of the year indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a corporation organized
in Nevada in July 1989. Our principal executive offices are located at 621 N. Shady Retreat Road, Doylestown, Pennsylvania 18901
and our telephone number is 215-345-0919. The terms, &ldquo;we&rdquo;, &ldquo;us&rdquo; and the &ldquo;Company&rdquo; refer to
the Company together with its consolidated subsidiaries unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2011, Phosphagenics
Ltd. (&ldquo;PSI Parent&rdquo;), entered into certain Private Resale Agreements (the &ldquo;PSAs&rdquo;) with seven third party
purchasers, under which the PSI Parent sold, with our consent, an aggregate of 750,000 shares of our common stock, $0.0005 par
value (&ldquo;Common Stock&rdquo;). PSI Parent is the parent company to Phosphagenics Inc. (&ldquo;PSI&rdquo;), our joint venture
partner in Phusion Laboratories, LLC (the &ldquo;Joint Venture&rdquo;). Under the PSAs, the purchasers may not, without the prior
written consent of the Company, prior to the one year anniversary of the PSAs, directly or indirectly, sell, give, pledge, hypothecate,
assign or otherwise transfer the purchased shares, in whole or in part. Contemporaneously with PSI Parent consummating the PSAs,
we consummated an agreement with PSI Parent to redeem the then remaining 690,000 shares of our Common Stock held by PSI Parent
(see Note 3). Under the terms of the redemption agreement, we redeemed 690,000 shares of our Common Stock held by PSI Parent for
the aggregate redemption price of $448,500 in cash. The redemption price was equal to $0.65 per share. The redemption agreement
contained customary representations and covenants of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>Description of Business Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;
</SUP></FONT>is one of our key OTC cold remedy products whose benefits are derived from its proprietary zinc gluconate formulation.
The product&rsquo;s effectiveness has been substantiated in two double-blind clinical studies proving that Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;
</SUP></FONT>lozenges reduce the duration and severity of symptoms of the common cold by nearly half. We acquired worldwide manufacturing
and distribution rights to our lozenge formulation in 1992 and commenced national marketing in 1996. The demand for our OTC cold
remedy products is seasonal, where the third and fourth quarters of each year generally have the largest sales volume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since June 1996, our continuing
business operations have concentrated on the manufacturing, marketing and development of our proprietary Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;
</SUP></FONT>cold-remedy lozenge products and on development of various product extensions. Our product line of OTC cold remedy
products are reviewed regularly to identify new consumer opportunities and/or trends in flavor, convenience, packaging and delivery
systems or forms to help improve market share for our products. Additionally, we are active in exploring new product technologies,
applications, product line extensions and other new product opportunities consistent with our brand image and standard of proven
consumer benefit and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>Manufacturing Facility
</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our wholly owned subsidiary,
Pharmaloz Manufacturing, Inc. (&ldquo;PMI&rdquo;), produces our Cold-EEZE<SUP>&reg;</SUP> and other lozenge products along with
performing such operational tasks as warehousing and shipping our Cold-EEZE<SUP>&reg;</SUP> and other OTC cold remedy products.
PMI is located in Lebanon, Pennsylvania. Additionally, PMI maintains a United States Food and Drug Administration (&ldquo;FDA&rdquo;)
registered facility that engages in contract manufacturing and distribution activities of lozenge-based products for unaffiliated
third parties. PMI also produces and sells therapeutic lozenges to wholesale and distribution outlets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Joint Venture &ndash; Phusion Laboratories,
LLC</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 22, 2010, the
Company, PSI Parent, an Australian corporation, Phosphagenics Inc. (&ldquo;PSI&rdquo;), a Delaware corporation and subsidiary
of PSI Parent, and the Joint Venture, a Delaware limited liability company, entered into a Limited Liability Company Agreement
(the &ldquo;LLC Agreement&rdquo;) of the Joint Venture and additional related agreements for the purpose of developing and commercializing,
for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent&rsquo;s proprietary patented TPM&trade;
technology (&ldquo;TPM&rdquo;). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical,
and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the &ldquo;Original
License Agreement&rdquo;), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit
OTC drugs (and certain other products) that embody certain of PSI Parent&rsquo;s TPM-related patents and related know-how (collectively,
the &ldquo;PSI Technology&rdquo;) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations) paid-up
license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds
with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Original
License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI
Parent (such shares, the &ldquo;PSI Shares&rdquo;), and made a one-time payment to PSI Parent of $1.0 million. As discussed above,
in September 2011 we consummated an agreement with PSI Parent to redeem 690,000 shares of our Common Stock held by PSI Parent
that had been originally issued in March 2010. In accordance with a Contribution Agreement, dated March 22, 2010 (the &ldquo;Contribution
Agreement&rdquo;), by and among us, PSI Parent, PSI, and the Joint Venture, we transferred, conveyed and assigned to the Joint
Venture all of our rights, title and interest in, to and under the Original License Agreement, and the Joint Venture assumed,
and undertook to pay, discharge and perform when due, all of our liabilities and obligations under and arising pursuant to the
Original License Agreement (such actions, collectively, the &ldquo;Assignment and Assumption&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Contribution
Agreement and in order to reflect the Assignment and Assumption, we, PSI Parent and the Joint Venture entered into an Amended
and Restated License Agreement, dated March 22, 2010 (the &ldquo;Amended License Agreement&rdquo;), which amends and restates
the Original License Agreement to reflect that the Joint Venture is the licensee thereunder and which otherwise contains substantially
the same terms as the Original License Agreement. The Joint Venture has the right to grant one or more sub-licenses of the rights
granted under the Amended License Agreement to one or more third parties for reasonable consideration in any part of the applicable
territory. The Amended License Agreement provides that PSI Parent shall not, directly or through third parties, exploit the covered
intellectual property during the term thereof, subject to certain limitations. The Amended License Agreement will remain in effect
until the expiration of the last to expire of the patents included within the PSI Technology or any extensions thereof. Either
party may terminate the Amended License Agreement upon written notice to the other party in the event of certain events involving
bankruptcy or insolvency. The Amended License Agreement also contains, among other things, provisions concerning the treatment
of confidential information, the ownership of intellectual property and indemnification obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">PSI Parent will conduct
and oversee much of the product development, formulation, testing and other research and development needed by the Joint Venture,
and we will oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may
be required, from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund
its operations, in accordance with agreed upon budgets for products to be developed. Specifically, in Fiscal 2010 we contributed
$500,000 of initial capital. In addition, we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have
not yet been formally established), toward the initial development and marketing costs of new products for the Joint Venture.
The Joint Venture has not engaged in any financial transactions, other than certain organizational expenses and general market
and product analysis. At December 31, 2011, cash and equivalents includes $425,000 related to the Joint Venture which is expected
to be used by the Joint Venture to fund future product development initiatives currently under consideration by PSI Parent, PSI
and us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The product development
effort of the Joint Venture is a multi-stage process that includes (i) market analysis and research, (ii) product formulation
research and development, (iii) product evaluation, (iv) product commercialization, (v) production and distribution, and (vi)
retail and consumer advertising and marketing. During Fiscal 2011, we conducted preliminary market analysis to identify market
opportunities to develop differentiated, science-based, efficacious products that deliver results to consumers and worked with
PSI and PSI Parent to provide initial formulations for certain identified OTC active ingredients. In December 2011, we initiated
a study of these preliminary formulations to evaluate product attributes, performance and potential commercial viability. These
studies are expected to be completed later in Fiscal 2012. For Fiscal 2011, any expenses, including organizational, marketing
analysis and preliminary formulations have been absorbed by the respective Joint Venture members. As of December 31, 2011, we
have not established a formal commercialization program timeline, pending the results of the recently initiated studies, for any
specific OTC product covered under the product license but we do not project that any such OTC products will be available for
shipment within the next twelve months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><I><U>OTC Cold-Remedy Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 1992, we entered
into an exclusive agreement for worldwide representation, manufacturing and marketing of Cold-EEZE<SUP>&reg;</SUP> products in
the United States. Cold-EEZE<SUP>&reg;</SUP>, a zinc gluconate formulation (ZIGG&trade;), is an OTC consumer product used to reduce
the duration and severity of the common cold and is available in lozenge and sugar-free tablet form. We have substantiated the
effectiveness of Cold-EEZE<SUP>&reg;</SUP> through a variety of studies. A randomized double-blind placebo-controlled study, conducted
at Dartmouth College of Health Science, Hanover, New Hampshire, concluded that the lozenge formulation treatment, initiated within
48 hours of symptom onset, resulted in a significant reduction in the total duration of the common cold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 22, 1992, &ldquo;Zinc
and the Common Cold, a Controlled Clinical Study,&rdquo; was published in England in the <I>Journal of International Medical Research</I>,
Volume 20, Number 3, Pages 234-246. According to this publication, (a) flavorings used in other Zinc lozenge products (citrate,
tartrate, separate, orotate, picolinate, mannitol or sorbitol) render the Zinc inactive and unavailable to the patient&rsquo;s
nasal passages, mouth and throat where cold symptoms have to be treated, (b) this patented formulation delivers approximately
93% of the active Zinc to the mucosal surfaces and (c) the patient has the same sequence of symptoms as in the absence of treatment
but goes through the phases at an accelerated rate and with reduced symptom severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 15, 1996, results
of a randomized double-blind placebo-controlled study on the common cold, which commenced at the Cleveland Clinic Foundation on
October 3, 1994, were published. The study <B>&ldquo;</B>Zinc Gluconate Lozenges for Treating the Common Cold&rdquo;<B> </B>was
completed and published in <I>The Annals of Internal Medicine</I> &ndash; Volume 125 Number 2. <B> </B>Using a 13.3mg lozenge
(almost half the strength of the lozenge used in the Dartmouth study), the result still showed a 42% reduction in the duration
of common cold symptoms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2002, we announced
the statistical results of a retrospective clinical adolescent study at the Heritage School facility in Provo, Utah that suggests
that the Cold-EEZE<SUP>&reg;</SUP> lozenge is also an effective means of preventing the common cold and statistically (a) lessens
the number of colds an individual suffers per year, reducing the median incidence of colds from 1.5 to zero and (b) reduces the
use of antibiotics for respiratory illnesses from 39.3% to 3.0% when Cold-EEZE<SUP>&reg;</SUP> lozenges are administered as a
first line treatment approach to the common cold. While these results are interesting, this study was not placebo controlled (every
student received one Cold-EEZE<SUP>&reg;</SUP> lozenge every day) and therefore, we cannot advertise Cold-EEZE<SUP>&reg;</SUP>
lozenges for prophylactic use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2003, we announced
the findings of a prospective study, conducted at the Heritage School facility in Provo, Utah, in which 178 children, ages 12
to 18 years, were given Cold-EEZE<SUP>&reg;</SUP> lozenges both symptomatically and prophylactically from October 5, 2001 to May
30, 2002. The study found a 54% reduction in the most frequently observed cold duration. Those subjects not receiving treatment
most frequently experienced symptom duration of 11 days compared with 5 days when Cold-EEZE<SUP>&reg;</SUP> lozenges were administered,
a reduction of 6 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to Cold-EEZE<SUP>&reg;
</SUP>lozenges, we market and distribute a Cold-EEZE<SUP>&reg;</SUP> Oral Spray, a new product launched in August 2011, Kids-EEZE<SUP>&reg;
</SUP>Chest Relief, Kids-EEZE<SUP>&reg;</SUP> Cough Cold and Kids-EEZE<SUP>&reg;</SUP> Allergy OTC products for children (&ldquo;Kids-EEZE<SUP>&reg;
</SUP>Products&rdquo;). In August 2011, we introduced Cold-EEZE<SUP>&reg;</SUP> Oral Spray containing our proprietary zinc gluconate
formulation in a liquid spray form. The Kids-EEZE<SUP>&reg;</SUP> Products are for children suffering upper respiratory infections,
allergy and/or chest congestion. Kids-EEZE<SUP>&reg;</SUP> Products are based upon specific OTC monographs and provide single
source, symptom relief through a uniquely formulated soft chew that is good-tasting, provides an accurate dose and is convenient-to-use.
We introduced Kids-EEZE<SUP>&reg;</SUP> Chest Relief in Fiscal 2008 and expanded the product line to include Kids-EEZE<SUP>&reg;
</SUP>Cough Cold and Kids-EEZE<SUP>&reg;</SUP> Allergy in Fiscal 2010. We also manufacture, market and distribute organic cough
drops and a Vitamin C supplement (&ldquo;Organix&rdquo;) and perform contract manufacturing services of cough drop and other OTC
cold remedy products for third parties.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business is subject
to federal and state health and safety laws and regulations. Our OTC cold remedies are subject to regulations by various federal,
state and local agencies, including the United States Food and Drug Administration (&ldquo;FDA&rdquo;). Additionally, Cold-EEZE<SUP>&reg;</SUP>,
a homeopathic cold remedy is subject to the Homeopathic Pharmacopoeia of the United States. See &ldquo;Regulatory Matters&rdquo;
below for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Patents,
Trademarks, Royalty and Commission Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently own
patents for our OTC cold-remedy products. We maintain various trademarks for each of our products including Cold-EEZE<SUP>&reg;</SUP>,
Kids-EEZE<SUP>&reg;</SUP> and Organix Rx Complete<SUP>&reg;</SUP> and Organix Rx Defense<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently own various
domestic and international patents covering certain product development initiatives principally developed under the now suspended
Pharma operations. To date, we have not realized any meaningful levels of revenues from such patents and we have suspended further
commercialization efforts for various products under such patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
Joint Venture&rsquo;s Amended License Agreement, the Joint Venture has (i) an exclusive, royalty-free, world-wide (subject to
certain limitations), paid-up license to exploit OTC drugs (and certain other products) that embody certain PSI Technology and
(ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations) paid-up license to exploit certain compounds that
embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is
part of a regimen that includes the application of an OTC drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: none; text-align: justify; text-indent: 0">Product
Distribution and Customers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products are distributed
through numerous food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers throughout the United
States. Revenues for Fiscal 2011, 2010 and 2009 were $17.5 million, $14.5 million and $19.8 million, respectively. Walgreen Company
(&ldquo;Walgreens&rdquo;), Wal-Mart Stores, Inc. (&ldquo;Wal-Mart&rdquo;), CVS Caremark Corporation (&ldquo;CVS&rdquo;) and Rite-Aid
Corp (&ldquo;Rite Aid&rdquo;) accounted for approximately 17%, 14%, 13% and 12% of our Fiscal 2011 revenues. Walgreens, Wal-Mart
and Rite Aid accounted for approximately 23%, 14% and 10% of our Fiscal 2010 revenues. CVS, Walgreens and Wal-Mart accounted for
approximately 15%, 15% and 13% of our revenues for Fiscal 2009. The loss of sales to any one or more of these large retail customers
could have a material adverse effect on our business operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we have several
national Broker, Distributor and Representative Agreements which provide for commission compensation based on sales performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: none; text-align: justify; text-indent: 0">Research
and Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have historically invested
significantly in research and development activities. Our research and development costs for Fiscal 2011, 2010 and 2009 were $1.1
million, $794,000 and $1.3 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During Fiscal 2011 and
2010, our research and development initiatives have been principally focused on product line development and/or line extensions
for OTC cold remedy products under the Cold-EEZE<SUP>&reg;</SUP> and Kids-EEZE<SUP>&reg;</SUP> brands. In addition, our Joint
Venture is at its early stage of development where product and market research has been initiated and new product initiatives
are being evaluated and prioritized for future development and commercialization utilizing the licensed PSI Technology. Through
the Joint Venture, PSI Parent will conduct and oversee much of the product development, formulation, testing and other research
and development needed by the Joint Venture, and we will oversee much of the production, distribution, sales and marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During Fiscal 2009, our
research and development activity was principally focused on potential natural base health products including compounds QR-333
(potential topical symptomatic relief of diabetic peripheral neuropathy), QR-440 (potential relief of inflammation and joint pain),
and QR-448 (potential anti-infective against infectious bronchitis in poultry) via our Quigley Pharma subsidiary. In Fiscal 2009
as part of our continuing efforts to focus on products and projects that are believed to be likely to generate sustainable profits,
we examined the commercial viability of our QR-333 compound for diabetic neuropathy treatment and our QR-448(a) veterinary drug
compound. There are no third parties who have expressed a current interest or willingness to co-develop, license or otherwise
commercially exploit these compounds. As a consequence, (i) we are not expending any significant additional sums on developing
any formulations in the Quigley Pharma subsidiary, (ii) we have suspended Quigley Pharma&rsquo;s operations and (iii) we are not
making any further investments in Quigley Pharma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, we fund our
research and development costs with cash generated from operations. In addition to funding from operations, we may seek to raise
capital through the issuance of securities or to other financing sources to support our research and development activities including
new product technologies, applications, licensing, commercialization and other development opportunities, as well as acquisitions
of new formulations, ingredients, applications and other products, including those products, if any, that may be developed through
the Joint Venture. Any such funding through the issuance of our equity securities would result in the dilution of current stockholder
ownership. Should research or commercialization activity progress on certain formulations, resulting expenditures may require
substantial financial support and may necessitate the consideration of alternative approaches such as licensing, joint venture
or partnership arrangements that meet our long term goals and objectives. Ultimately, should internal working capital be insufficient
and external funding methods or other business arrangements become unattainable, it could result in the deferral or loss of future
growth and development opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>Regulatory Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
are subject to federal and state laws and regulations adopted for the health and safety of users of pharmaceutical and health
care products. Our OTC cold remedy products are subject to regulation by various federal, state, and local agencies, including
the FDA. In addition, our Cold-EEZE<SUP>&reg;</SUP> product is subject to the standards established by the Homeopathic Pharmacopoeia
of the United States. These regulatory authorities have broad powers, and we may be subject to regulatory and legislative changes
that can affect the economics of the industry by requiring changes in operating practices or by influencing the demand for and
the costs of manufacturing or distributing its produc</FONT>ts.<FONT STYLE="font-size: 10pt"> Our Cold-EEZE<SUP>&reg;</SUP> product
is considered a homeopathic drug and is exempt from pre-approval requirements and other, but not all, FDA requirements. Many homeopathic
drug products, including Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT>, are manufactured and distributed
under FDA enforcement policies that provide criteria needed to market a homeopathic OTC drug product without FDA approval. We
believe we meet those requirements, which include registration of our manufacturing facility, listing of the product in FDA&rsquo;s
product database, and packaging, labeling, and manufacturing homeopathic drugs in compliance with current good manufacturing practice
(&ldquo;cGMP&rdquo;) regulations. Due to the unique nature of homeopathic drug products, some cGMP requirements are not applicable,
including expiration dating, and testing and release for distribution. In addition, the FDA is currently not enforcing the requirement
for a laboratory determination of identity and strength of each active ingredient prior to release for distribution, although
this exemption is pending FDA review and we cannot assure that the exemption will be permanently implemented. We also cannot assure
that the FDA will agree with our determination of compliance. If the FDA disagrees, the FDA could, upon inspection, issue a notice
of violations, referred to as a form FDA-483, or issue a Warning Letter, or both. If we fail to take timely corrective actions
to the satisfaction of FDA, the agency can initiate legal actions, such as seizure and injunction, which could include a recall
order or the entry of a consent decree, or both. In addition, we could be subject to monetary penalties and even criminal prosecution
for egregious conduct. Management believes that we are in compliance with all such laws, regulations, and standards currently
in effect including the Food, Drug, and Cosmetics Act as amended from time to time, and the standards established under the Homeopathic
Pharmacopoeia of the United States</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pre-clinical development,
clinical trials, product manufacturing, labeling, marketing, distribution and licensing and/or acquisition of potential new products
are also generally subject to federal and state regulation in the United States and other countries. Obtaining FDA and any other
required regulatory approval for certain OTC products, or seeking the issuance of a final monograph from the FDA for certain OTC
products, can require substantial resources and take several years. The length of this process depends on the type, complexity
and novelty of the product and the nature of the disease or other indications to be treated. If we cannot obtain regulatory approval
of, or final OTC monograph for, a new product(s) in a timely manner or if patents are not granted or are subsequently challenged,
it could have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We compete with other
suppliers of OTC cold-remedy products. These suppliers range widely in size. Some of our competitors have significantly greater
financial, technical or marketing resources than we do. Management believes that our Cold-EEZE<SUP>&reg; </SUP>lozenge products,
which have been clinically proven in two double-blind studies to reduce the severity and duration of common cold symptoms, offer
a significant advantage over many of our competitors in the OTC cold remedy market. We believe that our ability to compete depends
on a number of factors, including product quality and price, availability, speed to market, consumer marketing, reliability, credit
terms, brand name recognition, delivery time and post-sale service and support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At December 31, 2011,
we employed 49 full-time employees, the majority of which were employed at our manufacturing facility in a production function.
The remaining employees were involved in an executive, sales, marketing or administrative capacity. None of our employees are
covered by a collective bargaining agreement or are members of a union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Suppliers; Raw Materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We derive our sales principally
from our Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> zinc gluconate product which is available in various
flavors, both in lozenge and oral spray form, for purchase by consumers at retail stores. We also produce private label lozenge
products for sale to certain retail customers. Our zinc lozenge products are manufactured principally by us at our Lebanon, Pennsylvania
facility. The constituent raw materials and packaging used in the manufacture and presentation of these items are procured from
various sources with additional suppliers having been identified in the event that alternatives are required. While the absence
of a current raw materials or packaging source may cause short term interruption, identified alternative sources would fill our
needs in a short time and any transition period would be mitigated by adequate levels of finished product available for sale.
Certain products within our line of products such as Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT><SUP>
</SUP>Oral Spray and Kids-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> are manufactured for us by third party
contract manufacturers and while currently purchased from single sources do not constitute a material revenue risk to us if product
availability was jeopardized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Item 1A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any of the following risks
could materially affect our business, financial condition, or results of operations. These risks could also cause our actual results
to differ materially from those indicated in the forward-looking statements contained herein and elsewhere. The risks described
below are not the only risks facing us. Additional risks not currently known to us or those we currently deem to be immaterial
may also materially and adversely affect our business, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our business is subject to significant
competitive pressures </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The OTC healthcare product,
pharmaceutical and consumer product industries are highly competitive. Many of our competitors have substantially greater capital
resources, technical staffs, facilities, marketing resources, product development, distribution and experience than we do. As
a consequence, our competitors may have certain advantages, including the ability to allocate greater resources for new product
development, marketing and other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that our ability
to compete depends on a number of factors, including product quality and price, availability, speed to market, consumer marketing,
reliability, credit terms, brand name recognition, delivery time and post-sale service and support, and new and existing product
innovation and commercialization. There can be no assurance that we will be able to compete successfully in the future. If we
are unable to compete effectively, our earnings may be significantly negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have aligned our operations
to focus principally in the research, development, manufacture, marketing and sale of OTC cold remedy and consumer products, natural
base health products and other supplements and cosmeceuticals products. In addition, we may seek to acquire from third parties
or enter into other arrangements with respect to new formulations, ingredients, applications and other products developed by third
parties who may be seeking our commercialization, marketing and distribution expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that we will be able to effectuate this business plan successfully or that revenue growth will occur once the plan is effected.
In addition, we may not be successful in acquiring or otherwise entering into any new lines of business and, if we are successful
in doing so, there can be no assurance that such new business will achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>We will need to obtain
additional capital to support long term product development and commercialization programs</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to achieve
and sustain operating profitability depends in large part on our ability to commence, execute and complete new and existing product
innovation and commercialization, including the Joint Venture product development initiatives, and, if required, clinical programs
to obtain regulatory approvals in the United States and elsewhere. We can give no assurance that we will be able to achieve such
product innovation and commercialization, to obtain any required approvals or to achieve significant levels of sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Should research or commercialization
activity progress on certain formulations, resulting expenditures may require substantial financial support. The current sales
level of our OTC cold remedy products may not generate all the funds we anticipate will be needed to support future product acquisition
or development. Accordingly, in addition to funding from operations, we may in the short and long term seek to raise capital through
the issuance of securities or to secure other financing sources to support our research, new product technologies, applications,
licensing, commercialization and other development opportunities. If we obtain such funding through the issuance of equity securities,
it would result in the dilution of current stockholders&rsquo; ownership in the Company. Any debt financing, if available, may
include financial and other covenants that could restrict use of proceeds of such financing or impose other business and financial
restrictions on us. In addition, we may consider alternative approaches such as licensing, joint venture, or partnership arrangements
that meet our long term goals and objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The amount of capital
that may be needed to complete product development initiatives will depend on many factors which may include but are not limited
to (i) the cost involved in applying for and obtaining FDA, international regulatory or other technical approvals, (ii) whether
we elect to establish partnering arrangements for development, sales, manufacturing and marketing of such products, (iii) the
level of future sales of OTC cold remedy products, and expense levels for marketing efforts, (iv) whether we can establish and
maintain strategic arrangements for development, sales, manufacturing and marketing of our products, and (v) whether any or all
of the options for our Common Stock issued to employees of the Company are exercised and the timing and amount of these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Commodity price increases will increase
our operating costs and may negatively affect financial results </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Commodity
prices impact our business directly through the cost of raw materials used to make our products (such as corn syrup, sucrose and
other commodities and ingredients) and the amount we pay to purchase packaging for our products (such as paper, board and plastic).
Commodities such as these are susceptible to price volatility caused by conditions outside of our control, including fluctuations
in commodities markets, currency fluctuations, availability of supply, weather, consumer demand and changes in governmental agricultural
programs. Increases in the price of our commodities and other raw materials would negatively impact our gross margins and/or our
sales volume if we were unable to offset such increases through increases in our selling price, changes in product mix or cost
reduction/productivity enhancement efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>We may not be able to commercialize
new products through our Joint Venture</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Joint Venture is at
its early stage of development where product and market research has been initiated and new product initiatives are being evaluated
and prioritized for future development and commercialization. Prior to any new product being available for sale, substantial resources
will have to be committed to commercialize a product which may include research, development, preclinical testing, clinical trials,
manufacturing scale-up and regulatory approval. The Joint Venture may disrupt our ongoing operations, divert management from day-to-day
responsibilities and increase our expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We face significant technological
risks inherent in developing these products. The Joint Venture may be subject to delays and/or ultimately unable to successfully
implement its business plan and strategy to develop and commercialize one or more non-prescription remedies using certain patented
and proprietary TPM<SUP>TM</SUP> that exploit certain compounds that embody the TPM<SUP>TM</SUP> for use in a product combining
one or more of such compounds with an OTC drug. The commercialization and ultimate product market acceptance is subject to, among
other influences, consumer purchasing trends, demand for our OTC drug, health and wellness trends, regulatory factors, retail
acceptance and overall economic and market conditions. As a consequence, we may suspend or abandon some or all of our proposed
new products before they become commercially viable. Even if we develop and obtain approval of a new product, if we cannot successfully
commercialize it in a timely manner, our business and financial condition may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Instability and volatility in the financial
markets could have a negative impact on our business, financial condition, results of operations and cash flows</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During Fiscal 2009 through
2011, there has been substantial volatility in financial markets due at least in part to the global economic environment. In addition,
there has been substantial uncertainty in the capital markets and access to financing is uncertain. Moreover, customer spending
habits may be adversely affected by the current economic environment and prevailing high unemployment rates in the United States.&nbsp;
These conditions could have an adverse effect on our industry and business, including our access to funding sources, demand for
our products and our customers&rsquo; ability to continue to purchase our products, which could have a material adverse effect
on our financial condition, results of operations and cash flows.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent that we
do not generate sufficient cash from operations, we may need to issue equity or to incur indebtedness to finance our growth. Recent
turmoil and volatility in the credit markets and the potential impact on the liquidity of major financial institutions may have
an adverse effect on our ability to fund our business strategy through borrowings, under either existing or newly created instruments
in the public or private markets on terms that we believe to be reasonable, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>The sales of our primary
product fluctuates by season and from Cold Season to Cold Season </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our sales are derived
principally from our OTC cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which
causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest
sales volume for our OTC cold remedy products. In addition, our sales are influenced by and subject to fluctuations in the timing
of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each
cold season. Generally, a cold season is defined as the period of September to March (&ldquo;Cold Season&rdquo;) when the incidence
of the common cold rises as a consequence of the change in weather and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that we will be able to manage our working capital needs and inventory to meet the fluctuating demand for these products. Failure
to accurately predict and respond to consumer demand may result in the production of excess inventory which may be expensive to
store or which we may be required to dispose if such excess inventory remains unsold. Conversely, if products achieve greater
success than anticipated for any given quarter, this may result in insufficient inventory to meet customer demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our performance may fluctuate when our
retail customers are affected simultaneously by the same economic, regulatory or health and wellness factors</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our revenues are significantly
concentrated in OTC cold remedy products. Our retail customers are subject to fluctuations of business based upon consumer purchasing
trends, demand for cold remedy products and overall economic and market conditions. Consequently, many retailers will likely be
influenced at the same time by similar economic conditions, regulatory factors or health and wellness trends, which can affect
the level of demand for our products. It is reasonable to expect that, if one retailer reduces or delays its purchasing in response
to a general economic, regulatory or health and wellness factor, other retailers may also decide to reduce or delay their purchasing
at approximately the same time. Accordingly, our sales are subject to fluctuations as a result of such factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>We have a concentration of sales to
and accounts receivable from several large retail customers</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we have a broad
range of retail customers that includes many food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers,
our five largest customers account for a significant percentage of our sales &ndash; 60% and 61% of total sales for Fiscal 2011
and 2010, respectively. In addition, retail customers comprising the five largest accounts receivable balances represented 53%
and 51% of total accounts receivable balances at December 31, 2011 and 2010, respectively. We extend credit to retail customers
based upon an evaluation of their financial condition and credit history, and collateral is not generally required. If one or
more of these large retail customers cannot pay, the write-off of their accounts receivable could have a material adverse effect
on our operations and financial condition. The loss of sales to any one or more of these large retail customers would also have
a material adverse effect on our financial condition, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>Our future success depends
on the continued sales of our principal product</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For Fiscal 2011 and 2010,
our cold remedy products, principally Cold-EEZE<SUP>&reg;</SUP>, represented approximately 95% and 96%, respectively, of our total
sales. Accordingly, we depend on the continued acceptance of Cold-EEZE<SUP>&reg;</SUP> products by our customers. Our investments
in and strategies used for our brand marketing are critical to achieve brand awareness with current consumers, educate potential
new consumers and convert potential consumers into customers. However, there can be no assurance that Cold-EEZE<SUP>&reg;</SUP>
products will continue to receive, maintain or increase market acceptance. The inability to successfully commercialize Cold-EEZE<SUP>&reg;
</SUP>in the future and/or expand its product line, for any reason, would have a material adverse effect on our financial condition,
prospects and ability to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our products and potential new products
are or may be subject to extensive governmental regulation </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business is regulated
by various agencies of the states and localities where our products are sold. Governmental regulations in foreign countries where
we plan to commence or expand sales may prevent or delay entry into a market or prevent or delay the introduction, or require
the reformulation of certain of our products. In addition, no prediction can be made as to whether new domestic or foreign legislation
regulating our activities will be enacted. Any new legislation could have a material adverse effect on our business, financial
condition and operations. Non-compliance with any applicable requirements may subject us or the manufacturers of our products
to agency action, including warning letters, fines, product recalls, seizures and injunctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The manufacturing, processing,
formulation, packaging, labeling and advertising of our cold remedy products are subject to regulation by several federal agencies,
including (i) the FDA, (ii) the Federal Trade Commission (&ldquo;FTC&rdquo;), (iii) the Consumer Product Safety Commission, (iv)
the United States Department of Agriculture, (v) the United States Postal Service, (vi) the United States Environmental Protection
Agency and (vii) the United States Occupational Safety and Health Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to OTC and
prescription drug products, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements, including
vitamins, minerals and herbs, food additives, food supplements, over-the-counter and prescription drugs and cosmetics. The FTC
also has overlapping jurisdiction with the FDA to regulate the promotion and advertising of vitamins, over-the-counter drugs,
cosmetics and foods. In addition, our cold remedy products are homeopathic remedies which are subject to standards established
by the Homeopathic Pharmacopoeia of the United States (&ldquo;HPUS&rdquo;). HPUS sets the standards for source, composition and
preparation of homeopathic remedies which are officially recognized under the Federal Food, Drug and Cosmetics Act, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Preclinical development,
clinical trials, product manufacturing, labeling, distribution and marketing of potential new products are also subject to federal
and state regulation in the United States and other countries. Clinical trials and product marketing and manufacturing are subject
to the rigorous review and approval processes of the FDA and foreign regulatory authorities. To obtain approval of a new drug
product, a company must demonstrate through adequate and well-controlled clinical trials that the drug product is safe and effective
for its intended use. Obtaining FDA and other required regulatory approvals is lengthy and expensive. Typically, obtaining regulatory
approval for pharmaceutical products requires substantial resources and takes several years. The length of this process depends
on the type, complexity and novelty of the product and the nature of the disease or other indication to be treated. Preclinical
studies must comply with FDA regulations. Clinical trials must also comply with FDA regulations to ensure safety of the human
subjects in the trial and may require large numbers of test subjects, complex protocols and possibly lengthy follow-up periods.
Consequently, satisfaction of government regulations may take several years, may cause delays in introducing potential new products
for considerable periods of time and may require imposing costly procedures upon our activities. If regulatory approval of new
products is not obtained in a timely manner or not at all, we could be materially adversely affected. Even if regulatory approval
of new products is obtained, such approval may impose limitations on the indicated uses for which the products may be marketed
which could also materially adversely affect our business, financial condition and future operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-weight: normal"><I><U>We
have a history of losses and limited working capital</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have experienced net
losses for each of the past six fiscal years. As a consequence, we have aligned our operations for Fiscal 2011 and 2010 to focus
principally in the research, development, manufacture, marketing and sale of OTC cold remedy and consumer products, natural base
health products and other supplements and cosmeceuticals products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that this strategic focus will provide any revenue growth or that we will be successful in initiating or acquiring any new lines
of business, or that any such new lines of business will achieve profitability. Furthermore as part of our strategic initiatives,
we have implemented certain cost reduction programs and expanded our marketing investments during Fiscal 2011 that, in of themselves,
may not be sufficient to return the Company to profitability. As of December 31, 2011, we had working capital of approximately
$5.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our ability to use our net operating
loss carryforwards to offset future taxable income may be subject to certain limitations </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In general, under Section
382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &ldquo;ownership change&rdquo;
is subject to limitations on its ability to use its pre-change net operating loss carryforwards, or NOLs, to offset future taxable
income. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under
Section 382 of the Code. Furthermore, our ability to use NOLs of companies that we may acquire in the future may be subject to
limitations. For these reasons, we may not be able to use a material portion of the NOLs reflected on our balance sheet, even
if we attain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our success is dependent on key personnel
</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success depends, in
part, upon the continued service of key personnel, such as Mr. Ted Karkus, Chairman and Chief Executive Officer, Mr. Robert V.
Cuddihy, Jr., Chief Operating Officer and Chief Financial Officer, and certain managers and strategists within the Company. The
loss of the services of any one of them could have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>We may not be able to hire, train, motivate,
retain and manage professional staff; transitions in management may affect our business</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We must hire, train, motivate,
retain and manage highly skilled employees. Competition for skilled employees who can perform the services that we require is
intense and hiring, training, motivating, retaining and managing employees with the skills required is time-consuming and expensive.
If we are not be able to hire sufficient professional staff to support our operations, or to train, motivate, retain and manage
the employees we do hire, it could have a material adverse effect on our business operations or financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>We are dependent on
our manufacturing facility and suppliers for certain of our cold remedy products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our manufacturing, warehousing
and distribution center is located in Lebanon, Pennsylvania. In the event of a disruption of this facility, we would outsource,
at least temporarily, to third parties our manufacturing, warehousing and distribution requirements. While such secondary sources
have been identified for our products, if we are unable to find other sources or there were a delay in the ramp-up for the production
and distribution operations for some of our products, it could have a material adverse effect on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain raw material active
ingredients used in connection with the Cold-EEZE<SUP>&reg;</SUP> products are purchased from a single unaffiliated supplier.
Should the relationship terminate or the vendor become unable to supply material, we believe that current contingency plans would
prevent such termination from materially affecting our operations, although there may be delays in production of our products
until an acceptable replacement supplier is located.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We continue to look for
safe and reliable multiple-location sources for products and raw materials so that we can continue to obtain products and raw
materials in the event of a disruption in our business relationship with any single manufacturer or supplier. While secondary
sources have been identified for some of our manufacturing and raw materials needs, our inability to find alternative sources
for some of our manufacturing and raw materials may have a material adverse effect on our operations and financial condition.
In addition, the terms on which manufacturers and suppliers will make products and raw materials available to us could have a
material effect on our success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The manufacturing of OTC
products and dietary supplements is subject to applicable current good manufacturing practice (&ldquo;cGMP&rdquo;) regulations
and FDA inspections. We believe we are in substantial compliance with material provisions of the applicable cGMP regulations.
Contract manufacturers are also subject to these same requirements and we require such compliance in our contractual relationships
with such manufacturers. However, we cannot assure that the FDA will agree with our determination of compliance. If the FDA disagrees,
it could, upon inspection of our facility, issue a notice of violations, referred to as a form FDA-483, or issue a Warning Letter,
or both. If the FDA concludes that there is an imminent public health threat or if we fail to take timely corrective actions to
the satisfaction of the FDA, the agency can initiate legal actions, such as seizure and injunction, which could include a recall
order or the entry of a consent decree, or both. In addition, we could be subject to monetary penalties and even criminal prosecution
for egregious conduct. The FDA could initiate similar legal actions against the contract manufacturer if it concludes its facility
is not in compliance, which would affect the availability our products. While secondary sources have been identified for our products,
our inability to find other sources or a delay in the ramp-up for the production and distribution operations for some of its products
may have a material adverse effect on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>We are uncertain as
to whether we can protect our proprietary rights </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The strength of our patent
position and proprietary formulations and compounds may be important to our long-term success. We currently own numerous U.S.
and foreign patents in connection with potential products; however there can be no assurance that these patents and proprietary
formulations and compounds will effectively protect our products from duplication by others. In addition, we may not be able to
afford the expense of any litigation which may be necessary to enforce our rights under any of the patents. Furthermore, there
can be no assurance that third parties will not obtain access to or independently develop our technologies, know-how, ideas, concepts
and documentation, which could have a material adverse effect on our financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we believe that
current and future products do not and will not infringe upon the patents or violate the proprietary rights of others, if any
of our current or future products do infringe upon the patents or proprietary rights of others, we may have to modify the products
or obtain an additional license for the manufacture and/or sale of such products. We could also be prohibited from selling the
infringing products. If we were found to infringe on the proprietary rights of others, it is uncertain whether we would be able
to take corrective actions in a timely manner, upon acceptable terms and conditions, or at all, and the failure to do so could
have a material adverse effect upon our business, financial condition and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our existing products and potential
new products expose us to potential product liability claims </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business results in
exposure to an inherent risk of potential product liability claims, including claims for serious bodily injury or death caused
by the sales of our existing products and the products which are being developed. These claims could lead to substantial damage
awards. We currently maintain product liability insurance. A successful claim brought against us in excess of, or outside of,
existing insurance coverage could have a material adverse effect on our results of operations and financial condition. Claims
against us, regardless of their merit or eventual outcome, may also have a material adverse effect on the consumer demand for
our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>We are involved in litigation including
claims relating to certain of our Cold-EEZE<SUP>&reg;</SUP> products and other business matters </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are, from time-to-time,
subject to various legal proceedings and claims, either asserted or unasserted. Any such claims, whether with or without merit,
can be time-consuming and expensive to defend and can divert management's attention and resources. While management believes that
we have adequate insurance coverage and, if applicable, accrued loss contingencies for all known matters, there is no assurance
that the outcome of all current or future litigation will not have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>We are a defendant in a stockholder
derivative lawsuit filed by our former CEO</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A purported derivative
lawsuit was filed against us, our officers and directors, as described under &quot;Part I, Item 3, Legal Proceedings&quot;. The
Company believes the lawsuit is without merit and intends to engage in a vigorous defense of such litigation. If we are not successful
in our defense of such litigation, we could be forced to make significant payments to or other settlements with our stockholders
and their lawyers, and such payments or settlement arrangements could have a material adverse effect on our business, operating
results or financial condition. Regardless of the outcome, the litigation could result in substantial costs and significant adverse
impact on our reputation and divert management's attention and resources, which could have a material adverse effect on our business,
operating results or financial condition. We also have certain obligations to indemnify our officers and directors and to advance
expenses to such officers and directors. Although we have purchased liability insurance for our directors and officers, if our
insurance carriers should deny coverage, or if the indemnification costs exceed the insurance coverage, we may be forced to bear
some or all of these indemnification costs directly, which could be substantial and may have an adverse effect on our business,
financial condition, results of operations and cash flows. If the cost of our liability insurance increases significantly, or
if this insurance becomes unavailable, we may not be able to maintain or increase our levels of insurance coverage for our directors
and officers, which could make it difficult to attract or retain qualified directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Certain Officers, Directors and former
executives and their families own a substantial amount of our Common Stock</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 1, 2012, our
executive officers and directors beneficially owned approximately 15.9% of our Common Stock and our former executives, Mr. Guy
J. Quigley and Mr. Charles Phillips, and their immediate families beneficially owned, approximately 27.0% of our Common Stock.
These individuals have significant influence over the outcome of all matters submitted to stockholders for approval, including
the election of directors. Consequently, they exercise substantial influence over all major decisions including major corporate
actions such as mergers and other business combinations transactions which could result in or prevent a change of control of the
Company. Circumstances may occur in which the interests of these shareholders could be in conflict with the interests of other
shareholders. Accordingly, a stockholder&rsquo;s ability to influence us through voting their shares may be limited or the market
price of our Common Stock may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>We incur significant costs as a result
of operating as a public company, and our management devotes substantial time to new compliance initiatives</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have incurred and will
continue to incur significant legal, accounting and other expenses as a public company, including costs resulting from public
company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements
of The NASDAQ Global Market require that we satisfy certain corporate governance requirements relating to director independence,
distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest
and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to all of these requirements.
Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make
some activities more time-consuming and costly. These reporting requirements, rules and regulations, coupled with the increase
in potential litigation exposure associated with being a public company, could make it more difficult for us to attract and retain
qualified persons to serve on our board of directors or board committees or to serve as executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the Sarbanes-Oxley
Act of 2002 (&ldquo;Sarbanes-Oxley&rdquo;) and the related rules of the Securities and Exchange Commission require that we maintain
effective internal control over financial reporting and disclosure controls and procedures. During the course of our review and
testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. We or our independent
registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over
financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information
and cause the trading price of our stock to fall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of Sarbanes-Oxley may require that we incur substantial expense and expend significant management time on compliance related
issues. Moreover, if we are not able to comply with the requirements of Section 404 in a timely manner, or if we or our independent
registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be
material weaknesses, the market price of our stock would likely decline and we could be subject to sanctions or investigations
by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>Our stock price is volatile
</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market price of our
Common Stock has experienced significant volatility. From January 1, 2011 to March 1, 2012, the trading prices of our stock have
ranged from $0.70 to $1.60 per share. There are several factors which could affect the price of our Common Stock, including some
of which are announcements of technological innovations for new commercial products by us or our competitors, developments concerning
propriety rights, new or revised governmental regulation or general conditions in the market for our products. Sales of a substantial
number of shares by existing stockholders could also have an adverse effect on the market price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><I><U>Future
sales of shares of our Common Stock in the public market could adversely affect the trading price of shares of the Common Stock
and our ability to raise funds in new stock offerings</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Future sales of substantial
amounts of shares of our Common Stock in the public market, or the perception that such sales are likely to occur, could affect
prevailing trading prices of our Common Stock. As of March 1, 2012, we had 14,836,340 shares of Common Stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 1, 2012 we
also have outstanding options, which are fully vested, to purchase an aggregate of 375,770 shares of our Common Stock at an average
exercise price of $4.05 per share. If these options are exercised, and the holders of these options were to attempt to sell a
substantial amount of their holdings at once, the market price of our Common Stock would likely decline. Moreover, the perceived
risk of this potential dilution could cause stockholders to attempt to sell their shares and investors to &ldquo;short&rdquo;
our stock, a practice in which an investor sells shares that he or she does not own at prevailing market prices, hoping to purchase
shares later at a lower price to cover the sale. As each of these events would cause the number of shares of Common Stock being
offered for sale to increase, our Common Stock&rsquo;s market price would likely further decline. All of these events could combine
to make it very difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our Common Stock may be delisted from
The NASDAQ Global Market, which would adversely affect the price and liquidity of our Common Stock. </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock is currently
listed on The NASDAQ Global Market. On December 5, 2011, we were notified by Nasdaq that the Company had regained compliance with
Nasdaq Marketplace Rule 5450(a)(1) because for 11 consecutive trading days the bid price of the Company&rsquo;s Common Stock closed
above the $1.00 per share minimum required for listing. Previously on June 29, 2011, we were notified by Nasdaq that we did not
comply with Nasdaq Marketplace Rule 5450(a)(1) because for 30 consecutive trading days the bid price of the Company&rsquo;s Common
Stock closed below the $1.00 per share minimum required for listing. Should we fail to comply with the minimum bid price requirement
in the future or any of the other continued listing requirements, our Common Stock may be delisted from The NASDAQ Global Market.
If our Common Stock is delisted, it could reduce the price of our Common Stock and the levels of liquidity available to our stockholders.
In addition, the delisting of our Common Stock could materially adversely affect our access to the capital markets, and any limitation
on liquidity or reduction in the price of our Common Stock could materially adversely affect our ability to raise capital on terms
acceptable to us or at all. Delisting from The NASDAQ Global Market could also result in other negative implications, including
the potential loss of confidence by suppliers, customers and employees, the loss of institutional investor interest and fewer
business development opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>If securities or industry analysts do
not publish research or reports about our business or if they issue an adverse or misleading opinion regarding our stock, our
stock price and trading volume could decline</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The trading market for
our Common Stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.
If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, products or stock
performance, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports
on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume
to decline. Moreover, the unpredictability of our financial results likely reduces the certainty, and therefore reliability, of
the forecasts by securities or industry analysts of our future financial results, adding to the potential volatility of our stock
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>We do not intend to
pay cash dividends in the foreseeable future </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not paid cash
dividends on our Common Stock since our inception. Our intention is to retain earnings, if any, for use in the business and we
do not anticipate paying any cash dividends to stockholders in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Our Articles of Incorporation and By-laws
contain certain provisions that may be barriers to a takeover</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Articles of Incorporation
and By-laws contain certain provisions which may deter, discourage, or make it difficult for another person or entity to gain
control of the Company through a tender offer, merger, proxy contest or similar transaction or series of transactions. These provisions
may deter a future tender offer or other takeover attempt. Some stockholders may believe such an offer to be in their best interest
because it may include a premium over the market price of our Common Stock at the time. In addition, these provisions may assist
current management in retaining its position and place it in a better position to resist changes which some stockholders may want
to make if dissatisfied with the conduct of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>We have agreed to indemnify our Officers
and Directors from liability </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with sections
78.7502 and 78.751 of the Nevada General Corporation Law our Articles of Incorporation provide that we will indemnify any person
who is or was made a party to, or is or was threatened to be made a party to, any pending, completed, or threatened action, suit
or proceeding because he or she is or was a director, officer, employee or agent of the Company or is or was serving at the Company&rsquo;s
request as a director, officer, employee or agent of any corporation, partnership, joint venture, trust or other enterprise. These
provisions permit us to advance expenses to an indemnified party in connection with defending any such proceeding, upon receipt
of an undertaking by the indemnified party to repay those amounts if it is later determined that the party is not entitled to
indemnification. In August 2009, we entered into a standard form of indemnity agreement with each member of our Board of Directors,
Mr. Karkus and Mr. Cuddihy. These agreements provide, among other things, that we will indemnify each director, Mr. Karkus and
Mr. Cuddihy in the event they become a party or otherwise a participant in any action or proceeding on account of their service
as a director or officer of the Company (or service for another corporation or entity in any capacity at the request of the Company)
to the fullest extent permitted by applicable law. These indemnity provisions may reduce the likelihood of derivative litigation
against directors and officers and discourage or deter stockholders from suing directors or officers for breaches of their duties
to the Company, even though such an action, if successful, might otherwise benefit the Company or its stockholders. In addition,
to the extent that we expend funds to indemnify directors and officers, funds will be unavailable for operational purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Item 1B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unresolved
Staff Comments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Item 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
is located in Doylestown, Pennsylvania. We purchased this property in 1998. Our headquarters is approximately 13,000 square feet
and is comprised principally of office space and limited warehousing and storage area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our principal manufacturing
facility is located in Lebanon, Pennsylvania. The facility was purchased in October 2004. The facility has a total area of approximately
57,500 square feet, comprised of manufacturing, warehousing and office space. Effective in June 2009, we closed our 15,500 square
foot Elizabethtown, Pennsylvania manufacturing location and consolidated our manufacturing operations in the Lebanon facility.
At December 31, 2010, the net value of the Elizabethtown facility in the amount of $138,000 is classified as an asset held for
sale. In February 2011, the Elizabethtown facility was sold and we derived net proceeds from the sale of approximately $166,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that our existing
facilities are adequate at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.) VS.
JOHN C. GODFREY, ET AL.</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This action was commenced
by us in November 2004 in the Court of Common Pleas of Bucks County, Pennsylvania against John C. Godfrey, Nancy Jane Godfrey,
and Godfrey Science and Design, Inc. for injunctive relief regarding the Cold-EEZE<SUP>&reg;</SUP>&nbsp;trademark; injunctive
relief relating to the Cold-EEZE<SUP>&reg;</SUP> formulations and manufacturing methods; injunctive relief for breach of the duty
of loyalty, and declaratory judgment&nbsp;regarding&nbsp;various payments that the defendants assert are owing to them.&nbsp;
Our complaint is based in part upon certain contracts&nbsp;with defendants whereby we obtained the exclusive right to manufacture
and distribute product pursuant to&nbsp;a basic patent&nbsp;and&nbsp;also obtained various consulting services&nbsp;(the &quot;Agreements&quot;).&nbsp;
Subsequent to entering into the Agreements, the&nbsp;defendants&nbsp;took various actions that we believe were in breach of&nbsp;the
Agreements. We instituted the action because of&nbsp;defendants' threats to deal with other parties and&nbsp;to use the Company&rsquo;s
Cold-EEZE<SUP>&reg;</SUP> trademark and&nbsp;the trade secrets that&nbsp;we developed during our manufacture of Cold-EEZE<SUP>&reg;</SUP>.
Both because of their breaches and the expiration of the basic patent, we terminated the&nbsp;Agreements.&nbsp; Defendants have
answered the complaint and asserted counterclaims.&nbsp; They seek monetary damages and counter injunctive and&nbsp;declaratory
relief relative to the Company's trademark and other intellectual property.&nbsp; The monetary relief sought by the&nbsp;defendants&nbsp;is
based on their claim that they were not paid various amounts asserted to be due under the Agreements.&nbsp; This claim is estimated&nbsp;to
be in excess of $5.0 million.&nbsp; We believe that the defendants' counterclaims are without merit and are vigorously defending
those counterclaims and are prosecuting our action on the complaint.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pre-trial discovery is&nbsp;ongoing.&nbsp;
Defendants moved for partial summary judgment, and we filed a response and cross-motion for summary judgment.&nbsp; On August
21, 2008, the court denied both motions for summary judgment.&nbsp; The case has not been assigned to a trial calendar, although
it is possible that the case will be listed for trial in 2012.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At this time no prediction as to the outcome of this action can be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;<U>THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.)
VS. WACHOVIA INSURANCE SERVICES, INC. AND FIRST UNION INSURANCE SERVICES AGENCY, INC.</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We instituted a Writ of
Summons against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc. on December 8, 2005 in the Court
of Common Pleas of Bucks County, Pennsylvania. The purpose of this suit was to maintain an action and toll the statute of limitation
against our insurance broker who failed to place excess limits coverage for us for the period from November 29, 2003 until April
6, 2004. As a result of the defendants&rsquo; failure to place insurance and to notify us thereof, certain pending actions covered
by our underlying insurance, which are currently being defended by insurance counsel and the underlying insurance carrier may
cause an exhaustion of the underlying insurance for the policy periods ending November 29, 2004 and November 29, 2005. Any case
in which an alleged action arose relating to the use of Cold-EEZE<SUP>&reg;</SUP> Nasal Spray from November 29, 2003 to April
6, 2004 is not covered by excess insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our claim against Wachovia
Insurance Services, Inc. and First Union Insurance Services Agency, Inc. is for negligence and for equitable insurance for these
claims based on our undertaking of certain attorneys' fees and costs of settlement for claims that should have been covered by
underlying insurance placed by Wachovia Insurance Services, Inc. At this time no prediction can be made as to the outcome of any
action against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>PROPHASE LABS, INC.(formerly THE QUIGLEY
CORPORATION) <FONT STYLE="text-transform: uppercase; color: windowtext">vs. Guy Quigley, Gary Quigley, Scanda Systems Limited,
Scanda Systems LTD, Chilesha Holdings LTD, Kevin Brogan, Innerlight Holdings, Inc., George Longo, Graham Brandon, Pacific Rim
Pharmaceuticals LTD and John Doe Defendants</FONT></U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: windowtext">On
August 23, 2010, we initiated an action in the Court of Common Pleas of Bucks County, </FONT>Pennsylvania<FONT STYLE="color: windowtext">.
This action&nbsp;is against certain former officers and directors of the Company, including a shareholder that beneficially owns
approximately 20.1% of our Common Stock, and against certain third parties (a &ldquo;Complaint&rdquo;). The Company has asserted
claims arising from, among other things, a variety of transactions and payments previously made or entered into by the Company.
All of the transactions and events that are the subject of the Complaint occurred prior to June 2009 and the installation of the
current Board of Directors. Pre-trial discovery is on-going and at this time, no prediction as to the outcome of this action can
be made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>GUY QUIGLEY VS. TED KARKUS, ROBERT V.
CUDDIHY, JR., MARK BURNETT, MARK LEVENTHAL, MARK FRANK, LOUIS GLECKEL, MD, JAMES McCUBBIN AND PROPHASE LABS, INC. AS A NOMINAL
DEFENDANT</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company was named
as a nominal defendant in a purported derivative complaint filed on February 2, 2012 by stockholder and former director and Chief
Executive Officer Guy Quigley in the Court of Common Pleas of Philadelphia County, Pennsylvania (No. 111200409). The complaint
also names as a defendant each of our directors and executive officers. Among other things, the suit alleges various breaches
of fiduciary and other duties, and seeks recovery of unspecified damages and other relief. Prior to filing this complaint, the
plaintiff applied to the same court for permission to take pre-complaint discovery on the basis that the plaintiff required such
discovery in order to assert claims. The court denied the plaintiff's request. The Company believes the lawsuit is without merit
and intends to vigorously defend against it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, the Company previously
commenced litigation against the plaintiff, Guy Quigley, and other parties in August 2010 in the Bucks County Court of Common
Pleas, Pennsylvania (No. 2010-08227). The August 2010 action remains pending. &#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Other Litigation </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the normal course of
its business, we are named as defendant in legal proceedings. It is our policy to vigorously defend litigation and/or enter into
settlements of claims where management deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>PART II</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><B>Item&nbsp;5.</B></TD><TD><B>Market for Registrant&rsquo;s
                                                                                              Common Equity, Related Stockholder
                                                                                              Matters and Issuer Purchases of
                                                                                              Equity Securities </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock is currently
traded on The NASDAQ Global Market under the trading symbol &ldquo;PRPH.&rdquo; The price set forth in the following table represents
the high and low bid prices for our Common Stock for each quarter of the Fiscal 2011 and 2010, as reported on The NASDAQ Global
Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Common Stock</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD COLSPAN="7" STYLE="padding-bottom: 1pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Quarter Ended</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; padding-left: 0">March 31,</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.64</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.07</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0">June 30,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0">September 30,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0">December 31,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Holders</U>&#9;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 1, 2012, there
were approximately 270 holders of record of our Common Stock, including brokerage firms, clearing houses, and/or depository firms
holding the Company&rsquo;s securities for their respective clients. The exact number of beneficial owners of our securities is
not known but exceeds 400.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><I><U>Dividends</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not declared,
nor paid, any cash dividends on our Common Stock since our Company&rsquo;s inception. At this time, we intend to retain our earnings
to finance future growth and maintain liquidity. Future cash dividends, if any, will be at the discretion of our Board of Directors
and will depend upon, among other things, our future operations and earnings, capital requirements, general financial condition,
contractual and financing restrictions and such other factors as our Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrants and Options </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to our outstanding
Common Stock, there were reserved for issuance 375,770 shares of our Common Stock underlying outstanding unexercised and vested
options as of December 31, 2011 at the price-per-share stated and expire on the date indicated, as follows:&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Description</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Number of <BR>
    Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise <BR>
    Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Expiration Date</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0; text-align: center">Option Plan</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">24,750</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$&nbsp;</TD>
    <TD STYLE="text-align: right">5.19</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">July 30, 2012</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; text-align: center">Option Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">October 29, 2013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center">Option Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">October 26 ,2014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Option Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">December 11, 2015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">Option Plan</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">237,020</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">December 14, 2017</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">375,770</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Securities Authorized Under Equity Compensation
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information regarding stock option and warrant grants made to employees, directors and consultants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AUTHORIZED FOR ISSUANCE UNDER
EQUITY COMPENSATION PLANS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Plan&nbsp;Category</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Number&nbsp;of<BR>Securities&nbsp;to&nbsp;be    <BR>Issued&nbsp;Upon<BR>Exercise&nbsp;of<BR>Outstanding<BR>Options<BR>(A)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Weighted<BR>Average<BR>Exercise&nbsp;Price    <BR>of&nbsp;Outstanding<BR>Options<BR>(B)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Number&nbsp;of&nbsp;Securities<BR>Remaining&nbsp;Available&nbsp;for   <BR>Future&nbsp;Issuance&nbsp;Under&nbsp;Equity<BR>Compensation&nbsp;Plans<BR>(Excluding&nbsp;Securities<BR>Reflected&nbsp;in&nbsp;Column&nbsp;A)   <BR>(&nbsp;C&nbsp;)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 46%; text-align: left">Equity Plans Approved by Security Holders <SUP>(1,2,3)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">1,332,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1.88</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">31,264</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">(1)&#9; An incentive stock option
plan was instituted in Fiscal 1997 (the &ldquo;1997 Plan&rdquo;), and approved by the stockholders in Fiscal 1998. Options pursuant
to the 1997 Option Plan have been granted to directors, executive officers and employees. At December 31, 2011, we are precluded
from issuing any additional options or grants in the future under the 1997 Option Plan pursuant to the terms of the plan document.
An aggregate of 138,750 stock options previously granted pursuant to the terms of the 1997 Option Plan remain available for exercise
at any time prior to such options&rsquo; respective expiration dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">(2)<B> </B>On May 5, 2010, our
shareholders approved the 2010 Equity Compensation Plan, which was subsequently amended, restated and approved by shareholders
on April 24, 2011 (the &ldquo;2010 Equity Compensation Plan&rdquo;). The 2010 Equity Compensation Plan provides that the total
number of shares of Common Stock that may be issued is equal to 900,000 shares plus up to 900,000 shares that were authorized
for issuance but unissued under the 1997 Plan, an aggregate of 1.8 million shares. All of our employees, including employees who
are officers or members of the Board are eligible to participate in the 2010 Equity Compensation Plan. Consultants and advisors
who perform services for us are also eligible to participate in the 2010 Equity Compensation Plan. At December 31, 2011, we have
outstanding 1,194,000 stock options, subject to vesting, under the 2010 Equity Compensation Plan. For the year ended December
31, 2011, we charged to operations $131,000 for compensation expense for the fair value of the vested portion of the stock options
(see Note 8 to Notes to Consolidated Financial Statements). At December 31, 2011, there are 13,659 shares of Common Stock that
may be issued in the future pursuant to the 2010 Equity Compensation Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">(3)&#9;On May 5, 2010, our shareholders
approved t<FONT STYLE="color: black">he 2010 Directors&rsquo; Equity Compensation Plan. </FONT>A primary purpose of the <FONT STYLE="color: black">2010
Directors&rsquo; Equity Compensation Plan</FONT> is to provide us with the ability to pay all or a portion of the fees of Directors
in restricted stock instead of cash. The 2010 Directors&rsquo; Equity Compensation Plan provides that the total number of shares
of Common Stock that may be issued under the 2010 Directors&rsquo; Equity Compensation Plan is equal to 250,000. For the year
ended December 31, 2011, we granted 164,770 shares of our Common Stock and charged to operations $162,000 for director compensation
for the fair value of the stock at the date of grant. At December 31, 2011, there are 17,605 shares of Common Stock that may be
issued pursuant to the 2010 Directors Equity Compensation Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>Other Stock Issuances</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of Mr. Cuddihy&rsquo;s prior employment agreement dated August 19, 2009, Mr. Cuddihy received an annual grant of shares of Common
Stock equal to $50,000, payable quarterly,<B> </B>promptly following the close of each quarter. The value of the shares is calculated
based on the average closing price of our shares for the last five (5) trading days of the quarter in which the shares are earned.
For the year ended December 31, 2011, Mr. Cuddihy earned and was issued an aggregate of 51,642 shares pursuant to the terms of
the employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Item 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selected Financial
Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the selected financial data appearing in or derived from our consolidated financial statements for and at the end of the
years ended December 31, 2011, 2010, 2009, 2008 and 2007. The selected financial data should be read in conjunction with the consolidated
financial statements appearing elsewhere herein, and with Item 7 &ndash; Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations (in thousands, except per share amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2008</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2007</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Statement of Income Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left; padding-bottom: 2.5pt">Net sales</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">17,453</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">14,502</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">19,816</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">20,507</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">28,241</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Gross profit</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,830</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,569</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,413</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,556</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss - continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,710</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,501</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,842</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,409</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,856</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income (loss) - discontinued operations <SUP>(1)</SUP></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">875</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,710</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,842</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,534</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,458</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Basic and diluted earnings (loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.12in">Continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.25</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.30</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.50</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.12in">Discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.07</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Weighted average shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in">Basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,817</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,285</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,963</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,878</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,729</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2008</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2007</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left">Working capital</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,342</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7,521</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">11,475</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">14,071</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">18,578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21,695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21,330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33,502</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,774</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,244</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">(1)
On February 29, 2008, we sold Darius to InnerLight Holdings, Inc. The sale of this segment was treated as discontinued operations
and all periods presented have been reclassified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -1in">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding-left: 0"><B>Item 7.</B></TD><TD STYLE="width: 0.5in; text-align: center"></TD><TD><B>Management&rsquo;s
                                                                                                               Discussion and
                                                                                                               Analysis of Financial
                                                                                                               Condition and Results
                                                                                                               of Operations </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Our Business.</I> We
are a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the
general public. We are also engaged in the research and development of potential natural base health products along with supplements
and cosmeceuticals products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our primary business is
currently the manufacture, distribution, marketing and sale of over-the-counter (&ldquo;OTC&rdquo;) cold remedy products to consumers
through food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers. One flagship brand is Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;
</SUP></FONT> Cold Remedy and our principal product is Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT><SUP>
</SUP> zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold
by nearly half. Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> is an established product in the health
care and cold remedy market. For Fiscal 2011, 2010 and 2009, our revenues from continuing operations have come principally from
our OTC cold remedy products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>Recent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2011, Phosphagenics
Ltd. (&ldquo;PSI Parent&rdquo;), entered into certain Private Resale Agreements (&ldquo;PSAs&rdquo;) with seven third party purchasers,
under which the PSI Parent sold, with our consent, an aggregate of 750,000 shares of our common stock, $0.0005 par value (&ldquo;Common
Stock&rdquo;). PSI Parent is the parent company to Phosphagenics Inc. (&ldquo;PSI&rdquo;), our joint venture partner in Phusion
Laboratories, LLC (the &ldquo;Joint Venture&rdquo;). Under the PSAs, the purchasers may not, without the prior written consent
of the Company, prior to the one year anniversary of the PSAs, directly or indirectly, sell, give, pledge, hypothecate, assign
or otherwise transfer the purchased shares, in whole or in part. Contemporaneously with PSI Parent consummating the PSAs, we consummated
an agreement with PSI Parent to redeem the then remaining 690,000 shares of our Common Stock held by PSI Parent (see Note 3).
Under the terms of the redemption agreement, we redeemed 690,000 shares of our Common Stock held by PSI Parent for the aggregate
redemption price of $448,500 in cash. The redemption price was equal to $0.65 per share. The redemption agreement contained customary
representations and covenants of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>Critical Accounting Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in conformity with accounting principles generally accepted in the United States (&ldquo;GAAP&rdquo;) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities
at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual
results could differ from those estimates. Our significant accounting policies are described in Note 2 of the Notes to Consolidated
Financial Statements included under Item 8 of this Part II. However, certain accounting policies are deemed &ldquo;critical&rdquo;,
as they require management&rsquo;s highest degree of judgment, estimates and assumptions. These accounting estimates and disclosures
have been discussed with the Audit Committee of our Board of Directors. A discussion of our critical accounting policies, the
judgments and uncertainties affecting their application and the likelihood that materially different amounts would be reported
under different conditions or using different assumptions are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>Revenue Recognition
&ndash; Sales Allowances</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">When providing for the
appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (&ldquo;Sales Allowances&rdquo;),
we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions
are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial
statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis.
Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our primary product, Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;
</SUP></FONT>lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity
and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product
include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for
remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party
consumption data. In addition to Cold-EEZE<SUP>&reg;</SUP> lozenges, we market and distribute Cold-EEZE<SUP>&reg; </SUP>Oral Spray
and Kids-EEZE<SUP>&reg;</SUP> Chest Relief, Kids-EEZE<SUP>&reg;</SUP> Cough Cold and Kids-EEZE<SUP>&reg;</SUP> Allergy (&ldquo;Kids-EEZE<SUP>&reg;
</SUP>Products&rdquo;), children&rsquo;s OTC products. In August 2011, we introduced Cold-EEZE<SUP>&reg;</SUP> Oral Spray containing
our proprietary zinc gluconate formulation in a liquid spray form. We introduced Kids-EEZE<SUP>&reg;</SUP> Chest Relief in Fiscal
2008 and expanded the product line to include Kids-EEZE<SUP>&reg;</SUP> Cough Cold and Kids-EEZE<SUP>&reg;</SUP> Allergy in Fiscal
2010. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (&ldquo;Organix<SUP>&reg;</SUP>&rdquo;).
Each of the Cold-EEZE<SUP>&reg;</SUP> Oral Spray products, Kids-EEZE<SUP>&reg;</SUP> Products and Organix<SUP>&reg;</SUP> products
carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns
and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels
and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer,
market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our return policy accommodates
returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration
date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted
to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product
that is un-saleable and such return request activity fall within an acceptable range, (ii) we will accept returns for products
that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a
product provided that the customer will have the right to return only such items that it purchased directly from us. We will not
accept return requests pertaining to customer inventory &ldquo;Overstocking&rdquo; or &ldquo;Resets&rdquo;. We will only accept
return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers
who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the
customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product
only, also by way of an exchange. We do not have any significant product exchange history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We classify product
returns into principally three categories, (i) non-routine returns, (ii) obsolete product and (iii) product mix realignment by
certain of our customers. &ldquo;Non-routine&rdquo; returns are defined as product returned to us as a consequence of unanticipated
circumstances principally due to (i) retail store closings or (ii) unexpected poor retail sell through to consumers causing us
to discontinue the product. &ldquo;Obsolete&rdquo; returns are defined as product returned to us as a consequence of product shelf-life
&ldquo;use by&rdquo; expiration date. <B>&ldquo;</B>Product mix realignment&rdquo; returns are defined as product returned to
us due to initiatives by the trade to discontinue purchasing certain of our products. Product mix realignment returns are generally
nominal and are frequently related to discontinued or soon to be discontinued products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our return policy accommodates
returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded designated expiration
date. The following is a summary of the change in the return provision for the years ended December 31, 2011 and 2010 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 82%">Return provision at December 31, 2009</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,513</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net change in the return provision Fiscal 2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Return provision at December 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,546</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net change in the return provision Fiscal 2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">121</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Return<B> </B>provision at December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,667</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For Fiscal 2011, 2010
and 2009, net sales of products with limited shelf-life and expiration dates were $2.0 million, $617,000 and $311,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For Fiscal 2011,
the return provision increased by $121,000. The increase in the return provision was principally due to (i) a charge of $1.5 million,
including $408,000 for products with shelf-life expiration dates (obsolete returns), offset by (ii) net returns of $1.4 million
associated principally with Fiscal 2011 and Fiscal 2010 received and processed during Fiscal 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For Fiscal 2010, the return
provision increased by $33,000. The increase in the return provision was principally due to (i) a charge of $815,000, including
$462,000 for products with shelf-life expiration dates (obsolete returns), offset by (ii) net returns of $782,000 associated principally
with Fiscal 2009 and Fiscal 2010 received and processed during Fiscal 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A one percent deviation
for these sales allowance provisions for the Fiscal 2011, 2010 and 2009 would affect net sales by approximately $219,000, $188,000
and $261,000, respectively. A one percent deviation for cooperative incentive promotions reserve provisions for Fiscal 2011, 2010
and 2009 could affect net sales by approximately $210,000, $182,000 and $245,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><I><U>Income Taxes</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2011,
we have net operating loss carry-forwards of approximately $31.6 million for federal purposes that will expire beginning in Fiscal
2020 through 2031. Additionally, there are net operating loss carry-forwards of $20.0 million for state purposes that will expire
beginning in Fiscal 2018 through 2030. Until sufficient taxable income to offset the temporary timing differences attributable
to operations, the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling
the total deferred tax asset is being provided. As a consequence of the accumulated losses of the Company, management believes
that this allowance is required due to the uncertainty of realizing these tax benefits in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><BR>
<B>Seasonality of the Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our sales are derived
principally from our OTC cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which
causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest
sales volume for our OTC cold remedy products with a corresponding increase in marketing and advertising expenditures designed
to promote our products during the Cold Season (defined below). In addition, our sales are influenced by and subject to fluctuations
in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity
of each cold season. Generally, a cold season is defined as the period of September to March (&ldquo;Cold Season&rdquo;) when
the incidence of the common cold rises as a consequence of the change in weather and other factors. We track health and wellness
trends and develop retail promotional strategies to align its production scheduling, inventory management and marketing programs
to optimize consumer purchases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR>
<B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><I><U>Fiscal 2011 compared with Fiscal 2010</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net sales for Fiscal 2011
increased $3.0 million, or 20.3%, to $17.5 million as compared to $14.5 million for Fiscal 2010. The increase in net sales is
principally due to (i) an increase in our retail customers&rsquo; purchases in the first and fourth quarter of Fiscal 2011, as
compared to Fiscal 2010, in an effort by those retailers to maintain adequate shelf and warehouse stock during peak seasonal demand
to meet an increase in consumer demand at retail of our OTC cold remedy products, (ii) sales of our Cold-EEZE<SUP>&reg;</SUP>
Oral Spray, a new product launched in August 2011 and (iii) an increase associated with our retail customers increasing the number,
timing and value of our promotional and/or display programs as a consequence of, among other influences, (a) space availability,
(b) allocation of more promotional space to the Cold-EEZE<SUP>&reg;</SUP> brand and (c) a general increase in off-shelf, price
promotion opportunities scheduled for the 2011-2012 Cold Season. In addition, our net sales of our contract manufacturing operations
increased $262,000 in Fiscal 2011 to $856,000 as compared to $594,000 in Fiscal 2010 due to fluctuations in contract manufacturing
orders from non-related third party entities to produce lozenge-based products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Data suggests that the
highest incidence of upper respiratory disorders for the 2010-2011 Cold Season occurred late in the fourth quarter of Fiscal 2010
and during the first quarter of Fiscal 2011, and such incidences were at significantly lower levels during the second, third and
fourth quarters of Fiscal 2011 when compared to Fiscal 2010 and the 2009-2010 Cold Season. Furthermore, the data suggests that
incidence of upper respiratory disorders for the 2011-2012 Cold Season has been less than the 2010-2011 Cold Season. Although
the 2011-2012 Cold Season incidence of upper respiratory is below the prior Cold Season level, we have increased our net sales
through, among other factors, increased investments in our sales, marketing, advertising, consumer communication and promotion
of our flagship brand, Cold-EEZE<SUP>&reg;</SUP>. We continue to compete for market share with new products entering the category
and many retailer initiatives to reduce the number of products they carry on shelf within the cold and flu category. We are continuing
to support Cold-EEZE<SUP>&reg;</SUP> cold remedy products through in-store promotion, media advertising and coupon programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cost of sales increased
$499,000 for Fiscal 2011 to $6.2 million as compared to $5.7 million for Fiscal 2010. The increase in cost of sales is principally
due to (i) increased revenues from period to period, offset by (ii) an improvement in gross margin. We realized gross margins
of 64.6% for Fiscal 2011 as compared to 60.9% in Fiscal 2010, an improvement of 3.7%. <FONT STYLE="color: black">Our improved
gross margin reflects </FONT>the net effect of <FONT STYLE="color: black">(i) an increase in the absorption rate of fixed production
overhead costs as a percentage of revenues as a consequence of increased shipments to retailers, offset by (ii) an increase in
raw ingredient and packaging costs</FONT>. Gross margins are principally influenced by fluctuations in quarter-to-quarter and
year-to-year production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to
market write-downs, if any, and the timing of shipments to customers which are factors of the seasonality of our sales activities
and products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales and marketing expense
for Fiscal 2011 increased $2.3 million, or 41.7%, to $7.9 million as compared to $5.6 million for Fiscal 2010. The increase in
sales and marketing expense for Fiscal 2011 as compared to Fiscal 2010 was principally due to (i) an increase in personnel expense
due principally to an increase in head count, (ii) an increase in sales commission as a consequence of an increase in sales and
(iii) an increase in advertising expenditures as we expanded the scope and timing of our media and product promotion advertising
campaigns with the cold season from period to period as we continue to make significant, strategic marketing investments in an
effort to build and grow the sales of our OTC cold remedy products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative
(&ldquo;G&amp;A&rdquo;) expenses decreased $1.0 million for Fiscal 2011 to $5.0 million as compared to $6.0 million in Fiscal
2010. The decrease in G&amp;A expense for Fiscal 2011 as compared to Fiscal 2010 was primarily due a decrease in personnel expenses,
professional fees and other general expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
costs for Fiscal 2011 and 2010 were $1.1 million and $794,000, respectively. The increase of $294,000 in research and development
costs for Fiscal 2011 as compared to Fiscal 2010 was principally due to an increase in personnel expenses and an increase in the
scope, timing and amount of research and development activity from period to period. In February 2011, we introduced to the retail
trade an offering of a new product, Cold-EEZE<SUP>&reg;</SUP> Oral Spray, an oral delivery application of our proprietary cold
remedy formula of zinc gluconate. The Cold-EEZE<SUP>&reg;</SUP> Oral Spray cold remedy commenced production in June 2011 and began
shipping to retailers in August 2011. Additionally, we continue to engage in other research and development activities that we
determine are appropriate and we may increase our research and development activities in future periods as a consequence of the
Joint Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest and other income
for Fiscal 2011 was $28,000 as compared to $53,000 for Fiscal 2010. The decrease of $25,000 for Fiscal 2011 as compared to Fiscal
2010 was principally the result of decreased bank balances and lower interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, we have
net operating loss carry-forwards for both federal and certain states. As a consequence of these loss carryforwards and our loss
realized during Fiscal 2011, we did not incur income tax expense for Fiscal 2011. For Fiscal 2010, we had a current tax benefit
of $40,000 as a consequence of a carry back of an alternative minimum tax net operating loss to a prior period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a consequence of the
effects of the above, the net loss for Fiscal 2011, was $2.7 million, or ($0.18) per share, as compared to a net loss of $3.5
million, or ($0.25) per share, for Fiscal 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Fiscal 2010 compared with Fiscal 2009</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net sales for Fiscal 2010
were $14.5 million as compared to $19.8 million for Fiscal 2009. Net sales decreased $5.3 million in Fiscal 2010 as compared to
Fiscal 2009. The decline in net sales is principally due to (i) an acceleration in Fiscal 2009 of our retail customer purchases
and stocking for the 2009-2010 Cold Season into the fourth quarter of Fiscal 2009 which skewed net sales for that cold season,
(ii) a decrease of our retail customers purchases in the fourth quarter of Fiscal 2010 in an effort to better align their purchases
and inventory levels with the projected timing of the incidence levels of upper respiratory disorders during the 2010-2011 Cold
Season, (iii) a decrease associated with our retail customers reducing the number, timing and value of our promotional and/or
display programs as a consequence of, among other influences, (a) limited space availability, (b) allocation of more promotional
space to private label brands and/or other products and (c) a general reduction in off-shelf, price promotion opportunities for
the 2010-2011 Cold Season. In addition, our net sales of our contract manufacturing operations decreased $911,000 in Fiscal 2010
to $594,000 as compared to $1.5 million in Fiscal 2009 due to (i) the decline in candy product sales as a consequence of the closure
of the Elizabethtown manufacturing facility in June 2009 and (ii) fluctuations in contract manufacturing orders from non-related
third party entities to produce lozenge-based products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Data suggests that the
highest incidence of upper respiratory disorders for the 2009-2010 Cold Season occurred in the fourth quarter of Fiscal 2009 and
were at significantly lower levels during the first, second and third quarters of Fiscal 2010 when compared to the 2008-2009 and
prior Cold Seasons. As a consequence, there was a reduced consumer demand at retail and therefore a corresponding reduction in
retailer purchases and stocking during Fiscal 2010 as compared to Fiscal 2009. Furthermore, a significant increase in the incidence
of upper respiratory disorders for the 2010-2011 Cold Season was not observed until late in the fourth quarter in Fiscal 2010.
Our flagship product, Cold-EEZE<SUP>&reg;</SUP> continues to compete for market share with new products entering the category
and many retailer initiatives to reduce the number of products it carries on shelf within the cold and flu remedy category. We
are continuing to support Cold-EEZE<SUP>&reg;</SUP> as a clinically proven cold remedy product through in-store promotion, media
advertising and coupon programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cost of sales decreased
$2.5 million for Fiscal 2010 to $5.7 million as compared to $8.2 million for Fiscal 2009. The decrease in cost of sales is principally
due to (i) lower revenues from period to period, offset by (ii) an improvement in gross margin. We realized gross margins of 60.9%
for Fiscal 2010 as compared to 58.4% in Fiscal 2009, an improvement of 2.5%. <FONT STYLE="color: black">Our improved gross margin
reflects </FONT>the net effect of (i) the elimination of the production and facility overhead expenses attributable to the closing
of the Elizabethtown manufacturing facility, (ii) improved production margins of the OTC cold remedy segment, (iii) improved overhead
cost management at our Lebanon production and distribution facility, offset by (iv) an adverse impact of a reduction to net sales
to absorb fixed production overhead expenses at our manufacturing facility and (v) increased product promotion with retailers
to support the launch of our new products. Gross margins are influenced by fluctuations in quarter-to-quarter production volume,
fixed production costs and related overhead absorption, and the timing of shipments to customers which are factors of the seasonality
of our sales activities and products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales and marketing expense
for Fiscal 2010 increased $724,000, or 14.9%, to $5.6 million as compared to $4.9 million for Fiscal 2009. The increase in sales
and marketing expense for Fiscal 2010 as compared to Fiscal 2009 was principally due to the net effect of (i) the implementation
of more cost effective and targeted marketing programs, (ii) improved timing of marketing campaigns to better match the timing
and product demand of the 2010-2011 Cold Season, (iii) the discontinuation of certain ineffective marketing programs, offset by
(iv) an increase in traditional media purchases in print, digital, out-of-home and television, and (v) an increase in marketing
research and development costs associated with the development of new product packaging for our Cold-EEZE<SUP>&reg;</SUP> and
Kids-EEZE<SUP>&reg;</SUP> product lines introduced during the 2010-2011 Cold Season.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative
(&ldquo;G&amp;A&rdquo;) expenses for Fiscal 2010 were $6.0 million as compared to $9.3 million in Fiscal 2009. The decrease in
G&amp;A expense of $3.3 million for Fiscal 2010 as compared to Fiscal 2009 was primarily due to the net effects of (i) a decrease
in stock promotion costs of $2.3 million, principally related to the Board of Directors proxy contest in Fiscal 2009 and (ii)
a decrease in professional fees and other expenses of $601,000 and (iii) a decrease of $606,000 in personnel expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">Research and development
costs for Fiscal 2010 and 2009 were $794,000 and $1.3 million, respectively. The decrease of $514,000 in research and development
costs for Fiscal 2010 as compared to Fiscal 2009 was due to a decline in the scope, timing and amount of research and development
activity from period to period. In Fiscal 2009 and as a result of a strategic review, we determined to curtail and now have discontinued
further investment in certain of our wholly owned subsidiaries, Quigley Pharma, products then under development. This was determined
in light of our view concerning market opportunities, regulatory pathways, the need for further robust and consistent preclinical
and clinical testing and continued requirements in the areas of commercial formulation and development. However, we continue to
engage in other research and development activities that we determine are appropriate and we may increase our research and development
activities in future periods as a consequence of the Joint Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest and other income
for Fiscal 2010 was $53,000 as compared to $9,000 for Fiscal 2009. The increase of $44,000 for Fiscal 2010 as compared to Fiscal
2009 was principally the result of the allocation of funds into interest bearing accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, we have
net operating loss carry-forwards for both federal and certain states. For Fiscal 2010 and Fiscal 2009, we had a current tax benefit
of $40,000 and $84,000, respectively, principally due to a carry back of an alternative minimum tax net operating loss to a prior
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a consequence of the
effects of the above, the net loss for Fiscal 2010, was $3.5 million, or ($0.25) per share, as compared to a net loss of $3.8
million, or ($0.30) per share, for Fiscal 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Liquidity and Capital Resources</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our aggregate cash and
cash equivalents as of December 31, 2011 were $5.5 million compared to $8.2 million at December 31, 2010. Our working capital
was $5.3 million and $7.5 million as of December 31, 2011 and December 31, 2010, respectively. Changes in working capital for
Fiscal 2011 were principally due to the net effect of (i) cash used in operations of $2.1 million, (ii) capital expenditures of
$300,000, (iii) the cash payment of $449,000 to purchase treasury stock from PSI Parent, offset by, (iv) proceeds of $166,000
from the sale of fixed assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management believes that
its strategy to maintain Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> as a recognized brand name, its
broader range of products, its adequate manufacturing capacity, together with its current working capital, should provide an internal
source of capital to fund normal business operations. Our operations support the current research and development expenditures
related to new products. In addition to the funding from operations, we may in the short and long term raise capital through the
issuance of securities or secure other financing sources to support such product development research, new product acquisitions
or a venture investment or acquisition. Such funding through the issuance of equity securities would result in the dilution of
current stockholders&rsquo; ownership in the Company. Should our product development initiatives progress on certain formulations,
additional development expenditures may require substantial financial support and may necessitate the consideration of alternative
approaches such as licensing, joint venture, or partnership arrangements that we determine will meet our long term goals and objectives.
Ultimately, should internal working capital be insufficient and external funding methods or other business arrangements become
unattainable, it would likely result in the deferral or abandonment of future development relative to current and prospective
product development initiatives and formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Joint
Venture LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. PSI Parent will conduct and oversee
much of the product development, formulation, testing and other research and development needed by the Joint Venture, and we will
oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may be required,
from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund its operations,
in accordance with agreed upon budgets for products to be developed. Specifically, we contributed in Fiscal 2010 $500,000 in cash
as initial capital and we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established
to date), toward the initial development and marketing costs of new products for the Joint Venture. The newly formed Joint Venture
has not engaged in any financial transactions, other than organizational expenses and general market and product analysis. At
December 31, 2011, cash and equivalents includes $425,000 which is expected to be used by the Joint Venture to fund future product
development initiatives currently under consideration by PSI Parent, PSI and us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The product development
effort of the Joint Venture is a multi-stage process that includes (i) market analysis and research, (ii) product formulation
research and development, (iii) product evaluation, (iv) product commercialization, (v) production and distribution, and (vi)
retail and consumer advertising and marketing. During Fiscal 2011, we conducted preliminary market analysis to identify market
opportunities to develop differentiated, science-based, efficacious products that deliver results to consumers and worked with
PSI and PSI Parent to provide initial formulations for certain identified OTC active ingredients. In December 2011, we initiated
a study of these preliminary formulations to evaluate product attributes, performance and potential commercial viability. These
studies are expected to be completed later in Fiscal 2012. For Fiscal 2011, any expenses, including organizational, marketing
analysis and preliminary formulations have been absorbed by the respective Joint Venture members. As of December 31, 2011, we
have not established a formal commercialization program timeline, pending the results of the recently initiated studies, for any
specific OTC product covered under the product license but we do not project that any such OTC products will be available for
shipment within the next twelve months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management is not aware
of any trends, events or uncertainties that have or are reasonably likely to have a material negative impact upon our (i) short-term
or long-term liquidity, or (ii) net sales or income from continuing operations. Any challenge to our patent rights could have
a material adverse effect on our future; however, we are not aware of any condition that would make such an event probable. Our
business is subject to seasonal variations thereby impacting liquidity and working capital during the course of our fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management believes that
cash generated from operations, along with its current cash balances, will be sufficient to finance working capital and capital
expenditure requirements for at least the next twelve months. However, in the longer term, as previously discussed, we may require
additional capital to support, among other items, (i) new product introductions, (ii) expansion of our product marketing and promotion
activities, (iii) additional research development activities, (iv) further investment in our Joint Venture, (iv) venture investments
or acquisitions and/or (v) support current operations. Since late Fiscal 2008, there has been substantial volatility and a decline
in&nbsp;the capital and financial markets due at least in part to the constricted global economic environment resulting in substantial
uncertainty and access to financing is uncertain. Moreover, consumer and as a consequence, customer spending habits may be adversely
affected by the current economic crisis. These conditions could have an adverse effect on our industry and business, including
our financial condition, results of operations and cash flows.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent that we
do not generate sufficient cash from operations, we may need to incur indebtedness to finance plans for growth. Recent turmoil
in the credit markets and the potential impact on the liquidity of major financial institutions may have an adverse effect on
our ability to fund our business strategy through borrowings, under either existing or newly created instruments in the public
or private markets on terms that we believe to be reasonable, if at all.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future contractual
obligations and commitments at December 31, 2011 consist of the following (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; padding-left: 0">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Employment <BR>Contracts</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Purchase <BR>Commitments</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 46%; text-align: center; padding-left: 0">2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,106</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,377</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,483</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-left: 0">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-left: 0">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-left: 0">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 1pt; padding-left: 0">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0; text-align: center">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,712</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,377</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,089</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Off-Balance Sheet Arrangements </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is not our usual business
practice to enter into off-balance sheet arrangements such as guarantees on loans and financial commitments and retained interests
in assets transferred to an unconsolidated entity for securitization purposes. Consequently, we have no off-balance sheet arrangements
that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Impact of Inflation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to normal
inflationary trends and anticipate that any increased costs would be passed on to our customers. Inflation has not had a material
effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Effect of Recent Accounting Pronouncements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2008, the
SEC issued for comment a proposed roadmap regarding the potential use by U.S. issuers of financial statements prepared in accordance
with International Financial Reporting Standards (&ldquo;IFRS&rdquo;). IFRS is a comprehensive series of accounting standards
published by the International Accounting Standards Board (&ldquo;IASB&rdquo;). The proposed roadmap has since been superseded
by an SEC work plan and no date is currently proposed that we could be required to prepare financial statements in accordance
with IFRS. The SEC has targeted Fiscal 2012 to make a determination regarding the mandatory adoption of IFRS. We are currently
assessing the impact that this potential change would have on our consolidated financial statements and we will continue to monitor
the development of the potential implementation of IFRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June&nbsp;2011, the
Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update No. 2011-05, &ldquo;Comprehensive
Income (ASC Topic 220): Presentation of Comprehensive Income,&rdquo; (&ldquo;ASU 2011-05&rdquo;) which amends current comprehensive
income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part
of the statement of shareholders&rsquo; equity. Instead, comprehensive income must be presented in either a single continuous
statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but
consecutive statements. ASU 2011-05 will be effective for fiscal periods beginning after December 15, 2011 with early adoption
permitted. The adoption of ASU 2011-05 will not have a material impact on our consolidated financial position, results of operations
or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2011, the
FASB issued Accounting Standards Update No. 2011-08, &ldquo;Intangibles &ndash; Goodwill and Other Topics&rdquo; (&ldquo;ASU 2011-08&rdquo;)
which provides authoritative guidance on testing goodwill for impairment that will become effective beginning January&nbsp;1,
2012, with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill
impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform
the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value
of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its
fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider
in conducting the qualitative assessment. We are currently assessing the potential impact on the adoption of this guidance on
our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>Item 7A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative
Disclosures About Market Risk </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Like virtually all commercial
enterprises, we can be exposed to the risk (&ldquo;market risk&rdquo;) that the cash flows to be received or paid relating to
certain financial instruments could change as a result of changes in interest rate, exchange rates, commodity prices, equity prices
and other market changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operations are not
subject to risks of material foreign currency fluctuations, nor do we use derivative financial instruments in our investment practices.
We place our marketable investments in instruments that meet high credit quality standards. We do not expect material losses with
respect to our investment portfolio or excessive exposure to market risks associated with interest rates. The impact on our results
of one percentage point change in short-term interest rates would not have a material impact on our future earnings, fair value,
or cash flows related to investments in cash equivalents or interest-earning marketable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current economic conditions
may cause a decline in business and consumer spending which could adversely affect our business and financial performance including
the collection of accounts receivables, realization of inventory and recoverability of assets. In addition, our business and financial
performance may be adversely affected by current and future economic conditions, including a reduction in the availability of
credit, financial market volatility and recession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>Item 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Supplementary
Data </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ProPhase Labs, Inc.<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">We have audited
the accompanying consolidated balance sheets of ProPhase Labs, Inc. and Subsidiaries (the &ldquo;Company&rdquo;) as of December
31, 2011 and 2010, and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for each
of the years in the two-year period ended December 31, 2011. The financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">We conducted our
audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In our opinion,
the financial statements referred to above present fairly, in all material respects, the consolidated financial position of ProPhase
Labs, Inc. and Subsidiaries as of December 31, 2011 and 2010, and the consolidated results of their operations and their cash
flows for each of the years in the two-year period ended December 31, 2011, in conformity with accounting principles generally
accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">/S/ EisnerAmper LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Edison, New Jersey</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>March 6, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ProPhase Labs, Inc.<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of operations, stockholders&rsquo; equity, and cash flows of ProPhase Labs, Inc. and Subsidiaries for
the year ended December 31, 2009. These consolidated financial statements are the responsibility of the Company&rsquo;s management.
Our responsibility is to express an opinion on these consolidated financial statements based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We conducted our audits
in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly we express no such opinion. An audit also includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that
our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In our opinion, the consolidated
financial statements referred to above present fairly, in all material respects, the consolidated results of operations and cash
flows of ProPhase Labs, Inc. and Subsidiaries for the year ended December 31, 2009 in conformity with accounting principles generally
accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">/S/ Amper, Politziner &amp; Mattia, LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Edison, New Jersey</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>March 24, 2010</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC AND SUBSIDARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(in thousands, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center; text-indent: -0.1in">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash and cash equivalents (Note 2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,541</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,232</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accounts receivable, net of allowance for doubtful accounts of &nbsp;zero and $13, respectively (Note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,821</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Inventory (Note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,688</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,682</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">883</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Assets held for sale (Notes 2 and 4)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">138</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.24in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,195</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,756</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Intangible asset, licensed technology (Note 3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,577</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Property, plant and equipment, net of accumulated depreciation of $3,608 and $3,389, respectively (Note 4)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,307</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,362</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,079</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,695</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; text-indent: -0.1in; padding-left: 0.1in">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">489</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accrued royalties and sales commissions (Note 5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,524</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accrued advertising and other allowances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,524</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">485</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">698</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.24in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,853</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">COMMITMENTS AND CONTINGENCIES (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Common stock, $.0005 par value; authorized 50,000,000; issued: 20,161,636 and 19,353,672 shares, respectively (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,699</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,989</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Treasury stock, at cost, 5,336,053 and 4,646,053 shares, respectively (Note 8)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,637</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,188</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,226</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,460</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,079</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,695</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC &amp; SUBSIDARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(in thousands, except per share amounts)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left">Net sales (Notes 2 and 12)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">17,453</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">14,502</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">19,816</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cost of sales (Note 2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,282</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,830</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.12in">Sales and marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,576</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,852</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.12in">Administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,054</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,344</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.12in">Research and development (Note 2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,088</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">794</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,308</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.12in">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,020</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,504</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,738</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,594</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,935</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Loss from operations before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,710</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,541</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,926</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax (benefit) (Note 10)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(84</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,710</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,842</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and dilutive loss per share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Weighted average common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in">Basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,817</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,285</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,963</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC &amp; SUBSIDARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(in thousands, except share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Additional</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Retained</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Common Stock</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Par</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Paid-In</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Earnings</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Treasury</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Value</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Capital</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(Deficit)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 34%; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">Balance at December 31, 2008</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">12,908,383</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">9</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">37,599</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">5,354</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">(25,188</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">17,774</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Net loss</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(3,842</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(3,842</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Proceeds from exercise
    of stock options</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">125,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">127</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">127</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Tax benefits from exercise
    of stock options</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">88</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">88</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Tax benefit allowance</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(88</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(88</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">Balance at December 31, 2009</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">13,033,383</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">37,726</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,512</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(25,188</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">14,059</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Net loss</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(3,501</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(3,501</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Proceeds from exercise
    of stock options</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">130,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">133</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">133</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Common Stock Issued to
    Phosphangenics Limited&nbsp; pursuant to an Exclusive License Agreement (Note 3)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,440,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,576</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,577</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Common stock granted
    pursuant to an employment&nbsp; agreement</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">36,111</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Common stock granted
    pursuant to a compensation&nbsp; agreement</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">67,625</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Share-based compensation
    expense</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Tax benefits from exercise
    of stock options</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Tax benefit allowance</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(42</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(42</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">Balance at December 31, 2010</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">14,707,619</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">40,627</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,989</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(25,188</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">13,460</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Net loss</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2,710</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2,710</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Share-based compensation
    expense</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">131</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">131</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Common stock granted
    pursuant to an employment&nbsp; agreement</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">341,254</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">294</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">294</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in"><FONT STYLE="font-size: 8pt">Common stock granted
    pursuant to a compensation&nbsp; plan</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">466,710</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Treasury
    stock purchase (Note 8)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(690,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(449</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(449</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">Balance at December
    31, 2011</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">14,825,583</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">10</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">41,552</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(4,699</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(25,637</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">11,226</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC &amp; SUBSIDARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(2,710</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,501</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(3,842</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">363</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">522</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">(Gain) loss on the sales of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Impairment charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Share-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">631</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Sales discounts and provision for bad debts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(133</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Inventory valuation provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(115</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">633</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.36in">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(891</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">451</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(864</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(219</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(109</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Accrued advertising and other allowances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(565</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,384</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(597</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.36in">Other operating assets and liabilities, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">81</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(201</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(45</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.48in">Net cash provided by (used in) operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,108</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,549</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">445</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Capital expenditures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(153</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(208</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Acquisition of product license</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.36in">Proceeds from the sale of fixed assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">166</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">480</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.48in">Net cash flows provided by (used in) investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,153</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">272</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.36in">Proceeds from the exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.36in">Purchase of treasury stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(449</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.48in">Net cash provided by (used in) financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(449</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">133</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net increase (decrease) in cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,691</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">844</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Cash and cash equivalents at beginning of year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,232</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,801</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,957</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Cash and cash equivalents at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,541</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,232</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,801</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.42in">Income taxes paid</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.36in">Common stock issued to Phosphagenics Limited pursuant to a product license agreement</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,577</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.36in">Common stock issued, in lieu of cash, as payment of accrued compensation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">294</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 &ndash; ORGANIZATION AND BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ProPhase Labs, Inc (&ldquo;we&rdquo;,
&ldquo;us&rdquo; or the &ldquo;Company&rdquo;), organized under the laws of the State of Nevada, is a manufacturer, marketer and
distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged
in the research and development of potential over-the-counter (&ldquo;OTC&rdquo;) drug, natural base health products along with
supplements, personal care and cosmeceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our primary business is
currently the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional,
specialty and local retail stores. Our flagship brand is Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT><SUP>
</SUP>Cold Remedy and our principal product is Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> zinc gluconate
lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by nearly half. Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT>
is an established product in the health care and cold remedy market. For Fiscal 2011, Fiscal 2010 and Fiscal 2009 (as each is defined
below), our revenues from continuing operations have come principally from our OTC cold remedy products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 22, 2010, the
Company, Phosphagenics Limited (&ldquo;PSI Parent&rdquo;), an Australian corporation, Phosphagenics Inc. (&ldquo;PSI&rdquo;), a
Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the &ldquo;Joint Venture&rdquo;), a Delaware
limited liability company, entered into a Limited Liability Company Agreement (the &ldquo;LLC Agreement&rdquo;) of the Joint Venture
and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide
range of non-prescription remedies using PSI Parent&rsquo;s proprietary patented TPM&trade; technology (&ldquo;TPM&rdquo;). TPM
facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant
to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture (see Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use a December 31 year-end
for financial reporting purposes. References herein to the fiscal year ended December 31, 2011 shall be the term &ldquo;Fiscal
2011&rdquo; and references to other &ldquo;Fiscal&rdquo; years shall mean the year, which ended on December 31 of the year indicated.
Our consolidated balance sheet at December 31, 2010 and our consolidated statement of cash flows for Fiscal 2010 and 2009 have
been reclassified to conform with our Fiscal 2011 presentation. The term the &ldquo;we&rdquo;, &ldquo;us: or the &ldquo;Company&rdquo;
as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Basis of Presentation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements (&ldquo;Financial Statements&rdquo;) include the accounts of the Company and its wholly owned subsidiaries and its Joint
Venture, a variable interest entity (see Note 3). All intercompany transactions and balances have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Seasonality of the
Business</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">Our net sales are derived
principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing
of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold
season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as
a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels
of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote its products during
the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer
demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production
scheduling, inventory management and marketing programs to optimize consumer purchases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"><U>Use of Estimates</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements and the accompanying notes thereto, in conformity with generally accepted accounting principles in the United States
(&ldquo;GAAP&rdquo;), requires management to make estimates and assumptions that affect reported amounts of assets and liabilities
and disclosure of contingent assets <FONT STYLE="color: black">and liabilities</FONT> at the date of the financial statements and
reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt,
sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment
of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing
for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (&ldquo;Sales Allowances&rdquo;),
we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions
are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial
statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis.
Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">Our primary product, Cold-EEZE<FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT><SUP>
</SUP>lozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of
common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it
being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life
as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data.
In addition to Cold-EEZE<SUP>&reg;</SUP> lozenges we market and distribute Cold-EEZE<SUP>&reg; </SUP>Oral Spray and Kids-EEZE<SUP>&reg;</SUP>
Chest Relief, Kids-EEZE<SUP>&reg;</SUP> Cough Cold and Kids-EEZE<SUP>&reg;</SUP> Allergy (&ldquo;Kids-EEZE<SUP>&reg;</SUP> Products&rdquo;),
children&rsquo;s OTC cold remedies. In August 2011, we introduced Cold-EEZE<SUP>&reg;</SUP> Oral Spray containing our proprietary
zinc formulation in a liquid spray form. We introduced Kids-EEZE<SUP>&reg;</SUP> Chest Relief in Fiscal 2008 and expanded the product
line to include Kids-EEZE<SUP>&reg;</SUP> Cough Cold and Kids-EEZE<SUP>&reg;</SUP> Allergy in Fiscal 2010. We also manufacture,
market and distribute an organic cough drop and a Vitamin C supplement (&ldquo;Organix<SUP>&reg;</SUP>&rdquo;). Each of the Cold-EEZE<SUP>&reg;</SUP>
Oral Spray products, Kids-EEZE<SUP>&reg;</SUP> Products and Organix<SUP>&reg;</SUP> products carry shelf-life expiration dates
for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly.
Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical
basis, and reviewed quarterly. <FONT STYLE="letter-spacing: -0.15pt">Additionally, we monitor current developments by customer,
market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><U>Cash
Equivalents</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider all highly
liquid investments with an initial maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents
include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the
short-term maturity of these investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Inventories</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Inventory is valued at
the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost
and the market value and appropriate valuation adjustments are established. At December 31, 2011 and 2010, the Financial Statements
include an adjustment for excess or obsolete inventory of $991,000 and $1.1 million, respectively. At December 31, 2011 and 2010,
inventory included raw material, work in progress and packaging amounts of $981,000 and $742,000, respectively, and finished goods
of $1.7 million and $940,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Property, Plant and Equipment</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property, plant and equipment
are recorded at cost. We use a combination of straight-line and accelerated methods in computing depreciation for financial reporting
purposes. The depreciation expense is computed in accordance with the estimated asset lives (see Note 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 2; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Concentration of Risks</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Future revenues, costs,
margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together
with our marketing and distribution capabilities and the requirements associated with the development of OTC and other personal
care products in order to continue to compete on a national and/or international level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business is subject
to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products
are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (&ldquo;FDA&rdquo;)
and, as applicable, the Homeopathic Pharmacopoeia of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financial instruments that
potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts
receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We maintain cash and cash
equivalents with certain major financial institutions. As of December 31, 2011, our cash was $5.5 million and our bank balance
was $5.9 million. Of the total bank balance, $704,000 was covered by federal depository insurance and $5.2 million was uninsured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Trade accounts receivable
potentially subjects us to credit risk. We extend credit to our customers based upon an evaluation of the customer&rsquo;s financial
condition and credit history and generally we do not require collateral. Our broad range of customers includes many food, multi-outlet
pharmacy and chain drug stores, large wholesalers and mass merchandisers (see Note 12). During Fiscal 2011, 2010 and 2009, effectively
all of our revenues were related to domestic markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our revenues are principally
generated from the sale of OTC cold remedy products which approximated 95%, 96% and 92% of total revenues for Fiscal 2011, 2010
and 2009, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results
from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Raw materials used in the
production of the products are available from numerous sources. Certain raw material active ingredients used in connection with
Cold-EEZE<SUP>&reg;</SUP> products are purchased from a single unaffiliated supplier. Should the relationship terminate or the
vendor become unable supply material, we believe that the current contingency plans would prevent a termination from materially
affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until
an acceptable replacement supplier is located.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Long-lived Assets</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We review our carrying
value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount
of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum
of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount,
if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based
on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future
cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value
utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing
costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition;
and general economic and business conditions, among other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fair value is based on
the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value
hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as
quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly
or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring
an entity to develop its own assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In Fiscal 2009 we recognized
impairment charges of $74,000 principally for the land and building assets of our Elizabethtown manufacturing facility. The fair
value of the reported <I>Assets Held For Sale </I>at December 31, 2010<I> </I>of $138,000<I> </I>was arrived at through bids generated
from interested third party purchasers and guidance from a third party real estate advisor thereby relating to Level 3 fair value
hierarchy. In February 2011, we derived net proceeds from the sale of these assets of $166,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Revenue Recognition</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales are recognized at
the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts
and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns
and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer
and consumer demand when evaluating the adequacy of the sales returns and other allowances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our return policy accommodates
returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration
date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted
to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product
that is un-saleable and such return request activity fall within an acceptable range, (ii) we will accept returns for products
that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product
provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept
return requests pertaining to customer inventory &ldquo;Overstocking&rdquo; or &ldquo;Resets&rdquo;. We will only accept return
requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers
who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the
customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product
only, also by way of an exchange. We do not have any significant product exchange history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">As of December 31, 2011
and December 31, 2010, we included a provision for sales allowances of $101,000 and $106,000, respectively, which are reported
as a reduction to account receivables. We also included an estimate of the uncollectability of our accounts receivable as an allowance
for doubtful accounts of zero and $13,000 as of December 31, 2011 and 2010, respectively. Additionally, accrued advertising and
other allowances as of December 31, 2011 include $1.7 million for estimated future sales returns, $1.0 million for cooperative
incentive promotion costs and $279,000 for certain other advertising and marketing promotions. As of December 31, 2010 accrued
advertising and other allowances include $1.5 million for estimated future sales returns, $1.2 million for cooperative incentive
promotion costs and $828,000 for certain other advertising and marketing promotions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Shipping and Handling </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Product sales carry shipping
and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs
related to this revenue are recorded in cost of sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Stock Compensation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We recognize all share-based
payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based
on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The
compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the
vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stock and stock options
for purchase of our common stock, $0.0005 par value, (&ldquo;Common Stock&rdquo;) have been granted to both employees and non-employees
pursuant to the terms of certain agreements and stock option plans (see Note 8). Stock options are exercisable during a period
determined by us, but in no event later than ten years from the date granted. In Fiscal 2011 and 2010, we charged to operations
$631,000 and $192,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and
vested stock options earned. There was no share-based compensation expense for Fiscal 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 4; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: none">NOTE 2 &ndash; SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (CONTINUED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Variable Interest Entity</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Joint Venture, of which
we own a 50% membership interest qualifies as a variable interest entity (&ldquo;VIE&rdquo;) and we have consolidated the Joint
Venture beginning with the quarter ended March 31, 2010 (see Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Advertising and Incentive Promotions </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Advertising and incentive
promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised
of media advertising, presented as part of sales and marketing expense; cooperative incentive promotions and coupon program expenses,
which are accounted for as part of net sales; and free product, which is accounted for as part of cost of sales. Advertising and
incentive promotion costs incurred for Fiscal 2011, 2010 and 2009 were $8.8 million, $6.9 million, and $5.8 million, respectively.
Included in prepaid expenses and other current assets was $1.2 million and $189,000 at December 31, 2011 and 2010, respectively,
relating to prepaid advertising and promotion expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: underline"><FONT STYLE="font-weight: normal"><I>Research
and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
costs are charged to operations in the period incurred. Expenditures for Fiscal 2011, 2010 and 2009 were $1.1 million, $794,000
and $1.3 million, respectively. For Fiscal 2011 and Fiscal 2010, research and development costs are related principally to new
product development initiatives and costs associated with OTC cold remedy products. For Fiscal 2009, research and development costs
are related principally to the Quigley Pharma&rsquo;s study activities; such studies and initiatives are no longer actively being
commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"><U>Income Taxes</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We utilize the asset and
liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events
that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider
all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset
the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities
are assured, a valuation allowance equaling the total net current and non-current deferred tax asset is being provided (see Note
10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We utilize a two-step approach
to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining
if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including
resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount
which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain
tax positions will be recorded as interest or administrative expense, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The major jurisdiction
for which we file income tax returns is the United States. The Internal Revenue Service (&ldquo;IRS&rdquo;) has examined our tax
year ended September 30, 2005 and has made no changes to the filed tax returns. The tax years 2006 and forward remain open to examination
by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective December 31,
2009, we elected to conform our tax reporting year, historically a fiscal period ending September 30, to our financial reporting
period ending December 31. As a consequence, we filed a full period tax return for the fiscal year ended September 30, 2009 with
the IRS and also filed with the IRS a &ldquo;short period return&rdquo; for the three months ended December 31, 2009 in compliance
with the election. In future fiscal periods, our tax and financial reporting periods will be the same, the period ending December
31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Fair Value of Financial Instruments</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents,
accounts receivable and accounts payable are reflected in the Financial Statements at carrying value which approximates fair value
because of the short-term maturity of these instruments. Determination of the fair value of related party payables, if any, is
not practicable due to their related party nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Recently Issued Accounting Standards</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2008, the SEC
issued for comment a proposed roadmap regarding the potential use by U.S. issuers of financial statements prepared in accordance
with International Financial Reporting Standards (&ldquo;IFRS&rdquo;). IFRS is a comprehensive series of accounting standards published
by the International Accounting Standards Board (&ldquo;IASB&rdquo;). The proposed roadmap has since been superseded by an SEC
work plan and no date is currently proposed that we could be required to prepare financial statements in accordance with IFRS.
The SEC has targeted Fiscal 2012 to make a determination regarding the mandatory adoption of IFRS. We are currently assessing the
impact that this potential change would have on our consolidated financial statements and we will continue to monitor the development
of the potential implementation of IFRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June&nbsp;2011, the
Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update No. 2011-05, &ldquo;Comprehensive
Income (ASC Topic 220): Presentation of Comprehensive Income,&rdquo; (&ldquo;ASU 2011-05&rdquo;) which amends current comprehensive
income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of
the statement of shareholders&rsquo; equity. Instead, comprehensive income must be presented in either a single continuous statement
of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive
statements. ASU 2011-05 will be effective for fiscal periods beginning after December 15, 2011 with early adoption permitted. The
adoption of ASU 2011-05 will not have a material impact on our consolidated financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2011, the
FASB issued Accounting Standards Update No. 2011-08, &ldquo;Intangibles &ndash; Goodwill and Other Topics&rdquo; (&ldquo;ASU 2011-08&rdquo;)
which provides authoritative guidance on testing goodwill for impairment that will become effective beginning January&nbsp;1, 2012,
with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment
test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step
quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting
unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less
than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the
qualitative assessment. We are currently assessing the potential impact on the adoption of this guidance on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 3 &ndash; INVESTMENT IN PHUSION LABORATORIES,
LLC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 22, 2010, the
Company, PSI Parent, PSI and the Joint Venture entered into the LLC Agreement of the Joint Venture and additional related agreements
for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies
using PSI Parent&rsquo;s proprietary patented TPM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the &ldquo;Original
License Agreement&rdquo;), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit
OTC drugs and certain other products that embody certain of PSI Parent&rsquo;s TPM-related patents and related know-how (collectively,
the &ldquo;PSI Technology&rdquo;) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up
license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds
with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 3 &ndash; INVESTMENT IN PHUSION LABORATORIES,
LLC. (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Original
License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI
Parent (such shares, the &ldquo;PSI Shares&rdquo;), and made a one-time payment to PSI Parent of $1.0 million. On the date the
PSI Shares were issued, PSI Parent agreed, pursuant to a Share Transfer Restriction Agreement, dated March 22, 2010 (the &ldquo;Share
Transfer Restriction Agreement&rdquo;), between us and PSI Parent, that, with certain exceptions, it would not sell or otherwise
dispose of any of the PSI Shares prior to June 1, 2012 (see discussion below). The PSI Shares were issued pursuant to an exemption
from registration under the Securities Act, by virtue of Section 4(2) of the Securities Act and by virtue of Rule 506 of Regulation
D under the Securities Act. Such sale and issuance did not involve any public offering and was made without general solicitation
or advertising. Additionally, PSI Parent represented to us, among other things, that PSI Parent is not a US Person (as defined
in Regulation S under the Securities Act), that PSI Parent is an accredited investor with access to all relevant information necessary
to evaluate its investment and that the PSI Shares were being acquired for investment purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2011, PSI
Parent entered into certain Private Resale Agreements (&ldquo;PSAs&rdquo;) with seven third party purchasers, under which Phosphagenics
sold, with our consent, an aggregate of 750,000 shares of our Common Stock. Under the PSAs, the purchasers may not, without the
prior written consent of the Company, prior to the one year anniversary of the PSAs, directly or indirectly, sell, give, pledge,
hypothecate, assign or otherwise transfer the purchased shares, in whole or in part. Contemporaneously with PSI Parent consummating
the PSAs, we consummated an agreement with PSI Parent to redeem the then remaining 690,000 PSI Shares held by PSI Parent (see Note
8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with a Contribution
Agreement, dated March 22, 2010 (the &ldquo;Contribution Agreement&rdquo;), by and among us, PSI Parent, PSI, and the Joint Venture,
we transferred, conveyed and assigned to the Joint Venture all of our rights, title and interest in, to and under the Original
License Agreement, and the Joint Venture assumed, and undertook to pay, discharge and perform when due, all of our liabilities
and obligations under and arising pursuant to the Original License Agreement (such actions, collectively, the &ldquo;Assignment
and Assumption&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Contribution
Agreement and in order to reflect the Assignment and Assumption, we, PSI Parent and the Joint Venture entered into an Amended and
Restated License Agreement, dated March 22, 2010 (the &ldquo;Amended License Agreement&rdquo;), which amends and restates the Original
License Agreement to reflect that the Joint Venture is the licensee thereunder and which otherwise contains substantially the same
terms as the Original License Agreement. The Joint Venture has the right to grant one or more sub-licenses of the rights granted
under the Amended License Agreement to one or more third parties for reasonable consideration in any part of the applicable territory.
The Amended License Agreement provides that PSI Parent shall not, directly or through third parties, exploit the covered intellectual
property during the term thereof, subject to certain limitations. The Amended License Agreement will remain in effect until the
expiration of the last to expire of the patents included within the PSI Technology or any extensions thereof. Either party may
terminate the Amended License Agreement upon written notice to the other party in the event of certain events involving bankruptcy
or insolvency. The Amended License Agreement also contains, among other things, provisions concerning the treatment of confidential
information, the ownership of intellectual property and indemnification obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the LLC Agreement,
we and PSI each own a 50% membership interest in the Joint Venture. PSI Parent will conduct and oversee much of the product development,
formulation, testing and other research and development needed by the Joint Venture, and we will oversee much of the production,
distribution, sales and marketing. The LLC Agreement provides that each member may be required, from time to time and subject to
certain limitations, to make capital contributions to the Joint Venture to fund its operations, in accordance with agreed upon
budgets for products to be developed. Specifically, we contributed in Fiscal 2010 $500,000 in cash as initial capital and we are
committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established to date), toward the initial
development and marketing costs of new products for the Joint Venture. The newly formed Joint Venture has not engaged in any financial
transactions, other than organizational expenses and general market and product analysis. At December 31, 2011, cash and equivalents
includes $425,000 which is expected to be used by the Joint Venture to fund future product development initiatives currently under
consideration by PSI Parent, PSI and us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 3 &ndash; INVESTMENT IN PHUSION LABORATORIES,
LLC. (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Joint Venture is managed
by a four-person Board of Managers, with two managers appointed by each member. The LLC Agreement contains other normally found
terms in such arrangements, including provisions relating to governance of the Joint Venture, indemnification obligations of the
Joint Venture, allocation of profits and losses, the distribution of funds to the members and restrictions on transfer of a member&rsquo;s
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our determination is that
the Joint Venture qualifies as a VIE and that we are the primary beneficiary. As a consequence, we have consolidated the Joint
Venture financial statements beginning with the quarter ended March 31, 2010. Since inception and including Fiscal 2011, the newly
formed Joint Venture has not engaged in any financial transactions, other than certain organizational expenses and general market
and product analysis, as formal operations are not expected to commence until later in Fiscal 2012. Furthermore, the liabilities
and other obligations incurred, if any, by the Joint Venture is without recourse to us and do not create a claim on our general
assets. At December 31, 2011, we have recorded the $3.6 million payment representing the estimated fair value to acquire the product
license as an intangible asset. We currently estimate the expected useful life of the product license to be approximately 10 years
which we will begin amortizing the cost of intangible asset once product commercialization is completed with PSI Parent and the
OTC drug products begin to ship to our retail customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The product development
effort of the Joint Venture is a multi-stage process that includes (i) market analysis and research, (ii) product formulation research
and development, (iii) product evaluation, (iv) product commercialization, (v) production and distribution, and (vi) retail and
consumer advertising and marketing. During Fiscal 2011, we conducted preliminary market analysis to identify market opportunities
to develop differentiated, science-based, efficacious products that deliver results to consumers and worked with PSI and PSI Parent
to provide initial formulations for certain identified OTC active ingredients. In December 2011, we initiated a study of these
preliminary formulations to evaluate product attributes, performance and potential commercial viability. These studies are expected
to be completed later in Fiscal 2012. For Fiscal 2011, any expenses, including organizational, marketing analysis and preliminary
formulations have been absorbed by the respective Joint Venture members. As of December 31, 2011, we have not established a formal
commercialization program timeline, pending the results of the recently initiated studies, for any specific OTC product covered
under the product license but we do not project that any such OTC products will be available for shipment within the next twelve
months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 4 &ndash; PROPERTY, PLANT AND EQUIPMENT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The components of property and equipment are
as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Estimated&nbsp;Useful Life</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: justify">Land</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">504</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">504</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Buildings and improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,494</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,281</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">15 - 39 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Machinery and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,567</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">3 - 7 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Computer software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">3 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Furniture and fixtures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">5 years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,915</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,751</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Less: Accumulated&nbsp; depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,608</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,389</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,307</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,362</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Depreciation expense for
Fiscal 2011, 2010 and 2009 was $355,000, $363,000, and $522,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 8; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 5 &ndash; PATENT RIGHTS AND RELATED
ROYALTY COMMITMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have maintained a separate
representation and distribution agreement relating to the development of the zinc gluconate product formulation. In return for
exclusive worldwide distribution rights, we agreed to pay the developer a 3% royalty and a 2% consulting fee based on sales collected,
less certain deductions, throughout the term of this agreement, which expired May 2007. However, we and the developer are in litigation
(see Note 7) and as such no potential offset for these fees from such litigation has been recorded. The amount accrued for this
expense at each of December 31, 2011 and 2010 was $3.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 6 &ndash; OTHER CURRENT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At December 31, 2011 and
2010, other current liabilities include $237,000 and $483,000, respectively, related to accrued compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain operating leases
for office and warehouse space maintained by us in Fiscal 2010 and 2009 resulted in rent expense of $11,000 and $44,000, respectively.
We did not incur rent expense in Fiscal 2011. We have approximate future obligations over the next five years as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Employment <BR>Contracts</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Purchase <BR>Commitments</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 31%; text-align: center">2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">1,106</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">1,377</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">2,483</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,712</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,377</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,089</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August, 2009, we entered
into a standard form of indemnity agreement with each member of our Board of Directors, Mr. Ted Karkus, our Chairman and Chief
Executive Officer, and Mr. Robert V. Cuddihy, Jr., our Chief Operating Officer. These agreements provide, among other things, that
we will indemnify each director, Mr. Karkus and Mr. Cuddihy in the event that they become a party or otherwise a participant in
any action or proceeding on account of their service as a director or officer of the Company (or service for another corporation
or entity in any capacity at the request of the Company) to the fullest extent permitted by applicable law. Under the indemnity
agreement, we will pay, in advance of the final disposition of any such action or proceeding, expenses (including attorneys&rsquo;
fees) incurred by our directors or officers in defending or otherwise responding to such action or proceeding upon receipt of a
written undertaking from the directors or officers to repay the amount advanced consistent with applicable law in the event that
a court shall ultimately determine that he or she is not entitled to be indemnified for such expenses. The contractual rights to
indemnification provided by the indemnity agreements are subject to the limitations and conditions specified in the agreements,
and are in addition to any other rights each director and officer may have under our Articles of Incorporation and Amended and
Restated Bylaws, each as amended from time to time, and applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 8, 2011, we
entered into new employment agreements, effective as of January 1, 2012, with each of Mr. Ted Karkus and Mr. Cuddihy (the &ldquo;Employment
Agreements&rdquo;). The Employment Agreements supersede the employment agreements of Mr. Karkus and Mr. Cuddihy, dated August 19,
2009, that had been scheduled to terminate on July 15, 2012. The scheduled termination dates of the Employment Agreements is July
15, 2015, which is three years following the scheduled expiration date set forth in the executives&rsquo; former employment agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES
(CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under his new employment agreement
with the Company, Mr. Karkus agreed to an annual base salary of $675,000 as Chief Executive Officer. Under the terms of his former
employment agreement with the Company, as amended, Mr. Karkus was entitled to annual base compensation of $750,000, consisting
of a $600,000 base salary and $150,000 in stock based compensation. He is eligible to receive an annual increase in base salary
and may be awarded a bonus in the sole discretion of the Compensation Committee and also will receive regular benefits routinely
provided to other senior executives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under his new employment agreement
with the Company, Mr. Cuddihy agreed to an annual base salary of $350,000 as Chief Financial Officer and Chief Operating Officer.
Under the terms of his former employment agreement with the Company as the Company&rsquo;s Chief Operating Officer, Mr. Cuddihy
was entitled to annual base compensation of $325,000, consisting of a $275,000 base salary and $50,000 in stock based compensation.
Mr. Cuddihy is eligible to receive an annual increase in base salary and may be awarded a bonus in the sole discretion of the Compensation
Committee and also will receive regular benefits routinely provided to other senior executives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each executive is subject to non-competition
restrictions for up to a period of either six (6) months or eighteen (18) months following termination of employment depending
on the nature of the termination. Each executive is also eligible for a gross up payment in the event that any amounts payable
under the agreements (or any other plan, program, policy or arrangement with the Company) become subject to the excise tax imposed
by Section 4999 of the Internal Revenue Code.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Employment Agreements
also provide for payments upon certain terminations and change in control benefits to ensure that they work to secure the best
outcome for stockholders in the event of a possible change in control, even if it means that they lose their jobs as a result.
Under the Employment Agreements, in the event of the termination by the Company of the employment of Mr. Karkus or Mr. Cuddihy
without cause or due to a voluntary resignation by either executive with Good Reason (as defined in the agreements), each executive
will be paid a lump sum severance payment in cash equal to the greater of (A) the amount equal to eighteen (18) months base salary
or (B) the amount equal to the his base salary for the remainder of the term as if the agreement had not been terminated. Additionally,
each executive is entitled to receive a lump sum severance payment in cash equal to the greater of A or B, if he, within twenty
four (24) months of a Change in Control (as defined in the agreements) of the Company, is terminated without cause or due to a
voluntary resignation by him with Good Reason (as defined in the agreements). Each executive may also participate at Company expense
in all medical and dental plans for the remainder of the term of his employment agreement in the event the Company terminates the
employment agreement for any reason, except for the Company&rsquo;s termination for Cause (as defined in the agreements) or a voluntary
resignation by him without Good Reason (as defined in the agreements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.) VS.
JOHN C. GODFREY, ET AL.</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This action was commenced
by us in November 2004 in the Court of Common Pleas of Bucks County, Pennsylvania against John C. Godfrey, Nancy Jane Godfrey,
and Godfrey Science and Design, Inc. for injunctive relief regarding the Cold-EEZE<SUP>&reg;</SUP>&nbsp;trademark; injunctive relief
relating to the Cold-EEZE<SUP>&reg;</SUP> formulations and manufacturing methods; injunctive relief for breach of the duty of loyalty,
and declaratory judgment&nbsp;regarding&nbsp;various payments that the defendants assert are owing to them.&nbsp; Our complaint
is based in part upon certain contracts&nbsp;with defendants whereby we obtained the exclusive right to manufacture and distribute
product pursuant to&nbsp;a basic patent&nbsp;and&nbsp;also obtained various consulting services&nbsp;(the &quot;Agreements&quot;).&nbsp;
Subsequent to entering into the Agreements, the&nbsp;defendants&nbsp;took various actions that we believe were in breach of&nbsp;the
Agreements. We instituted the action because of&nbsp;defendants' threats to deal with other parties and&nbsp;to use the Company&rsquo;s
Cold-EEZE<SUP>&reg;</SUP> trademark and&nbsp;the trade secrets that&nbsp;we developed during our manufacture of Cold-EEZE<SUP>&reg;</SUP>.
Both because of their breaches and the expiration of the basic patent, we terminated the&nbsp;Agreements.&nbsp; Defendants have
answered the complaint and asserted counterclaims.&nbsp; They seek monetary damages and counter injunctive and&nbsp;declaratory
relief relative to the Company's trademark and other intellectual property.&nbsp; The monetary relief sought by the&nbsp;defendants&nbsp;is
based on their claim that they were not paid various amounts asserted to be due under the Agreements.&nbsp; This claim is estimated&nbsp;to
be in excess of $5.0 million.&nbsp; We believe that the defendants' counterclaims are without merit and are vigorously defending
those counterclaims and are prosecuting our action on the complaint.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES
(CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pre-trial discovery is&nbsp;ongoing.&nbsp;
Defendants moved for partial summary judgment, and we filed a response and cross-motion for summary judgment.&nbsp; On August 21,
2008, the court denied both motions for summary judgment.&nbsp; The case has not been assigned to a trial calendar, although it
is possible that the case will be listed for trial in 2012.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
this time no prediction as to the outcome of this action can be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.) VS.
WACHOVIA INSURANCE SERVICES, INC. AND FIRST UNION INSURANCE SERVICES AGENCY, INC.</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We instituted a Writ of
Summons against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc. on December 8, 2005 in the Court
of Common Pleas of Bucks County, Pennsylvania. The purpose of this suit was to maintain an action and toll the statute of limitation
against our insurance broker who failed to place excess limits coverage for us for the period from November 29, 2003 until April
6, 2004. As a result of the defendants&rsquo; failure to place insurance and to notify us thereof, certain pending actions covered
by our underlying insurance, which are currently being defended by insurance counsel and the underlying insurance carrier may cause
an exhaustion of the underlying insurance for the policy periods ending November 29, 2004 and November 29, 2005. Any case in which
an alleged action arose relating to the use of Cold-EEZE<SUP>&reg;</SUP> Nasal Spray from November 29, 2003 to April 6, 2004 is
not covered by excess insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our claim against Wachovia
Insurance Services, Inc. and First Union Insurance Services Agency, Inc. is for negligence and for equitable insurance for these
claims based on our undertaking of certain attorneys' fees and costs of settlement for claims that should have been covered by
underlying insurance placed by Wachovia Insurance Services, Inc. At this time no prediction can be made as to the outcome of any
action against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>PROPHASE LABS, INC.(formerly THE QUIGLEY
CORPORATION) <FONT STYLE="text-transform: uppercase; color: windowtext">vs. Guy Quigley, Gary Quigley, Scanda Systems Limited,
Scanda Systems LTD, Chilesha Holdings LTD, Kevin Brogan, Innerlight Holdings, Inc., George Longo, Graham Brandon, Pacific Rim Pharmaceuticals
LTD and John Doe Defendants</FONT></U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: windowtext">On
August 23, 2010, we initiated an action in the Court of Common Pleas of Bucks County, </FONT>Pennsylvania<FONT STYLE="color: windowtext">.
This action&nbsp;is against certain former officers and directors of the Company, including a shareholder that beneficially owns
approximately 20.1% of our Common Stock, and against certain third parties (a &ldquo;Complaint&rdquo;). The Company has asserted
claims arising from, among other things, a variety of transactions and payments previously made or entered into by the Company.
All of the transactions and events that are the subject of the Complaint occurred prior to June 2009 and the installation of the
current Board of Directors. Pre-trial discovery is on-going and at this time, no prediction as to the outcome of this action can
be made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>GUY QUIGLEY VS. TED KARKUS, ROBERT V.
CUDDIHY, JR., MARK BURNETT, MARK LEVENTHAL, MARK FRANK, LOUIS GLECKEL, MD, JAMES McCUBBIN AND PROPHASE LABS, INC. AS A NOMINAL
DEFENDANT</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company was named as
a nominal defendant in a purported derivative complaint filed on February 2, 2012 by stockholder and former director and Chief
Executive Officer Guy Quigley in the Court of Common Pleas of Philadelphia County, Pennsylvania (No. 111200409). The complaint
also names as a defendant each of our directors and executive officers. Among other things, the suit alleges various breaches of
fiduciary and other duties, and seeks recovery of unspecified damages and other relief. Prior to filing this complaint, the plaintiff
applied to the same court for permission to take pre-complaint discovery on the basis that the plaintiff required such discovery
in order to assert claims. The court denied the plaintiff's request. The Company believes the lawsuit is without merit and intends
to vigorously defend against it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, the Company previously
commenced litigation against the plaintiff, Guy Quigley, and other parties in August 2010 in the Bucks County Court of Common Pleas,
Pennsylvania (No. 2010-08227). The August 2010 action remains pending. &#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 11; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY
AND STOCK COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stockholder Rights Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 8, 1998, our
Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a &ldquo;Right&rdquo; and
collectively, the &ldquo;Rights&rdquo;) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder
Rights Plan (the &ldquo;Rights Agreement&rdquo;). The Plan was amended effective May 23, 2008 (&ldquo;First Amendment&rdquo;) and
further amended effective August 18, 2009 (&ldquo;Second Amendment&rdquo;). The Rights Agreement, as amended, provides that each
Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value
equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be
the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the
outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer
resulting in the ownership of 15% or more of the outstanding common shares. The dividend has the effect of giving the stockholder
a 50% discount on the share&rsquo;s current market value for exercising such right. In the event of a cashless exercise of the
Right, and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for
one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors
may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors
determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving
advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is September 25, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>T<FONT STYLE="font-size: 10pt">he 1997 Option
Plan</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 2, 1997, our
Board of Directors approved a Stock Option Plan (the &ldquo;1997 Plan&rdquo;), which was amended in 2005, and provided for the
granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers
or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option
could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns
more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal
1998. No options were granted under this Plan during Fiscal 2011, 2010 or 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At December 31, 2011, we
are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan
document. Options previously granted continue to be available for exercise at any time prior to such options&rsquo; respective
expiration dates, but in no event later than ten years from the date granted. At December 31, 2011, there are 138,750 options outstanding
with various expiration dates ranging from July 2012 through December 2015, depending upon the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>T<FONT STYLE="font-size: 10pt">he 2010 Equity
Compensation Plan</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 5, 2010, our shareholders
approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011
(the &ldquo;2010 Equity Compensation Plan&rdquo;). The 2010 Equity Compensation Plan provides that the total number of shares of
Common Stock that may be issued is equal to 900,000 shares plus up to 900,000 shares that are authorized for issuance, Issued Options
(defined below) but unissued under the 1997 Plan an aggregate of 1.8 million shares. <FONT STYLE="color: black">The 1997 Plan expired
on December 2, 2007 and no additional awards may be made; however, a</FONT>s of March 31, 2010, there remained 1,449,750 shares
subject to vested options that were authorized for issuance (the &ldquo;Issued Options&rdquo;) but were unissued under the 1997
Plan. As of December 31, 2011, 1,311,000 of the Issued Options under the 1997 Plan expired unexercised or were terminated (the
&ldquo;Expired Options&rdquo;). As a consequence, these shares are deemed and remain unissued which up to a maximum of 900,000
shares became available for issuance under the 2010 Equity Compensation Plan and the remaining 411,000 options are deemed cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 12; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY
AND STOCK COMPENSATION (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Stock Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the Company&rsquo;s
employees, including employees who are officers or members of the Board are eligible to participate in the 2010 Equity Compensation
Plan. Consultants and advisors who perform services for the Company are also eligible to participate in the 2010 Equity Compensation
Plan. For Fiscal 2011, 2010 and 2009, we granted 220,000, 982,000 and zero options, respectively, to employees to acquire our Common
Stock pursuant to the terms of 2010 Equity Compensation Plan. Presented below is a summary of the terms of the grant of options:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.1in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left">Number of options granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">220,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">982,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Vesting period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3-6 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Maximum term of option from date of grant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercise price per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0.87 - $1.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt; text-indent: -9pt">Weighted average fair value per share of options granted&nbsp;during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use the Black-Scholes
option pricing model during Fiscal 2011 and 2010 to determine the fair value of the stock options at the date of grant. Based upon
our limited historical experience, we estimated approximately 33,000 and 27,300, respectively, of the options granted in Fiscal
2011 and Fiscal 2010 may ultimately be forfeited. Additionally, we determined the expected term of the stock option grants to be
a range between 4.5 to 6.5 years, calculated using the &ldquo;simplified&rdquo; method in accordance with the SEC Staff Accounting
Bulletin 110. We use the &ldquo;simplified&rdquo; method since we changed the vesting terms, tax treatment and the recipients of
our stock options beginning in 2010 such that we believe our historical data does not provide a reasonable basis upon which to
estimate expected term. Presented below is a summary of assumptions used in determining the fair value of the stock options at
the date of grant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.1in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;Expected option life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.75 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5 - 6.5 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%">&nbsp;Weighted average risk free rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">1.28</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">2.10</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;Dividend yield</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0</TD><TD NOWRAP STYLE="text-align: left">%</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Expected volatility</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">75.84% - 78.62</TD><TD NOWRAP STYLE="text-align: left">%&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">72.17% - 77.63</TD><TD STYLE="text-align: left">%&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of the stock
options at the time of the grant in Fiscal 2011 and 2010 was approximately $127,000 and $618,000, respectively. Each of the stock
options granted were subject to vesting such that the fair value of the stock options granted is charged to operations over the
vesting period. For Fiscal 2011 and 2010, we charged to operations $131,000 and $42,000, respectively, for share-based compensation
expense for the aggregate fair value of the stock grants and vested stock options earned. There was no share-based compensation
expense for Fiscal 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At December 31, 2011, 237,020
of the options granted in Fiscal 2011 and 2010 were vested and 956,980 are subject to vesting. At December 31, 2011, there are
13,659 options available for grant to purchase shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity
Compensation Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 13; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY
AND STOCK COMPENSATION (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the status
of our stock options granted to both employees and non-employees as of December 31, 2011, 2010 and 2009 and changes during the
years then ended is presented below (in thousands, except per share data):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="22" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year&nbsp;Ended&nbsp;December&nbsp;31,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2009</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Weighted&nbsp;Average</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Weighted Average</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Weighted Average</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Exercise&nbsp;Price</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Exercise&nbsp;Price</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Exercise&nbsp;Price</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 34%; text-align: left"><FONT STYLE="font-size: 8pt">Options outstanding - beginning of year</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">1,300</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">2.99</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">1,488</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">8.64</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">2,268</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">7.76</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 8pt">Granted</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">220</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">982</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 8pt">Exercised</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(131</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(125</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.01</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Cancelled</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(187</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">8.67</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(1,039</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">9.45</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(655</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">7.02</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Options outstanding - end of year</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,333</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1.88</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,300</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">2.99</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,488</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">8.64</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Options granted and subject to future vesting</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">957</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1.02</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">937</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1.00</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Exercisable, at end of year</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">376</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">363</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,488</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Available for grant</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">14</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">818</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unrecognized share-based
compensation expense related to the options granted but not vested, (options to acquire 956,980 shares) was approximately $572,000
at December 31, 2011. These options subject to vesting (i) vest over the next 2 to 5 years, (ii) have a 7 year term from the date
of grant, (iii) are exercisable at a weighted average price of $1.02 and (iv) the unrecognized share-based compensation expense
is expected to be recognized over a weighted average period of 4 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">The following table summarizes
information about stock options outstanding and stock options exercisable at December 31, 2011 (in thousands, except remaining
life and per share data):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Options&nbsp;Outstanding&nbsp;and&nbsp;Exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Range&nbsp;of<BR>Exercise Prices</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Number <BR>Outstanding</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted Average <BR>Remaining <BR>Contractual Life</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted Average <BR>Exercise&nbsp;Price
    Per<BR>
Share</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$0.81 - $1.17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">237</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">6.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$1.18 - $5.19</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">0.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$5.20 - $8.11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">1.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$8.12 - $9.50</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">$9.51 - $13.80</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">4.0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13.80</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; width: 26%">Total</TD><TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 21%">376</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right; width: 21%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 21%">4.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The total intrinsic value
of options exercised during Fiscal 2010 and 2009 was<FONT STYLE="color: red"> </FONT>$107,000 and<FONT STYLE="color: red"> </FONT>$226,000,
respectively. There were no options exercised during Fiscal 2011. The aggregate intrinsic value of (i) options outstanding, (ii)
options outstanding and expected to vest in the future and (iii) options outstanding and exercisable at December 31, 2011 was $159,000,
$123,000 and $36,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 14; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY
AND STOCK COMPENSATION (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Stock Grants</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2011, the Compensation
Committee of the Board of Directors approved an amendment to Mr. Karkus&rsquo; then employment agreement, dated August 19, 2009
(the &ldquo;Amendment&rdquo;) to lower his annual salary by $150,000 (or $12,500 per month) in exchange for a grant of restricted
stock equal in value to the salary reduction. Pursuant to the Amendment, Mr. Karkus&rsquo; annual base salary was decreased from
$750,000 per year to $600,000 per year, effective May 1, 2011 thru July 15, 2012, which is the end of the term of his then employment
agreement, as amended. As a consequence of the Amendment, a restricted stock grant under the 2010 Equity Compensation Plan equal
to $12,500 of shares per month thru the end of the term (14.5 months). The restricted stock grant was made in an upfront grant
of 161,830 shares, subject to certain future vesting conditions, at a value of $181,000 as of the grant date. The grant was made
in April 2011, and the amount of the shares issued was calculated based on the average closing price of our Common Stock for the
last five (5) trading days prior to and including the issuance date of April 21, 2011. For Fiscal 2011, we have charged to operations
$100,000 as share-based compensation expense for the restricted stock grant and we have unrecognized compensation expense of $81,250
at December 31, 2011 that will be charged to operations in equal monthly installments of $12,500 over the remaining vesting period
ending July 15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, in April 2011,
the Compensation Committee of the Board of Directors granted Mr. Karkus 133,928 shares of Common Stock under the 2010 Equity Compensation
Plan as payment for his Fiscal 2010 bonus. Furthermore, in December 2011, the Compensation Committee of the Board of Directors
granted Mr. Karkus 128,571 shares of Common Stock under the 2010 Equity Compensation Plan as payment for his Fiscal 2011 bonus.
Mr. Karkus agreed to accept his Fiscal 2011 and Fiscal 2010 cash bonus of $150,000 for each year in shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2011, Mr. Karkus
also agreed to convert into shares of our Common Stock $144,000 of deferred and unpaid cash compensation owed to him thru April
2011, resulting in an issuance of 128,571 shares under the 2010 Equity Compensation Plan. The amount of these shares issued to
Mr. Karkus was calculated based on the average closing price of the Company&rsquo;s shares for the last five (5) trading days prior
to and including the issuance dates of April 21, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2011, the Compensation
Committee of the Board of Directors granted Mr. Cuddihy 33,603 shares of Common Stock, under the 2010 Equity Compensation Plan
valued at $37,500 as payment for 50% of his Fiscal 2011 bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The 2010 Directors Equity Compensation Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 5, 2010, our shareholders
approved t<FONT STYLE="color: black">he 2010 Directors&rsquo; Equity Compensation Plan. </FONT>A primary purpose of the <FONT STYLE="color: black">2010
Directors&rsquo; Equity Compensation Plan</FONT> is to provide us with the ability to pay all or a portion of the fees of Directors
in restricted stock instead of cash. The 2010 Directors&rsquo; Equity Compensation Plan provides that the total number of shares
of Common Stock that may be issued under the 2010 Directors&rsquo; Equity Compensation Plan is equal to 250,000. In Fiscal 2011
and 2010, we granted 164,770 and 67,625 shares, respectively, of our Common Stock valued at $162,000 and $90,000, respectively,
for director compensation. At December 31, 2011, there are 17,605 shares of Common Stock that may be issued pursuant to the terms
of the 2010 Directors Equity Compensation Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock Option Exercises and Other Grants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of
Mr. Cuddihy&rsquo;s prior employment agreement dated August 19, 2009, Mr. Cuddihy received an annual grant of shares of Common
Stock that is equal to $50,000, payable quarterly,<B> </B>promptly following the close of each quarter calculated based on the
average closing price of our Common Stock for the last five (5) trading days of the quarter. For Fiscal 2011, 2010 and 2009, Mr.
Cuddihy earned 51,642, 35,075 and 11,004 shares, respectively, valued at $50,000, $50,000 and $23,000, respectively, as share-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For Fiscal 2010 and 2009,
we derived net proceeds of $133,000 and $127,000, respectively, as a consequence of the exercise of options to acquire 130,500
and 125,000 shares, respectively, of our Common Stock pursuant to the terms of our 1997 Option Plan. There were no stock options
exercised in Fiscal 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY
AND STOCK COMPENSATION (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Purchase of Treasury Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2011, we entered
into a redemption agreement with <FONT STYLE="letter-spacing: -0.15pt">PSI Parent. </FONT>Under the terms of the redemption agreement,
we redeemed 690,000 shares of our Common Stock held by <FONT STYLE="letter-spacing: -0.15pt">PSI Parent</FONT> for the aggregate
redemption price of $448,500 in cash (see Note 3). The redemption price was equal to $0.65 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 9 &ndash; DEFINED CONTRIBUTION PLANS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We maintain the ProPhase
Labs, Inc 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are
based on the amount of the employee plan contributions and compensation. Our contributions to the plan in Fiscal 2011, 2010 and
2009 were $88,000, $90,000 and $141,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10 &ndash; INCOME TAXES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The components of the provision (benefit) for
income taxes, in the consolidated statement of operations are as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; padding-left: 9pt">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(40</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(84</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">State</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(84</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Deferred</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(877</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(107</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,297</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">State</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">160</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(61</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(898</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(898</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,442</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Income taxes from continuing operations before valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(898</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,442</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">898</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(53</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Income tax (benefit)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(40</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(84</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(40</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(84</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation of the
statutory federal income tax expense (benefit) to the effective tax is as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left">Statutory rate - federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(925</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,204</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,335</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Permanent differences and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">48</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,046</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.13in; padding-left: 0.25in">Income tax from continuing operation before valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(898</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,347</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,442</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(898</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,307</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax (benefit)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(40</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(84</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(40</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(84</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10 &ndash; INCOME TAXES (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The components of permanent
and other differences are as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Permanent items:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-left: 9pt">Meals and Entertainment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Officers life insurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Return to accrual for prior year, permanent items</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(479</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Capital loss carryforward utilization <SUP>(1)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(582</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Contribution of inventory<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(162</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Share-based compensation expense for stock options granted<SUP> (3)</SUP></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">45</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">14</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">47</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,046</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">This item represents the utilization for tax purposes of prior year capital losses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">This item represents the additional tax deduction available as a consequence of the contribution
of certain inventory to qualified charitable organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">This item relates to share-based compensation expense for financial reporting purposes not deducted
for tax purposes until such options are exercised.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The tax effects of the
primary &ldquo;temporary differences&rdquo; between values recorded for assets and liabilities for financial reporting purposes
and values utilized for measurement in accordance with tax laws giving rise to our deferred tax assets are as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left">Net operating loss and capital loss carryforward</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">13,170</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12,135</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,808</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Consulting-royalty costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,431</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">877</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">801</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(15,593</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(14,696</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(13,290</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A valuation allowance for
all of our net deferred tax assets has been provided as we are unable to determine, at this time, that the generation of future
taxable income against which the net operating loss (&ldquo;NOL&rdquo;) carryforwards could be used can be predicted to be more
likely than not. The net change in the valuation allowance for Fiscal 2011, 2010 and 2009 was $898,000, $1.4 million and $2.4 million,
respectively. Certain exercises of options and warrants, and restricted stock issued for services that became unrestricted resulted
in reductions to taxes currently payable and a corresponding increase to additional-paid-in-capital for prior years. In addition,
certain tax benefits for option and warrant exercises totaling $6.3 million are deferred and will be credited to additional-paid-in-capital
when the NOL&rsquo;s attributable to these exercises are utilized. As a result, these NOL&rsquo;s will not be available to offset
income tax expense. The net operating loss carry-forwards currently approximate $31.6 million for federal purposes will expire
beginning in Fiscal 2020 through 2031. Additionally, there are net operating loss carry-forwards of $20.0 million for state purposes
that will expire beginning in Fiscal 2018 through 2031.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 17; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10 &ndash; INCOME TAXES (CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, we have
net operating loss carry-forwards for both federal and certain states. However, effective December 31, 2009, we elected to conform
our tax reporting year, historically a fiscal period ending September 30, to our financial reporting period ending December 31.
As a consequence, we filed a full period tax return for the fiscal year ended September 30, 2009 with the IRS and also filed with
the IRS a &ldquo;short period return&rdquo; for the three months ended December 31, 2009 in compliance with the election. In future
fiscal periods, our tax and financial reporting periods will be the same, the period ending December 31. For Fiscal 2010, we had
a current tax benefit of $40,000 for an alternative minimum tax refund due us as a consequence of a carry back of an alternative
minimum tax net operating loss to a prior period. For Fiscal 2009, we had a current tax benefit of $84,000 for certain federal
and state alternative minimum income taxes incurred for the &ldquo;short period return&rdquo;, inclusive of an alternative minimum
tax refund of $110,000 due us as a consequence of a carry back of an alternative minimum tax net operating loss to a prior period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 11 &ndash; EARNINGS PER SHARE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic earnings per share
(&ldquo;EPS&rdquo;) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average
number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities
or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock
that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy
back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Since there is a large
number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period
presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation of the
applicable numerators and denominators of the income statement periods presented is as follows (in thousands, except per share
amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="34" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year&nbsp;Ended&nbsp;December&nbsp;31,</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2009</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">EPS</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">EPS</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">EPS</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 19%; text-align: justify"><FONT STYLE="font-size: 8pt">Basic EPS</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(2,710</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">14,817</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(0.18</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(3,501</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">14,285</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(0.25</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(3,842</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">12,963</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(0.30</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Dilutives:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Options/Warrants</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Diluted EPS</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(2,710</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">14,817</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(0.18</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(3,501</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">14,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(0.25</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(3,842</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">12,963</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(0.30</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For Fiscal 2011, 2010 and
2009, diluted earnings per share is the same as basic earnings per share due to the inclusion of common stock<FONT STYLE="color: black">,
in the form of stock options and warrants (&ldquo;Common Stock Equivalents&rdquo;), would have an anti-dilutive effect on the loss
per share. For Fiscal 2011, 2010 and 2009, there were Common Stock Equivalents in the amount of 48,375, 359,188 and 133,792, respectively,
which were in the money, that were excluded in the earnings per share computation due to their dilutive effect. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 18; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 12 &ndash; SIGNIFICANT CUSTOMERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products are distributed
through numerous food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers throughout the United
States. Revenues for Fiscal 2011, 2010 and 2009 were $17.5 million, $14.5 million and $19.8 million, respectively. Walgreen Company
(&ldquo;Walgreens&rdquo;), Wal-Mart Stores, Inc. (&ldquo;Wal-Mart&rdquo;), CVS Caremark Corporation (&ldquo;CVS&rdquo;) and Rite-Aid
Corp (&ldquo;Rite Aid&rdquo;) accounted for approximately 17%, 14%, 13% and 12% of our Fiscal 2011 revenues. Walgreens, Wal-Mart
and Rite Aid accounted for approximately 23%, 14% and 10% of our Fiscal 2010 revenues. CVS, Walgreens and Wal-Mart accounted for
approximately 15%, 15% and 13% of our revenues for Fiscal 2009. The loss of sales to any one or more of these large retail customers
could have a material adverse effect on our business operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to account
receivable credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes
or shipping schedules with our customers. These concentrations may impact our overall exposure to credit risk, either positively
or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may
impact the timing and collectability of amounts due to us. Customers comprising the five largest accounts receivable balances represented
53% and 51% of total trade receivable balances at December 31, 2011 and 2010, respectively. Management believes that the provision
for possible losses on uncollectible accounts receivable is adequate for our credit loss exposure. At December 31, 2011 and 2010,
the allowance for doubtful accounts was zero and $13,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 13 &ndash; QUARTERLY INFORMATION (UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presents
unaudited quarterly financial information for Fiscal 2011 and Fiscal 2010 (in thousands, except per share amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 96%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid">Quarter&nbsp;Ended</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><U>Fiscal 2011</U></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Net sales</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,166</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,744</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,083</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7,460</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">896</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,796</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Income (loss) from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,013</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(976</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,831</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Net income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,013</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(976</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,831</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Basic and diluted earnings (loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Income (loss) from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.07</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.07</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Net income&nbsp; (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.07</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.07</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Fiscal 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Net sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,170</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Income (loss) from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,062</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,254</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,132</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Net income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,062</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,254</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,132</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Basic and diluted earnings (loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Income (loss) from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.08</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.15</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.08</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Net income&nbsp; (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.08</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.15</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.08</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 63.35pt"><B>Item 9.</B></TD><TD STYLE="text-align: justify"><B><U>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -63pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Controls
and Procedures</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Disclosure Controls and Procedures</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We maintain disclosure
controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the
reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the
time periods specified in the SEC rules and forms, and that the information is accumulated and communicated to our management,
including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required
disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the disclosure controls and
procedures as of the end of the period covered by this report. Based on our review, our management, including our Chief Executive
Officer and Chief Financial Officer, concluded that the Company&rsquo;s disclosure controls and procedures were effective at the
reasonable assurance level as of the end of the period covered by this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Management's Report on Internal Control
Over Financial Reporting </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining an adequate system of internal control over financial reporting. Our system of internal control
over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with accounting principles generally accepted in the United States
of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our internal control over
financial reporting includes those policies and procedures that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
our transactions and dispositions of our assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provide reasonable assurance that our transactions are recorded as necessary to permit preparation
of our financial statements in accordance with accounting principles generally accepted in the United States of America, and that
our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use, or disposition of our assets that could have a material effect on the financial statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Changes in Internal Control Over Financial
Reporting </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There have been no changes
in our internal control over financial reporting during Fiscal 2011 that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because of its inherent
limitations, a system of internal control over financial reporting can provide only reasonable assurance and may not prevent or
detect misstatements. Further, because of changes in conditions, effectiveness of internal controls over financial reporting may
vary over time. Our system contains self-monitoring mechanisms, and actions are taken to correct deficiencies as they are identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management conducted
an evaluation of our effectiveness of the system of internal control over financial reporting based on the framework in <I>Internal
Control-Integrated Framework</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon our
review, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that the Company&rsquo;s internal
controls over financial reporting were effective as of December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Item 9B.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>PART III</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 10.</B></TD><TD><B>Directors, Executive Officers
and Corporate Governance</B></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
under this item is incorporated by reference to the Company&rsquo;s Proxy Statement for the 2012 Annual Meeting of Stockholders
(the &ldquo;2012 Proxy Statement&rdquo;) which is to be filed with the SEC not later than 120 days after the close of our fiscal
year ended December 31, 2011 and is hereby incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in"><B>Item 11.</B></TD><TD><B>Executive Compensation</B></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
under this item is incorporated by reference to the 2012 Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in"><B>Item 12.</B></TD><TD><B>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
under this item is incorporated by reference to the 2012 Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 13.</B></TD><TD><B>Certain Relationships and Related Transactions and Director Independence</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
under this item is incorporated by reference to the 2012 Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 14.</B></TD><TD><B>Principal Accountant Fees and Services</B></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
under this item is incorporated by reference to the 2012 Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: underline; text-align: center">PART IV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in">Item 15.</TD><TD STYLE="text-align: justify">Exhibits and Financial Statement Schedules</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.15in">(a) Exhibits:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 8%">3.1</TD>
    <TD STYLE="width: 81%; text-align: justify">Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 of Form 10-KSB/A filed on April 4, 1997).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>3.2</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment to the Articles of Incorporation effective May 5, 2010 (incorporated by reference to Exhibit 3.1 of Form 8-K filed on May 10, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>3.3</TD>
    <TD STYLE="text-align: justify">By-laws of the Company as amended and restated effective August 18, 2009, (incorporated by reference to Exhibit 3.1 of Form 8-K filed on August 18, 2009).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>4.1</TD>
    <TD STYLE="text-align: justify">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of Form 10-KSB/A filed on April 4, 1997).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.1*</TD>
    <TD STYLE="text-align: justify">1997 Stock Option Plan (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Registration Statement on Form S-8 (File No. 333-61313) filed on August 13, 1998).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.2</TD>
    <TD STYLE="text-align: justify">Exclusive Representation and Distribution Agreement dated May 4, 1992 between the Company and Godfrey Science and Design, Inc. et al (incorporated by reference to Exhibit 10.2 of Form 10-KSB/A filed on April 4, 1997).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.3</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consulting Agreement dated May 4, 1992 between
        the Company and Godfrey Science and Design, Inc. et al. (incorporated by reference to Exhibit 10.5 of Form 10-KSB/A filed on April
        4, 1997).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.4</TD>
    <TD STYLE="text-align: justify">Rights Agreement dated September 15, 1998 between the Company and American Stock Transfer and Trust Company (incorporated by reference to Exhibit 1 to the Company&rsquo;s Registration Statement on Form 8-A filed on September 18, 1998).&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.5</TD>
    <TD STYLE="text-align: justify">First Amendment to the Rights Agreement, dated as of May 20, 2008 between the Company and American Stock Transfer and Trust Company (incorporated by reference to Exhibit 99.1 of Form 8-K filed on May 23, 2008).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.6</TD>
    <TD>Sale agreement of Darius to Innerlight Holdings, Inc. dated February 29, 2008 incorporated by reference to Exhibit 99.1 of Form 8-K filed on March 3, 2008).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.7</TD>
    <TD>Second Amendment to the Rights Agreement, dated as of August 18, 2009 between the Company and American Stock Transfer and Trust Company (incorporated by reference to Exhibit 10.1 of Form 8-K filed on August 18, 2009).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.8</TD>
    <TD>Form of Indemnification Agreement between the Company and each of its Officers and Directors dated August 19, 2009 (incorporated by reference to Exhibit 10.1 of Form 8-K filed on August 19, 2009).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.9*</TD>
    <TD>Employment Agreement dated August 15, 2009 between Ted Karkus and the Company (incorporated by reference to Exhibit 10.2 of Form 8-K filed on August 19, 2009).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.10*</TD>
    <TD>Employment Agreement dated August 15, 2009 between Robert V. Cuddihy, Jr., and the Company (incorporated by reference to Exhibit 10.3 of Form 8-K filed on August 19, 2009).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.11</TD>
    <TD STYLE="text-align: justify">Limited Liability Company Agreement, dated March 22, 2010, between the Company, Phosphagenics Limited, Phosphagenics Inc., and Phusion Laboratories, LLC. (incorporated by reference to Exhibit 10.11 of Form 10-K filed on March 24, 2010).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 8%">10.12</TD>
    <TD STYLE="width: 81%; text-align: justify">Contribution Agreement, dated March 22, 2010, between the Company, Phosphagenics Limited, Phosphagenics Inc., and Phusion Laboratories, LLC. (incorporated by reference to Exhibit 10.12 of Form 10-K filed on March 24, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.13</TD>
    <TD STYLE="text-align: justify">License Agreement, dated March 22, 2010, between the Company and Phosphagenics Limited. (incorporated by reference to Exhibit 10.13 of Form 10-K filed on March 24, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.14</TD>
    <TD STYLE="text-align: justify">Amended and Restated License Agreement, dated March 22, 2010, between the Company, Phosphagenics Limited, Phosphagenics Inc., and Phusion Laboratories, LLC. (incorporated by reference to Exhibit 10.14 of Form 10-K filed on March 24, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.15</TD>
    <TD STYLE="text-align: justify">Share Transfer Restriction Agreement, dated March 22, 2010, between the Company, and Phosphagenics Limited. (incorporated by reference to Exhibit 10.15 of Form 10-K filed on March 24, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.16*</TD>
    <TD STYLE="text-align: justify">2010 Equity Compensation Plan (incorporated by reference to Exhibit B of the Company&rsquo;s Annual Proxy Statement on Schedule 14A filed on April 2, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.17 *</TD>
    <TD STYLE="text-align: justify">2010 Directors&rsquo; Equity Compensation Plan (incorporated by reference to Exhibit C of the Company&rsquo;s Annual Proxy Statement on Schedule 14A filed on April 2, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.18*</TD>
    <TD STYLE="text-align: justify">Amendment to 2010 Directors&rsquo; Equity Compensation Plan (incorporated by reference to Exhibit 10.3 of Form 8-K filed on May 10, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.19*</TD>
    <TD STYLE="text-align: justify">Form of Option Agreement pursuant to 2010 Equity Compensation Plan (incorporated by reference to Exhibit 10.4 of Form 8-K filed on May 10, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.20*</TD>
    <TD STYLE="text-align: justify">Form of Option Agreement pursuant to 2010 Directors Equity Compensation Plan (incorporated by reference to Exhibit 10.5 of Form 8-K filed on May 10, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.21*</TD>
    <TD STYLE="text-align: justify">Form of Restricted Stock Award Agreement pursuant to 2010 Directors Equity Compensation Plan (incorporated by reference to Exhibit 10.6 of Form 8-K filed on May 10, 2010).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.22*</TD>
    <TD STYLE="text-align: justify">2010 Amended and Restated Equity Compensation Plan (incorporated by reference to Exhibit A of the Company&rsquo;s Annual Proxy Statement on Schedule 14A filed on March 14, 2011).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.23</TD>
    <TD>Redemption Agreement with <FONT STYLE="letter-spacing: -0.15pt">Phosphagenics Ltd. </FONT>(incorporated by reference to Exhibit 10.1 of Form 8-K filed on September 23, 2011).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.24*</TD>
    <TD>Employment Agreement dated January 1, 2012 between Ted Karkus and the Company<FONT STYLE="letter-spacing: -0.15pt"> (</FONT>incorporated by reference to Exhibit 99.2 of Form 10-Q filed on November 10, 2011).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>10.25*</TD>
    <TD>Employment Agreement dated January 1, 2012 between Robert V. Cuddihy, Jr., and the Company (incorporated by reference to Exhibit 99.1 of Form 10-Q filed on November 10, 2011).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>14.1</TD>
    <TD STYLE="text-align: justify">Code of Ethics (incorporated by reference to Exhibit II of the Proxy Statement on Schedule 14A filed on March 31, 2003).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>21.1**</TD>
    <TD STYLE="text-align: justify">Subsidiaries of ProPhase Labs, Inc.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 8%">23.1**</TD>
    <TD STYLE="width: 81%; text-align: justify">Consent of EisnerAmper LLP, Independent Registered Public Accounting Firm, dated March 6, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>23.2**</TD>
    <TD STYLE="text-align: justify">Consent of Amper, Politziner &amp; Mattia, LLP, Independent Registered Public Accounting Firm, dated March 24, 2010.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 81%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>31.1**</TD>
    <TD STYLE="text-align: justify">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>31.2**</TD>
    <TD STYLE="text-align: justify">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>32.1**</TD>
    <TD STYLE="text-align: justify">Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>32.2**</TD>
    <TD STYLE="text-align: justify">Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 81%">* Indicates a management contract or compensatory plan or arrangement</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>** Filed herewith</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Signatures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 42%; font-weight: bold; text-decoration: underline; text-align: center">PROPHASE LABS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 0; text-align: center">Registrant</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Date:<U> March 6, 2012</U></TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Ted Karkus</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Ted Karkus, Chairman of the Board,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Chief Executive Officer and Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and
on the dates indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Principal Executive Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Principal Financial and Accounting Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">/s/Ted Karkus</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">/s/Robert V. Cuddihy, Jr.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Ted Karkus</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Robert V. Cuddihy, Jr.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Chairman of the Board and</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Chief Operating Officer and Chief</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Chief Executive Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Date<U>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 6, 2012</U>______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-decoration: underline; text-align: center">Directors</TD>
    <TD STYLE="width: 45%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in; border-bottom: Black 1pt solid">/s/Mark Burnett</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in">Mark Burnett</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in; border-bottom: Black 1pt solid">/s/Mark Frank</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in; border-bottom: Black 1pt solid">/s/Louis Gleckel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in">Mark Frank</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">Louis Gleckel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in; border-bottom: Black 1pt solid">/s/Mark Leventhal</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in; border-bottom: Black 1pt solid">/s/James McCubbin</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in">Mark Leventhal</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">James McCubbin</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="tab-stops: center 3.0in right 6.0in">Date<U>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 6, 2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD>
    <TD STYLE="tab-stops: center 3.0in right 6.0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>v303307_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SUBSIDIARIES OF PROPHASE LABS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"></TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>State or other&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify"></TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify">Jurisdiction of</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>Ownership&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">Subsidiaries</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">Incorporation</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; width: 74%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: left; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Pharmaloz Manufacturing Inc.</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Delaware</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Phusion Laboratories, LLC</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Delaware</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Quigley Pharma Inc.</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Delaware</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The above subsidiaries
are included in the consolidated financial statements for the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v303307_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and Stockholders of ProPhase Labs, Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">We
consent to the incorporation by reference in the Registration Statements of ProPhase Labs, Inc. and Subsidiaries on Forms S</FONT>-8
(No. 333-73456, No. 333-61313, No. 333-10059, No. 333-14687, No. 333-26589, 333-132770 and 333-169697), Form SB-2 (No. 333-31241)
and Forms S-3 (No. 333-86976, 333-104148 and 333-119748) <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">of
our report dated March 6, 2012, on our audits of the consolidated financial statements of Prophase Labs, Inc. and Subsidiaries
as of </FONT>December 31, 2011 and 2010<FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"> and for </FONT>each
of the years in the two-year period ended December 31, 2011<FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">,
to be filed on or about March 6, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">/s/ EISNERAMPER LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Edison, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 6, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>v303307_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and Stockholders of ProPhase Labs, Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">We
consent to the incorporation by reference in the Registration Statements of ProPhase Labs, Inc. and Subsidiaries on Forms S-</FONT>8
(No. 333-73456, No. 333-61313, No. 333-10059, No. 333-14687, No. 333-26589, 333-132770 and 333-169697), Form SB-2 (No. 333-31241)
and Forms S-3 (No. 333-86976, 333-104148 and 333-119748) <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">of
our report dated </FONT>March 24, 2010<FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">, on our audit of the
consolidated financial statements of Prophase Labs, Inc. and Subsidiaries for </FONT>the year ended December 31, 2009<FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">,
to be filed on or about March 6, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ AMPER, POLITZINER &amp; MATTIA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Edison, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 6, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>v303307_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>OFFICER&rsquo;S CERTIFICATION PURSUANT
TO</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RULE 13a-14(a)/15d-14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934</U></B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Ted Karkus, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of ProPhase Labs, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this Annual Report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this Annual Report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rule 131-15(f) and 15d015(f) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">designed such disclosure controls and procedures<I>, </I><FONT STYLE="color: black">or caused such
disclosure controls and procedures to be designed under our supervision, </FONT>to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this Annual Report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">(b)&nbsp;&nbsp;&nbsp;designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">e</FONT>valuated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures <FONT STYLE="color: black">and</FONT> presented in this Annual Report our conclusions about the effectiveness
of the disclosure controls and procedures<FONT STYLE="color: black">, as of the end of the period covered by this report </FONT>based
on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
evaluation <FONT STYLE="color: black">of internal control over financial reporting, </FONT>to the registrant&rsquo;s auditors and
the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">all significant deficiencies <FONT STYLE="color: black">and material weaknesses</FONT> in the design
or operation of internal control <FONT STYLE="color: black">over financial reporting which are reasonably likely to</FONT> adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial <FONT STYLE="color: black">information;
</FONT>and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control<I> </I><FONT STYLE="color: black">over financial reporting</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;Date: March 6, 2012&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">/s/ Ted Karkus</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Ted Karkus</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Chairman of the Board and Chief </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Executive Officer&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>v303307_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>OFFICER&rsquo;S CERTIFICATION PURSUANT
TO</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RULE 13a-14(a)/15d-14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934</U></B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Robert V. Cuddihy, Jr., certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of ProPhase Labs, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this Annual Report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this Annual Report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rule 131-15(f) and 15d015(f) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">designed such disclosure controls and procedures<I>, </I><FONT STYLE="color: black">or caused such
disclosure controls and procedures to be designed under our supervision, </FONT>to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this Annual Report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">(b)&nbsp;&nbsp;&nbsp;designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">e</FONT>valuated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures <FONT STYLE="color: black">and</FONT> presented in this Annual Report our conclusions about the effectiveness
of the disclosure controls and procedures<FONT STYLE="color: black">, as of the end of the period covered by this report </FONT>based
on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
evaluation <FONT STYLE="color: black">of internal control over financial reporting, </FONT>to the registrant&rsquo;s auditors and
the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">all significant deficiencies <FONT STYLE="color: black">and material weaknesses</FONT> in the design
or operation of internal control <FONT STYLE="color: black">over financial reporting which are reasonably likely to</FONT> adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial <FONT STYLE="color: black">information;
</FONT>and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control<I> </I><FONT STYLE="color: black">over financial reporting</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Date: March 6, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 33pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">/s/ Robert V. Cuddihy, Jr.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Robert V. Cuddihy, Jr.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">Chief Operating Officer and Chief </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">Financial Officer&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">(Principal Accounting and Financial</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2"> Officer)&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
</TABLE>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>v303307_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO RULE 13a-14(b) OF THE SECURITIES
EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">I, Ted Karkus, Chief Executive
Officer of ProPhase Labs, Inc., a Nevada corporation (the &ldquo;Registrant&rdquo;), in connection with the Registrant&rsquo;s
Annual Report on Form 10-K for the period ended December 31, 2011, as filed with the Securities and Exchange Commission on the
date hereof (the &ldquo;Report&rdquo;), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities
Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to
the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">(1) The Report
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">(2) The information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify; border-bottom: Black 1pt solid">/s/ Ted Karkus</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Ted Karkus</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Chairman of the Board and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">March 6, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>v303307_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROPHASE LABS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO RULE 13a-14(b) OF THE SECURITIES
EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">I, Robert V. Cuddihy, Jr.,
Chief Financial Officer of ProPhase Labs, Inc., a Nevada corporation (the &ldquo;Registrant&rdquo;), in connection with the Registrant&rsquo;s
Annual Report on Form 10-K for the period ended December 31, 2011, as filed with the Securities and Exchange Commission on the
date hereof (the &ldquo;Report&rdquo;), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities
Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to
the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">(1) The Report
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">(2) The information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-decoration: none; border-bottom: Black 1pt solid">/s/ Robert V. Cuddihy, Jr.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Robert V. Cuddihy, Jr.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Chief Operating Officer and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">(Principal Accounting and Financial Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">March 6, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 4.5pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>prph-20111231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- XBRL document created with Ez-XBRL version 4.0.0.7 [03/05/2012 11:49:16 AM] -->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 09:38:41 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:15:14 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:11:41 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:11:41 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:03:50 PM Document Version 1.0-->
<!-- Based on XBRL 2.1  -->
<xbrli:xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:prph="http://www.quigleyco.com/20111231">
	<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="prph-20111231.xsd"/>
	<!-- Context Section  -->
	<xbrli:context id="Context_FYE_31-Dec-2009">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2009-01-01
</xbrli:startDate>
			<xbrli:endDate>
2009-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2009-01-01
</xbrli:startDate>
			<xbrli:endDate>
2009-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2009-01-01
</xbrli:startDate>
			<xbrli:endDate>
2009-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2009-01-01
</xbrli:startDate>
			<xbrli:endDate>
2009-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2010-01-01
</xbrli:startDate>
			<xbrli:endDate>
2010-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_30-Jun-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-06-30
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-12-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_01-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-01
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2008">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2008-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2008-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2008-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2008-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2008-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2009-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<!-- Unit Section  -->
	<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
	<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
	<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
	<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_FYE_31-Dec-2011">ProPhase Labs, Inc.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef="Context_FYE_31-Dec-2011">0000868278</dei:EntityCentralIndexKey>
	<dei:CurrentFiscalYearEndDate contextRef="Context_FYE_31-Dec-2011">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityFilerCategory contextRef="Context_FYE_31-Dec-2011">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:TradingSymbol contextRef="Context_FYE_31-Dec-2011">prph</dei:TradingSymbol>
	<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_01-Mar-2012" unitRef="Shares" decimals="0">14836340</dei:EntityCommonStockSharesOutstanding>
	<dei:DocumentType contextRef="Context_FYE_31-Dec-2011">10-K</dei:DocumentType>
	<dei:AmendmentFlag contextRef="Context_FYE_31-Dec-2011">false</dei:AmendmentFlag>
	<dei:DocumentPeriodEndDate contextRef="Context_FYE_31-Dec-2011">2011-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="Context_FYE_31-Dec-2011">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="Context_FYE_31-Dec-2011">2011</dei:DocumentFiscalYearFocus>
	<dei:EntityWellKnownSeasonedIssuer contextRef="Context_FYE_31-Dec-2011">No</dei:EntityWellKnownSeasonedIssuer>
	<dei:EntityVoluntaryFilers contextRef="Context_FYE_31-Dec-2011">No</dei:EntityVoluntaryFilers>
	<dei:EntityCurrentReportingStatus contextRef="Context_FYE_31-Dec-2011">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityPublicFloat contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">6755730</dei:EntityPublicFloat>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">8232000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">5541000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2008" unitRef="USD" decimals="-3">11957000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2009" unitRef="USD" decimals="-3">12801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">4821000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">3219000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:InventoryNet contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">1682000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">2688000</us-gaap:InventoryNet>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">883000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">1747000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:AssetsHeldForSaleCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">138000</us-gaap:AssetsHeldForSaleCurrent>
	<us-gaap:AssetsHeldForSaleCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:AssetsHeldForSaleCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">15756000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">13195000</us-gaap:AssetsCurrent>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">3577000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">3577000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">2362000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">2307000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">21695000</us-gaap:Assets>
	<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">19079000</us-gaap:Assets>
	<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">489000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">885000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">3524000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">3524000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedMarketingCostsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">3524000</us-gaap:AccruedMarketingCostsCurrent>
	<us-gaap:AccruedMarketingCostsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">2959000</us-gaap:AccruedMarketingCostsCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">698000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">485000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">8235000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7853000</us-gaap:LiabilitiesCurrent>
	<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:CommitmentsAndContingencies>
	<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:CommitmentsAndContingencies>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">10000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">10000</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">40627000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">41552000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">-1989000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">-4699000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">25188000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">25637000</us-gaap:TreasuryStockValue>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">13460000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">11226000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2008" unitRef="USD" decimals="-3">17774000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009" unitRef="USD" decimals="-3">14059000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">9000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">9000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">37599000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">37726000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">5354000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">1512000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-25188000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-25188000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">10000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">40627000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-1989000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-25188000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">10000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">41552000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-4699000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-25637000</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">21695000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">19079000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">13000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">3389000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">3608000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2010" unitRef="USDPerShare" decimals="4">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USDPerShare" decimals="4">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="-3">50000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="-3">50000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="-3">19353672000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="-3">20161636000</us-gaap:CommonStockSharesIssued>
	<us-gaap:TreasuryStockShares contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="-3">4646053000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="-3">5336053000</us-gaap:TreasuryStockShares>
	<us-gaap:SalesRevenueNet contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">19816000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">14502000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">17453000</us-gaap:SalesRevenueNet>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">8247000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">5672000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">6171000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:GrossProfit contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">11569000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">8830000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">11282000</us-gaap:GrossProfit>
	<us-gaap:SellingAndMarketingExpense contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">4852000</us-gaap:SellingAndMarketingExpense>
	<us-gaap:SellingAndMarketingExpense contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">5576000</us-gaap:SellingAndMarketingExpense>
	<us-gaap:SellingAndMarketingExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">7904000</us-gaap:SellingAndMarketingExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">9344000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">6054000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">5028000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">1308000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">794000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1088000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:OperatingExpenses contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">15504000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">12424000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">14020000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-3935000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-3594000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2738000</us-gaap:OperatingIncomeLoss>
	<us-gaap:InterestAndOtherIncome contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">9000</us-gaap:InterestAndOtherIncome>
	<us-gaap:InterestAndOtherIncome contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">53000</us-gaap:InterestAndOtherIncome>
	<us-gaap:InterestAndOtherIncome contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">28000</us-gaap:InterestAndOtherIncome>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-3926000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-3541000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2710000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-84000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-40000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-3842000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-3842000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-3501000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-3501000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2710000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-2710000</us-gaap:NetIncomeLoss>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_31-Dec-2009" unitRef="USDPerShare" decimals="2">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_31-Dec-2010" unitRef="USDPerShare" decimals="2">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_31-Dec-2011" unitRef="USDPerShare" decimals="2">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
	<prph:WeightedAverageCommonSharesOutstandingBasicAndDiluted xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2009" unitRef="Shares" decimals="-3">12963000</prph:WeightedAverageCommonSharesOutstandingBasicAndDiluted>
	<prph:WeightedAverageCommonSharesOutstandingBasicAndDiluted xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010" unitRef="Shares" decimals="-3">14285000</prph:WeightedAverageCommonSharesOutstandingBasicAndDiluted>
	<prph:WeightedAverageCommonSharesOutstandingBasicAndDiluted xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011" unitRef="Shares" decimals="-3">14817000</prph:WeightedAverageCommonSharesOutstandingBasicAndDiluted>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">12908383000</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">13033383000</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">14707619000</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">14825583000</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">133000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">133000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">125000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">130500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<prph:StockIssuedDuringPeriodValueExlusiveLicenseAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">2577000</prph:StockIssuedDuringPeriodValueExlusiveLicenseAgreement>
	<prph:StockIssuedDuringPeriodValueExlusiveLicenseAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">1000</prph:StockIssuedDuringPeriodValueExlusiveLicenseAgreement>
	<prph:StockIssuedDuringPeriodValueExlusiveLicenseAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">2576000</prph:StockIssuedDuringPeriodValueExlusiveLicenseAgreement>
	<prph:StockIssuedDuringPeriodSharesExlusiveLicenseAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">1440000000</prph:StockIssuedDuringPeriodSharesExlusiveLicenseAgreement>
	<prph:StockGrantedDuringPeriodValueEmploymentAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">60000</prph:StockGrantedDuringPeriodValueEmploymentAgreement>
	<prph:StockGrantedDuringPeriodValueEmploymentAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">60000</prph:StockGrantedDuringPeriodValueEmploymentAgreement>
	<prph:StockGrantedDuringPeriodValueEmploymentAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">294000</prph:StockGrantedDuringPeriodValueEmploymentAgreement>
	<prph:StockGrantedDuringPeriodValueEmploymentAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">294000</prph:StockGrantedDuringPeriodValueEmploymentAgreement>
	<prph:StockGrantedDuringPeriodSharesEmploymentAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">36111000</prph:StockGrantedDuringPeriodSharesEmploymentAgreement>
	<prph:StockGrantedDuringPeriodSharesEmploymentAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">341254000</prph:StockGrantedDuringPeriodSharesEmploymentAgreement>
	<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">90000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
	<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">90000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
	<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">500000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
	<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">500000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">67625000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation><us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">466710000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation><us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">88000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">88000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-88000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation><us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-88000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation><us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation><us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation contextRef="Context_FYE_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation><us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-449000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="-3">-449000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockSharesAcquired contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="-3">-690000000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">522000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">363000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">355000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-104000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">28000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:AssetImpairmentCharges contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">74000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:ShareBasedCompensation contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">192000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">631000</us-gaap:ShareBasedCompensation>
	<prph:SalesDiscountsAndProvisionForBadDebts xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">133000</prph:SalesDiscountsAndProvisionForBadDebts>
	<prph:SalesDiscountsAndProvisionForBadDebts xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">33000</prph:SalesDiscountsAndProvisionForBadDebts>
	<prph:SalesDiscountsAndProvisionForBadDebts xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">18000</prph:SalesDiscountsAndProvisionForBadDebts>
	<prph:InventoryValuationProvision xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-633000</prph:InventoryValuationProvision>
	<prph:InventoryValuationProvision xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">728000</prph:InventoryValuationProvision>
	<prph:InventoryValuationProvision xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">115000</prph:InventoryValuationProvision>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-2485000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">1189000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-1620000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInInventories contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-963000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-451000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">891000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-390000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">68000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">864000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-109000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-219000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">396000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<prph:IncreaseDecreaseInAccruedMarketingCosts xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">-597000</prph:IncreaseDecreaseInAccruedMarketingCosts>
	<prph:IncreaseDecreaseInAccruedMarketingCosts xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">1384000</prph:IncreaseDecreaseInAccruedMarketingCosts>
	<prph:IncreaseDecreaseInAccruedMarketingCosts xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-565000</prph:IncreaseDecreaseInAccruedMarketingCosts>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">45000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">201000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-81000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">445000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-3549000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2108000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">208000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">153000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">1000000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">480000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">166000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">272000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-1153000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-134000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">127000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">133000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PaymentsForRepurchaseOfEquity contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">0</us-gaap:PaymentsForRepurchaseOfEquity>
	<us-gaap:PaymentsForRepurchaseOfEquity contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:PaymentsForRepurchaseOfEquity>
	<us-gaap:PaymentsForRepurchaseOfEquity contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">449000</us-gaap:PaymentsForRepurchaseOfEquity>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">127000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">133000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-449000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">844000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">-4569000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2691000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">43000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">34000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
	<prph:CommonStockIssuedForLicenseAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">0</prph:CommonStockIssuedForLicenseAgreement>
	<prph:CommonStockIssuedForLicenseAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">2577000</prph:CommonStockIssuedForLicenseAgreement>
	<prph:CommonStockIssuedForLicenseAgreement xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</prph:CommonStockIssuedForLicenseAgreement>
	<us-gaap:StockIssued1 contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-3">0</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-3">0</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">294000</us-gaap:StockIssued1>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 1 &amp;#8211; ORGANIZATION AND BUSINESS&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;ProPhase Labs, Inc (&amp;#8220;we&amp;#8221;, &amp;#8220;us&amp;#8221; or the &amp;#8220;Company&amp;#8221;), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (&amp;#8220;OTC&amp;#8221;) drug, natural base health products along with supplements, personal care and cosmeceutical products.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our primary business is currently the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE&lt;font style="font-family: symbol;"&gt;&lt;sup&gt;&amp;#210;&lt;/sup&gt;&lt;/font&gt;&lt;sup&gt; &lt;/sup&gt;Cold Remedy and our principal product is Cold-EEZE&lt;font style="font-family: symbol;"&gt;&lt;sup&gt;&amp;#210;&lt;/sup&gt;&lt;/font&gt; zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by nearly half. Cold-EEZE&lt;font style="font-family: symbol;"&gt;&lt;sup&gt;&amp;#210;&lt;/sup&gt;&lt;/font&gt; is an established product in the health care and cold remedy market. For Fiscal 2011, Fiscal 2010 and Fiscal 2009 (as each is defined below), our revenues from continuing operations have come principally from our OTC cold remedy products.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;On March 22, 2010, the Company, Phosphagenics Limited (&amp;#8220;PSI Parent&amp;#8221;), an Australian corporation, Phosphagenics Inc. (&amp;#8220;PSI&amp;#8221;), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the &amp;#8220;Joint Venture&amp;#8221;), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the &amp;#8220;LLC Agreement&amp;#8221;) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent&amp;#8217;s proprietary patented TPM&amp;#8482; technology (&amp;#8220;TPM&amp;#8221;). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture (see Note 3).&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We use a December 31 year-end for financial reporting purposes. References herein to the fiscal year ended December 31, 2011 shall be the term &amp;#8220;Fiscal 2011&amp;#8221; and references to other &amp;#8220;Fiscal&amp;#8221; years shall mean the year, which ended on December 31 of the year indicated. Our consolidated balance sheet at December 31, 2010 and our consolidated statement of cash flows for Fiscal 2010 and 2009 have been reclassified to conform with our Fiscal 2011 presentation. The term the &amp;#8220;we&amp;#8221;, &amp;#8220;us: or the &amp;#8220;Company&amp;#8221; as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 2 &amp;#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The consolidated financial statements (&amp;#8220;Financial Statements&amp;#8221;) include the accounts of the Company and its wholly owned subsidiaries and its Joint Venture, a variable interest entity (see Note 3). All intercompany transactions and balances have been eliminated.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Seasonality of the Business&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 31.5pt; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote its products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 31.5pt; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: italic 10pt times new roman, times, serif;"&gt;&lt;font style="font-weight: normal;"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The preparation of financial statements and the accompanying notes thereto, in conformity with generally accepted accounting principles in the United States (&amp;#8220;GAAP&amp;#8221;), requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets &lt;font style="color: black;"&gt;and liabilities&lt;/font&gt; at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (&amp;#8220;Sales Allowances&amp;#8221;), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 27pt; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our primary product, Cold-EEZE&lt;font style="font-family: symbol;"&gt;&lt;sup&gt;&amp;#210;&lt;/sup&gt;&lt;/font&gt;&lt;sup&gt; &lt;/sup&gt;lozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; lozenges we market and distribute Cold-EEZE&lt;sup&gt;&amp;#174; &lt;/sup&gt;Oral Spray and Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Chest Relief, Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Cough Cold and Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Allergy (&amp;#8220;Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Products&amp;#8221;), children&amp;#8217;s OTC cold remedies. In August 2011, we introduced Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Oral Spray containing our proprietary zinc formulation in a liquid spray form. We introduced Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Chest Relief in Fiscal 2008 and expanded the product line to include Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Cough Cold and Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Allergy in Fiscal 2010. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (&amp;#8220;Organix&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#8221;). Each of the Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Oral Spray products, Kids-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Products and Organix&lt;sup&gt;&amp;#174;&lt;/sup&gt; products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. &lt;font style="letter-spacing: -0.15pt;"&gt;Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: italic 10pt times new roman, times, serif;"&gt;&lt;font style="font-weight: normal;"&gt;&lt;u&gt;Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We consider all highly liquid investments with an initial maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin:
 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Inventories&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At December 31, 2011 and 2010, the Financial Statements include an adjustment for excess or obsolete inventory of $991,000 and $1.1 million, respectively. At December 31, 2011 and 2010, inventory included raw material, work in progress and packaging amounts of $981,000 and $742,000, respectively, and finished goods of $1.7 million and $940,000, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Property, Plant and Equipment&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Property, plant and equipment are recorded at cost. We use a combination of straight-line and accelerated methods in computing depreciation for financial reporting purposes. The depreciation expense is computed in accordance with the estimated asset lives (see Note 4).&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Concentration of Risks&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the requirements associated with the development of OTC and other personal care products in order to continue to compete on a national and/or international level.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) and, as applicable, the Homeopathic Pharmacopoeia of the United States.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We maintain cash and cash equivalents with certain major financial institutions. As of December 31, 2011, our cash was $5.5 million and our bank balance was $5.9 million. Of the total bank balance, $704,000 was covered by federal depository insurance and $5.2 million was uninsured.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Trade accounts receivable potentially subjects us to credit risk. We extend credit to our customers based upon an evaluation of the customer&amp;#8217;s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers (see Note 12). During Fiscal 2011, 2010 and 2009, effectively all of our revenues were related to domestic markets.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our revenues are principally generated from the sale of OTC cold remedy products which approximated 95%, 96% and 92% of total revenues for Fiscal 2011, 2010 and 2009, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Raw materials used in the production of the products are available from numerous sources. Certain raw material active ingredients used in connection with Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; products are purchased from a single unaffiliated supplier. Should the relationship terminate or the vendor become unable supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Long-lived Assets&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes
 significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In Fiscal 2009 we recognized impairment charges of $74,000 principally for the land and building assets of our Elizabethtown manufacturing facility. The fair value of the reported &lt;i&gt;Assets Held For Sale &lt;/i&gt;at December 31, 2010&lt;i&gt; &lt;/i&gt;of $138,000&lt;i&gt; &lt;/i&gt;was arrived at through bids generated from interested third party purchasers and guidance from a third party real estate advisor thereby relating to Level 3 fair value hierarchy. In February 2011, we derived net proceeds from the sale of these assets of $166,000.&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity fall within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory &amp;#8220;Overstocking&amp;#8221; or &amp;#8220;Resets&amp;#8221;. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 27pt; margin: 0px; font: 10pt times new roman, times, serif;"&gt;As of December 31, 2011 and December 31, 2010, we included a provision for sales allowances of $101,000 and $106,000, respectively, which are reported as a reduction to account receivables. We also included an estimate of the uncollectability of our accounts receivable as an allowance for doubtful accounts of zero and $13,000 as of December 31, 2011 and 2010, respectively. Additionally, accrued advertising and other allowances as of December 31, 2011 include $1.7 million for estimated future sales returns, $1.0 million for cooperative incentive promotion costs and $279,000 for certain other advertising and marketing promotions. As of December 31, 2010 accrued advertising and other allowances include $1.5 million for estimated future sales returns, $1.2 million for cooperative incentive promotion costs and $828,000 for certain other advertising and marketing promotions.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 27pt; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Shipping and Handling &lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Stock Compensation&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify;
 text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Stock and stock options for purchase of our common stock, $0.0005 par value, (&amp;#8220;Common Stock&amp;#8221;) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 8). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. In Fiscal 2011 and 2010, we charged to operations $631,000 and $192,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. There was no share-based compensation expense for Fiscal 2009.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Variable Interest Entity&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The Joint Venture, of which we own a 50% membership interest qualifies as a variable interest entity (&amp;#8220;VIE&amp;#8221;) and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010 (see Note 3).&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Advertising and Incentive Promotions &lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of media advertising, presented as part of sales and marketing expense; cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales; and free product, which is accounted for as part of cost of sales. Advertising and incentive promotion costs incurred for Fiscal 2011, 2010 and 2009 were $8.8 million, $6.9 million, and $5.8 million, respectively. Included in prepaid expenses and other current assets was $1.2 million and $189,000 at December 31, 2011 and 2010, respectively, relating to prepaid advertising and promotion expenses.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-decoration: underline;"&gt;&lt;font style="font-weight: normal;"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Research and development costs are charged to operations in the period incurred. Expenditures for Fiscal 2011, 2010 and 2009 were $1.1 million, $794,000 and $1.3 million, respectively. For Fiscal 2011 and Fiscal 2010, research and development costs are related principally to new product development initiatives and costs associated with OTC cold remedy products. For Fiscal 2009, research and development costs are related principally to the Quigley Pharma&amp;#8217;s study activities; such studies and initiatives are no longer actively being commercialized.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: italic 10pt times new roman, times, serif;"&gt;&lt;font style="font-weight: normal;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total net current and non-current deferred tax asset is being provided (see Note 10).&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The major jurisdiction for which we file income tax returns is the United States. The Internal Revenue Service (&amp;#8220;IRS&amp;#8221;) has examined our tax year ended September 30, 2005 and has made no changes to the filed tax returns. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Effective December 31, 2009, we elected to conform our tax reporting year, historically a fiscal period ending September 30, to our financial reporting period ending December 31. As a consequence, we filed a full period tax return for the fiscal year ended September 30, 2009 with the IRS and also filed with the IRS a &amp;#8220;short period return&amp;#8221; for the three months ended December 31, 2009 in compliance with the election. In future fiscal periods, our tax and financial reporting periods will be the same, the period ending December 31.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Cash and cash equivalents,
 accounts receivable and accounts payable are reflected in the Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments. Determination of the fair value of related party payables, if any, is not practicable due to their related party nature.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;Recently Issued Accounting Standards&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In November 2008, the SEC issued for comment a proposed roadmap regarding the potential use by U.S. issuers of financial statements prepared in accordance with International Financial Reporting Standards (&amp;#8220;IFRS&amp;#8221;). IFRS is a comprehensive series of accounting standards published by the International Accounting Standards Board (&amp;#8220;IASB&amp;#8221;). The proposed roadmap has since been superseded by an SEC work plan and no date is currently proposed that we could be required to prepare financial statements in accordance with IFRS. The SEC has targeted Fiscal 2012 to make a determination regarding the mandatory adoption of IFRS. We are currently assessing the impact that this potential change would have on our consolidated financial statements and we will continue to monitor the development of the potential implementation of IFRS.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In June&amp;#160;2011, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update No. 2011-05, &amp;#8220;Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income,&amp;#8221; (&amp;#8220;ASU 2011-05&amp;#8221;) which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders&amp;#8217; equity. Instead, comprehensive income must be presented in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 will be effective for fiscal periods beginning after December 15, 2011 with early adoption permitted. The adoption of ASU 2011-05 will not have a material impact on our consolidated financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In September 2011, the FASB issued Accounting Standards Update No. 2011-08, &amp;#8220;Intangibles &amp;#8211; Goodwill and Other Topics&amp;#8221; (&amp;#8220;ASU 2011-08&amp;#8221;) which provides authoritative guidance on testing goodwill for impairment that will become effective beginning January&amp;#160;1, 2012, with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. We are currently assessing the potential impact on the adoption of this guidance on our financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 3 &amp;#8211; INVESTMENT IN PHUSION LABORATORIES, LLC.&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;On March 22, 2010, the Company, PSI Parent, PSI and the Joint Venture entered into the LLC Agreement of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent&amp;#8217;s proprietary patented TPM.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In connection with the LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the &amp;#8220;Original License Agreement&amp;#8221;), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent&amp;#8217;s TPM-related patents and related know-how (collectively, the &amp;#8220;PSI Technology&amp;#8221;) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent (such shares, the &amp;#8220;PSI Shares&amp;#8221;), and made a one-time payment to PSI Parent of $1.0 million. On the date the PSI Shares were issued, PSI Parent agreed, pursuant to a Share Transfer Restriction Agreement, dated March 22, 2010 (the &amp;#8220;Share Transfer Restriction Agreement&amp;#8221;), between us and PSI Parent, that, with certain exceptions, it would not sell or otherwise dispose of any of the PSI Shares prior to June 1, 2012 (see discussion below). The PSI Shares were issued pursuant to an exemption from registration under the Securities Act, by virtue of Section 4(2) of the Securities Act and by virtue of Rule 506 of Regulation D under the Securities Act. Such sale and issuance did not involve any public offering and was made without general solicitation or advertising. Additionally, PSI Parent represented to us, among other things, that PSI Parent is not a US Person (as defined in Regulation S under the Securities Act), that PSI Parent is an accredited investor with access to all relevant information necessary to evaluate its investment and that the PSI Shares were being acquired for investment purposes only.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In September 2011, PSI Parent entered into certain Private Resale Agreements (&amp;#8220;PSAs&amp;#8221;) with seven third party purchasers, under which Phosphagenics sold, with our consent, an aggregate of 750,000 shares of our Common Stock. Under the PSAs, the purchasers may not, without the prior written consent of the Company, prior to the one year anniversary of the PSAs, directly or indirectly, sell, give, pledge, hypothecate, assign or otherwise transfer the purchased shares, in whole or in part. Contemporaneously with PSI Parent consummating the PSAs, we consummated an agreement with PSI Parent to redeem the then remaining 690,000 PSI Shares held by PSI Parent (see Note 8).&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In accordance with a Contribution Agreement, dated March 22, 2010 (the &amp;#8220;Contribution Agreement&amp;#8221;), by and among us, PSI Parent, PSI, and the Joint Venture, we transferred, conveyed and assigned to the Joint Venture all of our rights, title and interest in, to and under the Original License Agreement, and the Joint Venture assumed, and undertook to pay, discharge and perform when due, all of our liabilities and obligations under and arising pursuant to the Original License Agreement (such actions, collectively, the &amp;#8220;Assignment and Assumption&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Pursuant to the Contribution Agreement and in order to reflect the Assignment and Assumption, we, PSI Parent and the Joint Venture entered into an Amended and Restated License Agreement, dated March 22, 2010 (the &amp;#8220;Amended License Agreement&amp;#8221;), which amends and restates the Original License Agreement to reflect that the Joint Venture is the licensee thereunder and which otherwise contains substantially the same terms as the Original License Agreement. The Joint Venture has the right to grant one or more sub-licenses of the rights granted under the Amended License Agreement to one or more third parties for reasonable consideration in any part of the applicable territory. The Amended License Agreement provides that PSI Parent shall not, directly or through third parties, exploit the covered intellectual property during the term thereof, subject to certain limitations. The Amended License Agreement will remain in effect until the expiration of the last to expire of the patents included within the PSI Technology or any extensions thereof. Either party may terminate the Amended License Agreement upon written notice to the other party in the event of certain events involving bankruptcy or insolvency. The Amended License Agreement also contains, among other things, provisions concerning the treatment of confidential information, the ownership of intellectual property and indemnification obligations.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. PSI Parent will conduct and oversee much of the product development, formulation, testing and other research and development needed by the Joint Venture, and we will oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may be required, from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund its operations, in accordance with agreed upon budgets for products to be developed. Specifically, we contributed in Fiscal 2010 $500,000 in cash as initial capital and we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established to date), toward the initial development and marketing costs of new products for the Joint Venture. The newly formed Joint Venture has not engaged in any financial transactions, other than organizational expenses and general market and product analysis. At December 31, 2011, cash and equivalents includes $425,000 which is expected to be used by the Joint Venture to fund future product development initiatives currently under consideration by PSI Parent, PSI and us.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The Joint Venture is managed by a four-person Board of Managers, with two managers appointed by each member. The LLC Agreement contains other normally found terms in such arrangements, including provisions relating to governance of the Joint Venture, indemnification obligations of the Joint Venture, allocation of profits and losses, the distribution of funds to the members and restrictions on transfer of a member&amp;#8217;s interest.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our determination is that the Joint Venture qualifies as a VIE and that we are the primary beneficiary. As a consequence, we have consolidated the Joint Venture financial statements beginning with the quarter ended March 31, 2010. Since inception and including Fiscal 2011, the newly formed Joint Venture has not engaged in any financial transactions, other than certain organizational expenses and general market and product analysis, as formal operations are not expected to commence until later in Fiscal 2012. Furthermore, the liabilities and other obligations incurred, if any, by the Joint Venture is without recourse to us and do not create a claim on our general assets. At December 31, 2011, we have recorded the $3.6 million payment representing the estimated fair value to acquire the product license as an intangible asset. We currently estimate the expected useful life of the product license to be approximately 10 years which we will begin amortizing the cost of intangible asset once product commercialization is completed with PSI Parent and the OTC drug products begin to ship to our retail customers.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The product development effort of the Joint Venture is a multi-stage process that includes (i) market analysis and research, (ii) product formulation research and development, (iii) product evaluation, (iv) product commercialization, (v) production and distribution, and (vi) retail and consumer advertising and marketing. During Fiscal 2011, we conducted preliminary market analysis to identify market opportunities to develop differentiated, science-based, efficacious products that deliver results to consumers and worked with PSI and PSI Parent to provide initial formulations for certain identified OTC active ingredients. In December 2011, we initiated a study of these preliminary formulations to evaluate product attributes, performance and potential commercial viability. These studies are expected to be completed later in Fiscal 2012. For Fiscal 2011, any expenses, including organizational, marketing analysis and preliminary formulations have been absorbed by the respective Joint Venture members. As of December 31, 2011, we have not established a formal commercialization program timeline, pending the results of the recently initiated studies, for any specific OTC product covered under the product license but we do not project that any such OTC products will be available for shipment within the next twelve months.&lt;/p&gt;</us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;NOTE 4 &amp;#8211; PROPERTY, PLANT AND EQUIPMENT &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The components of property and equipment are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 87%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Estimated&amp;#160;Useful Life&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 61%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Land&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;504&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;504&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Buildings and improvements&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,494&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,281&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;15 - 39 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,567&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,592&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3 - 7 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Computer software&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;161&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;192&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;189&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;182&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,915&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,751&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Less: Accumulated&amp;#160; depreciation&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3,608&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3,389&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,307&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,362&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Depreciation expense for Fiscal 2011, 2010 and 2009 was $355,000, $363,000, and $522,000, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<prph:PatentRightsAndRelatedRoyaltyCommitmentsTextBlock xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 5 &amp;#8211; PATENT RIGHTS AND RELATED ROYALTY COMMITMENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We have maintained a separate representation and distribution agreement relating to the development of the zinc gluconate product formulation. In return for exclusive worldwide distribution rights, we agreed to pay the developer a 3% royalty and a 2% consulting fee based on sales collected, less certain deductions, throughout the term of this agreement, which expired May 2007. However, we and the developer are in litigation (see Note 7) and as such no potential offset for these fees from such litigation has been recorded. The amount accrued for this expense at each of December 31, 2011 and 2010 was $3.5 million.&lt;/p&gt;</prph:PatentRightsAndRelatedRoyaltyCommitmentsTextBlock>
	<us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 6 &amp;#8211; OTHER CURRENT LIABILITIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;At December 31, 2011 and 2010, other current liabilities include $237,000 and $483,000, respectively, related to accrued compensation.&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 7 &amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Certain operating leases for office and warehouse space maintained by us in Fiscal 2010 and 2009 resulted in rent expense of $11,000 and $44,000, respectively. We did not incur rent expense in Fiscal 2011. We have approximate future obligations over the next five years as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 60%; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;"&gt;Year&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Employment &lt;br /&gt;Contracts&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Purchase &lt;br /&gt;Commitments&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 31%;"&gt;2012&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 20%;"&gt;1,106&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 20%;"&gt;1,377&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 20%;"&gt;2,483&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,025&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,025&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,025&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,025&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;556&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;556&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;3,712&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,377&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;5,089&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif; color: red;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;In August, 2009, we entered into a standard form of indemnity agreement with each member of our Board of Directors, Mr. Ted Karkus, our Chairman and Chief Executive Officer, and Mr. Robert V. Cuddihy, Jr., our Chief Operating Officer. These agreements provide, among other things, that we will indemnify each director, Mr. Karkus and Mr. Cuddihy in the event that they become a party or otherwise a participant in any action or proceeding on account of their service as a director or officer of the Company (or service for another corporation or entity in any capacity at the request of the Company) to the fullest extent permitted by applicable law. Under the indemnity agreement, we will pay, in advance of the final disposition of any such action or proceeding, expenses (including attorneys&amp;#8217; fees) incurred by our directors or officers in defending or otherwise responding to such action or proceeding upon receipt of a written undertaking from the directors or officers to
 repay the amount advanced consistent with applicable law in the event that a court shall ultimately determine that he or she is not entitled to be indemnified for such expenses. The contractual rights to indemnification provided by the indemnity agreements are subject to the limitations and conditions specified in the agreements, and are in addition to any other rights each director and officer may have under our Articles of Incorporation and Amended and Restated Bylaws, each as amended from time to time, and applicable law.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;On November 8, 2011, we entered into new employment agreements, effective as of January 1, 2012, with each of Mr. Ted Karkus and Mr. Cuddihy (the &amp;#8220;Employment Agreements&amp;#8221;). The Employment Agreements supersede the employment agreements of Mr. Karkus and Mr. Cuddihy, dated August 19, 2009, that had been scheduled to terminate on July 15, 2012. The scheduled termination dates of the Employment Agreements is July 15, 2015, which is three years following the scheduled expiration date set forth in the executives&amp;#8217; former employment agreements.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Under his new employment agreement with the Company, Mr. Karkus agreed to an annual base salary of $675,000 as Chief Executive Officer. Under the terms of his former employment agreement with the Company, as amended, Mr. Karkus was entitled to annual base compensation of $750,000, consisting of a $600,000 base salary and $150,000 in stock based compensation. He is eligible to receive an annual increase in base salary and may be awarded a bonus in the sole discretion of the Compensation Committee and also will receive regular benefits routinely provided to other senior executives of the Company.&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Under his new employment agreement with the Company, Mr. Cuddihy agreed to an annual base salary of $350,000 as Chief Financial Officer and Chief Operating Officer. Under the terms of his former employment agreement with the Company as the Company&amp;#8217;s Chief Operating Officer, Mr. Cuddihy was entitled to annual base compensation of $325,000, consisting of a $275,000 base salary and $50,000 in stock based compensation. Mr. Cuddihy is eligible to receive an annual increase in base salary and may be awarded a bonus in the sole discretion of the Compensation Committee and also will receive regular benefits routinely provided to other senior executives of the Company.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Each executive is subject to non-competition restrictions for up to a period of either six (6) months or eighteen (18) months following termination of employment depending on the nature of the termination. Each executive is also eligible for a gross up payment in the event that any amounts payable under the agreements (or any other plan, program, policy or arrangement with the Company) become subject to the excise tax imposed by Section 4999 of the Internal Revenue Code.&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The Employment Agreements also provide for payments upon certain terminations and change in control benefits to ensure that they work to secure the best outcome for stockholders in the event of a possible change in control, even if it means that they lose their jobs as a result. Under the Employment Agreements, in the event of the termination by the Company of the employment of Mr. Karkus or Mr. Cuddihy without cause or due to a voluntary resignation by either executive with Good Reason (as defined in the agreements), each executive will be paid a lump sum severance payment in cash equal to the greater of (A) the amount equal to eighteen (18) months base salary or (B) the amount equal to the his base salary for the remainder of the term as if the agreement had not been terminated. Additionally, each executive is entitled to receive a lump sum severance payment in cash equal to the greater of A or B, if he, within twenty four (24) months of a Change in Control (as defined in the agreements) of the Company, is terminated without cause or due to a voluntary resignation by him with Good Reason (as defined in the agreements). Each executive may also participate at Company expense in all medical and dental plans for the remainder of the term of his employment agreement in the event the Company terminates the employment agreement for any reason, except for the Company&amp;#8217;s termination for Cause (as defined in the agreements) or a voluntary resignation by him without Good Reason (as defined in the agreements).&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.) VS. JOHN C. GODFREY, ET AL.&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;This action was commenced by us in November 2004 in the Court of Common Pleas of Bucks County, Pennsylvania against John C. Godfrey, Nancy Jane Godfrey, and Godfrey Science and Design, Inc. for injunctive relief regarding the Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;trademark; injunctive relief relating to the Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; formulations and manufacturing methods; injunctive relief for breach of the duty of loyalty, and declaratory judgment&amp;#160;regarding&amp;#160;various payments that the defendants assert are owing to them.&amp;#160; Our complaint is based in part upon certain contracts&amp;#160;with defendants whereby we obtained the exclusive right to manufacture and distribute product pursuant to&amp;#160;a basic patent&amp;#160;and&amp;#160;also obtained various consulting services&amp;#160;(the "Agreements").&amp;#160; Subsequent to entering into the Agreements, the&amp;#160;defendants&amp;#160;took various actions that we believe were in breach of&amp;#160;the Agreements. We instituted the action because of&amp;#160;defendants' threats to deal with other parties and&amp;#160;to use the Company&amp;#8217;s Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; trademark and&amp;#160;the trade secrets that&amp;#160;we developed during our manufacture of Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt;. Both
 because of their breaches and the expiration of the basic patent, we terminated the&amp;#160;Agreements.&amp;#160; Defendants have answered the complaint and asserted counterclaims.&amp;#160; They seek monetary damages and counter injunctive and&amp;#160;declaratory relief relative to the Company's trademark and other intellectual property.&amp;#160; The monetary relief sought by the&amp;#160;defendants&amp;#160;is based on their claim that they were not paid various amounts asserted to be due under the Agreements.&amp;#160; This claim is estimated&amp;#160;to be in excess of $5.0 million.&amp;#160; We believe that the defendants' counterclaims are without merit and are vigorously defending those counterclaims and are prosecuting our action on the complaint.&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Pre-trial discovery is&amp;#160;ongoing.&amp;#160; Defendants moved for partial summary judgment, and we filed a response and cross-motion for summary judgment.&amp;#160; On August 21, 2008, the court denied both motions for summary judgment.&amp;#160; The case has not been assigned to a trial calendar, although it is possible that the case will be listed for trial in 2012.&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;At this time no prediction as to the outcome of this action can be made.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.) VS. WACHOVIA INSURANCE SERVICES, INC. AND FIRST UNION INSURANCE SERVICES AGENCY, INC.&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We instituted a Writ of Summons against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc. on December 8, 2005 in the Court of Common Pleas of Bucks County, Pennsylvania. The purpose of this suit was to maintain an action and toll the statute of limitation against our insurance broker who failed to place excess limits coverage for us for the period from November 29, 2003 until April 6, 2004. As a result of the defendants&amp;#8217; failure to place insurance and to notify us thereof, certain pending actions covered by our underlying insurance, which are currently being defended by insurance counsel and the underlying insurance carrier may cause an exhaustion of the underlying insurance for the policy periods ending November 29, 2004 and November 29, 2005. Any case in which an alleged action arose relating to the use of Cold-EEZE&lt;sup&gt;&amp;#174;&lt;/sup&gt; Nasal Spray from November 29, 2003 to April 6, 2004 is not covered by excess insurance.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our claim against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc. is for negligence and for equitable insurance for these claims based on our undertaking of certain attorneys' fees and costs of settlement for claims that should have been covered by underlying insurance placed by Wachovia Insurance Services, Inc. At this time no prediction can be made as to the outcome of any action against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;PROPHASE LABS, INC.(formerly THE QUIGLEY CORPORATION) &lt;font style="text-transform: uppercase; color: windowtext;"&gt;vs. Guy Quigley, Gary Quigley, Scanda Systems Limited, Scanda Systems LTD, Chilesha Holdings LTD, Kevin Brogan, Innerlight Holdings, Inc., George Longo, Graham Brandon, Pacific Rim Pharmaceuticals LTD and John Doe Defendants&lt;/font&gt;&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="color: windowtext;"&gt;On August 23, 2010, we initiated an action in the Court of Common Pleas of Bucks County, &lt;/font&gt;Pennsylvania&lt;font style="color: windowtext;"&gt;. This action&amp;#160;is against certain former officers and directors of the Company, including a shareholder that beneficially owns approximately 20.1% of our Common Stock, and against certain third parties (a &amp;#8220;Complaint&amp;#8221;). The Company has asserted claims arising from, among other things, a variety of transactions and payments previously made or entered into by the Company. All of the transactions and events that are the subject of the Complaint occurred prior to June 2009 and the installation of the current Board of Directors. Pre-trial discovery is on-going and at this time, no prediction as to the outcome of this action can be made.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;u&gt;GUY QUIGLEY VS. TED KARKUS, ROBERT V. CUDDIHY, JR., MARK BURNETT, MARK LEVENTHAL, MARK FRANK, LOUIS GLECKEL, MD, JAMES McCUBBIN AND PROPHASE LABS, INC. AS A NOMINAL DEFENDANT&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The Company was named as a nominal defendant in a purported derivative complaint filed on February 2, 2012 by stockholder and former director and Chief Executive Officer Guy Quigley in the Court of Common Pleas of Philadelphia County, Pennsylvania (No. 111200409). The complaint also names as a defendant each of our directors and executive officers. Among other things, the suit alleges various breaches of fiduciary and other duties, and seeks recovery of unspecified damages and other relief. Prior to filing this complaint, the plaintiff applied to the same court for permission to take pre-complaint discovery on the basis that the plaintiff required such discovery in order to assert claims. The court denied the plaintiff's request. The Company believes the lawsuit is without merit and intends to vigorously defend against it.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;As noted above, the Company previously commenced litigation against the plaintiff, Guy Quigley, and other parties in August 2010 in the Bucks County Court of Common Pleas, Pennsylvania (No.
 2010-08227). The August 2010 action remains pending.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 10 &amp;#8211; INCOME TAXES&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The components of the provision (benefit) for income taxes, in the consolidated statement of operations are as follows (in thousands):&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Current&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-left: 9pt; width: 61%;"&gt;Federal&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(40&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(84&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 9pt;"&gt;State&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(40&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(84&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Deferred&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Federal&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(877&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(107&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,297&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 9pt;"&gt;State&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(21&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;160&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(61&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(898&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;53&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(2,358&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td
 style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(898&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;13&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(2,442&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;"&gt;Income taxes from continuing operations before valuation allowance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(898&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,442&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Change in valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;898&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(53&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,358&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;Income tax (benefit)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(40&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(84&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(40&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(84&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 61%;"&gt;Statutory rate - federal&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(925&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;(1,204&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width:
 10%;"&gt;(1,335&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;State taxes, net of federal benefit&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(21&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(61&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Permanent differences and other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;48&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(143&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1,046&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.13in; padding-left: 0.25in;"&gt;Income tax from continuing operation before valuation allowance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(898&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,347&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,442&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Change in valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(898&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;1,307&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,358&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Income tax (benefit)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(40&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(84&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(40&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;(84&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The components of permanent and other differences are as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;
 text-align: center;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Permanent items:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt; width: 61%;"&gt;Meals and Entertainment&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;2&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;6&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Officers life insurance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Return to accrual for prior year, permanent items&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(479&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Capital loss carryforward utilization &lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(582&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Contribution of inventory&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(162&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Share-based compensation expense for stock options granted&lt;sup&gt; (3)&lt;/sup&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;45&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;14&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;47&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(143&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1,046&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0px; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.35in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(1)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;This item represents the utilization for tax purposes of prior year capital losses.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: -0.25in; margin: 0px 0px 0px 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0px; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.35in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(2)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;This item represents the additional tax deduction available as a consequence of the contribution of certain inventory to qualified charitable organization.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: -0.25in; margin: 0px 0px 0px 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0px; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.35in;"&gt;&lt;/td&gt;
&lt;td
 style="width: 0.25in;"&gt;(3)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;This item relates to share-based compensation expense for financial reporting purposes not deducted for tax purposes until such options are exercised.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The tax effects of the primary &amp;#8220;temporary differences&amp;#8221; between values recorded for assets and liabilities for financial reporting purposes and values utilized for measurement in accordance with tax laws giving rise to our deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 61%;"&gt;Net operating loss and capital loss carryforward&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;13,170&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;12,135&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;10,808&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Consulting-royalty costs&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,431&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,431&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,431&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Depreciation&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;235&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;253&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;250&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Other&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;757&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;877&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;801&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(15,593&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(14,696&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(13,290&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;A valuation allowance for all of our net deferred tax assets has been provided as we are unable to determine, at this time, that the generation of future taxable income against which the net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards could be used can be predicted to be more likely than not. The net change in the valuation allowance for Fiscal 2011, 2010 and 2009 was $898,000, $1.4 million and $2.4 million, respectively. Certain exercises of options and warrants, and restricted stock issued for services that became unrestricted resulted in reductions to taxes
 currently payable and a corresponding increase to additional-paid-in-capital for prior years. In addition, certain tax benefits for option and warrant exercises totaling $6.3 million are deferred and will be credited to additional-paid-in-capital when the NOL&amp;#8217;s attributable to these exercises are utilized. As a result, these NOL&amp;#8217;s will not be available to offset income tax expense. The net operating loss carry-forwards currently approximate $31.6 million for federal purposes will expire beginning in Fiscal 2020 through 2031. Additionally, there are net operating loss carry-forwards of $20.0 million for state purposes that will expire beginning in Fiscal 2018 through 2031.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;As noted above, we have net operating loss carry-forwards for both federal and certain states. However, effective December 31, 2009, we elected to conform our tax reporting year, historically a fiscal period ending September 30, to our financial reporting period ending December 31. As a consequence, we filed a full period tax return for the fiscal year ended September 30, 2009 with the IRS and also filed with the IRS a &amp;#8220;short period return&amp;#8221; for the three months ended December 31, 2009 in compliance with the election. In future fiscal periods, our tax and financial reporting periods will be the same, the period ending December 31. For Fiscal 2010, we had a current tax benefit of $40,000 for an alternative minimum tax refund due us as a consequence of a carry back of an alternative minimum tax net operating loss to a prior period. For Fiscal 2009, we had a current tax benefit of $84,000 for certain federal and state alternative minimum income taxes incurred for the &amp;#8220;short period return&amp;#8221;, inclusive of an alternative minimum tax refund of $110,000 due us as a consequence of a carry back of an alternative minimum tax net operating loss to a prior period.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 11 &amp;#8211; EARNINGS PER SHARE&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Since there is a large number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;A reconciliation of the applicable numerators and denominators of the income statement periods presented is as follows (in thousands, except per share amounts):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 93%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="34"&gt;&lt;font style="font-size: 8pt;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;&lt;font style="font-size: 8pt;"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;&lt;font style="font-size: 8pt;"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;&lt;font style="font-size: 8pt;"&gt;2009&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Loss&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Shares&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;EPS&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Loss&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Shares&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;EPS&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Loss&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Shares&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;EPS&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size:
 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 19%;"&gt;&lt;font style="font-size: 8pt;"&gt;Basic EPS&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;(2,710&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;14,817&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;(3,501&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;14,285&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;(0.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;(3,842&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;12,963&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 6%;"&gt;&lt;font style="font-size: 8pt;"&gt;(0.30&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 8pt;"&gt;Dilutives:&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;Options/Warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size:
 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;Diluted EPS&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;(2,710&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td
 style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;14,817&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;(3,501&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;14,285&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;(0.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;(3,842&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;12,963&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;(0.30&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;For Fiscal 2011, 2010 and 2009, diluted earnings per share is the same as basic earnings per share due to the inclusion of common stock&lt;font style="color: black;"&gt;, in the form of stock options and warrants (&amp;#8220;Common Stock Equivalents&amp;#8221;), would have an anti-dilutive effect on the loss per share. For Fiscal 2011, 2010 and 2009, there were Common Stock Equivalents in the amount of 48,375, 359,188 and 133,792, respectively, which were in the money, that were excluded in the earnings per share computation due to their dilutive effect.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
	<prph:SignificantCustomersTextBlock xmlns:prph="http://www.quigleyco.com/20111231" contextRef="Context_FYE_31-Dec-2011">&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 12 &amp;#8211; SIGNIFICANT CUSTOMERS&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;Our products are distributed through numerous food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers throughout the United States. Revenues for Fiscal 2011, 2010 and 2009 were $17.5 million, $14.5 million and $19.8 million, respectively. Walgreen Company (&amp;#8220;Walgreens&amp;#8221;), Wal-Mart Stores, Inc. (&amp;#8220;Wal-Mart&amp;#8221;), CVS Caremark Corporation (&amp;#8220;CVS&amp;#8221;) and Rite-Aid Corp (&amp;#8220;Rite Aid&amp;#8221;) accounted for approximately 17%, 14%, 13% and 12% of our Fiscal 2011 revenues. Walgreens, Wal-Mart and Rite Aid accounted for approximately 23%, 14% and 10% of our Fiscal 2010 revenues. CVS, Walgreens and Wal-Mart accounted for approximately 15%, 15% and 13% of our revenues for Fiscal 2009. The loss of sales to any one or more of these large retail customers could have a material adverse effect on our business operations and financial condition.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We are subject to account receivable credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. These concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. Customers comprising the five largest accounts receivable balances represented 53% and 51% of total trade receivable balances at December 31, 2011 and 2010, respectively. Management believes that the provision for possible losses on uncollectible accounts receivable is adequate for our credit loss exposure. At December 31, 2011 and 2010, the allowance for doubtful accounts was zero and $13,000, respectively.&lt;/p&gt;</prph:SignificantCustomersTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 13 &amp;#8211; QUARTERLY INFORMATION (UNAUDITED)&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: -0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;The following table presents unaudited quarterly financial information for Fiscal 2011 and Fiscal 2010 (in thousands, except per share amounts):&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;table style="width: 96%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="14"&gt;Quarter&amp;#160;Ended&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;March&amp;#160;31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;June&amp;#160;30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;September 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;u&gt;Fiscal 2011&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt; width: 48%;"&gt;Net sales&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3,166&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1,744&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;5,083&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;7,460&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Gross profit&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,994&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;896&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,596&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4,796&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Income (loss) from continuing operations&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,013&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(976&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,110&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,831&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Net income (loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,013&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(976&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,110&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,831&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Basic and diluted earnings (loss) per share:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in;"&gt;Income (loss) from continuing operations&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.07&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.07&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.07&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.12&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in;"&gt;Net income&amp;#160; (loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.07&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.07&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.07&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.12&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; text-decoration: underline;"&gt;Fiscal 2010&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Net sales&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,976&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,131&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5,204&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;6,191&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Gross profit&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,170&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;471&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,610&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,579&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Income (loss) from continuing operations&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,062&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,254&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;947&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,132&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Net income (loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,062&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,254&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;947&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,132&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Basic and diluted earnings (loss) per share:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in;"&gt;Income (loss) from continuing operations&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.08&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.15&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.06&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.08&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in;"&gt;Net income&amp;#160; (loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.08&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.15&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.06&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(0.08&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;NOTE 8 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY AND STOCK COMPENSATION&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;Stockholder Rights Plan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a &amp;#8220;Right&amp;#8221; and collectively, the &amp;#8220;Rights&amp;#8221;) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the &amp;#8220;Rights Agreement&amp;#8221;). The Plan was amended effective May 23, 2008 (&amp;#8220;First Amendment&amp;#8221;) and further amended effective August 18, 2009 (&amp;#8220;Second Amendment&amp;#8221;). The Rights Agreement, as amended, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The dividend has the effect of giving the stockholder a 50% discount on the share&amp;#8217;s current market value for exercising such right. In the event of a cashless exercise of the Right, and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is September 25, 2018.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;T&lt;font style="font-size: 10pt;"&gt;he 1997 Option Plan&lt;/font&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;On December 2, 1997, our Board of Directors approved a Stock Option Plan (the &amp;#8220;1997 Plan&amp;#8221;), which was amended in 2005, and provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan during Fiscal 2011, 2010 or 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;At December 31, 2011, we are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options&amp;#8217; respective expiration dates, but in no event later than ten years from the date granted. At December 31, 2011, there are 138,750 options outstanding with various expiration dates ranging from July 2012 through December 2015, depending upon the date of grant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;T&lt;font style="font-size: 10pt;"&gt;he 2010 Equity Compensation Plan&lt;/font&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 (the &amp;#8220;2010 Equity Compensation Plan&amp;#8221;). The 2010 Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued is equal to 900,000 shares plus up to 900,000 shares that are authorized for issuance, Issued Options (defined below) but unissued under the 1997 Plan an aggregate of 1.8 million shares. &lt;font style="color: black;"&gt;The 1997 Plan expired on December 2, 2007 and no additional awards may be made; however, a&lt;/font&gt;s of March 31, 2010, there remained 1,449,750 shares subject to vested options that were authorized for issuance (the &amp;#8220;Issued Options&amp;#8221;) but were unissued under the 1997 Plan. As of December 31, 2011, 1,311,000 of the Issued Options under the 1997 Plan expired unexercised or were terminated (the &amp;#8220;Expired Options&amp;#8221;). As a consequence, these shares are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Equity Compensation Plan and the remaining 411,000 options are deemed cancelled.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;i&gt;&lt;u&gt;&lt;br  /&gt;Stock Options&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;All of the Company&amp;#8217;s employees, including employees who are officers or members of the Board are eligible to participate in the 2010 Equity Compensation Plan. Consultants and advisors who perform services for the Company are also eligible to participate in the 2010 Equity Compensation Plan. For Fiscal 2011, 2010 and 2009, we granted 220,000, 982,000 and zero options, respectively, to employees to acquire our Common Stock pursuant to the terms of 2010 Equity Compensation Plan. Presented below is a summary of the terms of the grant of options:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt times new roman, times, serif; margin-left: 0.1in; width: 93%;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2009&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 61%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Number of options granted&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;220,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;982,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Vesting period&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;4 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;3-6 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Maximum term of option from date of grant&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;7 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;7 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Exercise price per share&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;0.87 - $1.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 9pt; text-indent: -9pt; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Weighted average fair value per share of options granted&amp;#160;during the year&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;0.58&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;0.65&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;We use the Black-Scholes option pricing model during Fiscal 2011 and 2010 to determine the fair value of the stock options at the date of grant. Based upon our limited historical experience, we estimated approximately 33,000 and 27,300, respectively, of the options granted in Fiscal 2011 and Fiscal 2010 may ultimately be forfeited. Additionally, we determined the expected term of the stock option grants to be a range between 4.5 to 6.5 years, calculated using the &amp;#8220;simplified&amp;#8221; method in accordance with the SEC Staff Accounting Bulletin 110. We use the &amp;#8220;simplified&amp;#8221; method since we changed the vesting terms, tax treatment and the recipients of our stock options beginning in 2010 such that we believe our historical data does not provide a reasonable basis upon which to estimate expected term. Presented below is a summary of assumptions used in determining the fair value of the stock options at the date of grant:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt times new roman, times, serif; margin-left: 0.1in; width: 93%;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2009&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;Expected option life&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;4.75 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;4.5 - 6.5 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 46%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;Weighted average risk free rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;1.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2.10&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15%; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;Dividend yield&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;Expected volatility&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;75.84% - 78.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;72.17% - 77.63&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The fair value of the stock options at the time of the grant in Fiscal 2011 and 2010 was approximately $127,000 and $618,000, respectively. Each of the stock options granted were subject to vesting such that the fair value of the stock options granted is charged to operations over the vesting period. For Fiscal 2011 and 2010, we charged to operations $131,000 and $42,000, respectively, for share-based compensation expense for the aggregate fair value of the stock grants and vested stock options earned. There was no share-based compensation expense for Fiscal 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;At December 31, 2011, 237,020 of the options granted in Fiscal 2011 and 2010 were vested and 956,980 are subject to vesting. At December 31, 2011, there are 13,659 options available for grant to purchase shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.&lt;br  /&gt;&lt;br  /&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;A summary of the status of our stock options granted to both employees and non-employees as of December 31, 2011, 2010 and 2009 and changes during the years then ended is presented below (in thousands, except per share data):&lt;/font&gt;&lt;/div&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt times new roman, times, serif; width: 100%;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="22"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="6"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="6"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="6"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;2009&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Weighted Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Weighted Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Shares&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Shares&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Shares&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 34%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Options outstanding - beginning of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 8%; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1,300&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 8%; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;2.99&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 8%; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1,488&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 8%; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;8.64&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 8%; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;2,268&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 8%; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;7.76&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 9pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;220&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1.10&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;982&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 9pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Exercised&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;(131&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;(125&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 9pt; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;(187&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;8.67&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;(1,039&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;9.45&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;(655&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;7.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Options outstanding - end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1,333&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1.88&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1,300&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;2.99&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1,488&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;8.64&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Options granted and subject to future vesting&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;957&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;937&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Exercisable, at end of year&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;376&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;363&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;1,488&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;Available for grant&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;14&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;818&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&lt;font style="font-size: 8pt; ; font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 22.5pt; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The unrecognized share-based compensation expense related to the options granted but not vested, (options to acquire 956,980 shares) was approximately $572,000 at December 31, 2011. These options subject to vesting (i) vest over the next 2 to 5 years, (ii) have a 7 year term from the date of grant, (iii) are exercisable at a weighted average price of $1.02 and (iv) the unrecognized share-based compensation expense is expected to be recognized over a weighted average period of 4 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 27pt; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The following table summarizes information about stock options outstanding and stock options exercisable at December 31, 2011 (in thousands, except remaining life and per share data):&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt times new roman, times, serif; margin-left: 0.5in; width: 75%;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="10"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Options&amp;#160;Outstanding&amp;#160;and&amp;#160;Exercisable&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Range&amp;#160;of&lt;/font&gt;&lt;br  /&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Exercise Prices&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Number &lt;/font&gt;&lt;br  /&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Weighted Average &lt;/font&gt;&lt;br  /&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Remaining &lt;/font&gt;&lt;br  /&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Contractual Life&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Weighted Average &lt;/font&gt;&lt;br  /&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Exercise&amp;#160;Price Per&lt;/font&gt;&lt;br  /&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Share&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$0.81 - $1.17&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;237&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;6.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$1.18 - $5.19&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;25&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;5.19&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$5.20 - $8.11&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;38&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;1.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;8.11&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$8.12 - $9.50&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;47&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;2.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;9.50&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$9.51 - $13.80&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;29&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center;" colspan="2"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;4.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;13.80&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt; width: 26%; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 21%; border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;376&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 21%; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 21%; border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;4.05&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The total intrinsic value of options exercised during Fiscal 2010 and 2009 was&lt;font style="color: red;"&gt; &lt;/font&gt;$107,000 and&lt;font style="color: red;"&gt; &lt;/font&gt;$226,000, respectively. There were no options exercised during Fiscal 2011. The aggregate intrinsic value of (i) options outstanding, (ii) options outstanding and expected to vest in the future and (iii) options outstanding and exercisable at December 31, 2011 was $159,000, $123,000 and $36,000, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;br  /&gt;&lt;em&gt;&lt;u&gt;Stock Grants&lt;/u&gt;&lt;/em&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;In April 2011, the Compensation Committee of the Board of Directors approved an amendment to Mr. Karkus&amp;#8217; then employment agreement, dated August 19, 2009 (the &amp;#8220;Amendment&amp;#8221;) to lower his annual salary by $150,000 (or $12,500 per month) in exchange for a grant of restricted stock equal in value to the salary reduction. Pursuant to the Amendment, Mr. Karkus&amp;#8217; annual base salary was decreased from $750,000 per year to $600,000 per year, effective May 1, 2011 thru July 15, 2012, which is the end of the term of his then employment agreement, as amended. As a consequence of the Amendment, a restricted stock grant under the 2010 Equity Compensation Plan equal to $12,500 of shares per month thru the end of the term (14.5 months). The restricted stock grant was made in an upfront grant of 161,830 shares, subject to certain future vesting conditions, at a value of $181,000 as of the grant date. The grant was made in April 2011, and the amount of the shares issued was calculated based on the average closing price of our Common Stock for the last five (5) trading days prior to and including the issuance date of April 21, 2011. For Fiscal 2011, we have charged to operations $100,000 as share-based compensation expense for the restricted stock grant and we have unrecognized compensation expense of $81,250 at December 31, 2011 that will be charged to operations in equal monthly installments of $12,500 over the remaining vesting period ending July 15, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;In addition, in April 2011, the Compensation Committee of the Board of Directors granted Mr. Karkus 133,928 shares of Common Stock under the 2010 Equity Compensation Plan as payment for his Fiscal 2010 bonus. Furthermore, in December 2011, the Compensation Committee of the Board of Directors granted Mr. Karkus 128,571 shares of Common Stock under the 2010 Equity Compensation Plan as payment for his Fiscal 2011 bonus. Mr. Karkus agreed to accept his Fiscal 2011 and Fiscal 2010 cash bonus of $150,000 for each year in shares of our Common Stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;In April 2011, Mr. Karkus also agreed to convert into shares of our Common Stock $144,000 of deferred and unpaid cash compensation owed to him thru April 2011, resulting in an issuance of 128,571 shares under the 2010 Equity Compensation Plan. The amount of these shares issued to Mr. Karkus was calculated based on the average closing price of the Company&amp;#8217;s shares for the last five (5) trading days prior to and including the issuance dates of April 21, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;In December 2011, the Compensation Committee of the Board of Directors granted Mr. Cuddihy 33,603 shares of Common Stock, under the 2010 Equity Compensation Plan valued at $37,500 as payment for 50% of his Fiscal 2011 bonus.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;The 2010 Directors Equity Compensation Plan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;On May 5, 2010, our shareholders approved t&lt;font style="color: black;"&gt;he 2010 Directors&amp;#8217; Equity Compensation Plan. &lt;/font&gt;A primary purpose of the &lt;font style="color: black;"&gt;2010 Directors&amp;#8217; Equity Compensation Plan&lt;/font&gt; is to provide us with the ability to pay all or a portion of the fees of Directors in restricted stock instead of cash. The 2010 Directors&amp;#8217; Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors&amp;#8217; Equity Compensation Plan is equal to 250,000. In Fiscal 2011 and 2010, we granted 164,770 and 67,625 shares, respectively, of our Common Stock valued at $162,000 and $90,000, respectively, for director compensation. At December 31, 2011, there are 17,605 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors Equity Compensation Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;Stock Option Exercises and Other Grants&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Pursuant to the terms of Mr. Cuddihy&amp;#8217;s prior employment agreement dated August 19, 2009, Mr. Cuddihy received an annual grant of shares of Common Stock that is equal to $50,000, payable quarterly,&lt;b&gt; &lt;/b&gt;promptly following the close of each quarter calculated based on the average closing price of our Common Stock for the last five (5) trading days of the quarter. For Fiscal 2011, 2010 and 2009, Mr. Cuddihy earned 51,642, 35,075 and 11,004 shares, respectively, valued at $50,000, $50,000 and $23,000, respectively, as share-based compensation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;For Fiscal 2010 and 2009, we derived net proceeds of $133,000 and $127,000, respectively, as a consequence of the exercise of options to acquire 130,500 and 125,000 shares, respectively, of our Common Stock pursuant to the terms of our 1997 Option Plan. There were no stock options exercised in Fiscal 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;font size="3"&gt;&lt;br  /&gt;&lt;/font&gt;&lt;strong&gt;Purchase of Treasury Stock&lt;/strong&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;In September 2011, we entered into a redemption agreement with &lt;font style="letter-spacing: -0.15pt;"&gt;PSI Parent. &lt;/font&gt;Under the terms of the redemption agreement, we redeemed 690,000 shares of our Common Stock held by &lt;font style="letter-spacing: -0.15pt;"&gt;PSI Parent&lt;/font&gt; for the aggregate redemption price of $448,500 in cash (see Note 3). The redemption price was equal to $0.65 per share.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="Context_FYE_31-Dec-2011">&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 9 &amp;#8211; DEFINED CONTRIBUTION PLANS&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"&gt;We maintain the ProPhase Labs, Inc 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in Fiscal 2011, 2010 and 2009 were $88,000, $90,000 and $141,000, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<!-- Footnote Section -->
	<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>prph-20111231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 09:38:41 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:15:14 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:11:42 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:11:42 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:03:51 PM Document Version 1.0-->
<schema elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://www.quigleyco.com/20111231" xmlns:prph="http://www.quigleyco.com/20111231">
	<annotation><appinfo>
			<link:roleType roleURI="http://www.quigleyco.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
				<link:definition>001 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
				<link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
				<link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/StatementOfIncome" id="StatementOfIncome">
				<link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="StatementOfShareholdersEquityAndOtherComprehensiveIncome">
				<link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
				<link:definition>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
				<link:definition>007 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
				<link:definition>008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/InvestmentInPhusionLaboratoriesLlc" id="InvestmentInPhusionLaboratoriesLlc">
				<link:definition>009 - Disclosure - INVESTMENT IN PHUSION LABORATORIES, LLC.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
				<link:definition>010 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/PatentRightsAndRelatedRoyaltyCommitments" id="PatentRightsAndRelatedRoyaltyCommitments">
				<link:definition>011 - Disclosure - PATENT RIGHTS AND RELATED ROYALTY COMMITMENTS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
				<link:definition>012 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/Commitmentsandcontingencies" id="Commitmentsandcontingencies">
				<link:definition>013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/StockholdersEquityAndStockCompensation" id="StockholdersEquityAndStockCompensation">
				<link:definition>014 - Disclosure - STOCKHOLDERS' EQUITY AND STOCK COMPENSATION</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/DefinedContributionPlans" id="DefinedContributionPlans">
				<link:definition>015 - Disclosure - DEFINED CONTRIBUTION PLANS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/IncomeTaxes" id="IncomeTaxes">
				<link:definition>016 - Disclosure - INCOME TAXES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
				<link:definition>017 - Disclosure - EARNINGS PER SHARE</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/SignificantCustomers" id="SignificantCustomers">
				<link:definition>018 - Disclosure - SIGNIFICANT CUSTOMERS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.quigleyco.com/role/QuarterlyInformation" id="QuarterlyInformation">
				<link:definition>019 - Disclosure - QUARTERLY INFORMATION (UNAUDITED)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:linkbaseRef xlink:type="simple" xlink:href="prph-20111231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="prph-20111231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="prph-20111231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="prph-20111231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
		</appinfo></annotation>
	<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
	<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
	<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
	<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
	<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
	<element name="DocumentAndEntityInformationAbstract" id="prph_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="BalanceSheetsParentheticalAbstract" id="prph_BalanceSheetsParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="WeightedAverageCommonSharesOutstandingBasicAndDiluted" id="prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedDuringPeriodValueExlusiveLicenseAgreement" id="prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="credit"/>
	<element name="StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" id="prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true"/>
	<element name="StockGrantedDuringPeriodValueEmploymentAgreement" id="prph_StockGrantedDuringPeriodValueEmploymentAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockGrantedDuringPeriodSharesEmploymentAgreement" id="prph_StockGrantedDuringPeriodSharesEmploymentAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="SalesDiscountsAndProvisionForBadDebts" id="prph_SalesDiscountsAndProvisionForBadDebts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="InventoryValuationProvision" id="prph_InventoryValuationProvision" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IncreaseDecreaseInAccruedMarketingCosts" id="prph_IncreaseDecreaseInAccruedMarketingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="CommonStockIssuedForLicenseAgreement" id="prph_CommonStockIssuedForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="PatentRightsAndRelatedRoyaltyCommitmentsAbstract" id="prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" id="prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="SignificantCustomersAbstract" id="prph_SignificantCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="SignificantCustomersTextBlock" id="prph_SignificantCustomersTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>prph-20111231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 09:38:41 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:15:14 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:11:42 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:11:42 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:03:51 PM Document Version 1.0-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.quigleyco.com/role/StatementOfFinancialPositionClassified"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsHeldForSaleCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsHeldForSaleCurrent" order="100" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" order="80" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="20" use="optional" weight="1"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="40" use="optional" weight="1"/>
	</calculationLink>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfIncome" roleURI="http://www.quigleyco.com/role/StatementOfIncome"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfIncome">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_SalesRevenueNet" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" order="40" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingAndMarketingExpense" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InterestAndOtherIncome" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="40" use="optional" weight="-1"/>
	</calculationLink>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.quigleyco.com/role/StatementOfCashFlowsIndirect"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="60" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AssetImpairmentCharges" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="100" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SalesDiscountsAndProvisionForBadDebts" xlink:label="loc_prph_SalesDiscountsAndProvisionForBadDebts"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_prph_SalesDiscountsAndProvisionForBadDebts" order="120" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_InventoryValuationProvision" xlink:label="loc_prph_InventoryValuationProvision"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_prph_InventoryValuationProvision" order="140" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="160" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" order="180" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="200" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="220" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_IncreaseDecreaseInAccruedMarketingCosts" xlink:label="loc_prph_IncreaseDecreaseInAccruedMarketingCosts"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_prph_IncreaseDecreaseInAccruedMarketingCosts" order="240" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="260" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" order="40" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity" order="40" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="20" use="optional" weight="1"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" weight="1"/>
	</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>prph-20111231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 09:38:41 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:15:14 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:11:42 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:11:42 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:03:51 PM Document Version 1.0-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#DocumentAndEntityInformation" roleURI="http://www.quigleyco.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.quigleyco.com/role/StatementOfFinancialPositionClassified"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#BalanceSheetsParenthetical" roleURI="http://www.quigleyco.com/role/BalanceSheetsParenthetical"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfIncome" roleURI="http://www.quigleyco.com/role/StatementOfIncome"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.quigleyco.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.quigleyco.com/role/StatementOfCashFlowsIndirect"/>
	<definitionLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_8" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_10" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="110" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" order="120" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_14" order="130" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_15" order="140" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityPublicFloat_16" order="150" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_InventoryNet_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsHeldForSaleCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleCurrent_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsHeldForSaleCurrent_7" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_8" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_11" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAbstract_12" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_12" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_14" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_12" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_15" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_12" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_16" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_18" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_19" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_CommonStockValue_20" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_TreasuryStockValue_23" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_19" xlink:to="loc_us-gaap_StockholdersEquity_24" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_25" order="50" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/BalanceSheetsParenthetical">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TreasuryStockShares_7" order="60" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfIncome">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SalesRevenueNet_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_GrossProfit_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5" xlink:to="loc_us-gaap_OperatingExpenses_9" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5" xlink:to="loc_us-gaap_OperatingIncomeLoss_10" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5" xlink:to="loc_us-gaap_InterestAndOtherIncome_11" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_13" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_16" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_16" xlink:to="loc_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted_17" order="0" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7_Default"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_7_Default" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_TreasuryStockMember_6" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_RetainedEarningsMember_5" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_CommonStockMember_3" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_9" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_10" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" xlink:label="loc_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement_13" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" xlink:label="loc_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement_14" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockGrantedDuringPeriodValueEmploymentAgreement" xlink:label="loc_prph_StockGrantedDuringPeriodValueEmploymentAgreement_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_prph_StockGrantedDuringPeriodValueEmploymentAgreement_15" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockGrantedDuringPeriodSharesEmploymentAgreement" xlink:label="loc_prph_StockGrantedDuringPeriodSharesEmploymentAgreement_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_prph_StockGrantedDuringPeriodSharesEmploymentAgreement_16" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_17" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18" order="110" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19" order="120" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_20" order="130" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_21" order="140" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_22" order="150" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_23" order="160" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_AssetImpairmentCharges_7" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_ShareBasedCompensation_8" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SalesDiscountsAndProvisionForBadDebts" xlink:label="loc_prph_SalesDiscountsAndProvisionForBadDebts_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_prph_SalesDiscountsAndProvisionForBadDebts_9" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_InventoryValuationProvision" xlink:label="loc_prph_InventoryValuationProvision_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_prph_InventoryValuationProvision_10" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_13" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_IncreaseDecreaseInAccruedMarketingCosts" xlink:label="loc_prph_IncreaseDecreaseInAccruedMarketingCosts_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_prph_IncreaseDecreaseInAccruedMarketingCosts_16" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_17" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_21" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_22" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_25" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_26"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_26" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_30"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_30" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_31"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_30" xlink:to="loc_us-gaap_IncomeTaxesPaid_31" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_CommonStockIssuedForLicenseAgreement" xlink:label="loc_prph_CommonStockIssuedForLicenseAgreement_32"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_30" xlink:to="loc_prph_CommonStockIssuedForLicenseAgreement_32" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_33"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_30" xlink:to="loc_us-gaap_StockIssued1_33" order="20" use="optional"/>
	</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>prph-20111231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 09:38:41 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:15:14 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:11:42 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:11:42 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:03:51 PM Document Version 1.0-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_DocumentAndEntityInformationAbstract" xlink:label="loc_prph_DocumentAndEntityInformationAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_DocumentAndEntityInformationAbstract" xlink:to="lab_prph_DocumentAndEntityInformationAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-Known Seasoned Issuer</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-Known Seasoned Issuer</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents (Note 2)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of year</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of zero and $13, respectively (Note 2)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory (Note 2)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsHeldForSaleCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldForSaleCurrent" xml:lang="en-US">Assets Held-For-Sale, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsHeldForSaleCurrent" xml:lang="en-US">Assets held for sale (Notes 2 and 4)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsHeldForSaleCurrent" xml:lang="en-US">Assets held for sale (Notes 2 and 4)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible asset, licensed technology (Note 3)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, plant and equipment, net of accumulated depreciation of $3,608 and $3,389, respectively (Note 4)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, plant and equipment, net of accumulated depreciation of $3,608 and $3,389, respectively (Note 4)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US">Accrued Royalties, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US">Accrued royalties and sales commissions (Note 5)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued Marketing Costs, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued advertising and other allowances</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Note 7)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $.0005 par value; authorized 50,000,000; issued: 20,161,636 and 19,353,672 shares, respectively (Note 8)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in-capital</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 5,336,053 and 4,646,053 shares, respectively (Note 8)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value, Ending Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 5,336,053 and 4,646,053 shares, respectively (Note 8)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 5,336,053 and 4,646,053 shares, respectively (Note 8)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders Equity Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders' Equity, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders' Equity, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_BalanceSheetsParentheticalAbstract" xlink:label="loc_prph_BalanceSheetsParentheticalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_BalanceSheetsParentheticalAbstract" xml:lang="en-US">Balance Sheets Parenthetical [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_BalanceSheetsParentheticalAbstract" xml:lang="en-US">Balance Sheets Parenthetical [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_BalanceSheetsParentheticalAbstract" xml:lang="en-US">Balance Sheets Parenthetical.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_BalanceSheetsParentheticalAbstract" xlink:to="lab_prph_BalanceSheetsParentheticalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for doubtful accounts (in dollars)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation (in dollars)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, par value (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, shares authorized</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, shares issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury stock, shares</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales Revenue, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Net sales (Notes 2 and 12)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales Revenue, Net, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="lab_us-gaap_SalesRevenueNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost Of Goods and Services Sold</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of sales (Note 2)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of sales (Note 2)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">Administrative</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development (Note 2)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development (Note 2)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expense</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss), Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndOtherIncome" xml:lang="en-US">Interest and Other Income</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestAndOtherIncome" xml:lang="en-US">Interest income</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestAndOtherIncome" xml:lang="en-US">Interest income</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from operations before taxes</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from operations before taxes</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) (Note 10)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit) (Note 10)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and dilutive loss per share (in dollars per share)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Weighted average common shares outstanding:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Common Shares Outstanding Basic and Diluted</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xml:lang="en-US">The average number of shares issued and outstanding that are used in calculating common stock basic and diluted EPS, determined based on the timing of issuance of shares in the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xlink:to="lab_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" xlink:label="loc_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" xml:lang="en-US">Stock Issued During Period Value Exlusive License Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" xml:lang="en-US">Common Stock Issued to Phosphangenics Limited pursuant to an Exclusive License Agreement (Note 3)</label>
		<label xlink:type="resource" xlink:label="lab_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Value of common stock issued to phosphangenics limited pursuant to exclusive license agreement.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" xlink:to="lab_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" xlink:label="loc_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" xml:lang="en-US">Stock Issued During Period Shares Exlusive License Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" xml:lang="en-US">Common Stock Issued to Phosphangenics Limited pursuant to an Exclusive License Agreement (Note 3) (in shares)</label>
		<label xlink:type="resource" xlink:label="lab_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">Number of shares issued to phosphangenics limited pursuant to exclusive license agreement.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" xlink:to="lab_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockGrantedDuringPeriodValueEmploymentAgreement" xlink:label="loc_prph_StockGrantedDuringPeriodValueEmploymentAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_StockGrantedDuringPeriodValueEmploymentAgreement" xml:lang="en-US">Stock Granted During Period Value Employment Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_StockGrantedDuringPeriodValueEmploymentAgreement" xml:lang="en-US">Common stock granted pursuant to an employment agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_StockGrantedDuringPeriodValueEmploymentAgreement" xml:lang="en-US">Value of stock granted pursuant to an employment agreement.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_StockGrantedDuringPeriodValueEmploymentAgreement" xlink:to="lab_prph_StockGrantedDuringPeriodValueEmploymentAgreement"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockGrantedDuringPeriodSharesEmploymentAgreement" xlink:label="loc_prph_StockGrantedDuringPeriodSharesEmploymentAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_StockGrantedDuringPeriodSharesEmploymentAgreement" xml:lang="en-US">Stock Granted During Period Shares Employment Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_StockGrantedDuringPeriodSharesEmploymentAgreement" xml:lang="en-US">Common stock granted pursuant to an employment agreement (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_StockGrantedDuringPeriodSharesEmploymentAgreement" xml:lang="en-US">Number of shares granted pursuant to an employment agreement.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_StockGrantedDuringPeriodSharesEmploymentAgreement" xlink:to="lab_prph_StockGrantedDuringPeriodSharesEmploymentAgreement"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xml:lang="en-US">Stock Granted During Period, Value, Share-Based Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xml:lang="en-US">Common stock granted pursuant to a compensation agreement</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Common stock granted pursuant to a compensation agreement (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share-Based Compensation, Requisite Service Period Recognition</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation expense</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xml:lang="en-US">Adjustments To Additional Paid In Capital, Income Tax Benefit From Share-Based Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xml:lang="en-US">Tax benefits from exercise of stock options</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xml:lang="en-US">Income Tax Reconciliation, Change In Deferred Tax Assets Valuation Allowance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xml:lang="en-US">Tax benefit allowance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Treasury Stock Value Acquired Cost Method</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Treasury stock purchase (Note 8)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xml:lang="en-US">Treasury Stock Shares Acquired</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xml:lang="en-US">Treasury stock purchase (Note 8) (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) On Sale Of Property Plant Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">(Gain) loss on the sales of fixed assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">(Gain) loss on the sales of fixed assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairment charge</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SalesDiscountsAndProvisionForBadDebts" xlink:label="loc_prph_SalesDiscountsAndProvisionForBadDebts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_SalesDiscountsAndProvisionForBadDebts" xml:lang="en-US">Sales Discounts and Provision For Bad Debts</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_SalesDiscountsAndProvisionForBadDebts" xml:lang="en-US">Sales discounts and provision for bad debts</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_SalesDiscountsAndProvisionForBadDebts" xml:lang="en-US">Aggregate cash discounts given by the entity for goods sold to customers for early payments of accounts due. Also includes, amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_prph_SalesDiscountsAndProvisionForBadDebts" xml:lang="en-US">Sales discounts and provision for bad debts</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_SalesDiscountsAndProvisionForBadDebts" xlink:to="lab_prph_SalesDiscountsAndProvisionForBadDebts"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_InventoryValuationProvision" xlink:label="loc_prph_InventoryValuationProvision"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_InventoryValuationProvision" xml:lang="en-US">Inventory Valuation Provision</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_InventoryValuationProvision" xml:lang="en-US">Inventory valuation provision</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_InventoryValuationProvision" xml:lang="en-US">Net charge to cost of goods sold that represents the reduction of the carrying amount of inventory or the utilization of prior obsolesce provisions, generally attributable to obsolescence or market conditions.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_prph_InventoryValuationProvision" xml:lang="en-US">Inventory valuation provision</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_InventoryValuationProvision" xlink:to="lab_prph_InventoryValuationProvision"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) In Inventories</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_IncreaseDecreaseInAccruedMarketingCosts" xlink:label="loc_prph_IncreaseDecreaseInAccruedMarketingCosts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_IncreaseDecreaseInAccruedMarketingCosts" xml:lang="en-US">Increase (Decrease) In Accrued Marketing Costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_IncreaseDecreaseInAccruedMarketingCosts" xml:lang="en-US">Accrued advertising and other allowances</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_IncreaseDecreaseInAccruedMarketingCosts" xml:lang="en-US">Net change during the period in the amount of Accrued advertising and other allowances at the period end.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_IncreaseDecreaseInAccruedMarketingCosts" xlink:to="lab_prph_IncreaseDecreaseInAccruedMarketingCosts"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Increase (Decrease) In Other Operating Assets and Liabilities, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Other operating assets and liabilities, net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Other operating assets and liabilities, net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Other operating assets and liabilities, net</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Capital expenditures</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Capital expenditures</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments To Acquire Intangible Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Acquisition of product license</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Acquisition of product license</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Acquisition of product license</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds From Sale Of Property, Plant, and Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of fixed assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of fixed assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash flows provided by (used in) investing activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash flows provided by (used in) investing activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds From Stock Options Exercised</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from the exercise of stock options</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Payments For Repurchase Of Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Purchase of treasury stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Purchase of treasury stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Purchase of treasury stock</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income taxes paid</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income taxes paid</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_CommonStockIssuedForLicenseAgreement" xlink:label="loc_prph_CommonStockIssuedForLicenseAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_CommonStockIssuedForLicenseAgreement" xml:lang="en-US">Common Stock Issued For License Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_CommonStockIssuedForLicenseAgreement" xml:lang="en-US">Common stock issued to Phosphagenics Limited pursuant to a product license agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_prph_CommonStockIssuedForLicenseAgreement" xml:lang="en-US">Common stock issued to Phosphagenics Limited pursuant to a product license agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_CommonStockIssuedForLicenseAgreement" xml:lang="en-US">Consideration paid in the form of common shares for license agreement.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_CommonStockIssuedForLicenseAgreement" xlink:to="lab_prph_CommonStockIssuedForLicenseAgreement"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stockissued1</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Common stock issued, in lieu of cash, as payment of accrued compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Common stock issued, in lieu of cash, as payment of accrued compensation</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xml:lang="en-US">Investments In and Advances To Affiliates, Schedule Of Investments [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xml:lang="en-US">Investments in and Advances to Affiliates, Schedule of Investments [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xml:lang="en-US">Investments In and Advances To Affiliates, Schedule Of Investments [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xml:lang="en-US">Investments in and Advances to Affiliates, Schedule of Investments [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract" xlink:label="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract" xml:lang="en-US">Patent Rights and Related Royalty Commitments [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract" xml:lang="en-US">Patent Rights and Related Royalty Commitments [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract" xlink:to="lab_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" xlink:label="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" xml:lang="en-US">Patent Rights and Related Royalty Commitments [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" xml:lang="en-US">Patent Rights and Related Royalty Commitments [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" xml:lang="en-US">The entire disclosure for patent rights and related royalty commitments.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" xlink:to="lab_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders Equity Note [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SignificantCustomersAbstract" xlink:label="loc_prph_SignificantCustomersAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_SignificantCustomersAbstract" xml:lang="en-US">Significant Customers [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_SignificantCustomersAbstract" xml:lang="en-US">Significant Customers [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_SignificantCustomersAbstract" xlink:to="lab_prph_SignificantCustomersAbstract"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SignificantCustomersTextBlock" xlink:label="loc_prph_SignificantCustomersTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prph_SignificantCustomersTextBlock" xml:lang="en-US">Significant Customers [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prph_SignificantCustomersTextBlock" xml:lang="en-US">Significant Customers [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prph_SignificantCustomersTextBlock" xml:lang="en-US">The entire disclosure for significant customers.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prph_SignificantCustomersTextBlock" xlink:to="lab_prph_SignificantCustomersTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain"/>
	</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>prph-20111231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 09:38:42 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:15:14 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 05:11:42 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:11:42 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, March 06, 2012 03:03:51 PM Document Version 1.0-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#DocumentAndEntityInformation" roleURI="http://www.quigleyco.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.quigleyco.com/role/StatementOfFinancialPositionClassified"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#BalanceSheetsParenthetical" roleURI="http://www.quigleyco.com/role/BalanceSheetsParenthetical"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfIncome" roleURI="http://www.quigleyco.com/role/StatementOfIncome"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.quigleyco.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.quigleyco.com/role/StatementOfCashFlowsIndirect"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#OrganizationAndBusiness" roleURI="http://www.quigleyco.com/role/OrganizationAndBusiness"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.quigleyco.com/role/SummaryOfSignificantAccountingPolicies"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#InvestmentInPhusionLaboratoriesLlc" roleURI="http://www.quigleyco.com/role/InvestmentInPhusionLaboratoriesLlc"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#PropertyPlantAndEquipment" roleURI="http://www.quigleyco.com/role/PropertyPlantAndEquipment"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#PatentRightsAndRelatedRoyaltyCommitments" roleURI="http://www.quigleyco.com/role/PatentRightsAndRelatedRoyaltyCommitments"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#OtherCurrentLiabilities" roleURI="http://www.quigleyco.com/role/OtherCurrentLiabilities"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#Commitmentsandcontingencies" roleURI="http://www.quigleyco.com/role/Commitmentsandcontingencies"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#StockholdersEquityAndStockCompensation" roleURI="http://www.quigleyco.com/role/StockholdersEquityAndStockCompensation"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#DefinedContributionPlans" roleURI="http://www.quigleyco.com/role/DefinedContributionPlans"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#IncomeTaxes" roleURI="http://www.quigleyco.com/role/IncomeTaxes"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#EarningsLossPerShare" roleURI="http://www.quigleyco.com/role/EarningsLossPerShare"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#SignificantCustomers" roleURI="http://www.quigleyco.com/role/SignificantCustomers"/>
	<roleRef xlink:type="simple" xlink:href="prph-20111231.xsd#QuarterlyInformation" roleURI="http://www.quigleyco.com/role/QuarterlyInformation"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_DocumentAndEntityInformationAbstract" xlink:label="loc_prph_DocumentAndEntityInformationAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prph_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_6" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_TradingSymbol_7" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_9" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_10" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalYearFocus_13" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_14" order="110" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityVoluntaryFilers_15" order="120" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCurrentReportingStatus_16" order="130" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityPublicFloat_17" order="140" use="optional"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_InventoryNet_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsHeldForSaleCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleCurrent_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsHeldForSaleCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_13" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_13" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_13" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_13" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_CommonStockValue_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_TreasuryStockValue_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_StockholdersEquity_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/BalanceSheetsParenthetical">
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_BalanceSheetsParentheticalAbstract" xlink:label="loc_prph_BalanceSheetsParentheticalAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prph_BalanceSheetsParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_TreasuryStockShares_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfIncome">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SalesRevenueNet_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_GrossProfit_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_SellingAndMarketingExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_OperatingExpenses_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_OperatingIncomeLoss_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_InterestAndOtherIncome_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17" xlink:to="loc_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_CommonStockMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_RetainedEarningsMember_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_TreasuryStockMember_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetIncomeLoss_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement" xlink:label="loc_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement" xlink:label="loc_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockGrantedDuringPeriodValueEmploymentAgreement" xlink:label="loc_prph_StockGrantedDuringPeriodValueEmploymentAgreement_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_prph_StockGrantedDuringPeriodValueEmploymentAgreement_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_StockGrantedDuringPeriodSharesEmploymentAgreement" xlink:label="loc_prph_StockGrantedDuringPeriodSharesEmploymentAgreement_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_prph_StockGrantedDuringPeriodSharesEmploymentAgreement_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_21" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_22" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_23" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_24" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_25" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_26" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetIncomeLoss_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AssetImpairmentCharges_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SalesDiscountsAndProvisionForBadDebts" xlink:label="loc_prph_SalesDiscountsAndProvisionForBadDebts_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_prph_SalesDiscountsAndProvisionForBadDebts_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_InventoryValuationProvision" xlink:label="loc_prph_InventoryValuationProvision_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_prph_InventoryValuationProvision_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_IncreaseDecreaseInAccruedMarketingCosts" xlink:label="loc_prph_IncreaseDecreaseInAccruedMarketingCosts_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_prph_IncreaseDecreaseInAccruedMarketingCosts_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_32"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_33"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_us-gaap_IncomeTaxesPaid_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_CommonStockIssuedForLicenseAgreement" xlink:label="loc_prph_CommonStockIssuedForLicenseAgreement_34"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_prph_CommonStockIssuedForLicenseAgreement_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_35"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_us-gaap_StockIssued1_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/OrganizationAndBusiness">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/SummaryOfSignificantAccountingPolicies">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/InvestmentInPhusionLaboratoriesLlc">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract_0" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/PropertyPlantAndEquipment">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/PatentRightsAndRelatedRoyaltyCommitments">
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract" xlink:label="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock" xlink:label="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract_0" xlink:to="loc_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/OtherCurrentLiabilities">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/Commitmentsandcontingencies">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/StockholdersEquityAndStockCompensation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/DefinedContributionPlans">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/IncomeTaxes">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/EarningsLossPerShare">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/SignificantCustomers">
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SignificantCustomersAbstract" xlink:label="loc_prph_SignificantCustomersAbstract_0"/>
		<loc xlink:type="locator" xlink:href="prph-20111231.xsd#prph_SignificantCustomersTextBlock" xlink:label="loc_prph_SignificantCustomersTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prph_SignificantCustomersAbstract_0" xlink:to="loc_prph_SignificantCustomersTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.quigleyco.com/role/QuarterlyInformation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVESTMENT IN PHUSION LABORATORIES, LLC.<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract', window );"><strong>Investments In and Advances To Affiliates, Schedule Of Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock', window );">Investments in and Advances to Affiliates, Schedule of Investments [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 3 &#8211; INVESTMENT IN PHUSION LABORATORIES, LLC.</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">On March 22, 2010, the Company, PSI Parent, PSI and the Joint Venture entered into the LLC Agreement of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent&#8217;s proprietary patented TPM.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In connection with the LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the &#8220;Original License Agreement&#8221;), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent&#8217;s TPM-related patents and related know-how (collectively, the &#8220;PSI Technology&#8221;) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent (such shares, the &#8220;PSI Shares&#8221;), and made a one-time payment to PSI Parent of $1.0 million. On the date the PSI Shares were issued, PSI Parent agreed, pursuant to a Share Transfer Restriction Agreement, dated March 22, 2010 (the &#8220;Share Transfer Restriction Agreement&#8221;), between us and PSI Parent, that, with certain exceptions, it would not sell or otherwise dispose of any of the PSI Shares prior to June 1, 2012 (see discussion below). The PSI Shares were issued pursuant to an exemption from registration under the Securities Act, by virtue of Section 4(2) of the Securities Act and by virtue of Rule 506 of Regulation D under the Securities Act. Such sale and issuance did not involve any public offering and was made without general solicitation or advertising. Additionally, PSI Parent represented to us, among other things, that PSI Parent is not a US Person (as defined in Regulation S under the Securities Act), that PSI Parent is an accredited investor with access to all relevant information necessary to evaluate its investment and that the PSI Shares were being acquired for investment purposes only.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In September 2011, PSI Parent entered into certain Private Resale Agreements (&#8220;PSAs&#8221;) with seven third party purchasers, under which Phosphagenics sold, with our consent, an aggregate of 750,000 shares of our Common Stock. Under the PSAs, the purchasers may not, without the prior written consent of the Company, prior to the one year anniversary of the PSAs, directly or indirectly, sell, give, pledge, hypothecate, assign or otherwise transfer the purchased shares, in whole or in part. Contemporaneously with PSI Parent consummating the PSAs, we consummated an agreement with PSI Parent to redeem the then remaining 690,000 PSI Shares held by PSI Parent (see Note 8).</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In accordance with a Contribution Agreement, dated March 22, 2010 (the &#8220;Contribution Agreement&#8221;), by and among us, PSI Parent, PSI, and the Joint Venture, we transferred, conveyed and assigned to the Joint Venture all of our rights, title and interest in, to and under the Original License Agreement, and the Joint Venture assumed, and undertook to pay, discharge and perform when due, all of our liabilities and obligations under and arising pursuant to the Original License Agreement (such actions, collectively, the &#8220;Assignment and Assumption&#8221;).</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Pursuant to the Contribution Agreement and in order to reflect the Assignment and Assumption, we, PSI Parent and the Joint Venture entered into an Amended and Restated License Agreement, dated March 22, 2010 (the &#8220;Amended License Agreement&#8221;), which amends and restates the Original License Agreement to reflect that the Joint Venture is the licensee thereunder and which otherwise contains substantially the same terms as the Original License Agreement. The Joint Venture has the right to grant one or more sub-licenses of the rights granted under the Amended License Agreement to one or more third parties for reasonable consideration in any part of the applicable territory. The Amended License Agreement provides that PSI Parent shall not, directly or through third parties, exploit the covered intellectual property during the term thereof, subject to certain limitations. The Amended License Agreement will remain in effect until the expiration of the last to expire of the patents included within the PSI Technology or any extensions thereof. Either party may terminate the Amended License Agreement upon written notice to the other party in the event of certain events involving bankruptcy or insolvency. The Amended License Agreement also contains, among other things, provisions concerning the treatment of confidential information, the ownership of intellectual property and indemnification obligations.</p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. PSI Parent will conduct and oversee much of the product development, formulation, testing and other research and development needed by the Joint Venture, and we will oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may be required, from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund its operations, in accordance with agreed upon budgets for products to be developed. Specifically, we contributed in Fiscal 2010 $500,000 in cash as initial capital and we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established to date), toward the initial development and marketing costs of new products for the Joint Venture. The newly formed Joint Venture has not engaged in any financial transactions, other than organizational expenses and general market and product analysis. At December 31, 2011, cash and equivalents includes $425,000 which is expected to be used by the Joint Venture to fund future product development initiatives currently under consideration by PSI Parent, PSI and us.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The Joint Venture is managed by a four-person Board of Managers, with two managers appointed by each member. The LLC Agreement contains other normally found terms in such arrangements, including provisions relating to governance of the Joint Venture, indemnification obligations of the Joint Venture, allocation of profits and losses, the distribution of funds to the members and restrictions on transfer of a member&#8217;s interest.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Our determination is that the Joint Venture qualifies as a VIE and that we are the primary beneficiary. As a consequence, we have consolidated the Joint Venture financial statements beginning with the quarter ended March 31, 2010. Since inception and including Fiscal 2011, the newly formed Joint Venture has not engaged in any financial transactions, other than certain organizational expenses and general market and product analysis, as formal operations are not expected to commence until later in Fiscal 2012. Furthermore, the liabilities and other obligations incurred, if any, by the Joint Venture is without recourse to us and do not create a claim on our general assets. At December 31, 2011, we have recorded the $3.6 million payment representing the estimated fair value to acquire the product license as an intangible asset. We currently estimate the expected useful life of the product license to be approximately 10 years which we will begin amortizing the cost of intangible asset once product commercialization is completed with PSI Parent and the OTC drug products begin to ship to our retail customers.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The product development effort of the Joint Venture is a multi-stage process that includes (i) market analysis and research, (ii) product formulation research and development, (iii) product evaluation, (iv) product commercialization, (v) production and distribution, and (vi) retail and consumer advertising and marketing. During Fiscal 2011, we conducted preliminary market analysis to identify market opportunities to develop differentiated, science-based, efficacious products that deliver results to consumers and worked with PSI and PSI Parent to provide initial formulations for certain identified OTC active ingredients. In December 2011, we initiated a study of these preliminary formulations to evaluate product attributes, performance and potential commercial viability. These studies are expected to be completed later in Fiscal 2012. For Fiscal 2011, any expenses, including organizational, marketing analysis and preliminary formulations have been absorbed by the respective Joint Venture members. As of December 31, 2011, we have not established a formal commercialization program timeline, pending the results of the recently initiated studies, for any specific OTC product covered under the product license but we do not project that any such OTC products will be available for shipment within the next twelve months.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the information required in the supplementary schedule applicable to management investment companies summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates.  It reflects specified information about ownership, financial results from, and financial position in such entities as of the balance sheet date and for the period then ended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 320<br><br> -Section S99<br><br> -Paragraph 6<br><br> -Subparagraph (SX 210.12-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6955306&amp;loc=d3e611322-123010<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 14<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y
M-3!B9F-C9F4S8V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C0Q
M-3`U9C1?.#AB,%\T-6$X7V$T,3E?.34P8F9C8V9E,V-F+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1$]#54U%3E1?04Y$7T5.5$E465])3D9/4DU!5$E//"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?4U1//"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0T%3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3U)'04Y)6D%424].7T%.1%]"55-)3D534SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-534U!4EE?3T9?
M4TE'3DE&24-!3E1?04-#3U5.5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DE.5D535$U%3E1?24Y?4$A54TE/3E],04)/4D%43SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!23U!%4E19
M7U!,04Y47T%.1%]%455)4$U%3E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y0051%3E1?4DE'2%137T%.1%]214Q!5$5$7U)/64$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/5$A%4E]#
M55)214Y47TQ)04))3$E42453/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T]-34E4345.5%-?04Y$7T-/3E1)3D=%3D-)15,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%
M4E-?15%525197T%.1%]35$]#2U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y$149)3D5$7T-/3E1224)55$E/3E]03$%.4SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.0T]-15]405A%
M4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5!4DY)
M3D=37U!%4E]32$%213PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-)1TY)1DE#04Y47T-54U1/34524SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E%505)415),65])3D9/4DU!5$E/3E]5
M3D%51$E413PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE
M<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z
M06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T
M<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T
M96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC
M96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\
M8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@
M36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8T,34P-68T7S@X8C!?-#5A
M.%]A-#$Y7SDU,&)F8V-F93-C9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y-3!B9F-C9F4S8V8O5V]R
M:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6%)!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY$3T-5345.5"!!3D0@14Y42519($E.1D]234%424].
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`P
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y0<F]0:&%S92!,86)S+"!);F,N/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A
M;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P
M,#`X-C@R-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE
M<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4VUA
M;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/G!R<&@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@
M4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30L.#,V+#,T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M2SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D1E8R`S,2P-"@D),C`Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&
M;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1ED\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"U+;F]W;B!396%S;VYE9"!)<W-U
M97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%!U8FQI8R!&
M;&]A=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#<U-2PW
M,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8T
M,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y
M-3!B9F-C9F4S8V8O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M4#-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4140@0D%,
M04Y#12!32$5%5%,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%34T544SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S("A.;W1E(#(I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4L-30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X+#(S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L92P@
M;F5T(&]F(&%L;&]W86YC92!F;W(@9&]U8G1F=6P@86-C;W5N=',@;V8@>F5R
M;R!A;F0@)#$S+"!R97-P96-T:79E;'D@*$YO=&4@,BD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,C$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX,C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2`H3F]T
M92`R*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV.#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8X
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S0W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E
M=',@:&5L9"!F;W(@<V%L92`H3F]T97,@,B!A;F0@-"D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,3DU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L-S4V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1A;F=I8FQE(&%S<V5T+"!L:6-E;G-E9"!T96-H;F]L;V=Y("A.;W1E
M(#,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4W-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3<W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]P97)T>2P@<&QA;G0@86YD(&5Q=6EP;65N="P@;F5T(&]F(&%C8W5M
M=6QA=&5D(&1E<')E8VEA=&EO;B!O9B`D,RPV,#@@86YD("0S+#,X.2P@<F5S
M<&5C=&EV96QY("A.;W1E(#0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#,P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.2PP-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,2PV.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3$E!0DE,251)15,@
M04Y$(%-43T-+2$],1$524R<@15%52519/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!R;WEA
M;'1I97,@86YD('-A;&5S(&-O;6UI<W-I;VYS("A.;W1E(#4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4R-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3(T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&%D
M=F5R=&ES:6YG(&%N9"!O=&AE<B!A;&QO=V%N8V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#DU.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3(T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C=7)R96YT(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#@U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU-251-14Y44R!!3D0@
M0T].5$E.1T5.0TE%4R`H3F]T92`W*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%D\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"`D+C`P,#4@<&%R('9A;'5E.R!A=71H;W)I>F5D(#4P+#`P,"PP
M,#`[(&ES<W5E9#H@,C`L,38Q+#8S-B!A;F0@,3DL,S4S+#8W,B!S:&%R97,L
M(')E<W!E8W1I=F5L>2`H3F]T92`X*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN+6-A<&ET86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#4U,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#8R-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-"PV.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PY.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@870@8V]S="P@-2PS
M,S8L,#4S(&%N9"`T+#8T-BPP-3,@<VAA<F5S+"!R97-P96-T:79E;'D@*$YO
M=&4@."D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U+#8S-RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-2PQ.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#(R-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#0V,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET
M:65S(&%N9"!3=&]C:VAO;&1E<G,G($5Q=6ET>2P@5&]T86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL,#<Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,2PV.34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8T,34P-68T7S@X
M8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y-3!B9F-C9F4S
M8V8O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5TE!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%
M5%,@6U!A<F5N=&AE=&EC86Q=("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E
M>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S("AI;B!D;VQL
M87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C=6UU;&%T960@9&5P<F5C:6%T:6]N("AI;B!D;VQL87)S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#8P.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPS.#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!3=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!3=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@4W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(P+#$V,2PV,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PS-3,L-C<R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C
M:RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,S
M-BPP-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#8T-BPP-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S8T,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C
M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V-#$U,#5F-%\X.&(P
M7S0U83A?830Q.5\Y-3!B9F-C9F4S8V8O5V]R:W-H965T<R]3:&5E=#`T+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%5%A!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY3
M3TQ)1$%4140@4U1!5$5-14Y44R!/1B!/4$52051)3TY3("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!E>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@<V%L97,@*$YO=&5S(#(@86YD(#$R*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPT-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T+#4P,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3DL.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T(&]F('-A;&5S("A.;W1E(#(I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV+#$W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C<R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PR-#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]F
M:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#(X,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.#,P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$L-38Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L97,@86YD(&UA
M<FME=&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY,#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#4W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L.#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PP,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV+#`U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,S0T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@*$YO=&4@,BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PS,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@97AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,#(P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-#(T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L
M-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,BPW,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPU.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPY,S4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O
M;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S
M<R!F<F]M(&]P97)A=&EO;G,@8F5F;W)E('1A>&5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R+#<Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#4T,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#DR-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T
M87@@*&)E;F5F:70I("A.;W1E(#$P*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(L-S$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RPU,#$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#@T,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC
M(&%N9"!D:6QU=&EV92!L;W-S('!E<B!S:&%R92`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,3@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,"XS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!A=F5R86=E(&-O;6UO
M;B!S:&%R97,@;W5T<W1A;F1I;F<Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D("AI;B!S:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PX,3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PR
M.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,BPY-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S8T,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C9@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V-#$U,#5F-%\X.&(P7S0U83A?
M830Q.5\Y-3!B9F-C9F4S8V8O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%0D)#23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4
M140@4U1!5$5-14Y44R!/1B!35$]#2TA/3$1%4E,G($5154E462`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<SPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M26X@0V%P:71A
M;"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y2
M971A:6YE9"!%87)N:6YG<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y4<F5A<W5R>2!3=&]C:R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y4;W1A;#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R
M,#`X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,W+#4Y
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-2PS-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#(U+#$X."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$W+#<W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S
M*2!A="!$96,N(#,Q+"`R,#`X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPY,#@L,S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,RPX-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPX-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C
M:7-E(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!S=&]C
M:R!O<'1I;VYS("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y487@@8F5N969I=',@9G)O;2!E>&5R8VES92!O
M9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y487@@8F5N969I="!A;&QO=V%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R
M,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L-S(V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU
M,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R-2PQ.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30L,#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@
M,S$L(#(P,#D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#`S
M,RPS.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#4P,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S+#4P,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@<W1O
M8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M,"PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!3=&]C:R!)<W-U960@=&\@4&AO<W!H86YG96YI8W,@
M3&EM:71E9"!P=7)S=6%N="!T;R!A;B!%>&-L=7-I=F4@3&EC96YS92!!9W)E
M96UE;G0@*$YO=&4@,RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#4W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VL@27-S=65D('1O(%!H;W-P:&%N
M9V5N:6-S($QI;6ET960@<'5R<W5A;G0@=&\@86X@17AC;'5S:79E($QI8V5N
M<V4@06=R965M96YT("A.;W1E(#,I("AI;B!S:&%R97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0T,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!G
M<F%N=&5D('!U<G-U86YT('1O(&%N(&5M<&QO>6UE;G0@86=R965M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@9W)A;G1E9"!P=7)S=6%N="!T;R!A;B!E;7!L;WEM96YT(&%G<F5E;65N
M="`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S8L,3$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VL@9W)A;G1E9"!P=7)S=6%N="!T;R!A(&-O
M;7!E;G-A=&EO;B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!G<F%N=&5D('!U<G-U86YT('1O
M(&$@8V]M<&5N<V%T:6]N(&%G<F5E;65N="`H:6X@<VAA<F5S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<L-C(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C
M;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&%X(&)E;F5F:71S(&9R;VT@97AE<F-I<V4@;V8@<W1O
M8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&%X(&)E;F5F:70@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PV,C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#DX.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-2PQ.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,L-#8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@,S$L
M(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#<P-RPV
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#<Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R+#<Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!G<F%N=&5D('!U<G-U86YT('1O
M(&%N(&5M<&QO>6UE;G0@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!G<F%N=&5D('!U<G-U
M86YT('1O(&%N(&5M<&QO>6UE;G0@86=R965M96YT("AI;B!S:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#$L,C4T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VL@9W)A;G1E9"!P=7)S=6%N="!T;R!A(&-O;7!E;G-A=&EO;B!A9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K(&=R86YT960@<'5R<W5A;G0@=&\@82!C;VUP96YS871I
M;VX@86=R965M96YT("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-C8L-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@
M97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4<F5A<W5R>2!S=&]C:R!P=7)C:&%S92`H3F]T92`X*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0T.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K
M('!U<F-H87-E("A.;W1E(#@I("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V.3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q
M+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M,2PU-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#0L-CDY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,C4L-C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$L,C(V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!S
M:&%R97,I(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#@R-2PU.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S8T,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F
M8V-F93-C9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V-#$U,#5F
M-%\X.&(P7S0U83A?830Q.5\Y-3!B9F-C9F4S8V8O5V]R:W-H965T<R]3:&5E
M=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-C9!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`P.3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#87-H(&9L;W=S(&9R;VT@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(L-S$P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,RPU,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@S+#@T,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC
M:6QE(&YE="!L;W-S('1O(&YE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN
M*2!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^*$=A:6XI(&QO<W,@;VX@=&AE('-A;&5S(&]F(&9I>&5D(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER
M;65N="!C:&%R9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE<R!D:7-C;W5N
M=',@86YD('!R;W9I<VEO;B!F;W(@8F%D(&1E8G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD@=F%L=6%T
M:6]N('!R;W9I<VEO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S
M971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$X.2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0X-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV
M96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X.3$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@V-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S
M('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D(&%D=F5R=&ES:6YG(&%N9"!O=&AE<B!A;&QO=V%N
M8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-C4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS.#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<RP@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@;W!E<F%T:6YG(&%C
M=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,3`X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,L-30Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@:6YV97-T:6YG
M(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<&ET86P@97AP96YD:71U<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,34S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P."D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N(&]F
M('!R;V1U8W0@;&EC96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE('-A;&4@;V8@9FEX960@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&-A<V@@9FQO=W,@<')O=FED960@8GD@*'5S960@:6XI(&EN=F5S
M=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PQ-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!F:6YA
M;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@97AE<F-I<V4@;V8@
M<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4'5R8VAA<V4@;V8@=')E87-U<GD@<W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0T.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I
M9&5D(&)Y("AU<V5D(&EN*2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#0Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-R
M96%S92`H9&5C<F5A<V4I(&EN(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-CDQ*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-38Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!B96=I;FYI;F<@;V8@
M>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PR,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPX
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,2PY-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@96YD(&]F
M('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-30Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PR
M,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,BPX,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F5S(&]F
M(&-A<V@@9FQO=R!I;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S('!A:60\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@
M:7-S=65D('1O(%!H;W-P:&%G96YI8W,@3&EM:71E9"!P=7)S=6%N="!T;R!A
M('!R;V1U8W0@;&EC96YS92!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#4W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960L(&EN
M(&QI974@;V8@8V%S:"P@87,@<&%Y;65N="!O9B!A8V-R=65D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8T
M,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y
M-3!B9F-C9F4S8V8O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3U)'04Y)6D%424].($%.1"!"
M55-)3D534SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<F=A;FEZ871I;VXL($-O;G-O;&ED871I;VX@86YD(%!R
M97-E;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]R
M9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F
M($9I;F%N8VEA;"!3=&%T96UE;G1S($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M
M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/CQB/DY/5$4@,2`F(S@R,3$[($]21T%.25I!5$E/3B!!3D0@
M0E5324Y%4U,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CXF
M(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E!R;U!H87-E($QA
M8G,L($EN8R`H)B,X,C(P.W=E)B,X,C(Q.RP@)B,X,C(P.W5S)B,X,C(Q.R!O
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M8V5U=&EC86P@<')O9'5C=',N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/=7(@<')I;6%R>2!B=7-I
M;F5S<R!I<R!C=7)R96YT;'D@=&AE(&UA;G5F86-T=7)E+"!D:7-T<FEB=71I
M;VXL(&UA<FME=&EN9R!A;F0@<V%L92!O9B!/5$,@8V]L9"!R96UE9'D@<')O
M9'5C=',@=&\@8V]N<W5M97)S('1H<F]U9V@@;F%T:6]N86P@8VAA:6XL(')E
M9VEO;F%L+"!S<&5C:6%L='D@86YD(&QO8V%L(')E=&%I;"!S=&]R97,N($]U
M<B!F;&%G<VAI<"!B<F%N9"!I<R!#;VQD+45%6D4\9F]N=#X\<W5P/B8C,C$P
M.SPO<W5P/CPO9F]N=#X\<W5P/B`\+W-U<#Y#;VQD(%)E;65D>2!A;F0@;W5R
M('!R:6YC:7!A;"!P<F]D=6-T(&ES($-O;&0M145:13QF;VYT/CQS=7`^)B,R
M,3`[/"]S=7`^/"]F;VYT/B!Z:6YC(&=L=6-O;F%T92!L;WIE;F=E<RP@<')O
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M;"`R,#$Q+"!&:7-C86P@,C`Q,"!A;F0@1FES8V%L(#(P,#D@*&%S(&5A8V@@
M:7,@9&5F:6YE9"!B96QO=RDL(&]U<B!R979E;G5E<R!F<F]M(&-O;G1I;G5I
M;F<@;W!E<F%T:6]N<R!H879E(&-O;64@<')I;F-I<&%L;'D@9G)O;2!O=7(@
M3U1#(&-O;&0@<F5M961Y('!R;V1U8W1S+CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@36%R8V@@
M,C(L(#(P,3`L('1H92!#;VUP86YY+"!0:&]S<&AA9V5N:6-S($QI;6ET960@
M*"8C.#(R,#M04TD@4&%R96YT)B,X,C(Q.RDL(&%N($%U<W1R86QI86X@8V]R
M<&]R871I;VXL(%!H;W-P:&%G96YI8W,@26YC+B`H)B,X,C(P.U!3228C.#(R
M,3LI+"!A($1E;&%W87)E(&-O<G!O<F%T:6]N(&%N9"!S=6)S:61I87)Y(&]F
M(%!322!087)E;G0L(&%N9"!0:'5S:6]N($QA8F]R871O<FEE<RP@3$Q#("AT
M:&4@)B,X,C(P.TIO:6YT(%9E;G1U<F4F(S@R,C$[*2P@82!$96QA=V%R92!L
M:6UI=&5D(&QI86)I;&ET>2!C;VUP86YY+"!E;G1E<F5D(&EN=&\@82!,:6UI
M=&5D($QI86)I;&ET>2!#;VUP86YY($%G<F5E;65N="`H=&AE("8C.#(R,#M,
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M;V=Y("@F(S@R,C`[5%!-)B,X,C(Q.RDN(%1032!F86-I;&ET871E<R!T:&4@
M9&5L:79E<GD@86YD(&1E<'1H(&]F('!E;F5T<F%T:6]N(&]F(&%C=&EV92!M
M;VQE8W5L97,@:6X@<&AA<FUA8V5U=&EC86PL(&YU=')A8V5U=&EC86PL(&%N
M9"!O=&AE<B!P<F]D=6-T<RX@4'5R<W5A;G0@=&\@=&AE($Q,0R!!9W)E96UE
M;G0L('=E(&%N9"!04TD@96%C:"!O=VX@82`U,"4@;65M8F5R<VAI<"!I;G1E
M<F5S="!I;B!T:&4@2F]I;G0@5F5N='5R92`H<V5E($YO=&4@,RDN/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SY792!U<V4@82!$96-E;6)E<B`S,2!Y96%R+65N9"!F;W(@9FEN86YC
M:6%L(')E<&]R=&EN9R!P=7)P;W-E<RX@4F5F97)E;F-E<R!H97)E:6X@=&\@
M=&AE(&9I<V-A;"!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q('-H86QL
M(&)E('1H92!T97)M("8C.#(R,#M&:7-C86P@,C`Q,28C.#(R,3L@86YD(')E
M9F5R96YC97,@=&\@;W1H97(@)B,X,C(P.T9I<V-A;"8C.#(R,3L@>65A<G,@
M<VAA;&P@;65A;B!T:&4@>65A<BP@=VAI8V@@96YD960@;VX@1&5C96UB97(@
M,S$@;V8@=&AE('EE87(@:6YD:6-A=&5D+B!/=7(@8V]N<V]L:61A=&5D(&)A
M;&%N8V4@<VAE970@870@1&5C96UB97(@,S$L(#(P,3`@86YD(&]U<B!C;VYS
M;VQI9&%T960@<W1A=&5M96YT(&]F(&-A<V@@9FQO=W,@9F]R($9I<V-A;"`R
M,#$P(&%N9"`R,#`Y(&AA=F4@8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R
M;2!W:71H(&]U<B!&:7-C86P@,C`Q,2!P<F5S96YT871I;VXN(%1H92!T97)M
M('1H92`F(S@R,C`[=V4F(S@R,C$[+"`F(S@R,C`[=7,Z(&]R('1H92`F(S@R
M,C`[0V]M<&%N>28C.#(R,3L@87,@=7-E9"!H97)E:6X@86QS;R!R969E<BP@
M=VAE<F4@87!P<F]P<FEA=&4L('1O('1H92!#;VUP86YY+"!T;V=E=&AE<B!W
M:71H(&ET<R!S=6)S:61I87)I97,@=6YL97-S('1H92!C;VYT97AT(&]T:&5R
M=VES92!R97%U:7)E<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y-3!B9F-C
M9F4S8V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C0Q-3`U9C1?
M.#AB,%\T-6$X7V$T,3E?.34P8F9C8V9E,V-F+U=O<FMS:&5E=',O4VAE970P
M."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-5
M34U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!
M8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^3D]412`R
M("8C.#(Q,3L@4U5-34%262!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/
M3$E#2453/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\:3X\=3Y"87-I<R!O9B!0<F5S
M96YT871I;VX\+W4^/"]I/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S("@F(S@R,C`[1FEN
M86YC:6%L(%-T871E;65N=',F(S@R,C$[*2!I;F-L=61E('1H92!A8V-O=6YT
M<R!O9B!T:&4@0V]M<&%N>2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S:61I
M87)I97,@86YD(&ET<R!*;VEN="!696YT=7)E+"!A('9A<FEA8FQE(&EN=&5R
M97-T(&5N=&ET>2`H<V5E($YO=&4@,RDN($%L;"!I;G1E<F-O;7!A;GD@=')A
M;G-A8W1I;VYS(&%N9"!B86QA;F-E<R!H879E(&)E96X@96QI;6EN871E9"X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&D^/'4^4V5A<V]N86QI='D@;V8@=&AE($)U<VEN
M97-S/"]U/CPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
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M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S,2XU<'0[(&UA<F=I;CH@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT
M.B!I=&%L:6,@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[)SX\=3Y5<V4@
M;V8@17-T:6UA=&5S/"]U/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^5&AE('!R97!A<F%T:6]N(&]F(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N
M9"!T:&4@86-C;VUP86YY:6YG(&YO=&5S('1H97)E=&\L(&EN(&-O;F9O<FUI
M='D@=VET:"!G96YE<F%L;'D@86-C97!T960@86-C;W5N=&EN9R!P<FEN8VEP
M;&5S(&EN('1H92!5;FET960@4W1A=&5S("@F(S@R,C`[1T%!4"8C.#(R,3LI
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M('!R;VUO=&EO;B!C;W-T<R`H)B,X,C(P.U-A;&5S($%L;&]W86YC97,F(S@R
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M871E<RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W
M<'0[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^3W5R('!R:6UA<GD@<')O9'5C="P@0V]L9"U%15I%
M/&9O;G0^/'-U<#XF(S(Q,#L\+W-U<#X\+V9O;G0^/'-U<#X@/"]S=7`^;&]Z
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M:6)U=&4@0V]L9"U%15I%/'-U<#XF(S$W-#L@/"]S=7`^3W)A;"!3<')A>2!A
M;F0@2VED<RU%15I%/'-U<#XF(S$W-#L\+W-U<#X@0VAE<W0@4F5L:65F+"!+
M:61S+45%6D4\<W5P/B8C,3<T.SPO<W5P/B!#;W5G:"!#;VQD(&%N9"!+:61S
M+45%6D4\<W5P/B8C,3<T.SPO<W5P/B!!;&QE<F=Y("@F(S@R,C`[2VED<RU%
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M<V-A;"`R,#`X(&%N9"!E>'!A;F1E9"!T:&4@<')O9'5C="!L:6YE('1O(&EN
M8VQU9&4@2VED<RU%15I%/'-U<#XF(S$W-#L\+W-U<#X@0V]U9V@@0V]L9"!A
M;F0@2VED<RU%15I%/'-U<#XF(S$W-#L\+W-U<#X@06QL97)G>2!I;B!&:7-C
M86P@,C`Q,"X@5V4@86QS;R!M86YU9F%C='5R92P@;6%R:V5T(&%N9"!D:7-T
M<FEB=71E(&%N(&]R9V%N:6,@8V]U9V@@9')O<"!A;F0@82!6:71A;6EN($,@
M<W5P<&QE;65N="`H)B,X,C(P.T]R9V%N:7@\<W5P/B8C,3<T.SPO<W5P/B8C
M.#(R,3LI+B!%86-H(&]F('1H92!#;VQD+45%6D4\<W5P/B8C,3<T.SPO<W5P
M/B!/<F%L(%-P<F%Y('!R;V1U8W1S+"!+:61S+45%6D4\<W5P/B8C,3<T.SPO
M<W5P/B!0<F]D=6-T<R!A;F0@3W)G86YI>#QS=7`^)B,Q-S0[/"]S=7`^('!R
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M960@<75A<G1E<FQY+B`\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@
M+3`N,35P=#LG/D%D9&ET:6]N86QL>2P@=V4@;6]N:71O<B!C=7)R96YT(&1E
M=F5L;W!M96YT<R!B>2!C=7-T;VUE<BP@;6%R:V5T(&-O;F1I=&EO;G,@86YD
M(&%N>2!O=&AE<B!O8V-U<G)E;F-E<R!T:&%T(&-O=6QD(&%F9F5C="!T:&4@
M97AP96-T960@<')O=FES:6]N<R!R96QA=&EV92!T;R!N970@<V%L97,@9F]R
M('1H92!P97)I;V0@<')E<V5N=&5D+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I
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M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!M87)G:6XZ#0H@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^
M/'4^26YV96YT;W)I97,\+W4^/"]I/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SY);G9E;G1O<GD@:7,@=F%L=65D(&%T('1H92!L;W=E<B!O9B!C;W-T+"!D
M971E<FUI;F5D(&]N(&$@9FER<W0M:6XL(&9I<G-T+6]U="!B87-I<R`H1DE&
M3RDL(&]R(&UA<FME="X@26YV96YT;W)Y(&ET96US(&%R92!A;F%L>7IE9"!T
M;R!D971E<FUI;F4@8V]S="!A;F0@=&AE(&UA<FME="!V86QU92!A;F0@87!P
M<F]P<FEA=&4@=F%L=6%T:6]N(&%D:G5S=&UE;G1S(&%R92!E<W1A8FQI<VAE
M9"X@070@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`L('1H92!&:6YA;F-I
M86P@4W1A=&5M96YT<R!I;F-L=61E(&%N(&%D:G5S=&UE;G0@9F]R(&5X8V5S
M<R!O<B!O8G-O;&5T92!I;G9E;G1O<GD@;V8@)#DY,2PP,#`@86YD("0Q+C$@
M;6EL;&EO;BP@<F5S<&5C=&EV96QY+B!!="!$96-E;6)E<B`S,2P@,C`Q,2!A
M;F0@,C`Q,"P@:6YV96YT;W)Y(&EN8VQU9&5D(')A=R!M871E<FEA;"P@=V]R
M:R!I;B!P<F]G<F5S<R!A;F0@<&%C:V%G:6YG(&%M;W5N=',@;V8@)#DX,2PP
M,#`@86YD("0W-#(L,#`P+"!R97-P96-T:79E;'DL(&%N9"!F:6YI<VAE9"!G
M;V]D<R!O9B`D,2XW(&UI;&QI;VX@86YD("0Y-#`L,#`P+"!R97-P96-T:79E
M;'DN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\:3X\=3Y0<F]P97)T>2P@4&QA
M;G0@86YD($5Q=6EP;65N=#PO=3X\+VD^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
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M;F-E('=I=&@@=&AE(&5S=&EM871E9"!A<W-E="!L:79E<R`H<V5E($YO=&4@
M-"DN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQI/B8C,38P.SPO:3X\:3XF
M(S$V,#L\+VD^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\:3X\=3Y#
M;VYC96YT<F%T:6]N(&]F(%)I<VMS/"]U/CPO:3X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA
M<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
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M9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
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M;FES=')A=&EO;B`H)B,X,C(P.T9$028C.#(R,3LI(&%N9"P@87,@87!P;&EC
M86)L92P@=&AE($AO;65O<&%T:&EC(%!H87)M86-O<&]E:6$@;V8@=&AE(%5N
M:71E9"!3=&%T97,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SY&:6YA;F-I86P@:6YS=')U;65N=',@
M=&AA="!P;W1E;G1I86QL>2!S=6)J96-T('5S('1O('-I9VYI9FEC86YT(&-O
M;F-E;G1R871I;VYS(&]F(&-R961I="!R:7-K(&-O;G-I<W0@<')I;F-I<&%L
M;'D@;V8@8V%S:"!I;G9E<W1M96YT<R!A;F0@=')A9&4@86-C;W5N=',@<F5C
M96EV86)L92X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/E=E(&UA:6YT86EN(&-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',@=VET:"!C97)T86EN(&UA:F]R(&9I;F%N8VEA;"!I;G-T
M:71U=&EO;G,N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!O=7(@8V%S:"!W
M87,@)#4N-2!M:6QL:6]N(&%N9"!O=7(@8F%N:R!B86QA;F-E('=A<R`D-2XY
M(&UI;&QI;VXN($]F('1H92!T;W1A;"!B86YK(&)A;&%N8V4L("0W,#0L,#`P
M('=A<R!C;W9E<F5D(&)Y(&9E9&5R86P@9&5P;W-I=&]R>2!I;G-U<F%N8V4@
M86YD("0U+C(@;6EL;&EO;B!W87,@=6YI;G-U<F5D+CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
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M86QE<G,@86YD(&UA<W,@;65R8VAA;F1I<V5R<R`H<V5E($YO=&4@,3(I+B!$
M=7)I;F<@1FES8V%L(#(P,3$L(#(P,3`@86YD(#(P,#DL(&5F9F5C=&EV96QY
M(&%L;"!O9B!O=7(@<F5V96YU97,@=V5R92!R96QA=&5D('1O(&1O;65S=&EC
M(&UA<FME=',N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M3W5R(')E=F5N=65S(&%R92!P<FEN8VEP86QL>2!G96YE<F%T960@9G)O;2!T
M:&4@<V%L92!O9B!/5$,@8V]L9"!R96UE9'D@<')O9'5C=',@=VAI8V@@87!P
M<F]X:6UA=&5D(#DU)2P@.38E(&%N9"`Y,B4@;V8@=&]T86P@<F5V96YU97,@
M9F]R($9I<V-A;"`R,#$Q+"`R,#$P(&%N9"`R,#`Y+"!R97-P96-T:79E;'DN
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M9"!R96UE9'D@<')O9'5C=',N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA
M<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^4F%W(&UA=&5R:6%L<R!U<V5D(&EN('1H92!P<F]D=6-T:6]N
M(&]F('1H92!P<F]D=6-T<R!A<F4@879A:6QA8FQE(&9R;VT@;G5M97)O=7,@
M<V]U<F-E<RX@0V5R=&%I;B!R87<@;6%T97)I86P@86-T:79E(&EN9W)E9&EE
M;G1S('5S960@:6X@8V]N;F5C=&EO;B!W:71H($-O;&0M145:13QS=7`^)B,Q
M-S0[/"]S=7`^('!R;V1U8W1S(&%R92!P=7)C:&%S960@9G)O;2!A('-I;F=L
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M97(L(&EF('1H92!R96QA=&EO;G-H:7`@=V%S('1E<FUI;F%T960L('1H97)E
M(&UA>2!B92!D96QA>7,@:6X@<')O9'5C=&EO;B!O9B!O=7(@<')O9'5C=',@
M=6YT:6P@86X@86-C97!T86)L92!R97!L86-E;65N="!S=7!P;&EE<B!I<R!L
M;V-A=&5D+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\:3X\=3Y,;VYG+6QI=F5D($%S<V5T<SPO=3X\+VD^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
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M<RP@86UO;F<@;W1H97(@9F%C=&]R<RX\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
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M979E;"`Q+"!D969I;F5D(&%S(&]B<V5R=F%B;&4@:6YP=71S('-U8V@@87,@
M<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<SL@3&5V96P@,BP@9&5F
M:6YE9"!A<R!I;G!U=',@;W1H97(@=&AA;B!Q=6]T960@<')I8V5S(&EN(&%C
M=&EV92!M87)K971S('1H870@87)E(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I
M<F5C=&QY(&]B<V5R=F%B;&4[(&%N9"!,979E;"`S+"!D969I;F5D(&%S('5N
M;V)S97)V86)L92!I;G!U=',@9F]R('=H:6-H(&QI='1L92!O<B!N;R!M87)K
M970@9&%T82!E>&ES=',L('1H97)E9F]R92!R97%U:7)I;F<@86X@96YT:71Y
M('1O(&1E=F5L;W`@:71S(&]W;B!A<W-U;7!T:6]N<RX\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SY);B!&:7-C86P@,C`P.2!W92!R96-O
M9VYI>F5D(&EM<&%I<FUE;G0@8VAA<F=E<R!O9B`D-S0L,#`P('!R:6YC:7!A
M;&QY(&9O<B!T:&4@;&%N9"!A;F0@8G5I;&1I;F<@87-S971S(&]F(&]U<B!%
M;&EZ86)E=&AT;W=N(&UA;G5F86-T=7)I;F<@9F%C:6QI='DN(%1H92!F86ER
M('9A;'5E(&]F('1H92!R97!O<G1E9"`\:3Y!<W-E=',@2&5L9"!&;W(@4V%L
M92`\+VD^870@1&5C96UB97(@,S$L(#(P,3`\:3X@/"]I/F]F("0Q,S@L,#`P
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M961S(&9R;VT@=&AE('-A;&4@;V8@=&AE<V4@87-S971S(&]F("0Q-C8L,#`P
M+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\:3X\=3Y2979E;G5E(%)E8V]G;FET:6]N
M/"]U/CPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T
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M9B!T:&4@<V%L97,@<F5T=7)N<R!A;F0@;W1H97(@86QL;W=A;F-E<RX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
M:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/D]U<B!R971U<FX@<&]L:6-Y(&%C8V]M;6]D871E<R!R971U<FYS
M(&9O<B`H:2D@9&ES8V]N=&EN=65D('!R;V1U8W1S+"`H:6DI('-T;W)E(&-L
M;W-I;F=S(&%N9"`H:6EI*2!P<F]D=6-T<R!T:&%T(&AA=F4@<F5A8VAE9"!O
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M<R!P;VQI8WD@87)E.B`H:2D@=V4@=VEL;"!A8V-E<'0@<F5T=7)N<R!T:&%T
M(&%R92!D=64@=&\@9&%M86=E9"!P<F]D=6-T('1H870@:7,@=6XM<V%L96%B
M;&4@86YD('-U8V@@<F5T=7)N(')E<75E<W0@86-T:79I='D@9F%L;"!W:71H
M:6X@86X@86-C97!T86)L92!R86YG92P@*&EI*2!W92!W:6QL(&%C8V5P="!R
M971U<FYS(&9O<B!P<F]D=6-T<R!T:&%T(&AA=F4@<F5A8VAE9"!O<B!E>&-E
M961E9"!D97-I9VYA=&5D(&5X<&ER871I;VX@9&%T97,@86YD("AI:6DI('=E
M('=I;&P@86-C97!T(')E='5R;G,@:6X@=&AE(&5V96YT('1H870@=V4@9&ES
M8V]N=&EN=64@82!P<F]D=6-T('!R;W9I9&5D('1H870@=&AE(&-U<W1O;65R
M('=I;&P@:&%V92!T:&4@<FEG:'0@=&\@<F5T=7)N(&]N;'D@<W5C:"!I=&5M
M<R!T:&%T(&ET('!U<F-H87-E9"!D:7)E8W1L>2!F<F]M('5S+B!792!W:6QL
M(&YO="!A8V-E<'0@<F5T=7)N(')E<75E<W1S('!E<G1A:6YI;F<@=&\@8W5S
M=&]M97(@:6YV96YT;W)Y("8C.#(R,#M/=F5R<W1O8VMI;F<F(S@R,C$[(&]R
M("8C.#(R,#M297-E=',F(S@R,C$[+B!792!W:6QL(&]N;'D@86-C97!T(')E
M='5R;B!R97%U97-T<R!F;W(@<')O9'5C="!I;B!I=',@:6YT96YD960@<&%C
M:V%G92!C;VYF:6=U<F%T:6]N+B!792!R97-E<G9E('1H92!R:6=H="!T;R!T
M97)M:6YA=&4@<VAI<&UE;G0@;V8@<')O9'5C="!T;R!C=7-T;VUE<G,@=VAO
M(&AA=F4@;6%D92!U;F%U=&AO<FEZ960@9&5D=6-T:6]N<R!C;VYT<F%R>2!T
M;R!O=7(@<F5T=7)N('!O;&EC>2!O<B!P=7)S=64@;W1H97(@;65T:&]D<R!O
M9B!R96EM8G5R<V5M96YT+B!792!C;VUP96YS871E('1H92!C=7-T;VUE<B!F
M;W(@875T:&]R:7IE9"!R971U<FYS(&)Y(&UE86YS(&]F(&$@8W)E9&ET(&%P
M<&QI960@=&\@86UO=6YT<R!O=V5D(&]R('1O(&)E(&]W960@86YD(&EN('1H
M92!C87-E(&]F(&1I<V-O;G1I;G5E9"!P<F]D=6-T(&]N;'DL(&%L<V\@8GD@
M=V%Y(&]F(&%N(&5X8VAA;F=E+B!792!D;R!N;W0@:&%V92!A;GD@<VEG;FEF
M:6-A;G0@<')O9'5C="!E>&-H86YG92!H:7-T;W)Y+CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!<R!O
M9B!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@1&5C96UB97(@,S$L(#(P,3`L('=E
M(&EN8VQU9&5D(&$@<')O=FES:6]N(&9O<B!S86QE<R!A;&QO=V%N8V5S(&]F
M("0Q,#$L,#`P(&%N9"`D,3`V+#`P,"P@<F5S<&5C=&EV96QY+"!W:&EC:"!A
M<F4@<F5P;W)T960@87,@82!R961U8W1I;VX@=&\@86-C;W5N="!R96-E:79A
M8FQE<RX@5V4@86QS;R!I;F-L=61E9"!A;B!E<W1I;6%T92!O9B!T:&4@=6YC
M;VQL96-T86)I;&ET>2!O9B!O=7(@86-C;W5N=',@<F5C96EV86)L92!A<R!A
M;B!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S(&]F('IE<F\@86YD
M("0Q,RPP,#`@87,@;V8@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`L(')E
M<W!E8W1I=F5L>2X@061D:71I;VYA;&QY+"!A8V-R=65D(&%D=F5R=&ES:6YG
M(&%N9"!O=&AE<B!A;&QO=V%N8V5S(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q
M(&EN8VQU9&4@)#$N-R!M:6QL:6]N(&9O<B!E<W1I;6%T960@9G5T=7)E('-A
M;&5S(')E='5R;G,L("0Q+C`@;6EL;&EO;B!F;W(@8V]O<&5R871I=F4@:6YC
M96YT:79E('!R;VUO=&EO;B!C;W-T<R!A;F0@)#(W.2PP,#`@9F]R(&-E<G1A
M:6X@;W1H97(@861V97)T:7-I;F<@86YD(&UA<FME=&EN9R!P<F]M;W1I;VYS
M+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,"!A8V-R=65D(&%D=F5R=&ES:6YG
M(&%N9"!O=&AE<B!A;&QO=V%N8V5S(&EN8VQU9&4@)#$N-2!M:6QL:6]N(&9O
M<B!E<W1I;6%T960@9G5T=7)E('-A;&5S(')E='5R;G,L("0Q+C(@;6EL;&EO
M;B!F;W(@8V]O<&5R871I=F4@:6YC96YT:79E('!R;VUO=&EO;B!C;W-T<R!A
M;F0@)#@R."PP,#`@9F]R(&-E<G1A:6X@;W1H97(@861V97)T:7-I;F<@86YD
M(&UA<FME=&EN9R!P<F]M;W1I;VYS+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!M87)G:6XZ(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&D^/'4^4VAI<'!I;F<@86YD($AA;F1L:6YG(#PO=3X\
M+VD^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE
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M:6X@8V]S="!O9B!S86QE<RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^/'4^4W1O8VL@
M0V]M<&5N<V%T:6]N/"]U/CPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
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M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.PT*('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY3=&]C:R!A
M;F0@<W1O8VL@;W!T:6]N<R!F;W(@<'5R8VAA<V4@;V8@;W5R(&-O;6UO;B!S
M=&]C:RP@)#`N,#`P-2!P87(@=F%L=64L("@F(S@R,C`[0V]M;6]N(%-T;V-K
M)B,X,C(Q.RD@:&%V92!B965N(&=R86YT960@=&\@8F]T:"!E;7!L;WEE97,@
M86YD(&YO;BUE;7!L;WEE97,@<'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F(&-E
M<G1A:6X@86=R965M96YT<R!A;F0@<W1O8VL@;W!T:6]N('!L86YS("AS964@
M3F]T92`X*2X@4W1O8VL@;W!T:6]N<R!A<F4@97AE<F-I<V%B;&4@9'5R:6YG
M(&$@<&5R:6]D(&1E=&5R;6EN960@8GD@=7,L(&)U="!I;B!N;R!E=F5N="!L
M871E<B!T:&%N('1E;B!Y96%R<R!F<F]M('1H92!D871E(&=R86YT960N($EN
M($9I<V-A;"`R,#$Q(&%N9"`R,#$P+"!W92!C:&%R9V5D('1O(&]P97)A=&EO
M;G,@)#8S,2PP,#`@86YD("0Q.3(L,#`P+"!R97-P96-T:79E;'DL(&9O<B!S
M:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS92!F;W(@=&AE(&%G9W)E
M9V%T92!F86ER('9A;'5E(&]F('-T;V-K(&=R86YT<R!I<W-U960@86YD('9E
M<W1E9"!S=&]C:R!O<'1I;VYS(&5A<FYE9"X@5&AE<F4@=V%S(&YO('-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O<B!&:7-C86P@,C`P.2X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^)B,Q-C`[/"]I/CPO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^/'4^5F%R:6%B;&4@26YT97)E<W0@
M16YT:71Y/"]U/CPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE($IO
M:6YT(%9E;G1U<F4L(&]F('=H:6-H('=E(&]W;B!A(#4P)2!M96UB97)S:&EP
M(&EN=&5R97-T('%U86QI9FEE<R!A<R!A('9A<FEA8FQE(&EN=&5R97-T(&5N
M=&ET>2`H)B,X,C(P.U9)128C.#(R,3LI(&%N9"!W92!H879E(&-O;G-O;&ED
M871E9"!T:&4@2F]I;G0@5F5N='5R92!B96=I;FYI;F<@=VET:"!T:&4@<75A
M<G1E<B!E;F1E9"!-87)C:"`S,2P@,C`Q,"`H<V5E($YO=&4@,RDN/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQI/CQU/D%D=F5R
M=&ES:6YG(&%N9"!);F-E;G1I=F4@4')O;6]T:6]N<R`\+W4^/"]I/CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
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M,3`@86YD(#(P,#D@=V5R92`D."XX(&UI;&QI;VXL("0V+CD@;6EL;&EO;BP@
M86YD("0U+C@@;6EL;&EO;BP@<F5S<&5C=&EV96QY+B!);F-L=61E9"!I;B!P
M<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<R!W87,@
M)#$N,B!M:6QL:6]N(&%N9"`D,3@Y+#`P,"!A="!$96-E;6)E<B`S,2P@,C`Q
M,2!A;F0@,C`Q,"P@<F5S<&5C=&EV96QY+"!R96QA=&EN9R!T;R!P<F5P86ED
M(&%D=F5R=&ES:6YG(&%N9"!P<F]M;W1I;VX@97AP96YS97,N/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T97AT+61E8V]R871I;VXZ
M('5N9&5R;&EN93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M
M86P[)SX\:3Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0\+VD^/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SY297-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@8V]S=',@87)E(&-H87)G960@=&\@;W!E<F%T:6]N<R!I;B!T:&4@<&5R
M:6]D(&EN8W5R<F5D+B!%>'!E;F1I='5R97,@9F]R($9I<V-A;"`R,#$Q+"`R
M,#$P(&%N9"`R,#`Y('=E<F4@)#$N,2!M:6QL:6]N+"`D-SDT+#`P,"!A;F0@
M)#$N,R!M:6QL:6]N+"!R97-P96-T:79E;'DN($9O<B!&:7-C86P@,C`Q,2!A
M;F0@1FES8V%L(#(P,3`L(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T
M<R!A<F4@<F5L871E9"!P<FEN8VEP86QL>2!T;R!N97<@<')O9'5C="!D979E
M;&]P;65N="!I;FET:6%T:79E<R!A;F0@8V]S=',@87-S;V-I871E9"!W:71H
M($]40R!C;VQD(')E;65D>2!P<F]D=6-T<RX@1F]R($9I<V-A;"`R,#`Y+"!R
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M.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XZ(#!P>#L@9F]N=#H@:71A;&EC(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^/'4^26YC;VUE(%1A>&5S/"]U/CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
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M<')O=FED960@*'-E92!.;W1E(#$P*2X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
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M+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H
M92!M86IO<B!J=7)I<V1I8W1I;VX@9F]R('=H:6-H('=E(&9I;&4@:6YC;VUE
M('1A>"!R971U<FYS(&ES('1H92!5;FET960@4W1A=&5S+B!4:&4@26YT97)N
M86P@4F5V96YU92!397)V:6-E("@F(S@R,C`[25)3)B,X,C(Q.RD@:&%S(&5X
M86UI;F5D(&]U<B!T87@@>65A<B!E;F1E9"!397!T96UB97(@,S`L(#(P,#4@
M86YD(&AA<R!M861E(&YO(&-H86YG97,@=&\@=&AE(&9I;&5D('1A>"!R971U
M<FYS+B!4:&4@=&%X('EE87)S(#(P,#8@86YD(&9O<G=A<F0@<F5M86EN(&]P
M96X@=&\@97AA;6EN871I;VX@8GD@=&AE($E24RX@5&AE('1A>"!Y96%R<R`R
M,#`T(&%N9"!F;W)W87)D(')E;6%I;B!O<&5N('1O(&5X86UI;F%T:6]N(&)Y
M('1H92!V87)I;W5S('-T871E('1A>&EN9R!A=71H;W)I=&EE<R!T;R!W:&EC
M:"!W92!A<F4@<W5B:F5C="X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D5F9F5C=&EV92!$96-E;6)E
M<B`S,2P@,C`P.2P@=V4@96QE8W1E9"!T;R!C;VYF;W)M(&]U<B!T87@@<F5P
M;W)T:6YG('EE87(L(&AI<W1O<FEC86QL>2!A(&9I<V-A;"!P97)I;V0@96YD
M:6YG(%-E<'1E;6)E<B`S,"P@=&\@;W5R(&9I;F%N8VEA;"!R97!O<G1I;F<@
M<&5R:6]D(&5N9&EN9R!$96-E;6)E<B`S,2X@07,@82!C;VYS97%U96YC92P@
M=V4@9FEL960@82!F=6QL('!E<FEO9"!T87@@<F5T=7)N(&9O<B!T:&4@9FES
M8V%L('EE87(@96YD960@4V5P=&5M8F5R(#,P+"`R,#`Y('=I=&@@=&AE($E2
M4R!A;F0@86QS;R!F:6QE9"!W:71H('1H92!)4E,@82`F(S@R,C`[<VAO<G0@
M<&5R:6]D(')E='5R;B8C.#(R,3L@9F]R('1H92!T:')E92!M;VYT:',@96YD
M960@1&5C96UB97(@,S$L(#(P,#D@:6X@8V]M<&QI86YC92!W:71H('1H92!E
M;&5C=&EO;BX@26X@9G5T=7)E(&9I<V-A;"!P97)I;V1S+"!O=7(@=&%X(&%N
M9"!F:6YA;F-I86P@<F5P;W)T:6YG('!E<FEO9',@=VEL;"!B92!T:&4@<V%M
M92P@=&AE('!E<FEO9"!E;F1I;F<@1&5C96UB97(@,S$N/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/B8C
M,38P.SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\:3X\
M=3Y&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<SPO=3X\+VD^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
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M92X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\:3X\=3Y296-E;G1L>2!)<W-U960@06-C;W5N
M=&EN9R!3=&%N9&%R9',\+W4^/"]I/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SY);B!.;W9E;6)E<B`R,#`X+"!T:&4@4T5#(&ES<W5E9"!F;W(@8V]M;65N
M="!A('!R;W!O<V5D(')O861M87`@<F5G87)D:6YG('1H92!P;W1E;G1I86P@
M=7-E(&)Y(%4N4RX@:7-S=65R<R!O9B!F:6YA;F-I86P@<W1A=&5M96YT<R!P
M<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@26YT97)N871I;VYA;"!&:6YA
M;F-I86P@4F5P;W)T:6YG(%-T86YD87)D<R`H)B,X,C(P.TE&4E,F(S@R,C$[
M*2X@24924R!I<R!A(&-O;7!R96AE;G-I=F4@<V5R:65S(&]F(&%C8V]U;G1I
M;F<@<W1A;F1A<F1S('!U8FQI<VAE9"!B>2!T:&4@26YT97)N871I;VYA;"!!
M8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"`H)B,X,C(P.TE!4T(F(S@R,C$[
M*2X@5&AE('!R;W!O<V5D(')O861M87`@:&%S('-I;F-E(&)E96X@<W5P97)S
M961E9"!B>2!A;B!314,@=V]R:R!P;&%N(&%N9"!N;R!D871E(&ES(&-U<G)E
M;G1L>2!P<F]P;W-E9"!T:&%T('=E(&-O=6QD(&)E(')E<75I<F5D('1O('!R
M97!A<F4@9FEN86YC:6%L('-T871E;65N=',@:6X@86-C;W)D86YC92!W:71H
M($E&4E,N(%1H92!314,@:&%S('1A<F=E=&5D($9I<V-A;"`R,#$R('1O(&UA
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M(&]F('1H92!P;W1E;G1I86P@:6UP;&5M96YT871I;VX@;V8@24924RX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY);B!*=6YE)B,Q-C`[
M,C`Q,2P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R
M9"`H)B,X,C(P.T9!4T(F(S@R,C$[*2!I<W-U960@06-C;W5N=&EN9R!3=&%N
M9&%R9',@57!D871E($YO+B`R,#$Q+3`U+"`F(S@R,C`[0V]M<')E:&5N<VEV
M92!);F-O;64@*$%30R!4;W!I8R`R,C`I.B!0<F5S96YT871I;VX@;V8@0V]M
M<')E:&5N<VEV92!);F-O;64L)B,X,C(Q.R`H)B,X,C(P.T%352`R,#$Q+3`U
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M4U4@,C`Q,2TP-2!W:6QL(&)E(&5F9F5C=&EV92!F;W(@9FES8V%L('!E<FEO
M9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$Q('=I=&@@96%R
M;'D@861O<'1I;VX@<&5R;6ET=&5D+B!4:&4@861O<'1I;VX@;V8@05-5(#(P
M,3$M,#4@=VEL;"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!O=7(@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!P;W-I=&EO;BP@<F5S=6QT<R!O9B!O
M<&5R871I;VYS(&]R(&-A<V@@9FQO=W,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY);B!397!T96UB
M97(@,C`Q,2P@=&AE($9!4T(@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S
M(%5P9&%T92!.;RX@,C`Q,2TP."P@)B,X,C(P.TEN=&%N9VEB;&5S("8C.#(Q
M,3L@1V]O9'=I;&P@86YD($]T:&5R(%1O<&EC<R8C.#(R,3L@*"8C.#(R,#M!
M4U4@,C`Q,2TP."8C.#(R,3LI('=H:6-H('!R;W9I9&5S(&%U=&AO<FET871I
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M="!T97-T+B!5;F1E<B!!4U4@,C`Q,2TP."P@86X@96YT:71Y('=O=6QD(&YO
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M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-C0Q-3`U9C1?.#AB,%\T-6$X7V$T,3E?.34P8F9C8V9E,V-F#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8T,34P-68T7S@X8C!?-#5A.%]A-#$Y
M7SDU,&)F8V-F93-C9B]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%4U1-14Y4($E.(%!(
M55-)3TX@3$%"3U)!5$]22453+"!,3$,N/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5S=&UE;G1S($EN(&%N
M9"!!9'9A;F-E<R!4;R!!9F9I;&EA=&5S+"!38VAE9'5L92!/9B!);G9E<W1M
M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S(&EN(&%N9"!!9'9A;F-E<R!T;R!!
M9F9I;&EA=&5S+"!38VAE9'5L92!O9B!);G9E<W1M96YT<R!;5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^3D]412`S("8C
M.#(Q,3L@24Y615-4345.5"!)3B!02%5324].($Q!0D]2051/4DE%4RP@3$Q#
M+CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!-87)C:"`R,BP@,C`Q,"P@=&AE
M($-O;7!A;GDL(%!322!087)E;G0L(%!322!A;F0@=&AE($IO:6YT(%9E;G1U
M<F4@96YT97)E9"!I;G1O('1H92!,3$,@06=R965M96YT(&]F('1H92!*;VEN
M="!696YT=7)E(&%N9"!A9&1I=&EO;F%L(')E;&%T960@86=R965M96YT<R!F
M;W(@=&AE('!U<G!O<V4@;V8@9&5V96QO<&EN9R!A;F0@8V]M;65R8VEA;&EZ
M:6YG+"!F;W(@=V]R;&1W:61E(&1I<W1R:6)U=&EO;B!A;F0@<V%L92P@82!W
M:61E(')A;F=E(&]F(&YO;BUP<F5S8W)I<'1I;VX@<F5M961I97,@=7-I;F<@
M4%-)(%!A<F5N="8C.#(Q-SMS('!R;W!R:65T87)Y('!A=&5N=&5D(%1032X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@3$Q#($%G<F5E;65N
M="P@4%-)(%!A<F5N="!G<F%N=&5D('1O('5S+"!P=7)S=6%N="!T;R!T:&4@
M=&5R;7,@;V8@82!,:6-E;G-E($%G<F5E;65N="P@9&%T960@36%R8V@@,C(L
M(#(P,3`@*'1H92`F(S@R,C`[3W)I9VEN86P@3&EC96YS92!!9W)E96UE;G0F
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M;F]W+6AO=R`H8V]L;&5C=&EV96QY+"!T:&4@)B,X,C(P.U!322!496-H;F]L
M;V=Y)B,X,C(Q.RD@86YD("AI:2D@82!N;VXM97AC;'5S:79E+"!R;WEA;'1Y
M+69R964L('=O<FQD+7=I9&4@*'-U8FIE8W0@=&\@8V5R=&%I;B!L:6UI=&%T
M:6]N<RDL('!A:60M=7`@;&EC96YS92!T;R!E>'!L;VET(&-E<G1A:6X@8V]M
M<&]U;F1S('1H870@96UB;V1Y('1H92!04TD@5&5C:&YO;&]G>2!F;W(@=7-E
M(&EN(&$@<')O9'5C="!C;VUB:6YI;F<@;VYE(&]R(&UO<F4@;V8@<W5C:"!C
M;VUP;W5N9',@=VET:"!A;B!/5$,@9')U9R!O<B!I;B!A('!R;V1U8W0@=&AA
M="!I<R!P87)T(&]F(&$@<F5G:6UE;B!T:&%T(&EN8VQU9&5S('1H92!A<'!L
M:6-A=&EO;B!O9B!A;B!/5$,@9')U9RX\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E!U<G-U86YT('1O
M('1H92!/<FEG:6YA;"!,:6-E;G-E($%G<F5E;65N="P@=V4@:7-S=65D(#$L
M-#0P+#`P,"!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!H879I;F<@86X@
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M96YT+"!D871E9"!-87)C:"`R,BP@,C`Q,"`H=&AE("8C.#(R,#M3:&%R92!4
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M<G-O;B`H87,@9&5F:6YE9"!I;B!296=U;&%T:6]N(%,@=6YD97(@=&AE(%-E
M8W5R:71I97,@06-T*2P@=&AA="!04TD@4&%R96YT(&ES(&%N(&%C8W)E9&ET
M960@:6YV97-T;W(@=VET:"!A8V-E<W,@=&\@86QL(')E;&5V86YT(&EN9F]R
M;6%T:6]N(&YE8V5S<V%R>2!T;R!E=F%L=6%T92!I=',@:6YV97-T;65N="!A
M;F0@=&AA="!T:&4@4%-)(%-H87)E<R!W97)E(&)E:6YG(&%C<75I<F5D(&9O
M<B!I;G9E<W1M96YT('!U<G!O<V5S(&]N;'DN/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
M:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY);B!397!T
M96UB97(@,C`Q,2P@4%-)(%!A<F5N="!E;G1E<F5D(&EN=&\@8V5R=&%I;B!0
M<FEV871E(%)E<V%L92!!9W)E96UE;G1S("@F(S@R,C`[4%-!<R8C.#(R,3LI
M('=I=&@@<V5V96X@=&AI<F0@<&%R='D@<'5R8VAA<V5R<RP@=6YD97(@=VAI
M8V@@4&AO<W!H86=E;FEC<R!S;VQD+"!W:71H(&]U<B!C;VYS96YT+"!A;B!A
M9V=R96=A=&4@;V8@-S4P+#`P,"!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C
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M4TD@4&%R96YT('1O(')E9&5E;2!T:&4@=&AE;B!R96UA:6YI;F<@-CDP+#`P
M,"!04TD@4VAA<F5S(&AE;&0@8GD@4%-)(%!A<F5N="`H<V5E($YO=&4@."DN
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SY);B!A8V-O<F1A;F-E('=I=&@@82!#;VYT<FEB=71I;VX@
M06=R965M96YT+"!D871E9"!-87)C:"`R,BP@,C`Q,"`H=&AE("8C.#(R,#M#
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M;G-E($%G<F5E;65N="`H<W5C:"!A8W1I;VYS+"!C;VQL96-T:79E;'DL('1H
M92`F(S@R,C`[07-S:6=N;65N="!A;F0@07-S=6UP=&EO;B8C.#(R,3LI+CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA
M<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^4'5R<W5A;G0@=&\@=&AE($-O;G1R:6)U=&EO;B!!9W)E96UE
M;G0@86YD(&EN(&]R9&5R('1O(')E9FQE8W0@=&AE($%S<VEG;FUE;G0@86YD
M($%S<W5M<'1I;VXL('=E+"!04TD@4&%R96YT(&%N9"!T:&4@2F]I;G0@5F5N
M='5R92!E;G1E<F5D(&EN=&\@86X@06UE;F1E9"!A;F0@4F5S=&%T960@3&EC
M96YS92!!9W)E96UE;G0L(&1A=&5D($UA<F-H(#(R+"`R,#$P("AT:&4@)B,X
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M:6YF;W)M871I;VXL('1H92!O=VYE<G-H:7`@;V8@:6YT96QL96-T=6%L('!R
M;W!E<G1Y(&%N9"!I;F1E;6YI9FEC871I;VX@;V)L:6=A=&EO;G,N/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM
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M;'DL('=E(&-O;G1R:6)U=&5D(&EN($9I<V-A;"`R,#$P("0U,#`L,#`P(&EN
M(&-A<V@@87,@:6YI=&EA;"!C87!I=&%L(&%N9"!W92!A<F4@8V]M;6ET=&5D
M('1O(&9U;F0@=7`@=&\@)#(N,"!M:6QL:6]N+"!S=6)J96-T('1O(&%G<F5E
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M86P@;6%R:V5T(&%N9"!P<F]D=6-T(&%N86QY<VES+B!!="!$96-E;6)E<B`S
M,2P@,C`Q,2P@8V%S:"!A;F0@97%U:79A;&5N=',@:6YC;'5D97,@)#0R-2PP
M,#`@=VAI8V@@:7,@97AP96-T960@=&\@8F4@=7-E9"!B>2!T:&4@2F]I;G0@
M5F5N='5R92!T;R!F=6YD(&9U='5R92!P<F]D=6-T(&1E=F5L;W!M96YT(&EN
M:71I871I=F5S(&-U<G)E;G1L>2!U;F1E<B!C;VYS:61E<F%T:6]N(&)Y(%!3
M22!087)E;G0L(%!322!A;F0@=7,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@
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M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M:&4@<75A<G1E<B!E;F1E9"!-87)C:"`S,2P@,C`Q,"X@4VEN8V4@:6YC97!T
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M+"`R,#$Q+"!W92!H879E(')E8V]R9&5D('1H92`D,RXV(&UI;&QI;VX@<&%Y
M;65N="!R97!R97-E;G1I;F<@=&AE(&5S=&EM871E9"!F86ER('9A;'5E('1O
M(&%C<75I<F4@=&AE('!R;V1U8W0@;&EC96YS92!A<R!A;B!I;G1A;F=I8FQE
M(&%S<V5T+B!792!C=7)R96YT;'D@97-T:6UA=&4@=&AE(&5X<&5C=&5D('5S
M969U;"!L:69E(&]F('1H92!P<F]D=6-T(&QI8V5N<V4@=&\@8F4@87!P<F]X
M:6UA=&5L>2`Q,"!Y96%R<R!W:&EC:"!W92!W:6QL(&)E9VEN(&%M;W)T:7II
M;F<@=&AE(&-O<W0@;V8@:6YT86YG:6)L92!A<W-E="!O;F-E('!R;V1U8W0@
M8V]M;65R8VEA;&EZ871I;VX@:7,@8V]M<&QE=&5D('=I=&@@4%-)(%!A<F5N
M="!A;F0@=&AE($]40R!D<G5G('!R;V1U8W1S(&)E9VEN('1O('-H:7`@=&\@
M;W5R(')E=&%I;"!C=7-T;VUE<G,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@
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M;'5A=&EO;BP@*&EV*2!P<F]D=6-T(&-O;6UE<F-I86QI>F%T:6]N+"`H=BD@
M<')O9'5C=&EO;B!A;F0@9&ES=')I8G5T:6]N+"!A;F0@*'9I*2!R971A:6P@
M86YD(&-O;G-U;65R(&%D=F5R=&ES:6YG(&%N9"!M87)K971I;F<N($1U<FEN
M9R!&:7-C86P@,C`Q,2P@=V4@8V]N9'5C=&5D('!R96QI;6EN87)Y(&UA<FME
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M:69I960@3U1#(&%C=&EV92!I;F=R961I96YT<RX@26X@1&5C96UB97(@,C`Q
M,2P@=V4@:6YI=&EA=&5D(&$@<W1U9'D@;V8@=&AE<V4@<')E;&EM:6YA<GD@
M9F]R;75L871I;VYS('1O(&5V86QU871E('!R;V1U8W0@871T<FEB=71E<RP@
M<&5R9F]R;6%N8V4@86YD('!O=&5N=&EA;"!C;VUM97)C:6%L('9I86)I;&ET
M>2X@5&AE<V4@<W1U9&EE<R!A<F4@97AP96-T960@=&\@8F4@8V]M<&QE=&5D
M(&QA=&5R(&EN($9I<V-A;"`R,#$R+B!&;W(@1FES8V%L(#(P,3$L(&%N>2!E
M>'!E;G-E<RP@:6YC;'5D:6YG(&]R9V%N:7IA=&EO;F%L+"!M87)K971I;F<@
M86YA;'ES:7,@86YD('!R96QI;6EN87)Y(&9O<FUU;&%T:6]N<R!H879E(&)E
M96X@86)S;W)B960@8GD@=&AE(')E<W!E8W1I=F4@2F]I;G0@5F5N='5R92!M
M96UB97)S+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2P@=V4@:&%V92!N;W0@
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M('1W96QV92!M;VYT:',N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C0Q-3`U9C1?.#AB,%\T-6$X7V$T,3E?.34P8F9C
M8V9E,V-F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8T,34P-68T
M7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C9B]7;W)K<VAE971S+U-H965T
M,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0
M4D]015)462P@4$Q!3E0@04Y$($5154E0345.5#QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA
M;G0@86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y+"!0;&%N="!A;F0@
M17%U:7!M96YT($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^/&(^3D]412`T("8C
M.#(Q,3L@4%)/4$525%DL(%!,04Y4($%.1"!%455)4$U%3E0@/"]B/CPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\8CXF
M(S$V,#L\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/E1H92!C;VUP;VYE
M;G1S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@87)E(&%S(&9O;&QO=W,@
M*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y
M;&4],T0G=VED=&@Z(#@W)3L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P
M86X],T0V(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D1E8V5M8F5R
M)B,Q-C`[,S$L/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,C`Q,3PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ
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M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D5S=&EM871E9"8C,38P
M.U5S969U;"!,:69E/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)R!C;VQS<&%N/3-$,CX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C
M8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('=I9'1H.B`V,24[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/DQA;F0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@,3`E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXU,#0\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C4P
M-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/D)U:6QD:6YG<R!A;F0@:6UP<F]V96UE;G1S/"]F;VYT/CPO
M=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^,BPT.30\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXR+#(X,3PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,34@
M+2`S.2!Y96%R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/C(L-3DR/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
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M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C$X,CPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/C4L-S4Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
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M-C`X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXS+#,X.3PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S
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M;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXR+#,P-SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXR+#,V,CPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY$97!R96-I
M871I;VX@97AP96YS92!F;W(@1FES8V%L(#(P,3$L(#(P,3`@86YD(#(P,#D@
M=V%S("0S-34L,#`P+"`D,S8S+#`P,"P@86YD("0U,C(L,#`P+"!R97-P96-T
M:79E;'DN/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4$%4
M14Y4(%))1TA44R!!3D0@4D5,051%1"!23UE!3%19($-/34U)5$U%3E13/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E!A=&5N="!2:6=H=',@86YD(%)E;&%T960@4F]Y86QT>2!#;VUM:71M96YT
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!A=&5N="!2:6=H=',@86YD(%)E;&%T960@4F]Y86QT>2!#
M;VUM:71M96YT<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^/&(^3D]412`U("8C.#(Q,3L@4$%414Y4(%))1TA44R!!3D0@
M4D5,051%1"!23UE!3%19($-/34U)5$U%3E13/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
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M9B!T:&ES(&%G<F5E;65N="P@=VAI8V@@97AP:7)E9"!-87D@,C`P-RX@2&]W
M979E<BP@=V4@86YD('1H92!D979E;&]P97(@87)E(&EN(&QI=&EG871I;VX@
M*'-E92!.;W1E(#<I(&%N9"!A<R!S=6-H(&YO('!O=&5N=&EA;"!O9F9S970@
M9F]R('1H97-E(&9E97,@9G)O;2!S=6-H(&QI=&EG871I;VX@:&%S(&)E96X@
M<F5C;W)D960N(%1H92!A;6]U;G0@86-C<G5E9"!F;W(@=&AI<R!E>'!E;G-E
M(&%T(&5A8V@@;V8@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`@=V%S("0S
M+C4@;6EL;&EO;BX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y-3!B9F-C9F4S
M8V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C0Q-3`U9C1?.#AB
M,%\T-6$X7V$T,3E?.34P8F9C8V9E,V-F+U=O<FMS:&5E=',O4VAE970Q,BYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]42$52
M($-54E)%3E0@3$E!0DE,251)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@3&EA8FEL:71I97,@1&ES
M8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]T:&5R($QI86)I;&ET:65S($1I<V-L;W-U<F4@
M6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/DY/5$4@-B`F(S@R,3$[($]42$52($-54E)%3E0@3$E!0DE,251)15,\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SY!="!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,"P@;W1H
M97(@8W5R<F5N="!L:6%B:6QI=&EE<R!I;F-L=61E("0R,S<L,#`P(&%N9"`D
M-#@S+#`P,"P@<F5S<&5C=&EV96QY+"!R96QA=&5D('1O(&%C8W)U960@8V]M
M<&5N<V%T:6]N+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S8T,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C
M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V-#$U,#5F-%\X.&(P
M7S0U83A?830Q.5\Y-3!B9F-C9F4S8V8O5V]R:W-H965T<R]3:&5E=#$S+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T]-34E4
M345.5%,@04Y$($-/3E1)3D=%3D-)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/DY/5$4@-R`F(S@R,3$[($-/
M34U)5$U%3E13($%.1"!#3TY424Y'14Y#2453/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/D-E<G1A:6X@;W!E<F%T:6YG(&QE87-E<R!F;W(@;V9F:6-E(&%N9"!W87)E
M:&]U<V4@<W!A8V4@;6%I;G1A:6YE9"!B>2!U<R!I;B!&:7-C86P@,C`Q,"!A
M;F0@,C`P.2!R97-U;'1E9"!I;B!R96YT(&5X<&5N<V4@;V8@)#$Q+#`P,"!A
M;F0@)#0T+#`P,"P@<F5S<&5C=&EV96QY+B!792!D:60@;F]T(&EN8W5R(')E
M;G0@97AP96YS92!I;B!&:7-C86P@,C`Q,2X@5V4@:&%V92!A<'!R;WAI;6%T
M92!F=71U<F4@;V)L:6=A=&EO;G,@;W9E<B!T:&4@;F5X="!F:79E('EE87)S
M(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
M:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@-C`E
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XM;&5F=#H@,"XU:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG/EEE87(\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
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M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E!U<F-H87-E(#QB<B`O/D-O
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M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M=VED=&@Z(#,Q)3LG/C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`R,"4[)SXQ+#$P-CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,C`E.R<^
M,2PS-S<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
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M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#`R-3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ+#`R-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-34V/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/C(P,38\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^5&]T86P\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
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M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!C;VQO<CH@<F5D.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/DEN($%U9W5S="P@,C`P
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M9"!A<'!L:6-A8FQE(&QA=RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R
M9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SY/;B!.;W9E;6)E<B`X+"`R,#$Q+"!W92!E;G1E<F5D(&EN=&\@
M;F5W(&5M<&QO>6UE;G0@86=R965M96YT<RP@969F96-T:79E(&%S(&]F($IA
M;G5A<GD@,2P@,C`Q,BP@=VET:"!E86-H(&]F($UR+B!4960@2V%R:W5S(&%N
M9"!-<BX@0W5D9&EH>2`H=&AE("8C.#(R,#M%;7!L;WEM96YT($%G<F5E;65N
M=',F(S@R,C$[*2X@5&AE($5M<&QO>6UE;G0@06=R965M96YT<R!S=7!E<G-E
M9&4@=&AE(&5M<&QO>6UE;G0@86=R965M96YT<R!O9B!-<BX@2V%R:W5S(&%N
M9"!-<BX@0W5D9&EH>2P@9&%T960@075G=7-T(#$Y+"`R,#`Y+"!T:&%T(&AA
M9"!B965N('-C:&5D=6QE9"!T;R!T97)M:6YA=&4@;VX@2G5L>2`Q-2P@,C`Q
M,BX@5&AE('-C:&5D=6QE9"!T97)M:6YA=&EO;B!D871E<R!O9B!T:&4@16UP
M;&]Y;65N="!!9W)E96UE;G1S(&ES($IU;'D@,34L(#(P,34L('=H:6-H(&ES
M('1H<F5E('EE87)S(&9O;&QO=VEN9R!T:&4@<V-H961U;&5D(&5X<&ER871I
M;VX@9&%T92!S970@9F]R=&@@:6X@=&AE(&5X96-U=&EV97,F(S@R,3<[(&9O
M<FUE<B!E;7!L;WEM96YT(&%G<F5E;65N=',N/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
M:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY5;F1E<B!H
M:7,@;F5W(&5M<&QO>6UE;G0@86=R965M96YT('=I=&@@=&AE($-O;7!A;GDL
M($UR+B!+87)K=7,@86=R965D('1O(&%N(&%N;G5A;"!B87-E('-A;&%R>2!O
M9B`D-C<U+#`P,"!A<R!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<BX@56YD97(@
M=&AE('1E<FUS(&]F(&AI<R!F;W)M97(@96UP;&]Y;65N="!A9W)E96UE;G0@
M=VET:"!T:&4@0V]M<&%N>2P@87,@86UE;F1E9"P@37(N($MA<FMU<R!W87,@
M96YT:71L960@=&\@86YN=6%L(&)A<V4@8V]M<&5N<V%T:6]N(&]F("0W-3`L
M,#`P+"!C;VYS:7-T:6YG(&]F(&$@)#8P,"PP,#`@8F%S92!S86QA<GD@86YD
M("0Q-3`L,#`P(&EN('-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;BX@2&4@:7,@
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M($-O;7!A;GDN/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^56YD97(@:&ES(&YE=R!E;7!L;WEM
M96YT(&%G<F5E;65N="!W:71H('1H92!#;VUP86YY+"!-<BX@0W5D9&EH>2!A
M9W)E960@=&\@86X@86YN=6%L(&)A<V4@<V%L87)Y(&]F("0S-3`L,#`P(&%S
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M("0S,C4L,#`P+"!C;VYS:7-T:6YG(&]F(&$@)#(W-2PP,#`@8F%S92!S86QA
M<GD@86YD("0U,"PP,#`@:6X@<W1O8VL@8F%S960@8V]M<&5N<V%T:6]N+B!-
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M8W5T:79E<R!O9B!T:&4@0V]M<&%N>2X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY%86-H(&5X96-U=&EV92!I<R!S=6)J96-T('1O(&YO
M;BUC;VUP971I=&EO;B!R97-T<FEC=&EO;G,@9F]R('5P('1O(&$@<&5R:6]D
M(&]F(&5I=&AE<B!S:7@@*#8I(&UO;G1H<R!O<B!E:6=H=&5E;B`H,3@I(&UO
M;G1H<R!F;VQL;W=I;F<@=&5R;6EN871I;VX@;V8@96UP;&]Y;65N="!D97!E
M;F1I;F<@;VX@=&AE(&YA='5R92!O9B!T:&4@=&5R;6EN871I;VXN($5A8V@@
M97AE8W5T:79E(&ES(&%L<V\@96QI9VEB;&4@9F]R(&$@9W)O<W,@=7`@<&%Y
M;65N="!I;B!T:&4@979E;G0@=&AA="!A;GD@86UO=6YT<R!P87EA8FQE('5N
M9&5R('1H92!A9W)E96UE;G1S("AO<B!A;GD@;W1H97(@<&QA;BP@<')O9W)A
M;2P@<&]L:6-Y(&]R(&%R<F%N9V5M96YT('=I=&@@=&AE($-O;7!A;GDI(&)E
M8V]M92!S=6)J96-T('1O('1H92!E>&-I<V4@=&%X(&EM<&]S960@8GD@4V5C
M=&EO;B`T.3DY(&]F('1H92!);G1E<FYA;"!2979E;G5E($-O9&4N/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA
M<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
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M=7(@*#(T*2!M;VYT:',@;V8@82!#:&%N9V4@:6X@0V]N=')O;"`H87,@9&5F
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M:6T@=VET:&]U="!';V]D(%)E87-O;B`H87,@9&5F:6YE9"!I;B!T:&4@86=R
M965M96YT<RDN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQI/CQU/E1(12!154E'3$59($-/4E!/4D%424].("AC=7)R96YT;'D@
M4%)/4$A!4T4@3$%"4RP@24Y#+BD@5E,N($I/2$X@0RX@1T]$1E)%62P@150@
M04PN/"]U/CPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AI<R!A8W1I
M;VX@=V%S(&-O;6UE;F-E9"!B>2!U<R!I;B!.;W9E;6)E<B`R,#`T(&EN('1H
M92!#;W5R="!O9B!#;VUM;VX@4&QE87,@;V8@0G5C:W,@0V]U;G1Y+"!096YN
M<WEL=F%N:6$@86=A:6YS="!*;VAN($,N($=O9&9R97DL($YA;F-Y($IA;F4@
M1V]D9G)E>2P@86YD($=O9&9R97D@4V-I96YC92!A;F0@1&5S:6=N+"!);F,N
M(&9O<B!I;FIU;F-T:79E(')E;&EE9B!R96=A<F1I;F<@=&AE($-O;&0M145:
M13QS=7`^)B,Q-S0[/"]S=7`^)B,Q-C`[=')A9&5M87)K.R!I;FIU;F-T:79E
M(')E;&EE9B!R96QA=&EN9R!T;R!T:&4@0V]L9"U%15I%/'-U<#XF(S$W-#L\
M+W-U<#X@9F]R;75L871I;VYS(&%N9"!M86YU9F%C='5R:6YG(&UE=&AO9',[
M(&EN:G5N8W1I=F4@<F5L:65F(&9O<B!B<F5A8V@@;V8@=&AE(&1U='D@;V8@
M;&]Y86QT>2P@86YD(&1E8VQA<F%T;W)Y(&IU9&=M96YT)B,Q-C`[<F5G87)D
M:6YG)B,Q-C`[=F%R:6]U<R!P87EM96YT<R!T:&%T('1H92!D969E;F1A;G1S
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M8V5S)B,Q-C`[*'1H92`B06=R965M96YT<R(I+B8C,38P.R!3=6)S97%U96YT
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M=7`^)B,Q-S0[/"]S=7`^('1R861E;6%R:R!A;F0F(S$V,#MT:&4@=')A9&4@
M<V5C<F5T<R!T:&%T)B,Q-C`[=V4@9&5V96QO<&5D(&1U<FEN9R!O=7(@;6%N
M=69A8W1U<F4@;V8@0V]L9"U%15I%/'-U<#XF(S$W-#L\+W-U<#XN($)O=&@-
M"B!B96-A=7-E(&]F('1H96ER(&)R96%C:&5S(&%N9"!T:&4@97AP:7)A=&EO
M;B!O9B!T:&4@8F%S:6,@<&%T96YT+"!W92!T97)M:6YA=&5D('1H928C,38P
M.T%G<F5E;65N=',N)B,Q-C`[($1E9F5N9&%N=',@:&%V92!A;G-W97)E9"!T
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M="!B>2!T:&4F(S$V,#MD969E;F1A;G1S)B,Q-C`[:7,@8F%S960@;VX@=&AE
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M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^4')E+71R:6%L(&1I<V-O=F5R
M>2!I<R8C,38P.V]N9V]I;F<N)B,Q-C`[($1E9F5N9&%N=',@;6]V960@9F]R
M('!A<G1I86P@<W5M;6%R>2!J=61G;65N="P@86YD('=E(&9I;&5D(&$@<F5S
M<&]N<V4@86YD(&-R;W-S+6UO=&EO;B!F;W(@<W5M;6%R>2!J=61G;65N="XF
M(S$V,#L@3VX@075G=7-T(#(Q+"`R,#`X+"!T:&4@8V]U<G0@9&5N:65D(&)O
M=&@@;6]T:6]N<R!F;W(@<W5M;6%R>2!J=61G;65N="XF(S$V,#L@5&AE(&-A
M<V4@:&%S(&YO="!B965N(&%S<VEG;F5D('1O(&$@=')I86P@8V%L96YD87(L
M(&%L=&AO=6=H(&ET(&ES('!O<W-I8FQE('1H870@=&AE(&-A<V4@=VEL;"!B
M92!L:7-T960@9F]R('1R:6%L(&EN(#(P,3(N)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.T%T('1H:7,@=&EM92!N;R!P<F5D:6-T:6]N(&%S('1O
M('1H92!O=71C;VUE(&]F('1H:7,@86-T:6]N(&-A;B!B92!M861E+CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQI/CQU/E1(12!1
M54E'3$59($-/4E!/4D%424].("AC=7)R96YT;'D@4%)/4$A!4T4@3$%"4RP@
M24Y#+BD@5E,N(%=!0TA/5DE!($E.4U5204Y#12!315)624-%4RP@24Y#+B!!
M3D0@1DE24U0@54Y)3TX@24Y355)!3D-%(%-%4E9)0T53($%'14Y#62P@24Y#
M+CPO=3X\+VD^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E=E(&EN<W1I='5T
M960@82!7<FET(&]F(%-U;6UO;G,@86=A:6YS="!786-H;W9I82!);G-U<F%N
M8V4@4V5R=FEC97,L($EN8RX@86YD($9I<G-T(%5N:6]N($EN<W5R86YC92!3
M97)V:6-E<R!!9V5N8WDL($EN8RX@;VX@1&5C96UB97(@."P@,C`P-2!I;B!T
M:&4@0V]U<G0@;V8@0V]M;6]N(%!L96%S(&]F($)U8VMS($-O=6YT>2P@4&5N
M;G-Y;'9A;FEA+B!4:&4@<'5R<&]S92!O9B!T:&ES('-U:70@=V%S('1O(&UA
M:6YT86EN(&%N(&%C=&EO;B!A;F0@=&]L;"!T:&4@<W1A='5T92!O9B!L:6UI
M=&%T:6]N(&%G86EN<W0@;W5R(&EN<W5R86YC92!B<F]K97(@=VAO(&9A:6QE
M9"!T;R!P;&%C92!E>&-E<W,@;&EM:71S(&-O=F5R86=E(&9O<B!U<R!F;W(@
M=&AE('!E<FEO9"!F<F]M($YO=F5M8F5R(#(Y+"`R,#`S('5N=&EL($%P<FEL
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M=F5M8F5R(#(Y+"`R,#`U+B!!;GD@8V%S92!I;B!W:&EC:"!A;B!A;&QE9V5D
M(&%C=&EO;B!A<F]S92!R96QA=&EN9R!T;R!T:&4@=7-E(&]F($-O;&0M145:
M13QS=7`^)B,Q-S0[/"]S=7`^($YA<V%L(%-P<F%Y(&9R;VT@3F]V96UB97(@
M,CDL(#(P,#,@=&\@07!R:6P@-BP@,C`P-"!I<R!N;W0@8V]V97)E9"!B>2!E
M>&-E<W,@:6YS=7)A;F-E+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
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M97)V:6-E<R!!9V5N8WDL($EN8RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\:3X\=3Y04D]0
M2$%312!,04)3+"!)3D,N*&9O<FUE<FQY(%1(12!154E'3$59($-/4E!/4D%4
M24].*2`\9F]N="!S='EL93TS1"=T97AT+71R86YS9F]R;3H@=7!P97)C87-E
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M9"!*;VAN($1O92!$969E;F1A;G1S/"]F;VYT/CPO=3X\+VD^/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!W:6YD;W=T
M97AT.R<^3VX@075G=7-T(#(S+"`R,#$P+"!W92!I;FET:6%T960@86X@86-T
M:6]N(&EN('1H92!#;W5R="!O9B!#;VUM;VX@4&QE87,@;V8@0G5C:W,@0V]U
M;G1Y+"`\+V9O;G0^4&5N;G-Y;'9A;FEA/&9O;G0@<W1Y;&4],T0G8V]L;W(Z
M('=I;F1O=W1E>'0[)SXN(%1H:7,@86-T:6]N)B,Q-C`[:7,@86=A:6YS="!C
M97)T86EN(&9O<FUE<B!O9F9I8V5R<R!A;F0@9&ER96-T;W)S(&]F('1H92!#
M;VUP86YY+"!I;F-L=61I;F<@82!S:&%R96AO;&1E<B!T:&%T(&)E;F5F:6-I
M86QL>2!O=VYS(&%P<')O>&EM871E;'D@,C`N,24@;V8@;W5R($-O;6UO;B!3
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M;F4@,C`P.2!A;F0@=&AE(&EN<W1A;&QA=&EO;B!O9B!T:&4@8W5R<F5N="!"
M;V%R9"!O9B!$:7)E8W1O<G,N(%!R92UT<FEA;"!D:7-C;W9E<GD@:7,@;VXM
M9V]I;F<@86YD(&%T('1H:7,@=&EM92P@;F\@<')E9&EC=&EO;B!A<R!T;R!T
M:&4@;W5T8V]M92!O9B!T:&ES(&%C=&EO;B!C86X@8F4@;6%D92X\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&D^/'4^1U59(%%524=,15D@5E,N(%1%1"!+05)+
M55,L(%)/0D525"!6+B!#541$24A9+"!*4BXL($U!4DL@0E523D545"P@34%2
M2R!,159%3E1(04PL($U!4DL@1E)!3DLL($Q/54E3($=,14-+14PL($U$+"!*
M04U%4R!-8T-50D))3B!!3D0@4%)/4$A!4T4@3$%"4RP@24Y#+B!!4R!!($Y/
M34E.04P@1$5&14Y$04Y4/"]U/CPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^5&AE($-O;7!A;GD@=V%S(&YA;65D(&%S(&$@;F]M:6YA;"!D969E;F1A
M;G0@:6X@82!P=7)P;W)T960@9&5R:79A=&EV92!C;VUP;&%I;G0@9FEL960@
M;VX@1F5B<G5A<GD@,BP@,C`Q,B!B>2!S=&]C:VAO;&1E<B!A;F0@9F]R;65R
M(&1I<F5C=&]R(&%N9"!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<B!'=7D@475I
M9VQE>2!I;B!T:&4@0V]U<G0@;V8@0V]M;6]N(%!L96%S(&]F(%!H:6QA9&5L
M<&AI82!#;W5N='DL(%!E;FYS>6QV86YI82`H3F\N(#$Q,3(P,#0P.2DN(%1H
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M9V]R;W5S;'D@9&5F96YD(&%G86EN<W0@:70N/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^07,@;F]T960@86)O=F4L('1H92!#;VUP86YY
M('!R979I;W5S;'D@8V]M;65N8V5D(&QI=&EG871I;VX@86=A:6YS="!T:&4@
M<&QA:6YT:69F+"!'=7D@475I9VQE>2P@86YD(&]T:&5R('!A<G1I97,@:6X@
M075G=7-T(#(P,3`@:6X@=&AE($)U8VMS($-O=6YT>2!#;W5R="!O9B!#;VUM
M;VX@4&QE87,L(%!E;FYS>6QV86YI82`H3F\N#0H@,C`Q,"TP.#(R-RDN(%1H
M92!!=6=U<W0@,C`Q,"!A8W1I;VX@<F5M86EN<R!P96YD:6YG+CPO<#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%D@04Y$
M(%-43T-+($-/35!%3E-!5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,@17%U:71Y($YO
M=&4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>2!.;W1E($1I<V-L;W-U
M<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/CQB/CQI/B8C,38P.SPO:3X\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/CQB/E-T;V-K:&]L9&5R(%)I9VAT<R!0;&%N/"]B/CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z(#`N-6EN.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/D]N(%-E<'1E
M;6)E<B`X+"`Q.3DX+"!O=7(@0F]A<F0@;V8@1&ER96-T;W)S(&1E8VQA<F5D
M(&$@9&EV:61E;F0@9&ES=')I8G5T:6]N(&]F($-O;6UO;B!3=&]C:R!0=7)C
M:&%S92!2:6=H=',@*&5A8V@@:6YD:79I9'5A;&QY+"!A("8C.#(R,#M2:6=H
M="8C.#(R,3L@86YD(&-O;&QE8W1I=F5L>2P@=&AE("8C.#(R,#M2:6=H=',F
M(S@R,C$[*2!P87EA8FQE('1O('1H92!S=&]C:VAO;&1E<G,@;V8@<F5C;W)D
M(&]N(%-E<'1E;6)E<B`R-2P@,3DY."P@=&AE<F5B>2!C<F5A=&EN9R!A(%-T
M;V-K:&]L9&5R(%)I9VAT<R!0;&%N("AT:&4@)B,X,C(P.U)I9VAT<R!!9W)E
M96UE;G0F(S@R,C$[*2X@5&AE(%!L86X@=V%S(&%M96YD960@969F96-T:79E
M($UA>2`R,RP@,C`P."`H)B,X,C(P.T9I<G-T($%M96YD;65N="8C.#(R,3LI
M(&%N9"!F=7)T:&5R(&%M96YD960@969F96-T:79E($%U9W5S="`Q."P@,C`P
M.2`H)B,X,C(P.U-E8V]N9"!!;65N9&UE;G0F(S@R,C$[*2X@5&AE(%)I9VAT
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M:7)E9"`Q-24@;W(@;6]R92!O9B!T:&4@;W5T<W1A;F1I;F<@8V]M;6]N('-H
M87)E<RP@;W(@=&AE(&%N;F]U;F-E;65N="!O9B!A;B!I;G1E;G1I;VX@8GD@
M82!S:6UI;&%R;'D@8V]N<W1I='5T960@<&%R='D@=&\@;6%K92!A('1E;F1E
M<B!O<B!E>&-H86YG92!O9F9E<B!R97-U;'1I;F<@:6X@=&AE(&]W;F5R<VAI
M<"!O9B`Q-24@;W(@;6]R92!O9B!T:&4@;W5T<W1A;F1I;F<@8V]M;6]N('-H
M87)E<RX@5&AE(&1I=FED96YD(&AA<R!T:&4@969F96-T(&]F(&=I=FEN9R!T
M:&4@<W1O8VMH;VQD97(@82`U,"4@9&ES8V]U;G0@;VX@=&AE('-H87)E)B,X
M,C$W.W,@8W5R<F5N="!M87)K970@=F%L=64@9F]R(&5X97)C:7-I;F<@<W5C
M:"!R:6=H="X@26X@=&AE(&5V96YT(&]F(&$@8V%S:&QE<W,@97AE<F-I<V4@
M;V8@=&AE(%)I9VAT+"!A;F0@=&AE(&%C<75I<F5R(&AA<R!A8W%U:7)E9"!L
M97-S('1H86X@-3`E(&)E;F5F:6-I86P@;W=N97)S:&EP(&]F('1H92!#;VUP
M86YY+"!A('-T;V-K:&]L9&5R(&UA>2!E>&-H86YG92!O;F4@4FEG:'0@9F]R
M(&]N92!C;VUM;VX@<VAA<F4@;V8@=&AE($-O;7!A;GDN(%1H92!2:6=H=',@
M06=R965M96YT+"!A<R!A;65N9&5D+"!I;F-L=61E<R!A('!R;W9I<VEO;B!P
M=7)S=6%N="!T;R!W:&EC:"!O=7(@0F]A<F0@;V8@1&ER96-T;W)S(&UA>2!E
M>&5M<'0@9G)O;2!T:&4@<')O=FES:6]N<R!O9B!T:&4@4FEG:'1S($%G<F5E
M;65N="!A;B!O9F9E<B!F;W(@86QL(&]U='-T86YD:6YG('-H87)E<R!O9B!O
M=7(@0V]M;6]N(%-T;V-K('1H870@=&AE(&1I<F5C=&]R<R!D971E<FUI;F4@
M=&\@8F4@9F%I<B!A;F0@;F]T(&EN861E<75A=&4@86YD('1O(&]T:&5R=VES
M92!B92!I;B!T:&4@8F5S="!I;G1E<F5S=',@;V8@=&AE($-O;7!A;GD@86YD
M(&ET<R!S=&]C:VAO;&1E<G,L(&%F=&5R(')E8V5I=FEN9R!A9'9I8V4@9G)O
M;2!O;F4@;W(@;6]R92!I;G9E<W1M96YT(&)A;FMI;F<@9FER;7,N(%1H92!E
M>'!I<F%T:6]N(&1A=&4@;V8@=&AE(%)I9VAT<R!!9W)E96UE;G0L(&%S(&%M
M96YD960L(&ES(%-E<'1E;6)E<B`R-2P@,C`Q."X\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA
M<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/CQB/E0\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SYH92`Q.3DW
M($]P=&EO;B!0;&%N/"]F;VYT/CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@
M:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CY/;B!$96-E;6)E<B`R+"`Q.3DW
M+"!O=7(@0F]A<F0@;V8@1&ER96-T;W)S(&%P<')O=F5D(&$@4W1O8VL@3W!T
M:6]N(%!L86X@*'1H92`F(S@R,C`[,3DY-R!0;&%N)B,X,C(Q.RDL('=H:6-H
M('=A<R!A;65N9&5D(&EN(#(P,#4L(&%N9"!P<F]V:61E9"!F;W(@=&AE(&=R
M86YT:6YG(&]F('5P('1O(#0N-2!M:6QL:6]N('-H87)E<R!O9B!#;VUM;VX@
M4W1O8VLN(%5N9&5R('1H92`Q.3DW(%!L86XL('=E('=E<F4@<&5R;6ET=&5D
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M92`Q.3DW(%!L86X@:6X@1FES8V%L(#$Y.3@N($YO(&]P=&EO;G,@=V5R92!G
M<F%N=&5D('5N9&5R('1H:7,@4&QA;B!D=7)I;F<@1FES8V%L(#(P,3$L(#(P
M,3`@;W(@,C`P.2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CY!="!$96-E;6)E<B`S,2P@,C`Q,2P@
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M97)E(&%R92`Q,S@L-S4P(&]P=&EO;G,@;W5T<W1A;F1I;F<@=VET:"!V87)I
M;W5S(&5X<&ER871I;VX@9&%T97,@<F%N9VEN9R!F<F]M($IU;'D@,C`Q,B!T
M:')O=6=H($1E8V5M8F5R(#(P,34L(&1E<&5N9&EN9R!U<&]N('1H92!D871E
M(&]F(&=R86YT+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CX\8CY4/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^:&4@,C`Q
M,"!%<75I='D@0V]M<&5N<V%T:6]N(%!L86X\+V9O;G0^/"]B/CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/D]N($UA
M>2`U+"`R,#$P+"!O=7(@<VAA<F5H;VQD97)S(&%P<')O=F5D('1H92`R,#$P
M($5Q=6ET>2!#;VUP96YS871I;VX@4&QA;B!W:&EC:"!W87,@<W5B<V5Q=65N
M=&QY(&%M96YD960L(')E<W1A=&5D(&%N9"!A<'!R;W9E9"!B>2!S:&%R96AO
M;&1E<G,@;VX@07!R:6P@,C0L(#(P,3$@*'1H92`F(S@R,C`[,C`Q,"!%<75I
M='D@0V]M<&5N<V%T:6]N(%!L86XF(S@R,C$[*2X@5&AE(#(P,3`@17%U:71Y
M($-O;7!E;G-A=&EO;B!0;&%N('!R;W9I9&5S('1H870@=&AE('1O=&%L(&YU
M;6)E<B!O9B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1H870@;6%Y(&)E(&ES
M<W5E9"!I<R!E<75A;"!T;R`Y,#`L,#`P('-H87)E<R!P;'5S('5P('1O(#DP
M,"PP,#`@<VAA<F5S('1H870@87)E(&%U=&AO<FEZ960@9F]R(&ES<W5A;F-E
M+"!)<W-U960@3W!T:6]N<R`H9&5F:6YE9"!B96QO=RD@8G5T('5N:7-S=65D
M('5N9&5R('1H92`Q.3DW(%!L86X@86X@86=G<F5G871E(&]F(#$N."!M:6QL
M:6]N('-H87)E<RX@/&9O;G0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<^5&AE
M(#$Y.3<@4&QA;B!E>'!I<F5D(&]N($1E8V5M8F5R(#(L(#(P,#<@86YD(&YO
M(&%D9&ET:6]N86P@87=A<F1S(&UA>2!B92!M861E.R!H;W=E=F5R+"!A/"]F
M;VYT/G,@;V8@36%R8V@@,S$L(#(P,3`L('1H97)E(')E;6%I;F5D(#$L-#0Y
M+#<U,"!S:&%R97,@<W5B:F5C="!T;R!V97-T960@;W!T:6]N<R!T:&%T('=E
M<F4@875T:&]R:7IE9"!F;W(@:7-S=6%N8V4@*'1H92`F(S@R,C`[27-S=65D
M($]P=&EO;G,F(S@R,C$[*2!B=70@=V5R92!U;FES<W5E9"!U;F1E<B!T:&4@
M,3DY-R!0;&%N+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2P@,2PS,3$L,#`P
M(&]F('1H92!)<W-U960@3W!T:6]N<R!U;F1E<B!T:&4@,3DY-R!0;&%N(&5X
M<&ER960@=6YE>&5R8VES960@;W(@=V5R92!T97)M:6YA=&5D("AT:&4@)B,X
M,C(P.T5X<&ER960@3W!T:6]N<R8C.#(R,3LI+B!!<R!A(&-O;G-E<75E;F-E
M+"!T:&5S92!S:&%R97,@87)E(&1E96UE9"!A;F0@<F5M86EN('5N:7-S=65D
M('=H:6-H('5P('1O(&$@;6%X:6UU;2!O9B`Y,#`L,#`P('-H87)E<R!B96-A
M;64@879A:6QA8FQE(&9O<B!I<W-U86YC92!U;F1E<B!T:&4@,C`Q,"!%<75I
M='D@0V]M<&5N<V%T:6]N(%!L86X@86YD('1H92!R96UA:6YI;F<@-#$Q+#`P
M,"!O<'1I;VYS(&%R92!D965M960@8V%N8V5L;&5D+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CX\:3X\=3X\
M8G(@("\^4W1O8VL@3W!T:6]N<SPO=3X\+VD^/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M:6=I8FQE('1O('!A<G1I8VEP871E(&EN('1H92`R,#$P($5Q=6ET>2!#;VUP
M96YS871I;VX@4&QA;BX@0V]N<W5L=&%N=',@86YD(&%D=FES;W)S('=H;R!P
M97)F;W)M('-E<G9I8V5S(&9O<B!T:&4@0V]M<&%N>2!A<F4@86QS;R!E;&EG
M:6)L92!T;R!P87)T:6-I<&%T92!I;B!T:&4@,C`Q,"!%<75I='D@0V]M<&5N
M<V%T:6]N(%!L86XN($9O<B!&:7-C86P@,C`Q,2P@,C`Q,"!A;F0@,C`P.2P@
M=V4@9W)A;G1E9"`R,C`L,#`P+"`Y.#(L,#`P(&%N9"!Z97)O(&]P=&EO;G,L
M(')E<W!E8W1I=F5L>2P@=&\@96UP;&]Y965S('1O(&%C<75I<F4@;W5R($-O
M;6UO;B!3=&]C:R!P=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@,C`Q,"!%<75I
M='D@0V]M<&5N<V%T:6]N(%!L86XN(%!R97-E;G1E9"!B96QO=R!I<R!A('-U
M;6UA<GD@;V8@=&AE('1E<FUS(&]F('1H92!G<F%N="!O9B!O<'1I;VYS.CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z
M(#`N,6EN.R!W:61T:#H@.3,E.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,3`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/EEE87(F(S$V,#M%;F1E
M9"8C,38P.T1E8V5M8F5R)B,Q-C`[,S$L/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^,C`Q,#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXR,#`Y/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`V,24[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^3G5M8F5R(&]F(&]P=&EO;G,@9W)A;G1E9#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^,C(P+#`P,#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
M969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/CDX,BPP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,3`E.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
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M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^-R!Y96%R<SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^-R!Y
M96%R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
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M,"XX-R`M("0Q+C$W/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^+3PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T
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M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/C`N
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M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M:6YD
M96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CY792!U<V4@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@
M;6]D96P@9'5R:6YG($9I<V-A;"`R,#$Q(&%N9"`R,#$P('1O(&1E=&5R;6EN
M92!T:&4@9F%I<B!V86QU92!O9B!T:&4@<W1O8VL@;W!T:6]N<R!A="!T:&4@
M9&%T92!O9B!G<F%N="X@0F%S960@=7!O;B!O=7(@;&EM:71E9"!H:7-T;W)I
M8V%L(&5X<&5R:65N8V4L('=E(&5S=&EM871E9"!A<'!R;WAI;6%T96QY(#,S
M+#`P,"!A;F0@,C<L,S`P+"!R97-P96-T:79E;'DL(&]F('1H92!O<'1I;VYS
M(&=R86YT960@:6X@1FES8V%L(#(P,3$@86YD($9I<V-A;"`R,#$P(&UA>2!U
M;'1I;6%T96QY(&)E(&9O<F9E:71E9"X@061D:71I;VYA;&QY+"!W92!D971E
M<FUI;F5D('1H92!E>'!E8W1E9"!T97)M(&]F('1H92!S=&]C:R!O<'1I;VX@
M9W)A;G1S('1O(&)E(&$@<F%N9V4@8F5T=V5E;B`T+C4@=&\@-BXU('EE87)S
M+"!C86QC=6QA=&5D('5S:6YG('1H92`F(S@R,C`[<VEM<&QI9FEE9"8C.#(R
M,3L@;65T:&]D(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@4T5#(%-T869F($%C
M8V]U;G1I;F<@0G5L;&5T:6X@,3$P+B!792!U<V4@=&AE("8C.#(R,#MS:6UP
M;&EF:65D)B,X,C(Q.R!M971H;V0@<VEN8V4@=V4@8VAA;F=E9"!T:&4@=F5S
M=&EN9R!T97)M<RP@=&%X('1R96%T;65N="!A;F0@=&AE(')E8VEP:65N=',@
M;V8@;W5R('-T;V-K(&]P=&EO;G,@8F5G:6YN:6YG(&EN(#(P,3`@<W5C:"!T
M:&%T('=E(&)E;&EE=F4@;W5R(&AI<W1O<FEC86P@9&%T82!D;V5S(&YO="!P
M<F]V:61E(&$@<F5A<V]N86)L92!B87-I<R!U<&]N('=H:6-H('1O(&5S=&EM
M871E(&5X<&5C=&5D('1E<FTN(%!R97-E;G1E9"!B96QO=R!I<R!A('-U;6UA
M<GD@;V8@87-S=6UP=&EO;G,@=7-E9"!I;B!D971E<FUI;FEN9R!T:&4@9F%I
M<B!V86QU92!O9B!T:&4@<W1O8VL@;W!T:6]N<R!A="!T:&4@9&%T92!O9B!G
M<F%N=#H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M
M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;BUL969T.B`P+C%I;CL@=VED=&@Z(#DS)3LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
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M-C`[16YD960F(S$V,#M$96-E;6)E<B8C,38P.S,Q+#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/C(P,3`\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^,C`P.3PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^-"XW-2!Y96%R<SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M
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M)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^,BXQ,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXE/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
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M+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B4\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXW-2XX
M-"4@+2`W."XV,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B4F
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXW
M,BXQ-R4@+2`W-RXV,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
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M('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z(#`N-6EN.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z(#`N-6EN.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/E1H92!F86ER
M('9A;'5E(&]F('1H92!S=&]C:R!O<'1I;VYS(&%T('1H92!T:6UE(&]F('1H
M92!G<F%N="!I;B!&:7-C86P@,C`Q,2!A;F0@,C`Q,"!W87,@87!P<F]X:6UA
M=&5L>2`D,3(W+#`P,"!A;F0@)#8Q."PP,#`L(')E<W!E8W1I=F5L>2X@16%C
M:"!O9B!T:&4@<W1O8VL@;W!T:6]N<R!G<F%N=&5D('=E<F4@<W5B:F5C="!T
M;R!V97-T:6YG('-U8V@@=&AA="!T:&4@9F%I<B!V86QU92!O9B!T:&4@<W1O
M8VL@;W!T:6]N<R!G<F%N=&5D(&ES(&-H87)G960@=&\@;W!E<F%T:6]N<R!O
M=F5R('1H92!V97-T:6YG('!E<FEO9"X@1F]R($9I<V-A;"`R,#$Q(&%N9"`R
M,#$P+"!W92!C:&%R9V5D('1O(&]P97)A=&EO;G,@)#$S,2PP,#`@86YD("0T
M,BPP,#`L(')E<W!E8W1I=F5L>2P@9F]R('-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;B!E>'!E;G-E(&9O<B!T:&4@86=G<F5G871E(&9A:7(@=F%L=64@;V8@
M=&AE('-T;V-K(&=R86YT<R!A;F0@=F5S=&5D('-T;V-K(&]P=&EO;G,@96%R
M;F5D+B!4:&5R92!W87,@;F\@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4@9F]R($9I<V-A;"`R,#`Y+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CX\8CXF(S$V,#L\+V(^/"]F;VYT/CPO<#X-"CQD:78@<W1Y;&4],T0G
M;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CY!="!$96-E;6)E<B`S,2P@,C`Q,2P@
M,C,W+#`R,"!O9B!T:&4@;W!T:6]N<R!G<F%N=&5D(&EN($9I<V-A;"`R,#$Q
M(&%N9"`R,#$P('=E<F4@=F5S=&5D(&%N9"`Y-38L.3@P(&%R92!S=6)J96-T
M('1O('9E<W1I;F<N($%T($1E8V5M8F5R(#,Q+"`R,#$Q+"!T:&5R92!A<F4@
M,3,L-C4Y(&]P=&EO;G,@879A:6QA8FQE(&9O<B!G<F%N="!T;R!P=7)C:&%S
M92!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1H870@;6%Y(&)E(&ES<W5E9"!P
M=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@=&AE(#(P,3`@17%U:71Y($-O;7!E
M;G-A=&EO;B!0;&%N+CQB<B`@+SX\8G(@("\^/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z(#`N-6EN.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/D$@<W5M;6%R>2!O
M9B!T:&4@<W1A='5S(&]F(&]U<B!S=&]C:R!O<'1I;VYS(&=R86YT960@=&\@
M8F]T:"!E;7!L;WEE97,@86YD(&YO;BUE;7!L;WEE97,@87,@;V8@1&5C96UB
M97(@,S$L(#(P,3$L(#(P,3`@86YD(#(P,#D@86YD(&-H86YG97,@9'5R:6YG
M('1H92!Y96%R<R!T:&5N(&5N9&5D(&ES('!R97-E;G1E9"!B96QO=R`H:6X@
M=&AO=7-A;F1S+"!E>&-E<'0@<&5R('-H87)E(&1A=&$I.CPO9F]N=#X\+V1I
M=CX-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T97AT+6EN9&5N=#H@,"XU:6X[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!W:61T:#H@,3`P)3LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,C(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/EEE87(F(S$V,#M%;F1E9"8C,38P.T1E8V5M8F5R)B,Q-C`[,S$L/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0V/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXR,#$Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#8^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/C(P,3`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$-CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^,C`P.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I
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M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
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M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/E=E:6=H=&5D($%V97)A9V4\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^4VAA<F5S/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/D5X97)C:7-E)B,Q-C`[4')I8V4\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/D5X97)C:7-E)B,Q-C`[4')I
M8V4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
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M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/D5X97)C:7-E
M)B,Q-C`[4')I8V4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,T)3L@=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CY/<'1I
M;VYS(&]U='-T86YD:6YG("T@8F5G:6YN:6YG(&]F('EE87(\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@<FEG:'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^,2PS,#`\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#@E.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXR+CDY/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#@E.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CXQ+#0X.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@."4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/C@N-C0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@."4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/C(L,C8X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^-RXW-CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CY'<F%N=&5D/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^,C(P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXQ+C$P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXY.#(\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/C$N,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^17AE<F-I<V5D/"]F;VYT/CPO=&0^
M#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
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M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
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M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BQT:6UE<SLG('-I>F4],T0R/C$N,#(\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BQT:6UE<SLG('-I>F4],T0R/B@Q,C4\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/BD\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXQ+C`Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CY#86YC96QL960\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B@Q.#<\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/BD\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/C@N-C<\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B@Q+#`S.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^.2XT-3PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXH-C4U/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXI/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXW+C`R
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CY/<'1I;VYS(&]U='-T86YD:6YG("T@96YD(&]F('EE
M87(\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
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M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CXQ+C@X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXQ+#,P,#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/C(N.3D\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/C$L-#@X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
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M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/CDU
M-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/C$N,#(\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/CDS-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
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M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/C,W-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXS-C,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
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M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXQ-#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXX,3@\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#L@.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^+3PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R`[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#L@.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[(#L@9F]N="UF86UI;'DZ('1I;65S(&YE
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M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CY4:&4@=6YR96-O9VYI>F5D('-H87)E+6)A<V5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@=&AE(&]P=&EO;G,@
M9W)A;G1E9"!B=70@;F]T('9E<W1E9"P@*&]P=&EO;G,@=&\@86-Q=6ER92`Y
M-38L.3@P('-H87)E<RD@=V%S(&%P<')O>&EM871E;'D@)#4W,BPP,#`@870@
M1&5C96UB97(@,S$L(#(P,3$N(%1H97-E(&]P=&EO;G,@<W5B:F5C="!T;R!V
M97-T:6YG("AI*2!V97-T(&]V97(@=&AE(&YE>'0@,B!T;R`U('EE87)S+"`H
M:6DI(&AA=F4@82`W('EE87(@=&5R;2!F<F]M('1H92!D871E(&]F(&=R86YT
M+"`H:6EI*2!A<F4@97AE<F-I<V%B;&4@870@82!W96EG:'1E9"!A=F5R86=E
M('!R:6-E(&]F("0Q+C`R(&%N9"`H:78I('1H92!U;G)E8V]G;FEZ960@<VAA
M<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@:7,@97AP96-T960@=&\@
M8F4@<F5C;V=N:7IE9"!O=F5R(&$@=V5I9VAT960@879E<F%G92!P97)I;V0@
M;V8@-"!Y96%R<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q
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M:6]N<R!E>&5R8VES86)L92!A="!$96-E;6)E<B`S,2P@,C`Q,2`H:6X@=&AO
M=7-A;F1S+"!E>&-E<'0@<F5M86EN:6YG(&QI9F4@86YD('!E<B!S:&%R92!D
M871A*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^/"]P/@T*/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`P+C5I;CL@
M=VED=&@Z(#<U)3LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT
M:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W
M<F%P(&-O;'-P86X],T0Q,#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^3W!T:6]N<R8C,38P
M.T]U='-T86YD:6YG)B,Q-C`[86YD)B,Q-C`[17AE<F-I<V%B;&4\+V9O;G0^
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M97,[)R!S:7IE/3-$,CY286YG928C,38P.V]F/"]F;VYT/CQB<B`@+SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^17AE<F-I<V4@4')I8V5S/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
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M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
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M;6%I;FEN9R`\+V9O;G0^/&)R("`O/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CY#;VYT<F%C
M='5A;"!,:69E/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
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M;VUA;BQT:6UE<SLG('-I>F4],T0R/D5X97)C:7-E)B,Q-C`[4')I8V4@4&5R
M/"]F;VYT/CQB<B`@+SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^4VAA<F4\+V9O;G0^/"]T
M9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXR,S<\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^-BXP
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL
M=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXD,2XQ."`M("0U
M+C$Y/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^,C4\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE
M<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M,"XU/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I
M;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^-2XQ.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O
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M+C$R("T@)#DN-3`\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)#DN-3$@+2`D,3,N.#`\+V9O;G0^
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M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
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M9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CXT+C`\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^
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M,BXU<'0[('=I9'1H.B`R-B4[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(Q)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXS-S8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`R
M,24[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=VED=&@Z(#$E.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,C$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/C0N,#4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SX\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CY4:&4@=&]T86P@:6YT
M<FEN<VEC('9A;'5E(&]F(&]P=&EO;G,@97AE<F-I<V5D(&1U<FEN9R!&:7-C
M86P@,C`Q,"!A;F0@,C`P.2!W87,\9F]N="!S='EL93TS1"=C;VQO<CH@<F5D
M.R<^(#PO9F]N=#XD,3`W+#`P,"!A;F0\9F]N="!S='EL93TS1"=C;VQO<CH@
M<F5D.R<^(#PO9F]N=#XD,C(V+#`P,"P@<F5S<&5C=&EV96QY+B!4:&5R92!W
M97)E(&YO(&]P=&EO;G,@97AE<F-I<V5D(&1U<FEN9R!&:7-C86P@,C`Q,2X@
M5&AE(&%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@*&DI(&]P=&EO;G,@
M;W5T<W1A;F1I;F<L("AI:2D@;W!T:6]N<R!O=71S=&%N9&EN9R!A;F0@97AP
M96-T960@=&\@=F5S="!I;B!T:&4@9G5T=7)E(&%N9"`H:6EI*2!O<'1I;VYS
M(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!A="!$96-E;6)E<B`S,2P@
M,C`Q,2!W87,@)#$U.2PP,#`L("0Q,C,L,#`P(&%N9"`D,S8L,#`P+"!R97-P
M96-T:79E;'DN/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/CQB<B`@+SX\
M96T^/'4^4W1O8VL@1W)A;G1S/"]U/CPO96T^/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!T97AT+6EN9&5N=#H@,"XU:6X[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^26X@07!R:6P@,C`Q,2P@
M=&AE($-O;7!E;G-A=&EO;B!#;VUM:71T964@;V8@=&AE($)O87)D(&]F($1I
M<F5C=&]R<R!A<'!R;W9E9"!A;B!A;65N9&UE;G0@=&\@37(N($MA<FMU<R8C
M.#(Q-SL@=&AE;B!E;7!L;WEM96YT(&%G<F5E;65N="P@9&%T960@075G=7-T
M(#$Y+"`R,#`Y("AT:&4@)B,X,C(P.T%M96YD;65N="8C.#(R,3LI('1O(&QO
M=V5R(&AI<R!A;FYU86P@<V%L87)Y(&)Y("0Q-3`L,#`P("AO<B`D,3(L-3`P
M('!E<B!M;VYT:"D@:6X@97AC:&%N9V4@9F]R(&$@9W)A;G0@;V8@<F5S=')I
M8W1E9"!S=&]C:R!E<75A;"!I;B!V86QU92!T;R!T:&4@<V%L87)Y(')E9'5C
M=&EO;BX@4'5R<W5A;G0@=&\@=&AE($%M96YD;65N="P@37(N($MA<FMU<R8C
M.#(Q-SL@86YN=6%L(&)A<V4@<V%L87)Y('=A<R!D96-R96%S960@9G)O;2`D
M-S4P+#`P,"!P97(@>65A<B!T;R`D-C`P+#`P,"!P97(@>65A<BP@969F96-T
M:79E($UA>2`Q+"`R,#$Q('1H<G4@2G5L>2`Q-2P@,C`Q,BP@=VAI8V@@:7,@
M=&AE(&5N9"!O9B!T:&4@=&5R;2!O9B!H:7,@=&AE;B!E;7!L;WEM96YT(&%G
M<F5E;65N="P@87,@86UE;F1E9"X@07,@82!C;VYS97%U96YC92!O9B!T:&4@
M06UE;F1M96YT+"!A(')E<W1R:6-T960@<W1O8VL@9W)A;G0@=6YD97(@=&AE
M(#(P,3`@17%U:71Y($-O;7!E;G-A=&EO;B!0;&%N(&5Q=6%L('1O("0Q,BPU
M,#`@;V8@<VAA<F5S('!E<B!M;VYT:"!T:')U('1H92!E;F0@;V8@=&AE('1E
M<FT@*#$T+C4@;6]N=&AS*2X@5&AE(')E<W1R:6-T960@<W1O8VL@9W)A;G0@
M=V%S(&UA9&4@:6X@86X@=7!F<F]N="!G<F%N="!O9B`Q-C$L.#,P('-H87)E
M<RP@<W5B:F5C="!T;R!C97)T86EN(&9U='5R92!V97-T:6YG(&-O;F1I=&EO
M;G,L(&%T(&$@=F%L=64@;V8@)#$X,2PP,#`@87,@;V8@=&AE(&=R86YT(&1A
M=&4N(%1H92!G<F%N="!W87,@;6%D92!I;B!!<')I;"`R,#$Q+"!A;F0@=&AE
M(&%M;W5N="!O9B!T:&4@<VAA<F5S(&ES<W5E9"!W87,@8V%L8W5L871E9"!B
M87-E9"!O;B!T:&4@879E<F%G92!C;&]S:6YG('!R:6-E(&]F(&]U<B!#;VUM
M;VX@4W1O8VL@9F]R('1H92!L87-T(&9I=F4@*#4I('1R861I;F<@9&%Y<R!P
M<FEO<B!T;R!A;F0@:6YC;'5D:6YG('1H92!I<W-U86YC92!D871E(&]F($%P
M<FEL(#(Q+"`R,#$Q+B!&;W(@1FES8V%L(#(P,3$L('=E(&AA=F4@8VAA<F=E
M9"!T;R!O<&5R871I;VYS("0Q,#`L,#`P(&%S('-H87)E+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E(&9O<B!T:&4@<F5S=')I8W1E9"!S=&]C:R!G<F%N
M="!A;F0@=V4@:&%V92!U;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&5X<&5N
M<V4@;V8@)#@Q+#(U,"!A="!$96-E;6)E<B`S,2P@,C`Q,2!T:&%T('=I;&P@
M8F4@8VAA<F=E9"!T;R!O<&5R871I;VYS(&EN(&5Q=6%L(&UO;G1H;'D@:6YS
M=&%L;&UE;G1S(&]F("0Q,BPU,#`@;W9E<B!T:&4@<F5M86EN:6YG('9E<W1I
M;F<@<&5R:6]D(&5N9&EN9R!*=6QY(#$U+"`R,#$R+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z(#`N-6EN.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R/DEN
M(&%D9&ET:6]N+"!I;B!!<')I;"`R,#$Q+"!T:&4@0V]M<&5N<V%T:6]N($-O
M;6UI='1E92!O9B!T:&4@0F]A<F0@;V8@1&ER96-T;W)S(&=R86YT960@37(N
M($MA<FMU<R`Q,S,L.3(X('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=6YD97(@
M=&AE(#(P,3`@17%U:71Y($-O;7!E;G-A=&EO;B!0;&%N(&%S('!A>6UE;G0@
M9F]R(&AI<R!&:7-C86P@,C`Q,"!B;VYU<RX@1G5R=&AE<FUO<F4L(&EN($1E
M8V5M8F5R(#(P,3$L('1H92!#;VUP96YS871I;VX@0V]M;6ET=&5E(&]F('1H
M92!";V%R9"!O9B!$:7)E8W1O<G,@9W)A;G1E9"!-<BX@2V%R:W5S(#$R."PU
M-S$@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!U;F1E<B!T:&4@,C`Q,"!%<75I
M='D@0V]M<&5N<V%T:6]N(%!L86X@87,@<&%Y;65N="!F;W(@:&ES($9I<V-A
M;"`R,#$Q(&)O;G5S+B!-<BX@2V%R:W5S(&%G<F5E9"!T;R!A8V-E<'0@:&ES
M($9I<V-A;"`R,#$Q(&%N9"!&:7-C86P@,C`Q,"!C87-H(&)O;G5S(&]F("0Q
M-3`L,#`P(&9O<B!E86-H('EE87(@:6X@<VAA<F5S(&]F(&]U<B!#;VUM;VX@
M4W1O8VLN/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T97AT
M+6EN9&5N=#H@,"XU:6X[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!T97AT+6EN9&5N=#H@,"XU:6X[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+'1I;65S.R<@<VEZ93TS1#(^26X@07!R:6P@,C`Q,2P@37(N($MA<FMU<R!A
M;'-O(&%G<F5E9"!T;R!C;VYV97)T(&EN=&\@<VAA<F5S(&]F(&]U<B!#;VUM
M;VX@4W1O8VL@)#$T-"PP,#`@;V8@9&5F97)R960@86YD('5N<&%I9"!C87-H
M(&-O;7!E;G-A=&EO;B!O=V5D('1O(&AI;2!T:')U($%P<FEL(#(P,3$L(')E
M<W5L=&EN9R!I;B!A;B!I<W-U86YC92!O9B`Q,C@L-3<Q('-H87)E<R!U;F1E
M<B!T:&4@,C`Q,"!%<75I='D@0V]M<&5N<V%T:6]N(%!L86XN(%1H92!A;6]U
M;G0@;V8@=&AE<V4@<VAA<F5S(&ES<W5E9"!T;R!-<BX@2V%R:W5S('=A<R!C
M86QC=6QA=&5D(&)A<V5D(&]N('1H92!A=F5R86=E(&-L;W-I;F<@<')I8V4@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!S:&%R97,@9F]R('1H92!L87-T(&9I
M=F4@*#4I('1R861I;F<@9&%Y<R!P<FEO<B!T;R!A;F0@:6YC;'5D:6YG('1H
M92!I<W-U86YC92!D871E<R!O9B!!<')I;"`R,2P@,C`Q,2X\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M:6YD96YT.B`P+C5I;CL@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M:6YD96YT
M.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$
M,CY);B!$96-E;6)E<B`R,#$Q+"!T:&4@0V]M<&5N<V%T:6]N($-O;6UI='1E
M92!O9B!T:&4@0F]A<F0@;V8@1&ER96-T;W)S(&=R86YT960@37(N($-U9&1I
M:'D@,S,L-C`S('-H87)E<R!O9B!#;VUM;VX@4W1O8VLL('5N9&5R('1H92`R
M,#$P($5Q=6ET>2!#;VUP96YS871I;VX@4&QA;B!V86QU960@870@)#,W+#4P
M,"!A<R!P87EM96YT(&9O<B`U,"4@;V8@:&ES($9I<V-A;"`R,#$Q(&)O;G5S
M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[)R!S:7IE/3-$,CX\8CY4:&4@
M,C`Q,"!$:7)E8W1O<G,@17%U:71Y($-O;7!E;G-A=&EO;B!0;&%N/"]B/CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG('-I>F4],T0R
M/D]N($UA>2`U+"`R,#$P+"!O=7(@<VAA<F5H;VQD97)S(&%P<')O=F5D('0\
M9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[)SYH92`R,#$P($1I<F5C=&]R
M<R8C.#(Q-SL@17%U:71Y($-O;7!E;G-A=&EO;B!0;&%N+B`\+V9O;G0^02!P
M<FEM87)Y('!U<G!O<V4@;V8@=&AE(#QF;VYT('-T>6QE/3-$)V-O;&]R.B!B
M;&%C:SLG/C(P,3`@1&ER96-T;W)S)B,X,C$W.R!%<75I='D@0V]M<&5N<V%T
M:6]N(%!L86X\+V9O;G0^(&ES('1O('!R;W9I9&4@=7,@=VET:"!T:&4@86)I
M;&ET>2!T;R!P87D@86QL(&]R(&$@<&]R=&EO;B!O9B!T:&4@9F5E<R!O9B!$
M:7)E8W1O<G,@:6X@<F5S=')I8W1E9"!S=&]C:R!I;G-T96%D(&]F(&-A<V@N
M(%1H92`R,#$P($1I<F5C=&]R<R8C.#(Q-SL@17%U:71Y($-O;7!E;G-A=&EO
M;B!0;&%N('!R;W9I9&5S('1H870@=&AE('1O=&%L(&YU;6)E<B!O9B!S:&%R
M97,@;V8@0V]M;6]N(%-T;V-K('1H870@;6%Y(&)E(&ES<W5E9"!U;F1E<B!T
M:&4@,C`Q,"!$:7)E8W1O<G,F(S@R,3<[($5Q=6ET>2!#;VUP96YS871I;VX@
M4&QA;B!I<R!E<75A;"!T;R`R-3`L,#`P+B!);B!&:7-C86P@,C`Q,2!A;F0@
M,C`Q,"P@=V4@9W)A;G1E9"`Q-C0L-S<P(&%N9"`V-RPV,C4@<VAA<F5S+"!R
M97-P96-T:79E;'DL(&]F(&]U<B!#;VUM;VX@4W1O8VL@=F%L=65D(&%T("0Q
M-C(L,#`P(&%N9"`D.3`L,#`P+"!R97-P96-T:79E;'DL(&9O<B!D:7)E8W1O
M<B!C;VUP96YS871I;VXN($%T($1E8V5M8F5R(#,Q+"`R,#$Q+"!T:&5R92!A
M<F4@,3<L-C`U('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=&AA="!M87D@8F4@
M:7-S=65D('!U<G-U86YT('1O('1H92!T97)M<R!O9B!T:&4@,C`Q,"!$:7)E
M8W1O<G,@17%U:71Y($-O;7!E;G-A=&EO;B!0;&%N+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM
M97,[)R!S:7IE/3-$,CX\8CXF(S$V,#L\+V(^/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/CQB/E-T;V-K($]P=&EO;B!%>&5R8VES97,@86YD($]T:&5R
M($=R86YT<SPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF
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M97%U86P@=&\@)#4P+#`P,"P@<&%Y86)L92!Q=6%R=&5R;'DL/&(^(#PO8CYP
M<F]M<'1L>2!F;VQL;W=I;F<@=&AE(&-L;W-E(&]F(&5A8V@@<75A<G1E<B!C
M86QC=6QA=&5D(&)A<V5D(&]N('1H92!A=F5R86=E(&-L;W-I;F<@<')I8V4@
M;V8@;W5R($-O;6UO;B!3=&]C:R!F;W(@=&AE(&QA<W0@9FEV92`H-2D@=')A
M9&EN9R!D87ES(&]F('1H92!Q=6%R=&5R+B!&;W(@1FES8V%L(#(P,3$L(#(P
M,3`@86YD(#(P,#DL($UR+B!#=61D:6AY(&5A<FYE9"`U,2PV-#(L(#,U+#`W
M-2!A;F0@,3$L,#`T('-H87)E<RP@<F5S<&5C=&EV96QY+"!V86QU960@870@
M)#4P+#`P,"P@)#4P+#`P,"!A;F0@)#(S+#`P,"P@<F5S<&5C=&EV96QY+"!A
M<R!S:&%R92UB87-E9"!C;VUP96YS871I;VXN/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BQT:6UE<SLG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@=&5X="UI;F1E;G0Z(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;BQT:6UE<SLG('-I>F4],T0R/D9O<B!&:7-C86P@,C`Q,"!A;F0@,C`P.2P@
M=V4@9&5R:79E9"!N970@<')O8V5E9',@;V8@)#$S,RPP,#`@86YD("0Q,C<L
M,#`P+"!R97-P96-T:79E;'DL(&%S(&$@8V]N<V5Q=65N8V4@;V8@=&AE(&5X
M97)C:7-E(&]F(&]P=&EO;G,@=&\@86-Q=6ER92`Q,S`L-3`P(&%N9"`Q,C4L
M,#`P('-H87)E<RP@<F5S<&5C=&EV96QY+"!O9B!O=7(@0V]M;6]N(%-T;V-K
M('!U<G-U86YT('1O('1H92!T97)M<R!O9B!O=7(@,3DY-R!/<'1I;VX@4&QA
M;BX@5&AE<F4@=V5R92!N;R!S=&]C:R!O<'1I;VYS(&5X97)C:7-E9"!I;B!&
M:7-C86P@,C`Q,2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<@<VEZ93TS1#(^/&9O;G0@
M<VEZ93TS1#,^/&)R("`O/CPO9F]N=#X\<W1R;VYG/E!U<F-H87-E(&]F(%1R
M96%S=7)Y(%-T;V-K/"]S=')O;F<^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
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M96YT+B`\+V9O;G0^56YD97(@=&AE('1E<FUS(&]F('1H92!R961E;7!T:6]N
M(&%G<F5E;65N="P@=V4@<F5D965M960@-CDP+#`P,"!S:&%R97,@;V8@;W5R
M($-O;6UO;B!3=&]C:R!H96QD(&)Y(#QF;VYT('-T>6QE/3-$)VQE='1E<BUS
M<&%C:6YG.B`M,"XQ-7!T.R<^4%-)(%!A<F5N=#PO9F]N=#X@9F]R('1H92!A
M9V=R96=A=&4@<F5D96UP=&EO;B!P<FEC92!O9B`D-#0X+#4P,"!I;B!C87-H
M("AS964@3F]T92`S*2X@5&AE(')E9&5M<'1I;VX@<')I8V4@=V%S(&5Q=6%L
M('1O("0P+C8U('!E<B!S:&%R92X\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C0Q-3`U9C1?.#AB,%\T-6$X
M7V$T,3E?.34P8F9C8V9E,V-F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S8T,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C9B]7;W)K
M<VAE971S+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY$149)3D5$($-/3E1224)55$E/3B!03$%.4SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUP
M96YS871I;VX@86YD(%)E=&ER96UE;G0@1&ES8VQO<W5R92!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E
M;G-I;VX@86YD($]T:&5R(%!O<W1R971I<F5M96YT($)E;F5F:71S($1I<V-L
M;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQB/DY/5$4@.2`F(S@R,3$[($1%1DE.140@0T].5%))0E5424].(%!,
M04Y3/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M,C`Q,2P@,C`Q,"!A;F0@,C`P.2!W97)E("0X."PP,#`L("0Y,"PP,#`@86YD
M("0Q-#$L,#`P+"!R97-P96-T:79E;'DN/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C0Q-3`U9C1?.#AB,%\T-6$X7V$T
M,3E?.34P8F9C8V9E,V-F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S8T,34P-68T7S@X8C!?-#5A.%]A-#$Y7SDU,&)F8V-F93-C9B]7;W)K<VAE
M971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY)3D-/344@5$%815,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CY.3U1%(#$P("8C.#(Q
M,3L@24Y#3TU%(%1!6$53/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@
M8V]M<&]N96YT<R!O9B!T:&4@<')O=FES:6]N("AB96YE9FET*2!F;W(@:6YC
M;VUE('1A>&5S+"!I;B!T:&4@8V]N<V]L:61A=&5D('-T871E;65N="!O9B!O
M<&5R871I;VYS(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DT)3L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,3`^665A<B8C,38P.T5N9&5D
M)B,Q-C`[1&5C96UB97(F(S$V,#LS,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/C(P
M,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(^,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,CXR,#`Y/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
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M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/BT\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG
M/B@T,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
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M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#0P/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/B@X-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
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M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
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M=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@.7!T.R<^4W1A=&4\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
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M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#8Q/"]T
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M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R<^*#@Y.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/BD\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C4S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXH,BPS-3@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/E1O=&%L/"]T9#X-"CQT9`T*('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@X.3@\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
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M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
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M=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M,"XQ:6X[('!A9&1I;F<M;&5F=#H@,"XQ:6X[)SY);F-O;64@
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M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXX.3@\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@U,SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
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M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('!A9&1I;F<M;&5F=#H@.7!T.R<^26YC;VUE('1A>"`H8F5N969I="D\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
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M;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E1O
M=&%L/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^*#@T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXI/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!(')E8V]N8VEL:6%T:6]N(&]F('1H
M92!S=&%T=71O<GD@9F5D97)A;"!I;F-O;64@=&%X(&5X<&5N<V4@*&)E;F5F
M:70I('1O('1H92!E9F9E8W1I=F4@=&%X(&ES(&%S(&9O;&QO=W,@*&EN('1H
M;W5S86YD<RDZ/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=W:61T:#H@.30E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CLG(&-O;'-P86X],T0Q,#Y996%R)B,Q-C`[16YD960F(S$V,#M$96-E
M;6)E<B8C,38P.S,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CXR,#$P/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/C(P
M,#D\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@8V]L<W!A;CTS
M1#(^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)R!C;VQS<&%N
M/3-$,CXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG(&-O;'-P
M86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`V,24[)SY3=&%T=71O<GD@<F%T92`M(&9E9&5R86P\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M,"4[)SXH.3(U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!W:61T:#H@,3`E.R<^*#$L,C`T/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXI/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H-"B`Q,"4[)SXH,2PS
M,S4\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY3=&%T92!T87AE<RP@;F5T
M(&]F(&9E9&5R86P@8F5N969I=#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@R,3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R<^-#@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/B@Q-#,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,2PP
M-#8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@+3`N,3-I;CL@<&%D9&EN9RUL969T.B`P+C(U:6X[)SY);F-O;64@
M=&%X(&9R;VT@8V]N=&EN=6EN9R!O<&5R871I;VX@8F5F;W)E('9A;'5A=&EO
M;B!A;&QO=V%N8V4\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH.#DX/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
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M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SXH.#DX/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^*3PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^,2PS,#<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C(L,S4X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/DEN8V]M92!T87@@
M*&)E;F5F:70I/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXH-#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SXH.#0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/E1O=&%L/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
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M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
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M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#@T/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXI/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE(&-O;7!O;F5N=',@;V8@<&5R
M;6%N96YT(&%N9"!O=&AE<B!D:69F97)E;F-E<R!A<F4@87,@9F]L;&]W<R`H
M:6X@=&AO=7-A;F1S*3H\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y-"4[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#$P/EEE87(F(S$V,#M%;F1E9"8C,38P
M.T1E8V5M8F5R)B,Q-C`[,S$L/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CXR,#$Q/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[#0H@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^
M,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,CXR,#`Y/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY097)M86YE;G0@
M:71E;7,Z/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE
M9G0Z(#EP=#L@=VED=&@Z(#8Q)3LG/DUE86QS(&%N9"!%;G1E<G1A:6YM96YT
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,3`E.R<^,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-3PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
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M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M=&EL:7IA=&EO;B`\<W5P/B@Q*3PO<W5P/CPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
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M<W5P/CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH,38R/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/E-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O<B!S=&]C:R!O<'1I;VYS
M(&=R86YT960\<W5P/B`H,RD\+W-U<#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0U/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
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M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#$T,SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,2PP-#8\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXI/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X.R!W:61T:#H@,3`P)3L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6)O
M='1O;3H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#`N,S5I;CLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#`N,C5I;CLG/B@Q*3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3LG/E1H:7,@:71E;2!R97!R97-E;G1S('1H92!U=&EL:7IA
M=&EO;B!F;W(@=&%X('!U<G!O<V5S(&]F('!R:6]R('EE87(@8V%P:71A;"!L
M;W-S97,N/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TP+C(U:6X[(&UA<F=I
M;CH@,'!X(#!P>"`P<'@@,"XU:6X[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4]
M,T0G;6%R9VEN+71O<#H@,'!X.R!W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6)O='1O;3H@
M,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#`N,S5I;CLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N
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M8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z("TP+C(U:6X[(&UA<F=I;CH@,'!X(#!P>"`P<'@@,"XU:6X[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X.R!W:61T
M:#H@,3`P)3L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN+6)O='1O;3H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,S5I;CLG/CPO=&0^#0H\
M=&0-"B!S='EL93TS1"=W:61T:#H@,"XR-6EN.R<^*#,I/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^5&AI<R!I=&5M(')E;&%T
M97,@=&\@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&9I
M;F%N8VEA;"!R97!O<G1I;F<@<'5R<&]S97,@;F]T(&1E9'5C=&5D(&9O<B!T
M87@@<'5R<&]S97,@=6YT:6P@<W5C:"!O<'1I;VYS(&%R92!E>&5R8VES960N
M/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#LF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
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M<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=W:61T:#H@.30E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CLG(&-O;'-P86X],T0Q,#Y996%R)B,Q-C`[16YD960F(S$V,#M$96-E
M;6)E<B8C,38P.S,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CXR,#$P/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/C(P
M,#D\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X]
M,T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P
M86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`V,24[)SY.970@;W!E<F%T:6YG(&QO<W,@86YD
M(&-A<&ET86P@;&]S<R!C87)R>69O<G=A<F0\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXQ,RPQ-S`\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED
M=&@Z(#$P)3LG/C$R+#$S-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,3`L.#`X/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/D-O
M;G-U;'1I;F<M<F]Y86QT>2!C;W-T<SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L-#,Q/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR-3`\+W1D/@T*/'1D
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M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^.#<W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^.#`Q/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY686QU871I;VX@86QL
M;W=A;F-E/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
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M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^*#$T+#8Y-CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/BD\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/B@Q,RPR.3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SY4;W1A;#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
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M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^02!V86QU871I;VX@86QL;W=A;F-E(&9O<B!A;&P@;V8@;W5R(&YE="!D
M969E<G)E9"!T87@@87-S971S(&AA<R!B965N('!R;W9I9&5D(&%S('=E(&%R
M92!U;F%B;&4@=&\@9&5T97)M:6YE+"!A="!T:&ES('1I;64L('1H870@=&AE
M(&=E;F5R871I;VX@;V8@9G5T=7)E('1A>&%B;&4@:6YC;VUE(&%G86EN<W0@
M=VAI8V@@=&AE(&YE="!O<&5R871I;F<@;&]S<R`H)B,X,C(P.TY/3"8C.#(R
M,3LI(&-A<G)Y9F]R=V%R9',@8V]U;&0@8F4@=7-E9"!C86X@8F4@<')E9&EC
M=&5D('1O(&)E(&UO<F4@;&EK96QY('1H86X@;F]T+B!4:&4@;F5T(&-H86YG
M92!I;B!T:&4@=F%L=6%T:6]N(&%L;&]W86YC92!F;W(@1FES8V%L(#(P,3$L
M(#(P,3`@86YD(#(P,#D@=V%S("0X.3@L,#`P+"`D,2XT(&UI;&QI;VX@86YD
M("0R+C0@;6EL;&EO;BP@<F5S<&5C=&EV96QY+B!#97)T86EN(&5X97)C:7-E
M<R!O9B!O<'1I;VYS(&%N9"!W87)R86YT<RP@86YD(')E<W1R:6-T960@<W1O
M8VL@:7-S=65D(&9O<B!S97)V:6-E<R!T:&%T(&)E8V%M92!U;G)E<W1R:6-T
M960@<F5S=6QT960@:6X@<F5D=6-T:6]N<R!T;R!T87AE<PT*(&-U<G)E;G1L
M>2!P87EA8FQE(&%N9"!A(&-O<G)E<W!O;F1I;F<@:6YC<F5A<V4@=&\@861D
M:71I;VYA;"UP86ED+6EN+6-A<&ET86P@9F]R('!R:6]R('EE87)S+B!);B!A
M9&1I=&EO;BP@8V5R=&%I;B!T87@@8F5N969I=',@9F]R(&]P=&EO;B!A;F0@
M=V%R<F%N="!E>&5R8VES97,@=&]T86QI;F<@)#8N,R!M:6QL:6]N(&%R92!D
M969E<G)E9"!A;F0@=VEL;"!B92!C<F5D:71E9"!T;R!A9&1I=&EO;F%L+7!A
M:60M:6XM8V%P:71A;"!W:&5N('1H92!.3TPF(S@R,3<[<R!A='1R:6)U=&%B
M;&4@=&\@=&AE<V4@97AE<F-I<V5S(&%R92!U=&EL:7IE9"X@07,@82!R97-U
M;'0L('1H97-E($Y/3"8C.#(Q-SMS('=I;&P@;F]T(&)E(&%V86EL86)L92!T
M;R!O9F9S970@:6YC;VUE('1A>"!E>'!E;G-E+B!4:&4@;F5T(&]P97)A=&EN
M9R!L;W-S(&-A<G)Y+69O<G=A<F1S(&-U<G)E;G1L>2!A<'!R;WAI;6%T92`D
M,S$N-B!M:6QL:6]N(&9O<B!F961E<F%L('!U<G!O<V5S('=I;&P@97AP:7)E
M(&)E9VEN;FEN9R!I;B!&:7-C86P@,C`R,"!T:')O=6=H(#(P,S$N($%D9&ET
M:6]N86QL>2P@=&AE<F4@87)E(&YE="!O<&5R871I;F<@;&]S<R!C87)R>2UF
M;W)W87)D<R!O9B`D,C`N,"!M:6QL:6]N(&9O<B!S=&%T92!P=7)P;W-E<R!T
M:&%T('=I;&P@97AP:7)E(&)E9VEN;FEN9R!I;B!&:7-C86P@,C`Q."!T:')O
M=6=H(#(P,S$N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/B8C,38P.SPO
M8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M86P@<&5R:6]D(&5N9&EN9R!397!T96UB97(@,S`L('1O(&]U<B!F:6YA;F-I
M86P@<F5P;W)T:6YG('!E<FEO9"!E;F1I;F<@1&5C96UB97(@,S$N($%S(&$@
M8V]N<V5Q=65N8V4L('=E(&9I;&5D(&$@9G5L;"!P97)I;V0@=&%X(')E='5R
M;B!F;W(@=&AE(&9I<V-A;"!Y96%R(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`P
M.2!W:71H('1H92!)4E,@86YD(&%L<V\@9FEL960@=VET:"!T:&4@25)3(&$@
M)B,X,C(P.W-H;W)T('!E<FEO9"!R971U<FXF(S@R,C$[(&9O<B!T:&4@=&AR
M964@;6]N=&AS(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#`Y(&EN(&-O;7!L:6%N
M8V4@=VET:"!T:&4@96QE8W1I;VXN($EN(&9U='5R92!F:7-C86P@<&5R:6]D
M<RP@;W5R('1A>"!A;F0@9FEN86YC:6%L(')E<&]R=&EN9R!P97)I;V1S('=I
M;&P@8F4@=&AE('-A;64L('1H92!P97)I;V0@96YD:6YG($1E8V5M8F5R(#,Q
M+B!&;W(@1FES8V%L(#(P,3`L('=E(&AA9"!A(&-U<G)E;G0@=&%X(&)E;F5F
M:70@;V8@)#0P+#`P,"!F;W(@86X@86QT97)N871I=F4@;6EN:6UU;2!T87@@
M<F5F=6YD(&1U92!U<R!A<R!A(&-O;G-E<75E;F-E(&]F(&$@8V%R<GD@8F%C
M:R!O9B!A;B!A;'1E<FYA=&EV92!M:6YI;75M('1A>"!N970@;W!E<F%T:6YG
M(&QO<W,@=&\@82!P<FEO<B!P97)I;V0N($9O<B!&:7-C86P@,C`P.2P@=V4@
M:&%D(&$@8W5R<F5N="!T87@@8F5N969I="!O9B`D.#0L,#`P(&9O<B!C97)T
M86EN(&9E9&5R86P@86YD('-T871E(&%L=&5R;F%T:79E(&UI;FEM=6T@:6YC
M;VUE('1A>&5S(&EN8W5R<F5D(&9O<B!T:&4@)B,X,C(P.W-H;W)T('!E<FEO
M9"!R971U<FXF(S@R,C$[+"!I;F-L=7-I=F4@;V8@86X@86QT97)N871I=F4@
M;6EN:6UU;2!T87@@<F5F=6YD(&]F("0Q,3`L,#`P(&1U92!U<R!A<R!A(&-O
M;G-E<75E;F-E(&]F(&$@8V%R<GD@8F%C:R!O9B!A;B!A;'1E<FYA=&EV92!M
M:6YI;75M('1A>"!N970@;W!E<F%T:6YG(&QO<W,@=&\@82!P<FEO<B!P97)I
M;V0N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C0Q-3`U9C1?.#AB,%\T-6$X7V$T,3E?.34P8F9C8V9E,V-F#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8T,34P-68T7S@X8C!?-#5A.%]A
M-#$Y7SDU,&)F8V-F93-C9B]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%05).24Y'4R!015(@
M4TA!4D4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16%R;FEN9W,@
M4&5R(%-H87)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\8CY.3U1%(#$Q("8C.#(Q,3L@14%23DE.1U,@4$52(%-(05)%
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D)A<VEC
M(&5A<FYI;F=S('!E<B!S:&%R92`H)B,X,C(P.T504R8C.#(R,3LI(&5X8VQU
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M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D$@<F5C;VYC
M:6QI871I;VX@;V8@=&AE(&%P<&QI8V%B;&4@;G5M97)A=&]R<R!A;F0@9&5N
M;VUI;F%T;W)S(&]F('1H92!I;F-O;64@<W1A=&5M96YT('!E<FEO9',@<')E
M<V5N=&5D(&ES(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RP@97AC97!T('!E
M<B!S:&%R92!A;6]U;G1S*3H\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y,R4[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#,T/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R<^665A<B8C,38P.T5N9&5D)B,Q-C`[1&5C96UB97(F(S$V,#LS,2P\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,3`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXR,#$Q/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,3`^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXR,#$P/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,3`^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXR,#`Y/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^
M3&]S<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SY3:&%R97,\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R<^15!3/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#LG/DQO<W,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^4VAA<F5S
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/D504SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SY,;W-S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG
M/E-H87)E<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SY%4%,\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)R!C;VQS<&%N/3-$
M,CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)R!C;VQS<&%N
M/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.@T*(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)R!C;VQS<&%N/3-$,CX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG(&-O
M;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)R!C;VQS<&%N/3-$,CX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T:#H@,3DE.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SY"87-I8R!%4%,\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@-B4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B@R+#<Q,#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^*3PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#8E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXQ-"PX,3<\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`V)3LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^*#`N,3@\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/BD\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@-B4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#LG/B@S+#4P,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R<^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#8E.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXQ-"PR.#4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`V)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.'!T.R<^*#`N,C4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#LG/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!W:61T:#H@-B4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#LG/B@S+#@T,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R<^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=VED=&@Z(#8E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXQ,BPY-C,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`V)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^
M*#`N,S`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#LG/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0[)SY$:6QU=&EV97,Z/"]F;VYT/CPO=&0^
M#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SY/<'1I;VYS+U=A<G)A;G1S/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H-"B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
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M9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
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M9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP=#LG/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^*3PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0-"B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
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M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG
M/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXH,"XQ.#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^*3PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^
M*#,L-3`Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0[)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
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M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B0\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0[)SXH,"XR-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R<^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^*#,L.#0R/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXI/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M=#LG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0[)SXH,"XS,#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T.R<^
M*3PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SY&;W(@1FES8V%L(#(P,3$L(#(P,3`@86YD(#(P
M,#DL(&1I;'5T960@96%R;FEN9W,@<&5R('-H87)E(&ES('1H92!S86UE(&%S
M(&)A<VEC(&5A<FYI;F=S('!E<B!S:&%R92!D=64@=&\@=&AE(&EN8VQU<VEO
M;B!O9B!C;VUM;VX@<W1O8VL\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[
M)SXL(&EN('1H92!F;W)M(&]F('-T;V-K(&]P=&EO;G,@86YD('=A<G)A;G1S
M("@F(S@R,C`[0V]M;6]N(%-T;V-K($5Q=6EV86QE;G1S)B,X,C(Q.RDL('=O
M=6QD(&AA=F4@86X@86YT:2UD:6QU=&EV92!E9F9E8W0@;VX@=&AE(&QO<W,@
M<&5R('-H87)E+B!&;W(@1FES8V%L(#(P,3$L(#(P,3`@86YD(#(P,#DL('1H
M97)E('=E<F4@0V]M;6]N(%-T;V-K($5Q=6EV86QE;G1S(&EN('1H92!A;6]U
M;G0@;V8@-#@L,S<U+"`S-3DL,3@X(&%N9"`Q,S,L-SDR+"!R97-P96-T:79E
M;'DL('=H:6-H('=E<F4@:6X@=&AE(&UO;F5Y+"!T:&%T('=E<F4@97AC;'5D
M960@:6X@=&AE(&5A<FYI;F=S('!E<B!S:&%R92!C;VUP=71A=&EO;B!D=64@
M=&\@=&AE:7(@9&EL=71I=F4@969F96-T+CPO9F]N=#X\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-#$U,#5F-%\X.&(P
M7S0U83A?830Q.5\Y-3!B9F-C9F4S8V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO-C0Q-3`U9C1?.#AB,%\T-6$X7V$T,3E?.34P8F9C8V9E,V-F
M+U=O<FMS:&5E=',O4VAE970Q."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-)1TY)1DE#04Y4($-54U1/34524SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N
M:69I8V%N="!#=7-T;VUE<G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!#=7-T;VUE
M<G,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/DY/5$4@,3(@)B,X,C$Q.R!3
M24=.249)0T%.5"!#55-43TU%4E,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P
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M,3$L(#(P,3`@86YD(#(P,#D@=V5R92`D,3<N-2!M:6QL:6]N+"`D,30N-2!M
M:6QL:6]N(&%N9"`D,3DN."!M:6QL:6]N+"!R97-P96-T:79E;'DN(%=A;&=R
M965N($-O;7!A;GD@*"8C.#(R,#M786QG<F5E;G,F(S@R,C$[*2P@5V%L+4UA
M<G0@4W1O<F5S+"!);F,N("@F(S@R,C`[5V%L+4UA<G0F(S@R,C$[*2P@0U93
M($-A<F5M87)K($-O<G!O<F%T:6]N("@F(S@R,C`[0U93)B,X,C(Q.RD@86YD
M(%)I=&4M06ED($-O<G`@*"8C.#(R,#M2:71E($%I9"8C.#(R,3LI(&%C8V]U
M;G1E9"!F;W(@87!P<F]X:6UA=&5L>2`Q-R4L(#$T)2P@,3,E(&%N9"`Q,B4@
M;V8@;W5R($9I<V-A;"`R,#$Q(')E=F5N=65S+B!786QG<F5E;G,L(%=A;"U-
M87)T(&%N9"!2:71E($%I9"!A8V-O=6YT960@9F]R(&%P<')O>&EM871E;'D@
M,C,E+"`Q-"4@86YD(#$P)2!O9B!O=7(@1FES8V%L(#(P,3`@<F5V96YU97,N
M($-64RP@5V%L9W)E96YS(&%N9"!786PM36%R="!A8V-O=6YT960@9F]R(&%P
M<')O>&EM871E;'D@,34E+"`Q-24@86YD(#$S)2!O9B!O=7(@<F5V96YU97,@
M9F]R($9I<V-A;"`R,#`Y+B!4:&4@;&]S<R!O9B!S86QE<R!T;R!A;GD@;VYE
M(&]R(&UO<F4@;V8@=&AE<V4@;&%R9V4@<F5T86EL(&-U<W1O;65R<R!C;W5L
M9"!H879E(&$@;6%T97)I86P@861V97)S92!E9F9E8W0@;VX@;W5R(&)U<VEN
M97-S(&]P97)A=&EO;G,@86YD(&9I;F%N8VEA;"!C;VYD:71I;VXN/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M<R!R97!R97-E;G1E9"`U,R4@86YD(#4Q)2!O9B!T;W1A;"!T<F%D92!R96-E
M:79A8FQE(&)A;&%N8V5S(&%T($1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"`R,#$P
M+"!R97-P96-T:79E;'DN($UA;F%G96UE;G0@8F5L:65V97,@=&AA="!T:&4@
M<')O=FES:6]N(&9O<B!P;W-S:6)L92!L;W-S97,@;VX@=6YC;VQL96-T:6)L
M92!A8V-O=6YT<R!R96-E:79A8FQE(&ES(&%D97%U871E(&9O<B!O=7(@8W)E
M9&ET(&QO<W,@97AP;W-U<F4N($%T($1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"`R
M,#$P+"!T:&4@86QL;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<R!W87,@
M>F5R;R!A;F0@)#$S+#`P,"P@<F5S<&5C=&EV96QY+CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^455!4E1%4DQ9($E.1D]234%424].("A53D%51$E4
M140I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E%U87)T97)L>2!&:6YA;F-I86P@26YF;W)M871I;VX@1&ES8VQO
M<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E%U87)T97)L>2!&:6YA;F-I86P@26YF;W)M871I;VX@
M6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/DY/5$4@,3,@)B,X,C$Q.R!154%25$523%D@24Y&3U)-051)3TX@*%5.055$
M251%1"D\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z("TP+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CXF(S$V,#L\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H92!F;VQL;W=I;F<@=&%B
M;&4@<')E<V5N=',@=6YA=61I=&5D('%U87)T97)L>2!F:6YA;F-I86P@:6YF
M;W)M871I;VX@9F]R($9I<V-A;"`R,#$Q(&%N9"!&:7-C86P@,C`Q,"`H:6X@
M=&AO=7-A;F1S+"!E>&-E<'0@<&5R('-H87)E(&%M;W5N=',I.CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\8CXF(S$V,#L\+V(^/"]P/@T*/'1A8FQE('-T
M>6QE/3-$)W=I9'1H.B`Y-B4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0Q-#Y1=6%R
M=&5R)B,Q-C`[16YD960\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^36%R8V@F(S$V
M,#LS,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^2G5N928C,38P.S,P+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y397!T96UB97(@,S`L/"]T9#X-
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M:6=H=#H@8F]L9#LG/CQU/D9I<V-A;"`R,#$Q/"]U/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@
M8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6QE9G0Z(#EP=#L@=VED=&@Z(#0X)3LG/DYE="!S86QE<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C,L
M,38V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q,"4[)SXQ+#<T-#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-2PP
M.#,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#$P)3LG/C<L-#8P/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[)SY'<F]S<R!P<F]F:70\
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C,L-3DV/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0L-SDV
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#EP=#LG/DEN8V]M
M92`H;&]S<RD@9G)O;2!C;VYT:6YU:6YG(&]P97)A=&EO;G,\+W1D/@T*/'1D
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$L
M,#$S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXH.3<V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXQ+#$Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
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M('!A9&1I;F<M;&5F=#H@.7!T.R<^3F5T(&EN8V]M92`H;&]S<RD\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M*#$L,#$S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXH.3<V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXQ+#$Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
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M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y
M<'0[)SY"87-I8R!A;F0@9&EL=71E9"!E87)N:6YG<R`H;&]S<RD@<&5R('-H
M87)E.CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUL969T.B`P+C(U:6X[)SY);F-O;64@*&QO<W,I(&9R
M;VT@8V]N=&EN=6EN9R!O<&5R871I;VYS/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@P+C`W/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)#PO
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M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXH,"XQ,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T
M.B`P+C(U:6X[)SY.970@:6YC;VUE)B,Q-C`[("AL;W-S*3PO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH,"XP
M-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^*#`N,#<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C`N,#<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^*#`N,3(\+W1D/@T*/'1D('-T>6QE/3-$
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M.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M9&5C;W)A=&EO;CH@=6YD
M97)L:6YE.R<^1FES8V%L(#(P,3`\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L,3,Q/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C4L,C`T/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C8L,3DQ/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
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M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0W,3PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXS+#8Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
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M9RUL969T.B`Y<'0[)SY);F-O;64@*&QO<W,I(&9R;VT@8V]N=&EN=6EN9R!O
M<&5R871I;VYS/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B@Q+#`V,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/BD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#(L,C4T/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T
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M97AT+6%L:6=N.B!R:6=H=#LG/B@Q+#`V,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#(L,C4T/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[
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M('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M;&5F=#H@.7!T.R<^0F%S:6,@86YD(&1I;'5T960@96%R
M;FEN9W,@*&QO<W,I('!E<B!S:&%R93H\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,"XR-6EN
M.R<^26YC;VUE("AL;W-S*2!F<F]M(&-O;G1I;G5I;F<@;W!E<F%T:6]N<SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXH,"XP.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/BD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^*#`N,34\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C`N,#8\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#`N,#@\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M;&5F=#H@,"XR-6EN.R<^3F5T(&EN8V]M928C,38P
M.R`H;&]S<RD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^*#`N,#@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@P+C$U/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+C`V/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@P+C`X
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V
M-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y-3!B9F-C9F4S8V8-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C0Q-3`U9C1?.#AB,%\T-6$X7V$T,3E?
M.34P8F9C8V9E,V-F+U=O<FMS:&5E=',O9FEL96QI<W0N>&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQX;6P@
M>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M.F]F9FEC93IO
M9F9I8V4B/@T*(#QO.DUA:6Y&:6QE($A2968],T0B+BXO5V]R:V)O;VLN:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$Y+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R
J=%\V-#$U,#5F-%\X.&(P7S0U83A?830Q.5\Y-3!B9F-C9F4S8V8M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Basis of Presentation</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The consolidated financial statements (&#8220;Financial Statements&#8221;) include the accounts of the Company and its wholly owned subsidiaries and its Joint Venture, a variable interest entity (see Note 3). All intercompany transactions and balances have been eliminated.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Seasonality of the Business</u></i></p>
<p style="text-align: justify; text-indent: 31.5pt; margin: 0px; font: 10pt times new roman, times, serif;">Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote its products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.</p>
<p style="text-align: justify; text-indent: 31.5pt; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="margin: 0px; font: italic 10pt times new roman, times, serif;"><font style="font-weight: normal;"><u>Use of Estimates</u></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The preparation of financial statements and the accompanying notes thereto, in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;), requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets <font style="color: black;">and liabilities</font> at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (&#8220;Sales Allowances&#8221;), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 27pt; margin: 0px; font: 10pt times new roman, times, serif;">Our primary product, Cold-EEZE<font style="font-family: symbol;"><sup>&#210;</sup></font><sup> </sup>lozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE<sup>&#174;</sup> lozenges we market and distribute Cold-EEZE<sup>&#174; </sup>Oral Spray and Kids-EEZE<sup>&#174;</sup> Chest Relief, Kids-EEZE<sup>&#174;</sup> Cough Cold and Kids-EEZE<sup>&#174;</sup> Allergy (&#8220;Kids-EEZE<sup>&#174;</sup> Products&#8221;), children&#8217;s OTC cold remedies. In August 2011, we introduced Cold-EEZE<sup>&#174;</sup> Oral Spray containing our proprietary zinc formulation in a liquid spray form. We introduced Kids-EEZE<sup>&#174;</sup> Chest Relief in Fiscal 2008 and expanded the product line to include Kids-EEZE<sup>&#174;</sup> Cough Cold and Kids-EEZE<sup>&#174;</sup> Allergy in Fiscal 2010. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (&#8220;Organix<sup>&#174;</sup>&#8221;). Each of the Cold-EEZE<sup>&#174;</sup> Oral Spray products, Kids-EEZE<sup>&#174;</sup> Products and Organix<sup>&#174;</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. <font style="letter-spacing: -0.15pt;">Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented. </font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: italic 10pt times new roman, times, serif;"><font style="font-weight: normal;"><u>Cash Equivalents</u></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We consider all highly liquid investments with an initial maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.</p>
<p style="text-align: justify; text-indent: 0.5in; margin:
 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Inventories</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At December 31, 2011 and 2010, the Financial Statements include an adjustment for excess or obsolete inventory of $991,000 and $1.1 million, respectively. At December 31, 2011 and 2010, inventory included raw material, work in progress and packaging amounts of $981,000 and $742,000, respectively, and finished goods of $1.7 million and $940,000, respectively.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Property, Plant and Equipment</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Property, plant and equipment are recorded at cost. We use a combination of straight-line and accelerated methods in computing depreciation for financial reporting purposes. The depreciation expense is computed in accordance with the estimated asset lives (see Note 4).</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i><i>&#160;</i></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Concentration of Risks</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the requirements associated with the development of OTC and other personal care products in order to continue to compete on a national and/or international level.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (&#8220;FDA&#8221;) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We maintain cash and cash equivalents with certain major financial institutions. As of December 31, 2011, our cash was $5.5 million and our bank balance was $5.9 million. Of the total bank balance, $704,000 was covered by federal depository insurance and $5.2 million was uninsured.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Trade accounts receivable potentially subjects us to credit risk. We extend credit to our customers based upon an evaluation of the customer&#8217;s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers (see Note 12). During Fiscal 2011, 2010 and 2009, effectively all of our revenues were related to domestic markets.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Our revenues are principally generated from the sale of OTC cold remedy products which approximated 95%, 96% and 92% of total revenues for Fiscal 2011, 2010 and 2009, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Raw materials used in the production of the products are available from numerous sources. Certain raw material active ingredients used in connection with Cold-EEZE<sup>&#174;</sup> products are purchased from a single unaffiliated supplier. Should the relationship terminate or the vendor become unable supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Long-lived Assets</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes
 significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In Fiscal 2009 we recognized impairment charges of $74,000 principally for the land and building assets of our Elizabethtown manufacturing facility. The fair value of the reported <i>Assets Held For Sale </i>at December 31, 2010<i> </i>of $138,000<i> </i>was arrived at through bids generated from interested third party purchasers and guidance from a third party real estate advisor thereby relating to Level 3 fair value hierarchy. In February 2011, we derived net proceeds from the sale of these assets of $166,000.</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Revenue Recognition</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity fall within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory &#8220;Overstocking&#8221; or &#8220;Resets&#8221;. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 27pt; margin: 0px; font: 10pt times new roman, times, serif;">As of December 31, 2011 and December 31, 2010, we included a provision for sales allowances of $101,000 and $106,000, respectively, which are reported as a reduction to account receivables. We also included an estimate of the uncollectability of our accounts receivable as an allowance for doubtful accounts of zero and $13,000 as of December 31, 2011 and 2010, respectively. Additionally, accrued advertising and other allowances as of December 31, 2011 include $1.7 million for estimated future sales returns, $1.0 million for cooperative incentive promotion costs and $279,000 for certain other advertising and marketing promotions. As of December 31, 2010 accrued advertising and other allowances include $1.5 million for estimated future sales returns, $1.2 million for cooperative incentive promotion costs and $828,000 for certain other advertising and marketing promotions.</p>
<p style="text-align: justify; text-indent: 27pt; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Shipping and Handling </u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Stock Compensation</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify;
 text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Stock and stock options for purchase of our common stock, $0.0005 par value, (&#8220;Common Stock&#8221;) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 8). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. In Fiscal 2011 and 2010, we charged to operations $631,000 and $192,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. There was no share-based compensation expense for Fiscal 2009.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Variable Interest Entity</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The Joint Venture, of which we own a 50% membership interest qualifies as a variable interest entity (&#8220;VIE&#8221;) and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010 (see Note 3).</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Advertising and Incentive Promotions </u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of media advertising, presented as part of sales and marketing expense; cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales; and free product, which is accounted for as part of cost of sales. Advertising and incentive promotion costs incurred for Fiscal 2011, 2010 and 2009 were $8.8 million, $6.9 million, and $5.8 million, respectively. Included in prepaid expenses and other current assets was $1.2 million and $189,000 at December 31, 2011 and 2010, respectively, relating to prepaid advertising and promotion expenses.</p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-decoration: underline;"><font style="font-weight: normal;"><i>Research and Development</i></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Research and development costs are charged to operations in the period incurred. Expenditures for Fiscal 2011, 2010 and 2009 were $1.1 million, $794,000 and $1.3 million, respectively. For Fiscal 2011 and Fiscal 2010, research and development costs are related principally to new product development initiatives and costs associated with OTC cold remedy products. For Fiscal 2009, research and development costs are related principally to the Quigley Pharma&#8217;s study activities; such studies and initiatives are no longer actively being commercialized.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: italic 10pt times new roman, times, serif;"><font style="font-weight: normal;"><u>Income Taxes</u></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total net current and non-current deferred tax asset is being provided (see Note 10).</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.</p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The major jurisdiction for which we file income tax returns is the United States. The Internal Revenue Service (&#8220;IRS&#8221;) has examined our tax year ended September 30, 2005 and has made no changes to the filed tax returns. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Effective December 31, 2009, we elected to conform our tax reporting year, historically a fiscal period ending September 30, to our financial reporting period ending December 31. As a consequence, we filed a full period tax return for the fiscal year ended September 30, 2009 with the IRS and also filed with the IRS a &#8220;short period return&#8221; for the three months ended December 31, 2009 in compliance with the election. In future fiscal periods, our tax and financial reporting periods will be the same, the period ending December 31.</p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Fair Value of Financial Instruments</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Cash and cash equivalents,
 accounts receivable and accounts payable are reflected in the Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments. Determination of the fair value of related party payables, if any, is not practicable due to their related party nature.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>Recently Issued Accounting Standards</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In November 2008, the SEC issued for comment a proposed roadmap regarding the potential use by U.S. issuers of financial statements prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;). IFRS is a comprehensive series of accounting standards published by the International Accounting Standards Board (&#8220;IASB&#8221;). The proposed roadmap has since been superseded by an SEC work plan and no date is currently proposed that we could be required to prepare financial statements in accordance with IFRS. The SEC has targeted Fiscal 2012 to make a determination regarding the mandatory adoption of IFRS. We are currently assessing the impact that this potential change would have on our consolidated financial statements and we will continue to monitor the development of the potential implementation of IFRS.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In June&#160;2011, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2011-05, &#8220;Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income,&#8221; (&#8220;ASU 2011-05&#8221;) which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders&#8217; equity. Instead, comprehensive income must be presented in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 will be effective for fiscal periods beginning after December 15, 2011 with early adoption permitted. The adoption of ASU 2011-05 will not have a material impact on our consolidated financial position, results of operations or cash flows.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In September 2011, the FASB issued Accounting Standards Update No. 2011-08, &#8220;Intangibles &#8211; Goodwill and Other Topics&#8221; (&#8220;ASU 2011-08&#8221;) which provides authoritative guidance on testing goodwill for impairment that will become effective beginning January&#160;1, 2012, with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. We are currently assessing the potential impact on the adoption of this guidance on our financial statements.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EP3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 2)</a></td>
        <td class="nump">$ 5,541<span></span></td>
        <td class="nump">$ 8,232<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of zero and $13, respectively (Note 2)</a></td>
        <td class="nump">3,219<span></span></td>
        <td class="nump">4,821<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory (Note 2)</a></td>
        <td class="nump">2,688<span></span></td>
        <td class="nump">1,682<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">1,747<span></span></td>
        <td class="nump">883<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleCurrent', window );">Assets held for sale (Notes 2 and 4)</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">138<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">13,195<span></span></td>
        <td class="nump">15,756<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, licensed technology (Note 3)</a></td>
        <td class="nump">3,577<span></span></td>
        <td class="nump">3,577<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net of accumulated depreciation of $3,608 and $3,389, respectively (Note 4)</a></td>
        <td class="nump">2,307<span></span></td>
        <td class="nump">2,362<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
        <td class="nump">19,079<span></span></td>
        <td class="nump">21,695<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">885<span></span></td>
        <td class="nump">489<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties and sales commissions (Note 5)</a></td>
        <td class="nump">3,524<span></span></td>
        <td class="nump">3,524<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued advertising and other allowances</a></td>
        <td class="nump">2,959<span></span></td>
        <td class="nump">3,524<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
        <td class="nump">485<span></span></td>
        <td class="nump">698<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">7,853<span></span></td>
        <td class="nump">8,235<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 7)</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.0005 par value; authorized 50,000,000; issued: 20,161,636 and 19,353,672 shares, respectively (Note 8)</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
        <td class="nump">41,552<span></span></td>
        <td class="nump">40,627<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(4,699)<span></span></td>
        <td class="num">(1,989)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 5,336,053 and 4,646,053 shares, respectively (Note 8)</a></td>
        <td class="num">(25,637)<span></span></td>
        <td class="num">(25,188)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">11,226<span></span></td>
        <td class="nump">13,460<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Stockholders' Equity, Total</a></td>
        <td class="nump">$ 19,079<span></span></td>
        <td class="nump">$ 21,695<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedMarketingCostsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedRoyaltiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Current assets (normally turning over within one year or one business cycle if longer) that are held for sale apart from normal operations and anticipated to be sold within one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 144<br><br><br><br> -Paragraph 46<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsHeldForSaleCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-6<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E66AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (2,710)<span></span></td>
        <td class="num">$ (3,501)<span></span></td>
        <td class="num">$ (3,842)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">355<span></span></td>
        <td class="nump">363<span></span></td>
        <td class="nump">522<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on the sales of fixed assets</a></td>
        <td class="num">(28)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">104<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">74<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
        <td class="nump">631<span></span></td>
        <td class="nump">192<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_SalesDiscountsAndProvisionForBadDebts', window );">Sales discounts and provision for bad debts</a></td>
        <td class="num">(18)<span></span></td>
        <td class="num">(33)<span></span></td>
        <td class="num">(133)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_InventoryValuationProvision', window );">Inventory valuation provision</a></td>
        <td class="num">(115)<span></span></td>
        <td class="num">(728)<span></span></td>
        <td class="nump">633<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump">1,620<span></span></td>
        <td class="num">(1,189)<span></span></td>
        <td class="nump">2,485<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="num">(891)<span></span></td>
        <td class="nump">451<span></span></td>
        <td class="nump">963<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(864)<span></span></td>
        <td class="num">(68)<span></span></td>
        <td class="nump">390<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">396<span></span></td>
        <td class="num">(219)<span></span></td>
        <td class="num">(109)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_IncreaseDecreaseInAccruedMarketingCosts', window );">Accrued advertising and other allowances</a></td>
        <td class="num">(565)<span></span></td>
        <td class="nump">1,384<span></span></td>
        <td class="num">(597)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities, net</a></td>
        <td class="nump">81<span></span></td>
        <td class="num">(201)<span></span></td>
        <td class="num">(45)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
        <td class="num">(2,108)<span></span></td>
        <td class="num">(3,549)<span></span></td>
        <td class="nump">445<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
        <td class="num">(300)<span></span></td>
        <td class="num">(153)<span></span></td>
        <td class="num">(208)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of product license</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of fixed assets</a></td>
        <td class="nump">166<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">480<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by (used in) investing activities</a></td>
        <td class="num">(134)<span></span></td>
        <td class="num">(1,153)<span></span></td>
        <td class="nump">272<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">133<span></span></td>
        <td class="nump">127<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Purchase of treasury stock</a></td>
        <td class="num">(449)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="num">(449)<span></span></td>
        <td class="nump">133<span></span></td>
        <td class="nump">127<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(2,691)<span></span></td>
        <td class="num">(4,569)<span></span></td>
        <td class="nump">844<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
        <td class="nump">8,232<span></span></td>
        <td class="nump">12,801<span></span></td>
        <td class="nump">11,957<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
        <td class="nump">5,541<span></span></td>
        <td class="nump">8,232<span></span></td>
        <td class="nump">12,801<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">34<span></span></td>
        <td class="nump">43<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_CommonStockIssuedForLicenseAgreement', window );">Common stock issued to Phosphagenics Limited pursuant to a product license agreement</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,577<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued, in lieu of cash, as payment of accrued compensation</a></td>
        <td class="nump">$ 294<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_CommonStockIssuedForLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consideration paid in the form of common shares for license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_CommonStockIssuedForLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_IncreaseDecreaseInAccruedMarketingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net change during the period in the amount of Accrued advertising and other allowances at the period end.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_IncreaseDecreaseInAccruedMarketingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_InventoryValuationProvision">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net charge to cost of goods sold that represents the reduction of the carrying amount of inventory or the utilization of prior obsolesce provisions, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_InventoryValuationProvision</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_SalesDiscountsAndProvisionForBadDebts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate cash discounts given by the entity for goods sold to customers for early payments of accounts due. Also includes, amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_SalesDiscountsAndProvisionForBadDebts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2420-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 45, 46, 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetImpairmentCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities less other operating liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets and liabilities, other noncurrent assets and liabilities, or a combination of other current and noncurrent assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common and preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of stock issued in noncash financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"><p style="margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 1 &#8211; ORGANIZATION AND BUSINESS</b></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">ProPhase Labs, Inc (&#8220;we&#8221;, &#8220;us&#8221; or the &#8220;Company&#8221;), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (&#8220;OTC&#8221;) drug, natural base health products along with supplements, personal care and cosmeceutical products.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Our primary business is currently the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE<font style="font-family: symbol;"><sup>&#210;</sup></font><sup> </sup>Cold Remedy and our principal product is Cold-EEZE<font style="font-family: symbol;"><sup>&#210;</sup></font> zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by nearly half. Cold-EEZE<font style="font-family: symbol;"><sup>&#210;</sup></font> is an established product in the health care and cold remedy market. For Fiscal 2011, Fiscal 2010 and Fiscal 2009 (as each is defined below), our revenues from continuing operations have come principally from our OTC cold remedy products.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">On March 22, 2010, the Company, Phosphagenics Limited (&#8220;PSI Parent&#8221;), an Australian corporation, Phosphagenics Inc. (&#8220;PSI&#8221;), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the &#8220;Joint Venture&#8221;), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the &#8220;LLC Agreement&#8221;) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent&#8217;s proprietary patented TPM&#8482; technology (&#8220;TPM&#8221;). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture (see Note 3).</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We use a December 31 year-end for financial reporting purposes. References herein to the fiscal year ended December 31, 2011 shall be the term &#8220;Fiscal 2011&#8221; and references to other &#8220;Fiscal&#8221; years shall mean the year, which ended on December 31 of the year indicated. Our consolidated balance sheet at December 31, 2010 and our consolidated statement of cash flows for Fiscal 2010 and 2009 have been reclassified to conform with our Fiscal 2011 presentation. The term the &#8220;we&#8221;, &#8220;us: or the &#8220;Company&#8221; as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name FASB Interpretation (FIN)<br><br> -Publisher FASB<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts (in dollars)</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 13<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation (in dollars)</a></td>
        <td class="nump">$ 3,608<span></span></td>
        <td class="nump">$ 3,389<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.0005<span></span></td>
        <td class="nump">$ 0.0005<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="nump">50,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
        <td class="nump">20,161,636<span></span></td>
        <td class="nump">19,353,672<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
        <td class="nump">5,336,053<span></span></td>
        <td class="nump">4,646,053<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 11 &#8211; EARNINGS PER SHARE</b></p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Basic earnings per share (&#8220;EPS&#8221;) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Since there is a large number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">A reconciliation of the applicable numerators and denominators of the income statement periods presented is as follows (in thousands, except per share amounts):</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 93%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="34"><font style="font-size: 8pt;">Year&#160;Ended&#160;December&#160;31,</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"><font style="font-size: 8pt;">2011</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"><font style="font-size: 8pt;">2010</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"><font style="font-size: 8pt;">2009</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">Loss</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">Shares</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">EPS</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">Loss</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">Shares</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">EPS</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">Loss</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">Shares</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-size: 8pt;">EPS</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size:
 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: justify;" colspan="2"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 19%;"><font style="font-size: 8pt;">Basic EPS</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">$</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">(2,710</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">)</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">14,817</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">$</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">(0.18</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">)</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">$</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">(3,501</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">)</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">14,285</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">$</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">(0.25</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">)</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">$</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">(3,842</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">)</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">12,963</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">$</font></td>
<td style="text-align: right; width: 6%;"><font style="font-size: 8pt;">(0.30</font></td>
<td style="text-align: left; width: 1%;"><font style="font-size: 8pt;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-size: 8pt;">Dilutives:</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt;"><font style="font-size: 8pt;">Options/Warrants</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size:
 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt;">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">Diluted EPS</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">(2,710</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td
 style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">14,817</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">(0.18</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">(3,501</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">14,285</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">(0.25</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">(3,842</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">)</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">12,963</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt;">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt;">(0.30</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font style="font-size: 8pt;">)</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">For Fiscal 2011, 2010 and 2009, diluted earnings per share is the same as basic earnings per share due to the inclusion of common stock<font style="color: black;">, in the form of stock options and warrants (&#8220;Common Stock Equivalents&#8221;), would have an anti-dilutive effect on the loss per share. For Fiscal 2011, 2010 and 2009, there were Common Stock Equivalents in the amount of 48,375, 359,188 and 133,792, respectively, which were in the money, that were excluded in the earnings per share computation due to their dilutive effect.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EXRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 01, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ProPhase Labs, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000868278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">prph<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,836,340<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6,755,730<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT CUSTOMERS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_SignificantCustomersAbstract', window );"><strong>Significant Customers [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_SignificantCustomersTextBlock', window );">Significant Customers [Text Block]</a></td>
        <td class="text"><p style="margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 12 &#8211; SIGNIFICANT CUSTOMERS</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Our products are distributed through numerous food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers throughout the United States. Revenues for Fiscal 2011, 2010 and 2009 were $17.5 million, $14.5 million and $19.8 million, respectively. Walgreen Company (&#8220;Walgreens&#8221;), Wal-Mart Stores, Inc. (&#8220;Wal-Mart&#8221;), CVS Caremark Corporation (&#8220;CVS&#8221;) and Rite-Aid Corp (&#8220;Rite Aid&#8221;) accounted for approximately 17%, 14%, 13% and 12% of our Fiscal 2011 revenues. Walgreens, Wal-Mart and Rite Aid accounted for approximately 23%, 14% and 10% of our Fiscal 2010 revenues. CVS, Walgreens and Wal-Mart accounted for approximately 15%, 15% and 13% of our revenues for Fiscal 2009. The loss of sales to any one or more of these large retail customers could have a material adverse effect on our business operations and financial condition.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We are subject to account receivable credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. These concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. Customers comprising the five largest accounts receivable balances represented 53% and 51% of total trade receivable balances at December 31, 2011 and 2010, respectively. Management believes that the provision for possible losses on uncollectible accounts receivable is adequate for our credit loss exposure. At December 31, 2011 and 2010, the allowance for doubtful accounts was zero and $13,000, respectively.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_SignificantCustomersAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_SignificantCustomersAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_SignificantCustomersTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant customers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_SignificantCustomersTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net sales (Notes 2 and 12)</a></td>
        <td class="nump">$ 17,453<span></span></td>
        <td class="nump">$ 14,502<span></span></td>
        <td class="nump">$ 19,816<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (Note 2)</a></td>
        <td class="nump">6,171<span></span></td>
        <td class="nump">5,672<span></span></td>
        <td class="nump">8,247<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">11,282<span></span></td>
        <td class="nump">8,830<span></span></td>
        <td class="nump">11,569<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
        <td class="nump">7,904<span></span></td>
        <td class="nump">5,576<span></span></td>
        <td class="nump">4,852<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative</a></td>
        <td class="nump">5,028<span></span></td>
        <td class="nump">6,054<span></span></td>
        <td class="nump">9,344<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (Note 2)</a></td>
        <td class="nump">1,088<span></span></td>
        <td class="nump">794<span></span></td>
        <td class="nump">1,308<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
        <td class="nump">14,020<span></span></td>
        <td class="nump">12,424<span></span></td>
        <td class="nump">15,504<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(2,738)<span></span></td>
        <td class="num">(3,594)<span></span></td>
        <td class="num">(3,935)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
        <td class="nump">28<span></span></td>
        <td class="nump">53<span></span></td>
        <td class="nump">9<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before taxes</a></td>
        <td class="num">(2,710)<span></span></td>
        <td class="num">(3,541)<span></span></td>
        <td class="num">(3,926)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) (Note 10)</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(40)<span></span></td>
        <td class="num">(84)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (2,710)<span></span></td>
        <td class="num">$ (3,501)<span></span></td>
        <td class="num">$ (3,842)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and dilutive loss per share (in dollars per share)</a></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="num">$ (0.25)<span></span></td>
        <td class="num">$ (0.30)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
        <td class="nump">14,817<span></span></td>
        <td class="nump">14,285<span></span></td>
        <td class="nump">12,963<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares issued and outstanding that are used in calculating common stock basic and diluted EPS, determined based on the timing of issuance of shares in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_WeightedAverageCommonSharesOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsAndServicesSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 10<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestAndOtherIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingAndMarketingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 6 &#8211; OTHER CURRENT LIABILITIES</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">At December 31, 2011 and 2010, other current liabilities include $237,000 and $483,000, respectively, related to accrued compensation.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PATENT RIGHTS AND RELATED ROYALTY COMMITMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract', window );"><strong>Patent Rights and Related Royalty Commitments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock', window );">Patent Rights and Related Royalty Commitments [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 5 &#8211; PATENT RIGHTS AND RELATED ROYALTY COMMITMENTS</b></p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We have maintained a separate representation and distribution agreement relating to the development of the zinc gluconate product formulation. In return for exclusive worldwide distribution rights, we agreed to pay the developer a 3% royalty and a 2% consulting fee based on sales collected, less certain deductions, throughout the term of this agreement, which expired May 2007. However, we and the developer are in litigation (see Note 7) and as such no potential offset for these fees from such litigation has been recorded. The amount accrued for this expense at each of December 31, 2011 and 2010 was $3.5 million.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_PatentRightsAndRelatedRoyaltyCommitmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for patent rights and related royalty commitments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_PatentRightsAndRelatedRoyaltyCommitmentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>QUARTERLY INFORMATION (UNAUDITED)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 13 &#8211; QUARTERLY INFORMATION (UNAUDITED)</b></p>
<p style="text-align: justify; text-indent: -0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The following table presents unaudited quarterly financial information for Fiscal 2011 and Fiscal 2010 (in thousands, except per share amounts):</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<table style="width: 96%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="14">Quarter&#160;Ended</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">March&#160;31,</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">September 30,</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">December 31,</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 1pt; font-weight: bold;"><u>Fiscal 2011</u></td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt; width: 48%;">Net sales</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">3,166</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">1,744</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">5,083</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">7,460</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Gross profit</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,994</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">896</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,596</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4,796</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Income (loss) from continuing operations</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,013</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(976</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,110</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,831</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Net income (loss)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,013</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(976</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,110</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,831</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Basic and diluted earnings (loss) per share:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 0.25in;">Income (loss) from continuing operations</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.07</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.07</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.07</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.12</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 0.25in;">Net income&#160; (loss)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.07</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.07</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.07</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.12</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="font-weight: bold; text-decoration: underline;">Fiscal 2010</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Net sales</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,976</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,131</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">5,204</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">6,191</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Gross profit</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,170</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">471</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,610</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,579</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Income (loss) from continuing operations</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,062</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(2,254</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">947</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,132</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Net income (loss)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,062</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(2,254</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">947</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,132</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Basic and diluted earnings (loss) per share:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 0.25in;">Income (loss) from continuing operations</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.08</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.15</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.06</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.08</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 0.25in;">Net income&#160; (loss)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.08</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.15</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.06</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.08</td>
<td style="text-align: left;">)</td>
</tr>
</table>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 23, 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 30<br><br> -Subparagraph a-j<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952194&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DEFINED CONTRIBUTION PLANS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 9 &#8211; DEFINED CONTRIBUTION PLANS</b></p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We maintain the ProPhase Labs, Inc 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in Fiscal 2011, 2010 and 2009 were $88,000, $90,000 and $141,000, respectively.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 87<br><br> -Paragraph 264<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 158<br><br> -Paragraph 7, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS106-2<br><br> -Paragraph 20, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Implementation Guide (Q and A)<br><br> -Number FAS88<br><br> -Paragraph 63<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 30<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-2<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 8<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph q<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 106<br><br> -Paragraph 518<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 7 &#8211; COMMITMENTS AND CONTINGENCIES</b></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Certain operating leases for office and warehouse space maintained by us in Fiscal 2010 and 2009 resulted in rent expense of $11,000 and $44,000, respectively. We did not incur rent expense in Fiscal 2011. We have approximate future obligations over the next five years as follows (in thousands):</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 60%; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;">Year</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Employment <br />Contracts</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Purchase <br />Commitments</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Total</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 31%;">2012</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 20%;">1,106</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 20%;">1,377</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 20%;">2,483</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2013</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,025</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,025</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center;">2014</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,025</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,025</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2015</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">556</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">556</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1pt;">2016</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">3,712</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,377</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">5,089</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif; color: red;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">In August, 2009, we entered into a standard form of indemnity agreement with each member of our Board of Directors, Mr. Ted Karkus, our Chairman and Chief Executive Officer, and Mr. Robert V. Cuddihy, Jr., our Chief Operating Officer. These agreements provide, among other things, that we will indemnify each director, Mr. Karkus and Mr. Cuddihy in the event that they become a party or otherwise a participant in any action or proceeding on account of their service as a director or officer of the Company (or service for another corporation or entity in any capacity at the request of the Company) to the fullest extent permitted by applicable law. Under the indemnity agreement, we will pay, in advance of the final disposition of any such action or proceeding, expenses (including attorneys&#8217; fees) incurred by our directors or officers in defending or otherwise responding to such action or proceeding upon receipt of a written undertaking from the directors or officers to
 repay the amount advanced consistent with applicable law in the event that a court shall ultimately determine that he or she is not entitled to be indemnified for such expenses. The contractual rights to indemnification provided by the indemnity agreements are subject to the limitations and conditions specified in the agreements, and are in addition to any other rights each director and officer may have under our Articles of Incorporation and Amended and Restated Bylaws, each as amended from time to time, and applicable law.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">On November 8, 2011, we entered into new employment agreements, effective as of January 1, 2012, with each of Mr. Ted Karkus and Mr. Cuddihy (the &#8220;Employment Agreements&#8221;). The Employment Agreements supersede the employment agreements of Mr. Karkus and Mr. Cuddihy, dated August 19, 2009, that had been scheduled to terminate on July 15, 2012. The scheduled termination dates of the Employment Agreements is July 15, 2015, which is three years following the scheduled expiration date set forth in the executives&#8217; former employment agreements.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Under his new employment agreement with the Company, Mr. Karkus agreed to an annual base salary of $675,000 as Chief Executive Officer. Under the terms of his former employment agreement with the Company, as amended, Mr. Karkus was entitled to annual base compensation of $750,000, consisting of a $600,000 base salary and $150,000 in stock based compensation. He is eligible to receive an annual increase in base salary and may be awarded a bonus in the sole discretion of the Compensation Committee and also will receive regular benefits routinely provided to other senior executives of the Company.</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Under his new employment agreement with the Company, Mr. Cuddihy agreed to an annual base salary of $350,000 as Chief Financial Officer and Chief Operating Officer. Under the terms of his former employment agreement with the Company as the Company&#8217;s Chief Operating Officer, Mr. Cuddihy was entitled to annual base compensation of $325,000, consisting of a $275,000 base salary and $50,000 in stock based compensation. Mr. Cuddihy is eligible to receive an annual increase in base salary and may be awarded a bonus in the sole discretion of the Compensation Committee and also will receive regular benefits routinely provided to other senior executives of the Company.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Each executive is subject to non-competition restrictions for up to a period of either six (6) months or eighteen (18) months following termination of employment depending on the nature of the termination. Each executive is also eligible for a gross up payment in the event that any amounts payable under the agreements (or any other plan, program, policy or arrangement with the Company) become subject to the excise tax imposed by Section 4999 of the Internal Revenue Code.</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The Employment Agreements also provide for payments upon certain terminations and change in control benefits to ensure that they work to secure the best outcome for stockholders in the event of a possible change in control, even if it means that they lose their jobs as a result. Under the Employment Agreements, in the event of the termination by the Company of the employment of Mr. Karkus or Mr. Cuddihy without cause or due to a voluntary resignation by either executive with Good Reason (as defined in the agreements), each executive will be paid a lump sum severance payment in cash equal to the greater of (A) the amount equal to eighteen (18) months base salary or (B) the amount equal to the his base salary for the remainder of the term as if the agreement had not been terminated. Additionally, each executive is entitled to receive a lump sum severance payment in cash equal to the greater of A or B, if he, within twenty four (24) months of a Change in Control (as defined in the agreements) of the Company, is terminated without cause or due to a voluntary resignation by him with Good Reason (as defined in the agreements). Each executive may also participate at Company expense in all medical and dental plans for the remainder of the term of his employment agreement in the event the Company terminates the employment agreement for any reason, except for the Company&#8217;s termination for Cause (as defined in the agreements) or a voluntary resignation by him without Good Reason (as defined in the agreements).</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.) VS. JOHN C. GODFREY, ET AL.</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">This action was commenced by us in November 2004 in the Court of Common Pleas of Bucks County, Pennsylvania against John C. Godfrey, Nancy Jane Godfrey, and Godfrey Science and Design, Inc. for injunctive relief regarding the Cold-EEZE<sup>&#174;</sup>&#160;trademark; injunctive relief relating to the Cold-EEZE<sup>&#174;</sup> formulations and manufacturing methods; injunctive relief for breach of the duty of loyalty, and declaratory judgment&#160;regarding&#160;various payments that the defendants assert are owing to them.&#160; Our complaint is based in part upon certain contracts&#160;with defendants whereby we obtained the exclusive right to manufacture and distribute product pursuant to&#160;a basic patent&#160;and&#160;also obtained various consulting services&#160;(the "Agreements").&#160; Subsequent to entering into the Agreements, the&#160;defendants&#160;took various actions that we believe were in breach of&#160;the Agreements. We instituted the action because of&#160;defendants' threats to deal with other parties and&#160;to use the Company&#8217;s Cold-EEZE<sup>&#174;</sup> trademark and&#160;the trade secrets that&#160;we developed during our manufacture of Cold-EEZE<sup>&#174;</sup>. Both
 because of their breaches and the expiration of the basic patent, we terminated the&#160;Agreements.&#160; Defendants have answered the complaint and asserted counterclaims.&#160; They seek monetary damages and counter injunctive and&#160;declaratory relief relative to the Company's trademark and other intellectual property.&#160; The monetary relief sought by the&#160;defendants&#160;is based on their claim that they were not paid various amounts asserted to be due under the Agreements.&#160; This claim is estimated&#160;to be in excess of $5.0 million.&#160; We believe that the defendants' counterclaims are without merit and are vigorously defending those counterclaims and are prosecuting our action on the complaint.&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Pre-trial discovery is&#160;ongoing.&#160; Defendants moved for partial summary judgment, and we filed a response and cross-motion for summary judgment.&#160; On August 21, 2008, the court denied both motions for summary judgment.&#160; The case has not been assigned to a trial calendar, although it is possible that the case will be listed for trial in 2012.&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At this time no prediction as to the outcome of this action can be made.</p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><i><u>THE QUIGLEY CORPORATION (currently PROPHASE LABS, INC.) VS. WACHOVIA INSURANCE SERVICES, INC. AND FIRST UNION INSURANCE SERVICES AGENCY, INC.</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">We instituted a Writ of Summons against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc. on December 8, 2005 in the Court of Common Pleas of Bucks County, Pennsylvania. The purpose of this suit was to maintain an action and toll the statute of limitation against our insurance broker who failed to place excess limits coverage for us for the period from November 29, 2003 until April 6, 2004. As a result of the defendants&#8217; failure to place insurance and to notify us thereof, certain pending actions covered by our underlying insurance, which are currently being defended by insurance counsel and the underlying insurance carrier may cause an exhaustion of the underlying insurance for the policy periods ending November 29, 2004 and November 29, 2005. Any case in which an alleged action arose relating to the use of Cold-EEZE<sup>&#174;</sup> Nasal Spray from November 29, 2003 to April 6, 2004 is not covered by excess insurance.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">Our claim against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc. is for negligence and for equitable insurance for these claims based on our undertaking of certain attorneys' fees and costs of settlement for claims that should have been covered by underlying insurance placed by Wachovia Insurance Services, Inc. At this time no prediction can be made as to the outcome of any action against Wachovia Insurance Services, Inc. and First Union Insurance Services Agency, Inc.</p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>PROPHASE LABS, INC.(formerly THE QUIGLEY CORPORATION) <font style="text-transform: uppercase; color: windowtext;">vs. Guy Quigley, Gary Quigley, Scanda Systems Limited, Scanda Systems LTD, Chilesha Holdings LTD, Kevin Brogan, Innerlight Holdings, Inc., George Longo, Graham Brandon, Pacific Rim Pharmaceuticals LTD and John Doe Defendants</font></u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><font style="color: windowtext;">On August 23, 2010, we initiated an action in the Court of Common Pleas of Bucks County, </font>Pennsylvania<font style="color: windowtext;">. This action&#160;is against certain former officers and directors of the Company, including a shareholder that beneficially owns approximately 20.1% of our Common Stock, and against certain third parties (a &#8220;Complaint&#8221;). The Company has asserted claims arising from, among other things, a variety of transactions and payments previously made or entered into by the Company. All of the transactions and events that are the subject of the Complaint occurred prior to June 2009 and the installation of the current Board of Directors. Pre-trial discovery is on-going and at this time, no prediction as to the outcome of this action can be made.</font></p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><i><u>GUY QUIGLEY VS. TED KARKUS, ROBERT V. CUDDIHY, JR., MARK BURNETT, MARK LEVENTHAL, MARK FRANK, LOUIS GLECKEL, MD, JAMES McCUBBIN AND PROPHASE LABS, INC. AS A NOMINAL DEFENDANT</u></i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The Company was named as a nominal defendant in a purported derivative complaint filed on February 2, 2012 by stockholder and former director and Chief Executive Officer Guy Quigley in the Court of Common Pleas of Philadelphia County, Pennsylvania (No. 111200409). The complaint also names as a defendant each of our directors and executive officers. Among other things, the suit alleges various breaches of fiduciary and other duties, and seeks recovery of unspecified damages and other relief. Prior to filing this complaint, the plaintiff applied to the same court for permission to take pre-complaint discovery on the basis that the plaintiff required such discovery in order to assert claims. The court denied the plaintiff's request. The Company believes the lawsuit is without merit and intends to vigorously defend against it.</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">As noted above, the Company previously commenced litigation against the plaintiff, Guy Quigley, and other parties in August 2010 in the Bucks County Court of Common Pleas, Pennsylvania (No.
 2010-08227). The August 2010 action remains pending.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY AND STOCK COMPENSATION<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>NOTE 8 &#8211; STOCKHOLDERS&#8217; EQUITY AND STOCK COMPENSATION</b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b><i>&#160;</i></b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>Stockholder Rights Plan</b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a &#8220;Right&#8221; and collectively, the &#8220;Rights&#8221;) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the &#8220;Rights Agreement&#8221;). The Plan was amended effective May 23, 2008 (&#8220;First Amendment&#8221;) and further amended effective August 18, 2009 (&#8220;Second Amendment&#8221;). The Rights Agreement, as amended, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The dividend has the effect of giving the stockholder a 50% discount on the share&#8217;s current market value for exercising such right. In the event of a cashless exercise of the Right, and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is September 25, 2018.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>T<font style="font-size: 10pt;">he 1997 Option Plan</font></b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">On December 2, 1997, our Board of Directors approved a Stock Option Plan (the &#8220;1997 Plan&#8221;), which was amended in 2005, and provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan during Fiscal 2011, 2010 or 2009.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">At December 31, 2011, we are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options&#8217; respective expiration dates, but in no event later than ten years from the date granted. At December 31, 2011, there are 138,750 options outstanding with various expiration dates ranging from July 2012 through December 2015, depending upon the date of grant.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>T<font style="font-size: 10pt;">he 2010 Equity Compensation Plan</font></b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 (the &#8220;2010 Equity Compensation Plan&#8221;). The 2010 Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued is equal to 900,000 shares plus up to 900,000 shares that are authorized for issuance, Issued Options (defined below) but unissued under the 1997 Plan an aggregate of 1.8 million shares. <font style="color: black;">The 1997 Plan expired on December 2, 2007 and no additional awards may be made; however, a</font>s of March 31, 2010, there remained 1,449,750 shares subject to vested options that were authorized for issuance (the &#8220;Issued Options&#8221;) but were unissued under the 1997 Plan. As of December 31, 2011, 1,311,000 of the Issued Options under the 1997 Plan expired unexercised or were terminated (the &#8220;Expired Options&#8221;). As a consequence, these shares are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Equity Compensation Plan and the remaining 411,000 options are deemed cancelled.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif;"><font style="font-family: times new roman,times;" size="2"><i><u><br  />Stock Options</u></i></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">All of the Company&#8217;s employees, including employees who are officers or members of the Board are eligible to participate in the 2010 Equity Compensation Plan. Consultants and advisors who perform services for the Company are also eligible to participate in the 2010 Equity Compensation Plan. For Fiscal 2011, 2010 and 2009, we granted 220,000, 982,000 and zero options, respectively, to employees to acquire our Common Stock pursuant to the terms of 2010 Equity Compensation Plan. Presented below is a summary of the terms of the grant of options:</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<table style="font: 10pt times new roman, times, serif; margin-left: 0.1in; width: 93%;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"><font style="font-family: times new roman,times;" size="2">Year&#160;Ended&#160;December&#160;31,</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">2011</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">2010</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">2009</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 61%; text-align: left;"><font style="font-family: times new roman,times;" size="2">Number of options granted</font></td>
<td style="width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: times new roman,times;" size="2">220,000</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: times new roman,times;" size="2">982,000</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 10%; text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td><font style="font-family: times new roman,times;" size="2">Vesting period</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">4 years</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">3-6 years</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">Maximum term of option from date of grant</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">7 years</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">7 years</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td><font style="font-family: times new roman,times;" size="2">Exercise price per share</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$&#160;</font></td>
<td style="text-align: right;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">0.87 - $1.17</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">1.00</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-left: 9pt; text-indent: -9pt; text-align: left;"><font style="font-family: times new roman,times;" size="2">Weighted average fair value per share of options granted&#160;during the year</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">0.58</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">0.65</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
</table>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">We use the Black-Scholes option pricing model during Fiscal 2011 and 2010 to determine the fair value of the stock options at the date of grant. Based upon our limited historical experience, we estimated approximately 33,000 and 27,300, respectively, of the options granted in Fiscal 2011 and Fiscal 2010 may ultimately be forfeited. Additionally, we determined the expected term of the stock option grants to be a range between 4.5 to 6.5 years, calculated using the &#8220;simplified&#8221; method in accordance with the SEC Staff Accounting Bulletin 110. We use the &#8220;simplified&#8221; method since we changed the vesting terms, tax treatment and the recipients of our stock options beginning in 2010 such that we believe our historical data does not provide a reasonable basis upon which to estimate expected term. Presented below is a summary of assumptions used in determining the fair value of the stock options at the date of grant:</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<table style="font: 10pt times new roman, times, serif; margin-left: 0.1in; width: 93%;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10"><font style="font-family: times new roman,times;" size="2">Year&#160;Ended&#160;December&#160;31,</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">2011</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">2010</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">2009</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;Expected option life</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">4.75 years</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">4.5 - 6.5 years</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 46%;"><font style="font-family: times new roman,times;" size="2">&#160;Weighted average risk free rate</font></td>
<td style="width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 15%; text-align: right;"><font style="font-family: times new roman,times;" size="2">1.28</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">%</font></td>
<td style="width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 15%; text-align: right;"><font style="font-family: times new roman,times;" size="2">2.10</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">%</font></td>
<td style="width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 15%; text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;Dividend yield</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">0</font></td>
<td style="text-align: left;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">%</font></td>
<td nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">0</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">%</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;Expected volatility</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">75.84% - 78.62</font></td>
<td style="text-align: left;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">%&#160;</font></td>
<td nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">72.17% - 77.63</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">%&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
</table>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">The fair value of the stock options at the time of the grant in Fiscal 2011 and 2010 was approximately $127,000 and $618,000, respectively. Each of the stock options granted were subject to vesting such that the fair value of the stock options granted is charged to operations over the vesting period. For Fiscal 2011 and 2010, we charged to operations $131,000 and $42,000, respectively, for share-based compensation expense for the aggregate fair value of the stock grants and vested stock options earned. There was no share-based compensation expense for Fiscal 2009.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>&#160;</b></font></p>
<div style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">At December 31, 2011, 237,020 of the options granted in Fiscal 2011 and 2010 were vested and 956,980 are subject to vesting. At December 31, 2011, there are 13,659 options available for grant to purchase shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.<br  /><br  /></font></div>
<div style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">A summary of the status of our stock options granted to both employees and non-employees as of December 31, 2011, 2010 and 2009 and changes during the years then ended is presented below (in thousands, except per share data):</font></div>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<table style="font: 10pt times new roman, times, serif; width: 100%;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="22"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Year&#160;Ended&#160;December&#160;31,</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="6"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">2011</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="6"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">2010</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="6"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">2009</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Weighted&#160;Average</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Weighted Average</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Weighted Average</font></td>
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Shares</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Shares</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Shares</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="width: 34%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Options outstanding - beginning of year</font></td>
<td style="width: 1%;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 8%; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1,300</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">$</font></td>
<td style="width: 8%; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">2.99</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 8%; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1,488</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">$</font></td>
<td style="width: 8%; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">8.64</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 8%; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">2,268</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">$</font></td>
<td style="width: 8%; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">7.76</font></td>
<td style="width: 1%; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-left: 9pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Granted</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">220</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1.10</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">982</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1.00</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-left: 9pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Exercised</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">-</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">(131</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">)</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1.02</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">(125</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">)</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1.01</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-left: 9pt; padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Cancelled</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">(187</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">8.67</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">(1,039</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">9.45</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">(655</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">)</font></td>
<td style="padding-bottom: 1pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">7.02</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Options outstanding - end of year</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1,333</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1.88</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1,300</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">2.99</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1,488</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">8.64</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Options granted and subject to future vesting</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">957</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1.02</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">937</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1.00</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">-</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">-</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Exercisable, at end of year</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">376</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">363</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">1,488</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">Available for grant</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">14</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">818</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">-</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: right;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;"><font style="font-size: 8pt; ; font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
</table>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 22.5pt; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">The unrecognized share-based compensation expense related to the options granted but not vested, (options to acquire 956,980 shares) was approximately $572,000 at December 31, 2011. These options subject to vesting (i) vest over the next 2 to 5 years, (ii) have a 7 year term from the date of grant, (iii) are exercisable at a weighted average price of $1.02 and (iv) the unrecognized share-based compensation expense is expected to be recognized over a weighted average period of 4 years.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 27pt; text-align: justify;"><font style="font-family: times new roman,times;" size="2">The following table summarizes information about stock options outstanding and stock options exercisable at December 31, 2011 (in thousands, except remaining life and per share data):</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"></p>
<table style="font: 10pt times new roman, times, serif; margin-left: 0.5in; width: 75%;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="10"><font style="font-family: times new roman,times;" size="2">Options&#160;Outstanding&#160;and&#160;Exercisable</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">Range&#160;of</font><br  /><font style="font-family: times new roman,times;" size="2">Exercise Prices</font></td>
<td nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-family: times new roman,times;" size="2">Number </font><br  /><font style="font-family: times new roman,times;" size="2">Outstanding</font></td>
<td nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-family: times new roman,times;" size="2">Weighted Average </font><br  /><font style="font-family: times new roman,times;" size="2">Remaining </font><br  /><font style="font-family: times new roman,times;" size="2">Contractual Life</font></td>
<td nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td nowrap="nowrap"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"><font style="font-family: times new roman,times;" size="2">Weighted Average </font><br  /><font style="font-family: times new roman,times;" size="2">Exercise&#160;Price Per</font><br  /><font style="font-family: times new roman,times;" size="2">Share</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$0.81 - $1.17</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">237</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">6.0</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">1.00</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$1.18 - $5.19</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">25</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">0.5</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">5.19</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$5.20 - $8.11</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">38</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">1.8</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">8.11</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$8.12 - $9.50</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">47</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">2.8</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="text-align: right;"><font style="font-family: times new roman,times;" size="2">9.50</font></td>
<td style="text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: times new roman,times;" size="2">$9.51 - $13.80</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-family: times new roman,times;" size="2">29</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt; text-align: center;" colspan="2"><font style="font-family: times new roman,times;" size="2">4.0</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font-family: times new roman,times;" size="2">13.80</font></td>
<td style="padding-bottom: 1pt; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt; width: 26%; text-align: justify;"><font style="font-family: times new roman,times;" size="2">Total</font></td>
<td style="padding-bottom: 2.5pt; width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; border-bottom: black 2.5pt double; text-align: right;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 21%; border-bottom: black 2.5pt double; text-align: right;"><font style="font-family: times new roman,times;" size="2">376</font></td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 21%; text-align: right;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 1%;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
<td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;"><font style="font-family: times new roman,times;" size="2">$</font></td>
<td style="width: 21%; border-bottom: black 2.5pt double; text-align: right;"><font style="font-family: times new roman,times;" size="2">4.05</font></td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"><font style="font-family: times new roman,times;" size="2">&#160;</font></td>
</tr>
</table>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">The total intrinsic value of options exercised during Fiscal 2010 and 2009 was<font style="color: red;"> </font>$107,000 and<font style="color: red;"> </font>$226,000, respectively. There were no options exercised during Fiscal 2011. The aggregate intrinsic value of (i) options outstanding, (ii) options outstanding and expected to vest in the future and (iii) options outstanding and exercisable at December 31, 2011 was $159,000, $123,000 and $36,000, respectively.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><br  /><em><u>Stock Grants</u></em></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">In April 2011, the Compensation Committee of the Board of Directors approved an amendment to Mr. Karkus&#8217; then employment agreement, dated August 19, 2009 (the &#8220;Amendment&#8221;) to lower his annual salary by $150,000 (or $12,500 per month) in exchange for a grant of restricted stock equal in value to the salary reduction. Pursuant to the Amendment, Mr. Karkus&#8217; annual base salary was decreased from $750,000 per year to $600,000 per year, effective May 1, 2011 thru July 15, 2012, which is the end of the term of his then employment agreement, as amended. As a consequence of the Amendment, a restricted stock grant under the 2010 Equity Compensation Plan equal to $12,500 of shares per month thru the end of the term (14.5 months). The restricted stock grant was made in an upfront grant of 161,830 shares, subject to certain future vesting conditions, at a value of $181,000 as of the grant date. The grant was made in April 2011, and the amount of the shares issued was calculated based on the average closing price of our Common Stock for the last five (5) trading days prior to and including the issuance date of April 21, 2011. For Fiscal 2011, we have charged to operations $100,000 as share-based compensation expense for the restricted stock grant and we have unrecognized compensation expense of $81,250 at December 31, 2011 that will be charged to operations in equal monthly installments of $12,500 over the remaining vesting period ending July 15, 2012.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">In addition, in April 2011, the Compensation Committee of the Board of Directors granted Mr. Karkus 133,928 shares of Common Stock under the 2010 Equity Compensation Plan as payment for his Fiscal 2010 bonus. Furthermore, in December 2011, the Compensation Committee of the Board of Directors granted Mr. Karkus 128,571 shares of Common Stock under the 2010 Equity Compensation Plan as payment for his Fiscal 2011 bonus. Mr. Karkus agreed to accept his Fiscal 2011 and Fiscal 2010 cash bonus of $150,000 for each year in shares of our Common Stock.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">In April 2011, Mr. Karkus also agreed to convert into shares of our Common Stock $144,000 of deferred and unpaid cash compensation owed to him thru April 2011, resulting in an issuance of 128,571 shares under the 2010 Equity Compensation Plan. The amount of these shares issued to Mr. Karkus was calculated based on the average closing price of the Company&#8217;s shares for the last five (5) trading days prior to and including the issuance dates of April 21, 2011.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">In December 2011, the Compensation Committee of the Board of Directors granted Mr. Cuddihy 33,603 shares of Common Stock, under the 2010 Equity Compensation Plan valued at $37,500 as payment for 50% of his Fiscal 2011 bonus.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>The 2010 Directors Equity Compensation Plan</b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">On May 5, 2010, our shareholders approved t<font style="color: black;">he 2010 Directors&#8217; Equity Compensation Plan. </font>A primary purpose of the <font style="color: black;">2010 Directors&#8217; Equity Compensation Plan</font> is to provide us with the ability to pay all or a portion of the fees of Directors in restricted stock instead of cash. The 2010 Directors&#8217; Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors&#8217; Equity Compensation Plan is equal to 250,000. In Fiscal 2011 and 2010, we granted 164,770 and 67,625 shares, respectively, of our Common Stock valued at $162,000 and $90,000, respectively, for director compensation. At December 31, 2011, there are 17,605 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors Equity Compensation Plan.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>&#160;</b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><b>Stock Option Exercises and Other Grants</b></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">Pursuant to the terms of Mr. Cuddihy&#8217;s prior employment agreement dated August 19, 2009, Mr. Cuddihy received an annual grant of shares of Common Stock that is equal to $50,000, payable quarterly,<b> </b>promptly following the close of each quarter calculated based on the average closing price of our Common Stock for the last five (5) trading days of the quarter. For Fiscal 2011, 2010 and 2009, Mr. Cuddihy earned 51,642, 35,075 and 11,004 shares, respectively, valued at $50,000, $50,000 and $23,000, respectively, as share-based compensation.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">For Fiscal 2010 and 2009, we derived net proceeds of $133,000 and $127,000, respectively, as a consequence of the exercise of options to acquire 130,500 and 125,000 shares, respectively, of our Common Stock pursuant to the terms of our 1997 Option Plan. There were no stock options exercised in Fiscal 2011.</font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-align: justify;"><font style="font-family: times new roman,times;" size="2"><font size="3"><br  /></font><strong>Purchase of Treasury Stock</strong></font></p>
<p style="margin: 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"><font style="font-family: times new roman,times;" size="2">In September 2011, we entered into a redemption agreement with <font style="letter-spacing: -0.15pt;">PSI Parent. </font>Under the terms of the redemption agreement, we redeemed 690,000 shares of our Common Stock held by <font style="letter-spacing: -0.15pt;">PSI Parent</font> for the aggregate redemption price of $448,500 in cash (see Note 3). The redemption price was equal to $0.65 per share.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>NOTE 10 &#8211; INCOME TAXES</b></p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The components of the provision (benefit) for income taxes, in the consolidated statement of operations are as follows (in thousands):</p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">Year&#160;Ended&#160;December&#160;31,</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2010</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2009</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Current</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 9pt; width: 61%;">Federal</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">(40</td>
<td style="text-align: left; width: 1%;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">(84</td>
<td style="text-align: left; width: 1%;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 9pt;">State</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(40</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(84</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Deferred</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 9pt;">Federal</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(877</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(107</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,297</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 9pt;">State</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(21</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">160</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(61</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(898</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">53</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(2,358</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Total</td>
<td
 style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(898</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">13</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(2,442</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Income taxes from continuing operations before valuation allowance</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(898</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">13</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(2,442</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Change in valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">898</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(53</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2,358</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;">Income tax (benefit)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(40</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(84</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(40</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(84</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
</tr>
</table>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows (in thousands):</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">Year&#160;Ended&#160;December&#160;31,</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2010</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2009</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 61%;">Statutory rate - federal</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">(925</td>
<td style="text-align: left; width: 1%;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">(1,204</td>
<td style="text-align: left; width: 1%;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width:
 10%;">(1,335</td>
<td style="text-align: left; width: 1%;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">State taxes, net of federal benefit</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(21</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(61</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Permanent differences and other</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">48</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(143</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(1,046</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.13in; padding-left: 0.25in;">Income tax from continuing operation before valuation allowance</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(898</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(1,347</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,442</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Change in valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(898</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">1,307</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2,358</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Income tax (benefit)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(40</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(84</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(40</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">(84</td>
<td style="text-align: left; padding-bottom: 2.5pt;">)</td>
</tr>
</table>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The components of permanent and other differences are as follows (in thousands):</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">Year&#160;Ended&#160;December&#160;31,</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid;
 text-align: center;" colspan="2">2010</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2009</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Permanent items:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt; width: 61%;">Meals and Entertainment</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">2</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">5</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">6</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Officers life insurance</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Return to accrual for prior year, permanent items</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(479</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Capital loss carryforward utilization <sup>(1)</sup></td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(582</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Contribution of inventory<sup>(2)</sup></td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(162</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Share-based compensation expense for stock options granted<sup> (3)</sup></td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">45</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">14</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">47</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(143</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(1,046</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
</table>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0px; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.35in;"></td>
<td style="width: 0.25in;">(1)</td>
<td style="text-align: justify;">This item represents the utilization for tax purposes of prior year capital losses.</td>
</tr>
</table>
<p style="text-align: justify; text-indent: -0.25in; margin: 0px 0px 0px 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0px; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.35in;"></td>
<td style="width: 0.25in;">(2)</td>
<td style="text-align: justify;">This item represents the additional tax deduction available as a consequence of the contribution of certain inventory to qualified charitable organization.</td>
</tr>
</table>
<p style="text-align: justify; text-indent: -0.25in; margin: 0px 0px 0px 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0px; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.35in;"></td>
<td
 style="width: 0.25in;">(3)</td>
<td style="text-align: justify;">This item relates to share-based compensation expense for financial reporting purposes not deducted for tax purposes until such options are exercised.</td>
</tr>
</table>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">The tax effects of the primary &#8220;temporary differences&#8221; between values recorded for assets and liabilities for financial reporting purposes and values utilized for measurement in accordance with tax laws giving rise to our deferred tax assets are as follows (in thousands):</p>
<p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 94%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">Year&#160;Ended&#160;December&#160;31,</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2010</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2009</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 61%;">Net operating loss and capital loss carryforward</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">13,170</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">12,135</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">10,808</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Consulting-royalty costs</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,431</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,431</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,431</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Depreciation</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">235</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">253</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">250</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Other</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">757</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">877</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">801</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Valuation allowance</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(15,593</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(14,696</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(13,290</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">A valuation allowance for all of our net deferred tax assets has been provided as we are unable to determine, at this time, that the generation of future taxable income against which the net operating loss (&#8220;NOL&#8221;) carryforwards could be used can be predicted to be more likely than not. The net change in the valuation allowance for Fiscal 2011, 2010 and 2009 was $898,000, $1.4 million and $2.4 million, respectively. Certain exercises of options and warrants, and restricted stock issued for services that became unrestricted resulted in reductions to taxes
 currently payable and a corresponding increase to additional-paid-in-capital for prior years. In addition, certain tax benefits for option and warrant exercises totaling $6.3 million are deferred and will be credited to additional-paid-in-capital when the NOL&#8217;s attributable to these exercises are utilized. As a result, these NOL&#8217;s will not be available to offset income tax expense. The net operating loss carry-forwards currently approximate $31.6 million for federal purposes will expire beginning in Fiscal 2020 through 2031. Additionally, there are net operating loss carry-forwards of $20.0 million for state purposes that will expire beginning in Fiscal 2018 through 2031.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;">As noted above, we have net operating loss carry-forwards for both federal and certain states. However, effective December 31, 2009, we elected to conform our tax reporting year, historically a fiscal period ending September 30, to our financial reporting period ending December 31. As a consequence, we filed a full period tax return for the fiscal year ended September 30, 2009 with the IRS and also filed with the IRS a &#8220;short period return&#8221; for the three months ended December 31, 2009 in compliance with the election. In future fiscal periods, our tax and financial reporting periods will be the same, the period ending December 31. For Fiscal 2010, we had a current tax benefit of $40,000 for an alternative minimum tax refund due us as a consequence of a carry back of an alternative minimum tax net operating loss to a prior period. For Fiscal 2009, we had a current tax benefit of $84,000 for certain federal and state alternative minimum income taxes incurred for the &#8220;short period return&#8221;, inclusive of an alternative minimum tax refund of $110,000 due us as a consequence of a carry back of an alternative minimum tax net operating loss to a prior period.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBBCI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)<br>In Thousands</strong></div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital [Member]</div>
        </th>
        <th class="th">
          <div>Retained Earnings [Member]</div>
        </th>
        <th class="th">
          <div>Treasury Stock [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2008</a></td>
        <td class="nump">$ 9<span></span></td>
        <td class="nump">$ 37,599<span></span></td>
        <td class="nump">$ 5,354<span></span></td>
        <td class="num">$ (25,188)<span></span></td>
        <td class="nump">$ 17,774<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2008</a></td>
        <td class="nump">12,908,383<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,842)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,842)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">127<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">127<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
        <td class="nump">125,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefits from exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">88<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">88<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation', window );">Tax benefit allowance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(88)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(88)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2009</a></td>
        <td class="nump">9<span></span></td>
        <td class="nump">37,726<span></span></td>
        <td class="nump">1,512<span></span></td>
        <td class="num">(25,188)<span></span></td>
        <td class="nump">14,059<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2009</a></td>
        <td class="nump">13,033,383<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,501)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,501)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">133<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">133<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
        <td class="nump">130,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement', window );">Common Stock Issued to Phosphangenics Limited pursuant to an Exclusive License Agreement (Note 3)</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">2,576<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,577<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement', window );">Common Stock Issued to Phosphangenics Limited pursuant to an Exclusive License Agreement (Note 3) (in shares)</a></td>
        <td class="nump">1,440,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_StockGrantedDuringPeriodValueEmploymentAgreement', window );">Common stock granted pursuant to an employment agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_StockGrantedDuringPeriodSharesEmploymentAgreement', window );">Common stock granted pursuant to an employment agreement (in shares)</a></td>
        <td class="nump">36,111<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Common stock granted pursuant to a compensation agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock granted pursuant to a compensation agreement (in shares)</a></td>
        <td class="nump">67,625<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefits from exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation', window );">Tax benefit allowance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(42)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(42)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">40,627<span></span></td>
        <td class="num">(1,989)<span></span></td>
        <td class="num">(25,188)<span></span></td>
        <td class="nump">13,460<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="nump">14,707,619<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,710)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,710)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_StockGrantedDuringPeriodValueEmploymentAgreement', window );">Common stock granted pursuant to an employment agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">294<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">294<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prph_StockGrantedDuringPeriodSharesEmploymentAgreement', window );">Common stock granted pursuant to an employment agreement (in shares)</a></td>
        <td class="nump">341,254<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Common stock granted pursuant to a compensation agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock granted pursuant to a compensation agreement (in shares)</a></td>
        <td class="nump">466,710<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">131<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">131<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock purchase (Note 8)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(449)<span></span></td>
        <td class="num">(449)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock purchase (Note 8) (in shares)</a></td>
        <td class="num">(690,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">$ 10<span></span></td>
        <td class="nump">$ 41,552<span></span></td>
        <td class="num">$ (4,699)<span></span></td>
        <td class="num">$ (25,637)<span></span></td>
        <td class="nump">$ 11,226<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="nump">14,825,583<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_StockGrantedDuringPeriodSharesEmploymentAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares granted pursuant to an employment agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_StockGrantedDuringPeriodSharesEmploymentAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_StockGrantedDuringPeriodValueEmploymentAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock granted pursuant to an employment agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_StockGrantedDuringPeriodValueEmploymentAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued to phosphangenics limited pursuant to exclusive license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_StockIssuedDuringPeriodSharesExlusiveLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of common stock issued to phosphangenics limited pursuant to exclusive license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>prph_StockIssuedDuringPeriodValueExlusiveLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>prph_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of tax deficiency associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP) that is deducted from additional paid in capital.  A tax deficiency results from the deductible amount for an award of an equity instrument on the entity's tax return being less than the cumulative compensation cost recognized for financial reporting purposes.  This element should not be used to report tax deficiencies that are charged to income tax expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax benefit associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP). The tax benefit results from the deduction by the entity on its tax return for an award of stock that exceeds the cumulative compensation cost for common stock or preferred stock recognized for financial reporting. Includes any resulting tax benefit that exceeds the previously recognized deferred tax asset (excess tax benefits).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 740<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6419406&amp;loc=d3e23524-113945<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 62<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. This element is not the recognition of equity-based compensation expense in pursuant to FAS 123R. That element is AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue (Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Value).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6743629&amp;loc=d3e3913-113898<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 30<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418191&amp;loc=d3e15009-113911<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased during the period and are being held in treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockSharesAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValueAcquiredCostMethod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b>NOTE 4 &#8211; PROPERTY, PLANT AND EQUIPMENT </b></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b>&#160;</b></font></p>
<p style="text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The components of property and equipment are as follows (in thousands):</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 87%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">December&#160;31,</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">2011</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">2010</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Estimated&#160;Useful Life</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 61%;"><font size="2" style="font-family:times new roman,times">Land</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">504</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">504</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">Buildings and improvements</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,494</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,281</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">15 - 39 years</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">Machinery and equipment</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,567</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,592</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">3 - 7 years</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">Computer software</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">161</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">192</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">3 years</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Furniture and fixtures</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">189</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">182</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">5 years</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">5,915</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">5,751</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Less: Accumulated&#160; depreciation</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">3,608</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">3,389</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2,307</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2,362</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Depreciation expense for Fiscal 2011, 2010 and 2009 was $355,000, $363,000, and $522,000, respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>35</ContextCount>
  <ElementCount>107</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>4</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/DocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/StatementOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/OrganizationAndBusiness</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - INVESTMENT IN PHUSION LABORATORIES, LLC.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/InvestmentInPhusionLaboratoriesLlc</Role>
      <ShortName>INVESTMENT IN PHUSION LABORATORIES, LLC.</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - PATENT RIGHTS AND RELATED ROYALTY COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/PatentRightsAndRelatedRoyaltyCommitments</Role>
      <ShortName>PATENT RIGHTS AND RELATED ROYALTY COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/Commitmentsandcontingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - STOCKHOLDERS' EQUITY AND STOCK COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/StockholdersEquityAndStockCompensation</Role>
      <ShortName>STOCKHOLDERS' EQUITY AND STOCK COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - DEFINED CONTRIBUTION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/DefinedContributionPlans</Role>
      <ShortName>DEFINED CONTRIBUTION PLANS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/EarningsLossPerShare</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - SIGNIFICANT CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/SignificantCustomers</Role>
      <ShortName>SIGNIFICANT CUSTOMERS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - QUARTERLY INFORMATION (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.quigleyco.com/role/QuarterlyInformation</Role>
      <ShortName>QUARTERLY INFORMATION (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>prph-20111231.xml</File>
    <File>prph-20111231.xsd</File>
    <File>prph-20111231_cal.xml</File>
    <File>prph-20111231_def.xml</File>
    <File>prph-20111231_lab.xml</File>
    <File>prph-20111231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>38
<FILENAME>0001144204-12-013420-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-013420-xbrl.zip
M4$L#!!0````(`'U59T#:$4Z3:Y(``$C!!0`1`!P`<')P:"TR,#$Q,3(S,2YX
M;6Q55`D``SZ"5T\^@E=/=7@+``$$)0X```0Y`0``[%UY;^,XEO][!ICOP,UB
M&SU`'%N2SU1U#5(Y:C.=2H(D?<UBT:`EVN:T+'DI*8G[T^\C)=N2+)F23=E.
MQ3V#[E@\WN\]OHOBH8__>!W;Z)DPC[K.#T?:2>,($<=T+>H,?SCZZ>FJUCWZ
MQZ>__?7C?]1JZ-?/#S?(<LU@3!P?F8Q@GUCHA?HC=/EG391&/:'F20/^UT'_
MTS#JC59=;V@ZTK339N]4:Z.SK_^+:K6H5]'L8M;I5Z`\H+%>?Z;DA3`$73X%
MQ+/P]!A]Q<P<H4;[&(EN&[U3HWO:U-#]UT4_/T<XM).F0DJM4PW^W\RA9*BE
MI.7SI"ND9*RDI"FE!/]O-7(H->:4T&?L0<_P5-#43S04J<MKG]GTE/\;@=HZ
MWJE-G3]^.!KY_N2T7G]Y>3GA92<N&X+&@>;QXCYT=A15YZ46G3>(5V[7P\)Y
MU:6N7PQ15^OU>G51.J_JT:R*T*E6__7KS:,Y(F-<HX[G8\=,8*$KL*?K4\]M
MZEIG58NPQJR!XSI.,,ZN;_FL[D\GI`Z5:E"+,&K.V\D;)1M89,*(R7U!+KA>
M'72!N3:I#[#IU\CKQ,8.]ETVO8+?LXX8&>3VT*Y#Z1PB\5>0$G2@2F+4_<Q1
M;X6C/J]JNH'CLVFRKD?,DZ'[7(\*N3/3:@VM9FCS9@%CX#7SVD6E&0TM0K/;
M0$%&=?)JCK+K\Y*,!M1Y)IZ?W20LRVCD8&IZV6U$4483CYK9#:`@J[H_83GU
MH22C0>#5AAA/YFT&V.N+,8P*\IO4L._G-X-"1ON!3[Q8,Z[C7F8;49)!Z]5>
M89:_WL1\Q81-1HFZ_Q?0H4VFIGMBNF/1M:9#Q^#M_O*1.YE33[B/!S)`PNF<
M1H:TVC75)\R=$.93@!MS@J(#SL0/1QX=3^SYLY$P/0ZN-H-P\NI91W6!@_OD
M<]?QR:N/'HGI<X<=>N2_1"[9C$HIN("HYN]7OUW^;FBU"V+6N%D*EF;UP?53
M?RJ>S!Y1BS^$F,*08#G)X4P_SJ]_//K4@'^Z[:[>Z7ZLIQN'5.I+9"(J(!3J
M6@G"X&:9?P'N"YYRH'QH&QI$F_IR^5]B'%CQ-IH.ZK!HLRA=@%F0GCV)I%9.
MCK\_^M`S#YZ7H#O^]-P=3UP'?GIGK]3['7Z.7>?1=\T_OI)QG[!MRGTN4C+D
M`,-GX4,+B(/7IR;U0US(HE`G3#LC<SQ=R=K1IUFU)1X_UC-)1)CJRZ#>L8*<
M61;E%HSM>TRM:^<<3ZB/[6]665;R>U"<XHKS0'Q,'6)=8N;`[-#[9C4FF]&#
MJLQ516N\D6"N-<K+$=IL3XZ'8+[;8/[6%>00S'<4S-^ZXAR"^3M6E3/O][O!
MFPCGX4M0/T<FBU)E,FG4_ADXXAW(VY`)*%:[9C2JD4G2I>RO1%+VIJUA;]KV
M7+-V2/IVG/2]<04Y)'V[2OK>N.(<DKZ#JA14E2=&L!>PZ;<=AC*X?-]*DIX9
M[&_.E\J"*Y\9P$!]Q8S+1'\;,M%K#2.A6Q7,EN9K!]TW(9-&=PLSR#>PXIV0
MR=*R0:5Z<IC[;'ONLT,#.`SV3@=[KRS[,&G=VJ1U?RW^H`2[48*]\@2'MQ#O
MTO8/P_XNK?WP(NF=V?EAP+\M"S]L4MOM-&XKVQX.&\[V.X/?+R4XI'+O<M@/
MD?T;&_##3J3=1O8M+%L>=A7M>V3?*R4X1/9W.>R'R/XF!IR?P__)H7F'\`->
MQ-7@<809`<:CYV/!-OD4<2,*9]W/RF:_>1]97?[T>+'47W3?R"F4K='=/6$"
MY[Q;BSZ#7GR*5;WE]XSP6T+6I+S4GC^\((X[IDY6MT4%E.BBGD2?9IR/V:4M
MM#,Q;!\M0D\OA18]D"'U?`:Z<(O'!$4C_L!O9,C=B7_/W/L1]@BZP7WO&%T[
MYLG'>EZ7`LBB\!RP,&Q?.Q9Y_9%,BQ&,&W%N5W-"Y^+*$_^*>B:V?R.878:;
MU(K1JH6F$A+*ZRK%U!6U"3N'YT.7%63I<8QM:(0>R,1E/D0!Q#T'=J9Q#A/]
MSFD^,<QOR'J<CONN78P:OUPC[#C1.#TVBW0TM.*[P.=N@C?(I+.\.PUQW1-U
M(C^`+&)2X-7[X:AQ]$EK=HVVT6PDAG$%U3G`V9U-3]-)P7&$V<R/(9EXVWF'
M9_#$XD^O;)S-W%*/`^""A%TF6B^!O!>.M)36+7QT$G.BJR5"H5Z&=:[@F5>,
MV-5O22)+W>00X@90@@S_=Q:A>3<I]?N%V/:/COOB/(+;@QAJ77M>`"92B-BM
M&]>IG*Y2!']V[<#Q,0OMK"!724*I+M(&%;J/N8WS7*&H]'[C84#658K>?="'
M1.+*=K&_PE[CY\P6]LJ#;-)8VYU6JV,D;#5&0)">3V2Q-SIS+/X?G@8]8UMD
M0/XY9FP*:'_&=I!M"<O'`7,AU8RC3UW=T"$8?*R7HEP1UA7BXUA;K::V+U@;
MW=58-:W7ZNP-V)X$K-YM;"K9,U/<J.8]$)-`_;Y-;HD?&9D*16UV]23$5035
M(I.HI:%KO?6073O/\`A2$2A7(2,-4KH$DCB!S2A+9*"WN]UBE.\9F6!J7;Y.
M8.)'0,?N_!%A9YY'?$^ANG2[1@)/`;*5P)3(3>LT.QOA#$O^F]B0:+!',%.%
M,M2,Y)CFT5('2"*M];"HE$BKTVIGR$0-<9FN&!!3"A*_HM`1N:'/D*E!.N4,
M*7BAL+HB7V.T.DG-74U2-3J93]X`W7UXV^+TWH89-U@@#X`3GFTKDIQNM/64
MS><35(M,YL6-1MH;%4062E*)=+1VII:O2TYF5+U&IR<E%P7T>SSET5QI5I.=
M.B0IJ0(CD46WVUH##`N(]>!.L<WO)U4H&J.E-]-PLF@IPR-U*>OC^8K9'X3/
M,L]=3VE`R@.525`M,IDOZ;665+L8,I'QW%#<IS95K%/M7C*CR2&E#(Y$1LV4
MP16!4XU@NKJ1A%(-"HD\.MV6408%?]-)_;&8FL)D%8B"7A''A.HJA!*?#^=3
M4HJH>`)<!E'T-EC92R,^$4]!B9/8G+XL:)>@G[,S(-9&21QOM/5DZB2G6P5,
MF</16BU]$YCIE79PZL$XL/GG`B[(@*^YJI!F3>NE\B(YW2I@2J19:[9[&\%,
MK&$KLTZ]I:5>QBS340%#E@"TVD:G#`SQ>.3:%F%>N/:OYB5&LYUT%\MT5,"0
MN2Q-U]O5PY"^ENYT.LTMP)"]<&XV4MEA1=(HO2=R)>QM0"Y_SG[GD#<[+;YZ
M?M-I]?9!ZANQT-F.Y:^W&W#UBIO1VHJWJ`"ZUM+T/9!ZUF:\U4G%<OC>C=#W
M%OD:9]C*S"9V@WD#![,\]]@-"^M8Z7*FOQOL^ZOLY8]U[%[9-SN=4'(&NQL6
MUE+VI?GB;K"OH^SIN9P$>>S%W9EC53.S6UXIDE%5#['TZE(IB&>V[;[PST9>
MN>S"#?K^(+"7-Y<H7?%/OAPJ0[]BY"6V!JR/.OZZAG\&DV+NIN!OF_`_8,3.
MQGR[X)_B>>[JJ)*5'6-Y:5`)N-UQ+%M@:S>ZU7,<BY?WF-TQX2HM\39J=HAA
MG>&;'X"(,=4$M3P!CEJ9KZKSJ%>"5MLVVG#G^5G@CUQ&_R16:9DN;W<7$]+&
M_)],F&FR2N%I6X8G]EBKDIS6,UI&NZ.OAA:25`9++C&HU-;:1KLTK$02$]92
M)*EFN]ENI!8B,Z@I05-`I0RC-!J^'PY"W3-Q`I*W-2C]05=)'M/54N^PDB0V
M(R]-2YJMAEXA>?DFS=0`K"+/]S7<#;ZXKB4R/,*>J4F\1TCR-A^'KI[:+II/
M3!DFV>"TEIU*]9@D(];6.MHZF+XPU_,@CQCD+!"6,QJMU4ZF<+'NUR=;;.>S
M<JKR]:W4WO,\LH_$MF'&#,,PWPH4[7;>7.3-;OKE0"XQ99BD]M'JM+>.2;;1
MIM=HKH/I"W$(PS9/O*TQ=<2I5)\^$V4#V#.:26`2BFK12;>/-5J[1"<['M70
MNVNC>R`>P<SDAWXN(*[9KI@Y*1M7S4C-[5;24XE,-J:=7G-'P*2;G+KKBNQN
MPD_*+VRXP`E)Z0"V6BF7L41D4PC2+%!OZE5#D(U)4^2AY2%<.Z8[)C<0$3<?
MBIK12VW6S""S.0SI)BVCU<L9#J4P9)NP]$[JF)(,QC50@1F3/SM<%593$+M2
M!^"RJ"@!(LTXC*TAD>T!2Q\*+(!D-F97S!USHM0)8"RC074=[S,9N(R$]9[P
M*_$N7R&NN<RB#F;3:Y^,O5O7X="9*Y*:&54EEI?:RE$AW/T12P%/D#J8_3[$
M(O=,J=76[8H%VD=!Z3,D@DJFM+5N,X.A)4)JP$C5KIDEW:K`%%]_*H+CEOAJ
M4X)N,SGQ31#8C'05*^'5X2W@K%)W'2@D78FHJL-;VH$I)%V%J$K@G?4[6\?Z
MC#UJ\ID5M0,_9W5CI4EF+:GI@*EQ8L0`2<BJA5ADC3*$J+=V!;'`PF0(4>N6
M@\AOZ#K]A=#A")Z</4.`'9)H72E]*58:]>O8=KQ3WD'B&D10TZ%-IJ9[`AI5
MY]@UW0#\Y50E9W5.[[7#K'U]W/O&=I%%R:8>'8'\AMB6K^EIS:[64<'V_/5M
MB=OEU)R.R%7C1M=(7;V2?0G=9M`W.261`]UH&,86H&^T>SE/G3J-3CMU"5$5
MT#?9BYIK"7JK54[JO/MP0\!%P*`TO&=/[$H197<3,96Z?"7,I-XZL7Q9K3,V
M/Y:!4#T#U>VXW7OFY9L:C7UGH,+1VP;SH<%6I;OKA*%6>A-6>>25,UY%)#`:
M+36,B\1DE;)<OMJ!1Y_)#37%365#1L)[D2M-(S//&7=BN=0ZD/>.8?5'/MZ1
M=#9PEOILJT9UP@KM;G^DM4[*UIQO<5V?TY2@OO#;S;/D/)[8[I0WV)V#::=Y
M+0%VK]BLSG"^%1%)[[1J?B-\5NA#JY51Y%7VP5[*NTZC#=3ETLGE<:_$H_YE
M@-&$Q+V`]JR63R+QS=,]T44?0[;+44-D$LNOF\>*7D;R70[#-GBHSOK?!/_2
M?91O@HGJ!K$2`>1.0:,%'.5:7-[_M#MMO55B\IR)_%/%;*MWN\UV.[UNNA'?
M9]:_`R^\F?#)S5'#;*UY(,"11WT2'=`(J3X0TQTZHI?\R\E*>>G4WH.J`:<N
M^MN]="J\GN%]2U9^@_O[%D^5[[GW7+1\/]A@0$R?;_U;U_M+SP=V2PNA`*Y=
M\5J=MGQ+<JH@V.TQKWL5NJJ0TWSW:'AA+'',:94>H[:&*92"6"XO5,Y]=?KR
M;4M.OOFZO+F\)>XKU)OM26[YPN4S$[AAO+[G?R7^R%5PV+[6;":W'A4A*[F`
M>CV<RN\]4\M9=/M+U&(G<_V:N)&@D<]4$F."ER)W,&T>D%IZTCR*4*T`IO1Z
MKK:Q%S"E'ZUI;0;S"Z8.WSQ_Y_`[3^X&B4NV5E__52X/T5+'BXL1K@1KB>^"
M[!)EN;.7:R`57\*Z'D\P9;SL'%S#4,59\M0-]-EDE"`I,9)5HBCY6</5**J:
M":0WX*Z>RE255VJ]U`4N%4*172*4>J6T`DJX7,DOA;J@7GC3)#A5,+%GZD&=
M*Y=]QM8%Z?M>M8=+5FP`+0YQUQS);\9\:PS)7@MWUV9H_IE=GHS.;L$,ZV]=
MTVKM^,BL0+8;^-*+8/3N/J.7WK_5*HX^=E*9Y_X$2(C_7CO+]^0JT`L]_9V[
M(G0K`"J-/5HW?8?';G#*)MQ:.W4+C0*@,YW)^U)=N2'OM=-WD*R@IQ*9_+U5
M:^FJBBTADWU]M:<.6/05\0LR(`RF\9E?$U=R'8I,#8L`V0HOTDV^Z9MJ]I<3
MF1ZUE^[H4,]*ZM/`2N;_17UO1%,U0JGGT+5=(Y2][.DM74Y4`&"4,6147?Y<
M[_9SRE:O$\]K"J'</5OR(XG=YEMD2Y:8M-JM]=C*5UGAD^97ND7K(4HNM6[*
MDM(\TI4AEAYU:\A2A.U#EJE$5PED^'V.O9&8QEC$^CS]R2,6M)TU.S-]^BR^
MJJ)`+U**49QV99"+W,#6VSO0TNN%M-2EL&N"AF@V6SX-UZW*?::DE'+H*<C%
M:5<&61IL4O=![@-D62:36J)4!?G:\;$SI)#ZJ)H#K0*9IJ8:6Z'/M*\48^4(
MBZ]\E,3&7),02]RCF+&>I=;FF]V4&(L3KPYTB:6M_<`K>X'9;BL1<DX,X>].
M/-69@I[Z\D5QVI5!EF8*6CH<[`-HZ0M/HZD"<T*GMG-5D)2D:H!E;\/9/L`2
M,:$<MBB"7+GL@4P"9HY@?G$W6/$UQTTC?28EE9C*./FM89*,7WK/7'%@.59]
M11WLF(I==]I.B].N#')9R]T'R&6WAJZ)F;>!B,__P_7F&?(!_A93G,Q)OU%0
M<(HF]0V:,M0KA%U@:2OUO:E]`2Y]$=!.K7VM#3QV<SK?0*T@]U]:QXSWOQEM
MZ4:7G,O6E=!>XS[S&%WQ@C>V_3@\*PPNOO(;C0J$Z<+@=LQ*N9O-W@)#<J4J
MQ\I\Z]VBJJ9VIV.LXPTHELC35%$L>%61E.P=&V(GVOD-E#S7IA:.=H7?,^+!
M4(B?=X,H2&-[?BA!;%2S72]@Y`D0?K:!1B'HG[ZS_0\3Y/E3F_QP-,9L2)U3
MU)B\?D`#:'**M,;$1SX=0Q+BD!<$^3]VCL,'Q\B#.##X</3=T/_`^^GS/V[O
MGBZ1AK[#X\F'_^SJFO8!W3U\.;N]_M?9T_7=+3J[O4"??WJ\OKU\?.2-ZOU9
M\_J$__6WORJ'%&+1VHT/!0AR,=6P38=`E)\'HH/I!R0>4L<BG'[CI$6=#V@#
M9)!UW?/D&]W@/I2`7T??SP2F-SZ\D/D/[<,QBI4$7JP$N0SY(Q(OY_MAL3.-
M5?K[,503B@53P@`X"-O8^,5#[D#\+;2(_[@ES]C"QXAZ"`-[3C#`I@\JQ8XY
MLW\0'QICQT(6_X`=[0<^`(!F&!X\$^;1`04:##M#T=L(8I4[P?Z(FJ+5B&#;
M'Z$)<ZW`]#T@C7W$/YOM#@:$'\/Q70%G&'XL#TV"ODW-$_0+$;7`H%Q$G"$>
M0E7JB*HL^A!;B&KQ*39.?N+Z\!<8"7(!7`VJU\22._`0E_7=TWE<6LABP?`8
M.1CXAJ;\3/H2<&R[SA"]4'CF!9.)'5K@,9J`#/B!,60*O`X/_MZ8F"3PJ<D9
MBCHXV:GNI8QA5S#N`@8"`3_)IJ@?>-0AGL<5SPP8`Q+V5`QP3`F/%VH'3G"F
MD?S";"YI#Q)3/NHPG"!U&]001L6:QK3-Y?[0"\8P2-`U<X/AB`\S#4=LA"GT
MR<A0_`:D$WXXQX9I..\=W"E48OQ+&#8(R06].T&<@X&-A]Z(3E"?\7J`_QR(
MURXO_W7))<I%,A,J_[LVP&-J3T^1-QWW77OAID"/%F.C:]'8S)[ROWGS5&T4
MK\3IHH>0:0[%#>4+86*R4+UM`$1_`E$TM`,0-_<KMOLG6"T??0#Q3!QNNZ9-
M'6$2GA]8?'X+HP,>(#")&'4K"#_"%(XLF#7C[T-@=`'5Q'?'<\]EBO0E'/#^
M%!0.,U"<$;8')]7SR;VD@XCG8_!3W@B\TES*H7>*_$;,&RST,M3>$P3Y%KJ"
MV`VRX/'X./:C(1K-?S=ZZ'OL(8+!W0%IBPSX5UE0'WS>"W?R,-XL_`ZVAP9@
M=B+\AU^U0N[\LU8@G&<A-[+0#A"9:,"[R+.?@\_B/LM!7T6XT?5C,4+'8IRC
MH'N,[D>N-QE!@`+E]M`-'5/^68MXM+E_O$;WF#NX9(@&13H+^%=A;8JY/K.)
M&PY8NE-(%4[2/::Z0A<$HCM7NE@_H2D%?8]:E+M<,*`%EF-1>C\*Q(9YR$EX
M([&[]1C=W)RC[U-9QC]="N;T,[0$OYQ+W8[X!Y;ZU`[?:$:"(CP,BS`.AH_G
MDKJ9UXQ$BA8SI#0&CFM>FHC@D6](@!0,XOF1;M!N&W.*>-8#V$R434T"$)HG
M@DF44<QB#/<V_'4W#!+X.,@2>),7E]G6"[5((CS-8Q*7B"B=IT6.Z]0F$$!,
M1L4[]-#2N!/D47"(EE5$ZWSPN"&"P4($@L&#I(I+T$)/]U^C2LVNSM7='#FN
M[0ZG"159U!(".N'-$$15+FKHR0M]+K%Y$C>-4JD)."Z>1$$NYD<:Q#,]_E(0
MHK)K$S.PH25X.M!--L:S)`=2IP`:+'Z*6,0W%BU<";H/F!=@&)THXTN,Y3%Z
M"8>+"T)X._<%Y(E:C?]"8W&V6@1<ZD1?!XR<;7*XO_<(0;>0`2+C[P?7!20A
MB0Y`J;EYFD*(R-#0%.)EC8"HN2(/9I-*4,@)/X,,NAC9`@S9`]^B3!P3Z,!8
M$B[T<.P&87SB78%96Z"4,0K"2VK(@X@,N708W&'8QG%#CD6_^-R&:P!;$`5J
MH18MM8PWXBB\B-R8X%`S^$-0*IB&C"*$_]_>NS:W;20-HY^?5.4_S.NCG$>N
M@FA>1%WLS5;)LIPH:TM:24[>G"];(#D4$8,`@XMH[:\_?9D9#"A0(B52!&E4
M[<8B"<ST]/3T;?H"Q&RC03$,6@)@'.@6SA;K=UUCAZ.H=7W`D(3QI03+);FW
MTKK1O'+OQ=I*QYFZ;CP`M3$<,\>9%/<DYTE&=Z1$WM#UW5A95JS"PEM#-CYP
M(@M[8F0Y">"0:UQ/,,Z'C,NW,YF4PD5>)7N:$L@RH[U"-$ODMB-F5[!N1Q.*
MD9))>"-I*VD1'K!>(Y>("P8^F@*LWI'3@G=^[,5H\%%$BJV.6.V&%^Q`R3N%
MX'C"-G0QXH%CM[$8(TS1!:!+X7-IYGPN5U\^?SZZ_%.<?Q17I[^<G7X\/3XZ
MNQ9'Q\?G7\ZN3\]^$1?GGTZ/3T]F<<(4<J@5,,5GXLK3?Z3X![;Q(DO"I@V"
M)S7(\.9'RX(9]S6?@XR;9'S:\)4X)^X-<8N,NG,*$JC]?MIC;NRJ/`3-!+7B
M1=8L?#T>A&@?@`B6O?PYU4_D!"^J.[?P.Z51&!&-?AA0ZG)"61P!CZ8GE%8H
M0&T(8M0PT$S!T16_C2U^*%&I#(@_?U_$>B5=\BTI0QBWZKWRFBR89%N-6GN4
M/-NW`WHC*<`Q.>]Z\.,M6<CSV)SB6#N#V+[-QO."OI^B9D!VO[)M_I)=4BGA
MIVZ2*GM7J8<)TLT-J;0J\('>PI]2'WXD3P6J^ZSW#UVE%;$;1?F06(<@<U[T
MTZ"KU>)L`@<&"6Z2P3W/!2FRM,B8=K(F?F$W)Z[-M7^QC7N7Y>"(KEMQF"M0
MS%GE@'6R+0H2EY>(F.TA3HJ\(Q%(SQC'<XF;@!C-/3D@ZP1P-98NR>9,;4?W
M6QC%Y(>]T3`+^0V!HC$TA@=>U!.,MS0"%/R=NA%Z6P?>#8Y#V"4^8Y%&YDE%
MN&"SXU'(7?`\=;F,P^==?6X/T)IX9"PA&/`\LA[$6@QTS8H2[-D0.0UR*+-_
M/:J@K'!C;<6E]INPTLFF839IEU)X<-NS]8/V!\-XL*QPC"Q.K4[A(I:`Y)[!
M`&V1]CYJZLK&ZDGTATE&,1I/7[7K")\;2]\GYV@"1Z$7VZYN[9'DQ;)EBTZ$
M1-XHIQJ==)N(D6+C[D#V4I_(U=,)ZNAJ=6]83<4ILN7#FS>1.V0=?(1T_E^9
MK48?IV=YB!;`<YYVV5,P(2:]>-VYYKWG71Q3']&W8.N#:6QY%XE+?V'GPDG,
M;&>2?]N.WI5J'2-,3LUL_T*]0_-05"-(BB/!!*%R*@!YA@[Y>]EL05Y(A]TZ
M1]TNLK2>5D28X$A(*/\"#O\E(/_0%;LK;&7GEZ.CB[P'2IL(-D$#Y0[=KQ*=
MM8QS9B0QD##',:K+*"HAJNQ?A&EH=".7X^SI,D!YJ;02U#.6`]EWY'6]H6/$
M[TQ2"+">,'HK.CX<=,;VQ*AY-S-S&M%3=W1L<T_9BB+((YNY2<XPSK%"9+J2
M'3N6Y4\B!UC2R3?`+F]%IC6.3'4-E)$=%SE2)W$45X=M3R.EP\$FAV/2XFQ>
M$W9`GY5Q%^6'@[9D/_4%^I\(XI$*+V>(36`[*9PF%4%A%T8U-9J>\"X%U(C$
M_09:JZ]5ADG:T!(!^2GG3=HR"+@VLG=""4DN[4BTC.`\8IP<5L@AT--U9I2C
M43GL;TFJH_I\*S,NKP22?0RH6`VJU&K8_)$8$S!XVC!2@1P(/$T`%A"Z$L60
M*SLBZ'!02.C!^EPT[BU$X,_J""GBB2U:B,GG$#]TRE"&4IEO=,$,/+Q)HVN@
M3)MP]`6@+>YRB@@?5>MP=\`HD+<L[SI(PR"+T;FH#@XRMP=.3:09';I\/F>C
MPK'QY#BVC20Z%\KB=^QU.1-+_BOMW?#PZ`G6:@#@OX,F)Y@^J)ZBGRT&W1.#
M.U,?V0A>@[-6#)MAXW$#/)C-_078%/J^6.DRSLHN6[,[S30!IOU?W/><AY[N
M0/&@I3X+4#8=0%%B.U9?@/IW^E8T?P-J3`<2,&DFA6V=7M^&UL1'=33H1/?4
MU<K$49W.CR88M6)@7FS=9S+K]_"PX7#;WFOF)6!&F*=(LNM+'U0'0'U$J!QX
M')[7WP`KHU5[8+S13_";TM;I\^UK&)@EL62.!&8A<"*<-QY(O[_C>WVI3",T
M!8%P0@,$<!)/88LD)BYM&X8$I"$P:L1,$BF]G3C*7_!+%Z@WI!@!5FW`IMD!
MYL#A^/K`X]!N39P&YDH)MR]'C#D::^SOYFC,W(DC9V9%.Q]7(Q\9+$>,YQBH
M<C6*7*:6?WF]>$8PC@=HNEPB_^P[<[U(T1,4<C#GE""B9#1Q/S7'ZQ?*E,O+
MM^[`\WL@+G(79GFO@H?FU2G>LM[`#JN[]C'YJ&A(((PY]L]".>I[BCJ5F36=
M":`XA1,"6@D<7GH;?R6SSX+CB1N(HV?!`@=:W7/IQD,I;71$T-9$>M6G^D7W
MW0:R4>?@+KP^R`7Z%!\)-U"1;%V4F`!'#W#-O$O\#E;;$,8^MB*R\F%>].:W
M1P'-7Y2>T/6C]HP^A3RT[V&NXW5A(LU@<;-"GKDYNFX$U&?QR@FFR!R>)1*J
MAC<WD;PAJ9#"-RB%-:FHC;"</<CY"*QTQ!:)<<M-$2:69@1:5(0:LG]7$U?*
M_U/T7*2\(*AGLPY'T5A]W'C%GFF6'$%K1HZSXP`P'JN9+OXO0'W+4CA)$7.4
MS82*GNQE:EKMGLGFRP1^V8E'+J;&O!4[]5H#'1:D4F25XM&7AQR=98W19*W`
MQ!C=E7H1AM#16>19MD=PIU3>L,MCT`THJKVL*BH[%3&#6T.",E/#V5Y!BP$.
M>>9K,_$-[$Q4EX6H]9;'[;!`5_O2W3B8$B.LG)@RNG'^D$8EQ+-&KEA0OI0(
M\BA)E\F2?;`HHCR*F1UB`*RY;(@D474RB/&"F.YG;>O*]JJS$49&K<R04Q/'
M$]\8\4./HCG(I-^CXT/^AEL^P^@`#@.I8^;0\]YC6Y,Y'?F%R=_!*NXWQ4?(
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MT`C<F^RPQPS2@072_FX3/^3!82G?!\9&,;HW8=CC5QNU?;T`?OUPMW[_]1>\
M9R[I,=?5/AQ!]3X(5Z;B1^D.?@;MR$!K^8$C=!"B'LK\`$\E&2$<'-<-AQTO
M,,X6O$M##6"'-$PZI]VN]-$UBQ>$Y#.-^7YC.$K)T=*SVGK,$%9W39&7UBO*
M04^9$#0H"T#6G2GZC"0UJ7Y*8^ZQ.UOYS[,@B]U51SX:2LK3LS?3C\M(!LO3
M]7%(KO7,MW;IQ5_+)\D^IA31JJ]Q'/;^.VK(6%M"?8K6`7:FX_ZU*I8/E4![
M30=9TZV81^X+^CZSP8G+WKJ>KQ^EZP(7S1]ZSP[@XS?M"_I<(#2^E;LNXRLG
MNJ-3DBV.0R1_`-#0]D0N%_IRK$#B7)Z5,7MQ%5&/0R-L'+#C4;)T-QD_,-P;
M\@2"T#%?DA%9_LBB):1BV2E8=BB-[%$N'H6S4)H@)0ZRW7RC_%KPN1>.M+?6
MRGSA(/B^9+T:6&Q$DM>.J>$PVZE96[C!%CCVG$#,&&D6IK&&TE$@9AE;F#7!
MMS6L:6A7^$=0`NBQ#U%Z(XYZ0]0.-"?(Q=)].,J%SL$[#D71C$9@76*4&VM:
MOUJYCA<<$!^.0NFYVGN4N\'>@/N<!?`U(QB!BR51RLR`O!PF=1-L5;W[*=WO
MQ5D4+I[QC'\3874CV?,2C'7ZJB\W<Q%G.OS:-GR))45NSPJ%C$RE_FJCV(E@
MQ`2ACX7!A#E/K%M?&O-=2C^WPUY"`@&O/VFS[ED('.-'`X_AB&VU:^V<?HZ_
M=MS@JXG#5T\=ZJ>`EZA8O#`A'U_VK`/&07V7+`5\JXLIP2P0-8<#+2R,/665
MQ&E$,Y!9T*XU#1SX<AK0`^L0@KKHJ*!IYZ3HQ,;JR%J'DC1M``E33M37&%.6
MVM=N'!Z0CMAS*S-C6(<JJB=S=ST9I1E7*E,I3\*.7]9BLM"C,:@9(08K:74$
M11!&>L#/+)8Z4>A:">T9D,INI1@CO,0)02H,,8X4O05@..ND**4X87(Q)9:K
MW&$'I&@$8V)PM43OK+IN'((J)##%#'UA'HG+3)UO-%_7Q`?6S7(9H[G<$4=(
M<@[S+2OZ_)3`-6%`8TG:I`EIZ<&2@%RZ2HF;5SBM/U6?V]AAC3(3&4PNI-MP
M8(9\/-5<A0EGOLB>.&S_Y(C#O9]HGPZ;/Q$U$Y?*<G8G,X$G]G7"Q9(3A618
M\AD))Y0YY?*-5?RX3H3JNFE,](N,FB+V3;ATJ(L\FP`56KH.9@6247^J'*,I
M<;^Q==0BJ:X;5.T);*6G[R5N0Q]DOU$=%Y2`O/YD>6FYQ%2^E8J&M$)Y%5/,
MZ<O*<`,BI7T+,$P7M>08MJ>+3H=C):5MIYM.[81M1YY)(EW/"3PUD#P?2?DY
M;D)S@.D[`G667('A<P`FA7N`B<C)<GA_ZR%Q70WHLHOM1:7U8^8G>U3I\I%)
M!@Y0#\,0)07SP6BX=AKGSG8J2ATIQDHF"Q.^H3-!F\"QT6T$9YCF'M'I3`!4
M/2FY=1!Z/3!R6>:X*@(@R[6O@5DPQD`>,#_Z]]>!NH192\]1X2Q#]PZM]AX\
M>1<K)ZBUV[E\!(Q)\\F12U&TM&XX:K[;Y0MPC4OD`V@0E2UM9J'NG$]A<+/C
M4Y8)EZDNG2?G#ZDNFY6BJ^ZN^!9`[:V?K4*%#].1HX00#\UO<O)A0@$2EB#R
M))<]IW"P-]*+NND0;&&Z-]89K1;53]R:*2:BYD,"1*6HPYY2F(4L(8YR58.%
M;,A;H;?RFQ=SZG9VY0%0DK\F[ZQ,`QWL2J=]:(*:V<]EY<>B!Q8C$A1@2,2<
M&<J)O5XTN1(,\>G30U11P0+/#UD:XHINN!:28J;\)IU0RDX%DX`EY!1,V1#A
MA8GLQ0H8*XZ:KAUI7XV/UV8@&$UOGD"P3$SLWVF8Y9YPD%S,_E].O&<5C:'5
M;)XNI)!*,15&JEM0UP/I&K]3,I8&`N*\"1,EZ*EX%#"2OU28W3WD6YN$D?$"
ME2#[KJR3RQA1M[Y8((&,IT1FSD&CC;`)<)U1PWU<<#@E.=*S^4$UD``9A15F
M`&H=_,<?<JI0%GN+02T4;Y(+0<XBXAU+T\EGO)"'%7`G?3]+.LI\1+?2Q-&_
MRY(<<='QNZD!Z#T[PB.">93[$T?H8>F/NRQ",@S>V;:*P&RB<*C*:!ET9E$C
M#M(GBI]<PE;ENTC>?2P^9JPS>2:LAJ4]<SQ)S!=]3;#])%SI=@6/"];SQ-@!
M3%3%6&W7JFWB!1R@UJ-`;RN7%89-QACSJP\U:,<>FA?D?6*./`3M/&6"H`@M
M"E4TSFR3"F<"]K5AB3DWD06!=9*L(9$^.(AC)_&(0,Q3`_B,6804D!M&0$[_
M59$37C!*M0Z(%P4\G/6NCO;'(<UI?"L^41)EP[%S&,,.;,FMR@FF8147U?QN
M&J-[IX9KYH938X1*N+C!8\-DI>:D1R_UX/1UL<88<T[SR<#)YX\G;^4F3X/[
MJ\G"Z6`C$I\4TR#4&TXA<R0?8Z7D(4-33@?F+SI#FB(&.+4/KW.H\$G&NTJE
MN[U,$$>N_-58YN1W)MV[JO\[WNKOLY<OEV@<ZIJ'*L*HDWJ^%@PR,7<2)R!Z
M7#BM@P01G[\-4^5R[EA^62<HU)J]RKPRBJGJS/*K!,Z"5;XPXE%DFFA1^1#S
MKO4<12JT#G!113^C$0%*"BN,B2ELU_%Z\:3O0DLJJ>+:!<>U:ZM,^:!N4H_O
MF96-9C\*7,BG(!2\9.G=>C$C-I*=.V7:X/U*J,]-(:,AUO91=J(40Z1-'+9.
M$`]([>%F`_==+AR:E>W:5F-O#S$S_62LD0&CLI#%)=-X*:M17)D,?.LDYD(!
MQX$NT!0;06D5]]0^5)-TS5HY1[[3024?L\EULW*K>I-9=`69<RP3K+!BG9#M
M#DWDJTJJUR[0.+<D#`PA-_5$OFBNH*C2EG7\L1WY?`\`R].JO0T*#J6&<@P\
MQXS9(<K9,G,)<8YV*1MKSPZ)GDPRI\QS[437>4`]D#SHFU:LZW[X]N0B*E72
MN(D129P$>,=)S\.00^HU_I"&,3V*Z)*#$$RDNDZ%HEL`@4G#L">,<I,'9=7&
MI;(G$5:.0*TU4N8F9W-XD2IW0,0U$>!/)*7N-D!,AA3;E!61H(.*YIFG\]*R
M>/\[UH)Q+11DZ/NDJ,A8J3F3-#_$;)H.7=(/0?=A0D_ULW*'O."W>*%R/>![
M1-):PT`&F>#5@VF\1J!'(@['DB-:V+UE'C/:G(KE[;E#*@JL8:/?/535=I"V
M25/C$B&P5+6%:E&L**+JU<>[$H64"8\:'C6U<U,@LC#SV-Y-WS6;$*;,H[@9
M.R79<I$VI7$6(B%AI!I[V,Y.Q2AH9`*0^"!&N'%P!6$F#.@.#ZN,4D@K8S.Q
MO+=&7R;YG'+="AH4"2X'<D8\(W8Z*PW!P)+%@MK).EA-&LNDP],3]:ZMIRXE
M>?FRWS,X:`U3`+&I&/#I4>10PH7A.,:4#*V^=Z/2+FE8O+Z()C&6>:)1XEDI
MZ$R&H75C.!Z$C/(ABK<T<--D`(S^OT01RK_+;5XBU(O4M6B>WX14;2-&I9,8
MM`Y`))>&-^S`;V3O$<#D3``;-)'YS<?E6Y-KRD)WCG39/^+J>U.*<E&)[SKF
M=LSTS`X?^L2Y]<I?I@IG%C`_VA2'L[W0R>:2`$+;YQM+,YMK$:KP;C5WRV5R
M/%6]&G6ONP'BZ=GIT5-B*CC(:=+.4)F/*O;:G2CG$$^F9I&B7;=#O^M[17'6
M67FDK`X%)D9'FL!5!05RI6;!`W&6!9C!9+*7C865!G@]#[-I?X<2'D7A""Z5
M9C9+H&7UPK238)T)N^39?V44JC6U>'T/X)%1-W$/FTO^*B@/4:P53IM&!^?G
M@M.ML@N9JW9"%X87ZKD79JLA04MO[A_2VNDU=3>H()Y81ZXHD%+0I\7SU&?'
MAK7J]KRK;CYUU0?-@^>L>I6'O1P5Z4#DF=+(O\)_R%=>.HM5Y=(JRM&IL1;H
M`PVZ]B(I2]7X11R++<7D"=$L"927$,L8L.-1,T`,W<^*MKIQ9NB=$D\B*:GC
MN&W[D&HNJ(?SF0H>4R[=/^$ZRN\)7"RIH2Y(I2E)HRFC8^0/RR-"FQP#-<D=
MOG$8J<:+N,ER./+#.VEJ1Z$J344RL@CEF\A5XHF48"JZQK<\<:;6Y9)%@ND%
M;NP[#R_*WTQFMR/W9U-E&\U]G_8LDBB.C51^CU6L=JZZ%,FFWJ7C@`L!VU@J
MRR\'-]%R_C:6);9>$-XZ9XD",5Y\H_J-EYB6&8N^C+$;]?3!2^.4_+W=D$LA
MQED^@>I&J]Y>2X7QQQ\6[LRC_>;0?GOG^V%6UD]K6:KN##T(<K=>`]'91F;(
M]./DHN:YJYB@\7/A\UDA5Z)Q9GL=D+H3QP)KY&??C";*Q2--<KRWKE&55?&?
M7(T*Y\G"*`]>UQBP'*%+[F-+RJ,JC68\)OE+[Q1PV$G)=`Q"98E3T*B*2X"U
M<15RX[RF.@EJO>S]MFIV9WKE6"H)U.-"BZ9CQ]9>R]:]#PMS'$EQMUA.(9\P
ME<E,Q8?\108C3K$?CUJ4T:0J$3M/);!(<A%=4]@2WD,`/F8"P;K3*7F&VO*=
M_K_K8LFG.H[@A*X"2R?@KB=[+#A(,::(R,,]&OX&QHSJD*I`.[U"M,5$?C\]
MF4R]P8E4_QJK('9RK_M#1\(JR=5D!(".7F4_#U?.-8;*,[I%K-']TM&$67-J
M[*,+8]:43W^?A/H!JRXR<3D][<FU"IX89S=\1SYF7;L-W=PS3#*1F1M1CW4X
M`EA<RK5M1B>KK6(;#,JMDK,GU9CO'K-;=5E(2HM0]7A-#)+M>%&^#7679LUN
MZL!P9$,?*WJ8,GK&;IGZ>M[ZF`E?O"GP2QKILFO3P]LY*V'KH':0U138VLM2
M>QR=BG,PK>;`J;;1*&164JR.J7::>1WT99H.KL04(MN)P#+V@!TB!7?TTSQ!
M3NX"7`,PZ4FX1TV/67(OJG4^;70^\#TT54G4O^4NDY@R_X32.A[?A%MM'3]D
MJ<`3+*D4)78NI[6@S)A2L5HWR9WXG&#!7:ND^4RG)E>)8VO_<-<NTM&:=F`F
M.L_1\U9I-F=Z<\UL9=IY84?;4-&IK(28_2(7%THHA)D96ER0_SV]'<#'O/+X
M'!`1]?_F[LHJ83>74(9]">_TY:"'7)-NQ'2[0N9YUF)@(M!^,7@;_8<Z_8J+
M9=IMP^8.P"\%%UAZ+2UN;"ZHL_F$!E**0_Z'41:R2'E.,S?QGW31[5(_!H^N
MF545<O9BF(@>;B^A8V+<;],*BVM33?F]\4FK;P-9ORKV/[MNUAVCK`AW--T+
MW4(X/(RI/.EDEEKE8J?,2D9JEM65*RUF"M&I=W5F0A:D*0,X&$-][V]%L)!-
M#U/Y[ACAHD#JFOA"R2UQVN]CP66T_MUORFC@HMTA-@[&C6"?P!!;'>+5*7?Z
MX'+*C"PWX7H4]'J>"^N*%#B_=1%[_PUNQCAVHTA7E6%S..,1K(#%E!K,?7!,
M'2=S$27)$E*!.)P`B)J9T4J4[R.K'#A)*13&+-5=!%_P6RFB]567?"E'J(YU
M7%V1C,.=.)&C[(12K`.?$G/%0^'-^"D-M%<)<4XYX::V.5<$$S2:Q]Y<WF1I
M:$B_H`H79^>^<V<<2=3>A/V7S!7I(MQD[<E;U<9%9^YD,1@PZ3"DUII?)75(
M=@.Z+C<Q'F9Z"H.@N)P8%Z.*FX'T2FQ/,S"HT$\U7S)-,4<CB3F'6.H/1KMQ
ME5,WQ/)@,M:Y,HP2U>K$PHD.%=<HZ0##Z&,T09S+_E0I-<;VH(71BOI>'^-2
M06:2<XW7"O`QW6,0*C<S1V/(-.^!LY'X*OSA*+C+7`OHS`36X],1M6Y;IFRT
MP5Q6)BK.#5:<"3)7T;#%>K#*V>*>P[TPN_@O.%@Q4+(Y%L9IU/<L=IY)(Z*C
M>S53B-I.N5R/;Z)'K]2U@.TY.KV\FO`Z8ZJ6JVK\I2SYK(:565.E5ATU['I;
M70S&'*T#FIV65J;II:^8LA&@UXK:V?D+@^RIG.@(KRA4#7.4/!0%P>"XFC/@
MF`!UP2B[<XZB2^)PD#8,11R.XWT2U10HJ_R;5=>IY`9,>:)+)TR:_6AK`+ZD
MSRJ.U8A3DU-6W(W;C6:!O-1V0W5)5<:>Y!97>;I3(5^%]>)RKUFP4>Q%KJ.7
MH\]5CWJ4^6;.C%@SW?)>Z]9[)^$P\Z`"?7(F'`;J\`SYW^S8/"JMF@4ZX[1V
M()^&(%=9MK![+$"@0D:Q,W:N_)W/.>FDNRJE,X?FV#&[HRI`3D%LQO-UJ+AC
MF^8%:']Y]O[H3<7<?:Z>[DBF:^/?]:515L?I-*OC5#HW\O&TPD7.CS\4AY`%
MO>S[D7O'7Y)#H:_8@#)="JNL8FW)?(+WO:H@L7W[UI%4D</$Y#]<FMC@N09D
M.9%9G-S+3S(N$,[WX;7$6<HS==#`\$JT9;KJ#E172:;$9OO]`.$I?V6L!:?F
MH"H*G/R4+T6S#L"XYT$/9'/Y2![8XEEXRSP+.T(P4[LZ.=97NQPP-^3\9$I<
M#O%.`XL>#=V1E3_-EH7.?D$R!6WC2PWT%1J)BP$4NAET:Z6B&J:GN=*+V2FZ
M-.S9X#:OWGW,ZW<@`.`;NK[@FQDY`(T<I3@B@WTE5@>GV`PZ2E4Q9:."Y2`J
MVF3Q/D0]+`?.T=7[/#C77)$ECTW4)F.\)V$W39QB%4O*"*`&IK0O5/<8`Q:4
M(X!#!_#"2?=!S<;5T?_=+'69/$X]<_\038D(*MJ*CUKY1#`0U`2M-#STF4NX
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MJZ1B'M$]JM>4W>(6#*/*H*C7J7.II$@MLHZZ*=EU&5<`TRG;4V,`F.)YJG:W
M;4Y8825N'V-)C$70:*N[86*F8$[Y%N\;(:-,$A4JE>.)]R#(4E^RPER*)S[,
M[;3[RC$UVY`\,C=W&%FE4TJON[T0,\NL78N1`5^:CQ<=Y'C1J6DR&INO&\!,
M?@G#'F?T84LG(F)B3O'C'.>@@.,HYW]L7#OLC#3)^\@Y5,CKC9Z9&M]E11-8
M@6"ZI^.5T7Y&Z+^Y`>;I9WO&5]!-)R-UCS(FBHD=RUW%%#G(Z$-=QB3;Y3L>
MFOX89.O+;U:C>]6^R2S$7@0Z93MW5O=5BB3C.UJ+A[+CGI4-CD93&#--1<."
MPE7L<0\D^KU55AXLD/P^Y+W0-PM_8W2JV8,I8.*-%EZ661OK6*4_6+$QA;<R
M70XX4!>+7LL"R\ZU?!DI*#/P'U4B2^IQS:HP;E7'@KLY'#!:$%!GMIL&S)G,
M%[#*"G-YN@%95C9+,3X4DA,M2+`X88>;L:C[0J*`7/TRBD2R*Z28:T<N34AW
M=DI_+%[5HVIG3M-3S#:9X-6DCMKG:]K5JL5=__$FC7=N7'?T]BI+8\RXRH7J
M)7L-G.V]'W:__O/''_[G'_J5TZQ(]6EP%/2.>K>$D.OP2%=+C*^XD[L\[UM/
MF^%(I,*'2]G_^=4Q__V?CW^>_*?5V`'9M8-4^.J?2\_E(,_4V?GUB6CE6.+I
MV>\G5]>?3\ZNX4]Q\>N7J]/S,_'IZ/WYY='U^>7IR94C/GTZKI7D0J.\5RWG
M@0IH;39U?B=2[S%W9'?$Q=6IN'`C.M_XM[[SS@?-2KKCHC;9?,D!N!='.K)>
M\^+\.UP936=`9A>(63R^Z3K'+4\X_(%,+7WU:H?'4/0D71&%D0]<M"?SS22X
MH0"6O',%_6IJ,^.M.6JDW<@;*9N4NWZ*E(YYAH-<G(_=KG/D)JS/7E]\KE0D
M5I$F2[_>HPN;NNRD#DR3F)JWX8I/7I>"::UQ6*7-$[+8QO=R;3P]6`V0VKT!
M\AUAJ4$QI9;[*=H(H!>'=ZZ?W.U@Y*O#]+5#)+1M]9?0-\+4Q9A59Q@,0SEW
MTA%\RW/2S=O(#T%,8JP:%O96@BN71IHO"`&*9MB[RQ[I3R-)H+Z=S..:&*FH
MO_L:A..=03@6VRH?6L6?3F`*1[^6W4$0^N'-W;U(>JIFX7*BS;*1I%\@XQ6;
M]^4P@G#G@24.D')>6U;0@GLS497=@"JLD7ZB*W)F8^M.AGIKE%F8#:3+@VC[
M&)6H&R#^0/VB:[N3!L!]/K028`U;<0A,KITXX=./)Y<<8+NJX>QRIS7V1)@R
M,';:&)K!JC9>EJV4Z;W9+0HH<UO-VIX)X`9(+(ZTS6&;-$WA$;FBG_+,@V/T
M23\%4MNA<CDJA7-B>&XC5[<:4`19RI<F;)Z"8W49`SFF2<*RE^>6+K\DKG6E
MR4N)4I`9\;P\<Y:A\@C0%2M3YCRV_H!'Q,DW^\#2-CI#U4LL0X8*:&(W062'
M8S`$49AK+8":W/8GD415*!$#Z&@4RMCD"#>L*9+&,5?4],.Q<K078SB/3811
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MM,9>M(M!&(\&V"3,ZV)_!+_G9&6KR6V,+"\G@N`@[[<?$U[:U</$<Z0DCU5H
M4]58=\PI3;@@,9)QA/ZS0$^?=9]7QISAD'1)`$R2PG?<(/"P:)8;65P5)RZN
M=.L0;W;$#6E](U_VL,+9X&Z$QQI#3K'6`)9>RK-O4_C87D[/B%?*L`NY_"UF
M80'N:X+\#A2;'<@PC;'O#F+8(@"N63C,"A0RY&.9_<(5@8Q9>6\(=B7"CRJJ
MB.+@AZK<V-XA[Y=UC`=8E!4X=4Y3L#+$JU-+IW;RFMBEW336^+R*2/'+$ZH'
M5[9F(8/B9L)YX11[+XA<K'*C>'<%+/E.);`S,6=52">\&%:7)`S'QO/J)5H"
MZ]!?[`B=<+&H3%X]I/`6NUFHGC,E".B!DC#\2JYE]\XA+8?2Q3A?4'F;J8QG
M#\LL6+#:Z2)T-0;:P(VZ[V$(:>D1IQ].&N/3(5=*LZMOX!XT,X\(LT9F'IEJ
MU;F0B.H\W;>5BD^#KJ9GBK^K<#-Z92JRD?SS1L7C+CY@J$=#OHG!IR^YKG/O
MR:X9/=@CGIG<C3G[-6CB^#&JS.%":6;YY:FP<>6!(#D0R>PD\,R9-#,7SG':
MP<L&U;Y.QX`J=Y7[&&!LAN0A&>@:P[I2)'G&<HX+F'1'01J;(N+$?8P;+6,S
M4W%+4</6J)G6HY/((F[\U?&EN3AA/9CJG-[EH@2RKJ:X^(BZ(?+RI@-@;B(G
M-770"OA&.Z^$9'6$+$@=XROBJ\!;3::26`_>_IF^&JH\BW8H\BZ'?4<\[*)Z
M;!UT9:?BZ]&HI<M0U6&)KM.R8JT*6[X;)\K-Y44F<E.[[$S-,*L2P82;BRZV
M[K@A8DQL6ZVE)DXXGH+55]06LU*C#],#)<5H'1*0C[D16EFTALP5DK4JZ:A;
M.+8R$<W81#-*1TE7:9`Q6I]!]U&RH"AQ?<**C493=3+F5JY18/85B#;)0D:"
M/B9$\?U<9LBQ*,KJC6,_HD*"88[:DT.^@>,MS&1EF3+P5R&')MSY8VE\/EB]
M^)'"+HJ.<MRO9G,!'71'GE?24M!,P:!_U#'R[>OL(#RZ!AHJ%X%C@AFR$*"I
MJ=^!U%&5!5JB'0KX`"0TIWWSY!25[^`SD+\FR[-#PB#C+:NMS6X#1Q6(\CB5
ME?[E(M4/<3''Q&!VW1&F97/)8`5E7*S?8OQ#BH<`PX),3)!3%`C*SDCF(IT4
MK,)DLKAUR-WI"-\8YG$UDETZ5^0Z8J.-`6)'CU520&RUZVR*F4["L4JC]\UZ
MU`[1=3V8U*:F.*T@'>&?6\W,Y9IC^T70;[/8IZ@JCJZ0E.KLZMC?A,-LT=<4
M4I(5!:(JJ&S"RI=NX0H#5%EEG*%'7W=.'`BD$WB.>Y&`]E^@+B!L,KBA0N9*
M-&?1!58[(<QJ24Q.=1C=N('W7QVRG"MXHCU_J@V-JC^B#J+KW\4>!L$5E#AQ
MLC;/=H=G<S&RM=ML<RMEG;MIDK^9/*AI4-$!-!LYT4%A6I&(+&"#=:&\!I,S
MX+.K[;0*<"LLV$4Q/=2RC6/.J5_KSHC=LQRA"^3\F9Y`3QE?^(Y#]5)$7>]Q
M0'[?XFU%C-!HUTRM7/:!#@#N/^O67J`:045TCZ]Z567IR9:&8%?7N4'.'7`<
M3D%4@O.0M)_R!F;H9]=\,&_?TT490LYYIFL=.Q8!4Q[X,I-YKA*/QJ91=RPQ
M!1-IQQE=-_*3N4M?+5`KRKWA3AOY!`,OGF;S3526^_WT)//=*S&B?*M#](UR
M+CKP5#1L"G,G9ZDO5UQH=;ZB<R`Y/4[R5[=GNI"6HOU<U9]D6?+#A",\3XY0
M:5K2S/U<<8V(9:XM'CCAJ"N5:<6E,W-Z0K,F/F(C:=C_,%*IF/=\7;0$^USK
M`DJY3IZ%/@+M<\<$?VR9H#J6D![)W0>PW1ZVN,(ZSMY0!_MI/'#%EFFB4Y.0
M*1^`,&RUK!MJ?95L[M:TV6-5.\^"*ZED/K>GMU5E'6;!=7,]$W7,T'$'"",\
M32E]9<CR9H"4QG+X<'SDI")N!7%TY,1M.^AQG)UNTLA5$/$-DMT0HU'_JU>D
MR\9-PB?0WK,C.TP$F#GO'`9LBD(5^+9,@(?1OA@&;-U(?:)-#PT7",VTXJA8
MK%(.BI0OV>^'T91@/TJP&V+!C1U@>S=25P29")O!T"O#*I@]:)E(!IOJI*-G
MM\R\J3:=DV^/9!I:H?J_[=V^GDY)\'OVLV:R><..HJ%N871%*!R3J-IH36T%
M4!,?V`^5X]-L_N!<5'%,I?1$=_<0@ET]R:?1-[^%(XSDQBAN5:9!=X+4E8P2
MC_N$QU@.J:NJ[#JX9:#G=*GJ0S[DK">Q6W1D4D)4['0ZU&H*YAO:!RP?[,&Y
M1V3.&GO(VJTXUSE!K08KWN.YO-]-GM+T#;\TZ%+:/I4KX*)K)LW9QE]N7OO>
MWD@B5;`)Z5S=FI""2-(J2R(T]"%N=>4NW<?4U':+Y*0]D_&B*>)JLDH?N_5T
M><Y,J.?%K&.9D[FC,G7E69DOMQ.'42<SLZSFT_E3J]32:5TZ+(E%DMHRC%TM
MT>_S9UV"%!D+%GI$G`<F`=1*0>*/*GDZVVN%:T<%]]^)6'D1B'BRT\Q^X,P/
M/BF?,+UK;)H&J7;63/PT*AH7UHA9H8>LVA(7SE;=FRQ?;0`,%ZP?B<$V7*"B
M,+#_^5'ZN:#_"^6TO/`Q4R#HG>@&TA^`O,`4@1TM6W@_5_KS_@O#-U_E2O[U
M75!Y[MY.CD.?"[(#=G/9`1>7YQ<GE]=_@EW_Z>CL6AR=?1`G__YR>D$)`Q.1
M]Z4H$K@H9$S-+YAME:59T/6]?-5IO='I6AR`\ZFQ^S:=0!!G\%3\^NWF;'!^
M7Z<MB6L.JI''7B\9O!4'^S_-`RQ(9=^/1RXVX?CY59T_CS!1@S];DT5Z)M)S
M0()I)';"!/3E=_:SO8>0O6P,);TB2-2B=AA:P,XH@>4'X3AR1S^_XG]7`UF'
M;O`-8!WLDX+@42!F3]&FPF&7+N9QWT+<MN#G5WO+6(26_=EB0`E8?TR7%[*'
M][A9#B#+AKXW2;04_E0A>XG\:BFTC`KL^B.VO)"5<\OKZX_8\D)6PBT_T5[O
M;#5?V#/]R>O+9Z%\`Z36BU+)RI4D"H#,4]SF(J#"]L9.]IUC>PHS[("PN8DP
M_F,'D!!&;\7_T^WV^]WN._%</BF4HV2O\=-">.8G-^C-NLEJZ@7-_#PB\V4_
M,<A8$$1;3Z=V`TE],:"TZ[MEP<K\^[3J^2LZJ>AD/3&R?()97RS-+&O'`R^1
MSY>TBUC;^]3ST5I3C=2&&&4@L[KQY5!B'MCJU5.<4B87`$?3V3U\.K/<6!6V
M-&M>]NXW#V;VL5:[7XK=7Q@8C;;8$:U##N=<"X2\O&&YB-5]=KL#+Y#11-Q#
M1>\OS^W:>_MK@HF5HWT3=_^PN2:86#G:2[+["P.C!:)N?Q,E78G,.JQ1E6)\
M=!SVD[$;/7IYMSGD518>U]BKM/GRKGG)>U])MQ*O><G2;0,EV^(N!Y<5'/(Q
MC0+/%,+O>]_P[YEW8=4A*T^+"EKAT9D'S`6RU8/#)Y^KI5'>@F+22K^-WR&U
M/5V(5]2V9EAZ.=C:SU005HZT=;2'*X5X=<90VSELM-<$$RM'^P;N_GZ[<H24
M=\W+W?TU0\=Z7FI6!%X1>$4"%0E4)%"10"DMN*69K)]D'+_%YN`I%6:R$Q=%
M#VOZ=3VJDC3KKJS:M*X\<S/!V7+VZ@=//FDK=Z!4]+9V]-:J;A[6U=^Z"!VA
MI,"5`W$EN$5NUMJE.5.KA*60/1)`HA>F'5\NB9'/G&\X)X"+C#AMU9\>;UP1
M7$5P\Q/<W@+OCRN"6P=,S:`YE`6\LB`OISV\H8J;V><-K"FZ3DOZ8+E0=!%M
MJM*<J[!-_:0PZJY9KQ]2U_.M5INZ$CGPUUZ+_\('MMK-)G_*:F3KQMSW\955
M=IZG%#/5<!Y%H\';"VK_=TF-'.&E2TD>HLOPSO63NV-J:)4O_RR^#?T@?HLO
M__QJD"2CMV_>C,?C&LQVX\N[;ECKAL,WN.A&L]5X59*BSQW\XPRK-K?S59N/
MKK$\\^7I+[]>7U'-YLN33_`=_'O^Y]&GZS_%\?GGSZ?76,3YBK#>F9]>U[_]
MPA^JY#IVF\3R^5S^7H[<"&O:F\8@;F'+`JL/MMT5B1H46:T<5/7U_WI!5]SX
M*="-72_?*BM/E?DCF:110.=,?NOZ:8R5Y,=AY/?&6/\_-[]NDHS]=;CC&G<O
MMD'`W@FB]1.@@"B?6Q&+YD_<@<`GH/M2"FIB@!U6N+^>ZC6,?0U\;"VAVPOT
MI&K@0)V8J(.H;IM.34!IL5@]WVID2.U)N#EG3WP&\(!5[-?$K^$80(Q,I\,)
MH+'1!;;<2U1G&:LQ^/YKU4R:"\L'H=59(.SWL:^)ZO^&'$O"<JC%'SUL#8C=
M>JB&OVX1P^VSW"&8K0EVY(M2;`%#(ZG>:M3I1;43+"KBKS@AL$3FA+6V[C:3
M*UK_-`Z5*U!_CHUW/F7=>,I;ESYC47LY%G5^_>O)I3C^<GF)G.K3Z='[TT^G
MUZ<G3V9'BQ:?Y6!11=V-#)GI'E*JQ5"N/9-J!".VFJU]ZA)(0GCWH'5?"#O,
MP)B!:,+'DO%`\,R:B@3S#"28(UF+IH'>D2"!^<B@NR;4NY^C7DM\DG@]/C^[
M/CW[Y>3L>#8*7G_"/-8MR[C/&,@17[K8JPPY9HC-<)BO8P(B=A&0`BOAYV1M
MYPX;?DTT)S7*)+<OX39J1-V:`P/GW0+=,Z/IW0*]$CMO];P>-22AGF3Y,7*3
M-NAIT@2L'ENZ.6:N:^&MZH!";4GZ*)RY"=<C?1/*Q\2*VAOLU>=I;Z#@VD%C
M4L.Z])8'3RF<B^/\";OTI+N1/`*??S$U:S7?D^'(#[E!'?&A2+RA4P>[$[E=
M5:%ICL445@R>97&+'6T9J+I(HRXH<W("44;:5*@R$U^'B>LO^!R\W!606J6N
M\-;2)=ZP^]<#BYHL"#<+\A\M*[<UGR=0O=W4=?(:3J.^]YSY9UI%.5?>VM__
M+E?>=$#[7M+*7RJJRY:I<.R*EO-T?#]MJZQK&U`*F^W%SKC"U>QLS$H6OB\O
M+G,TP>]N.&(K@B_GOJR(OQ>M885H;;?GTIE*32*;0^P+WI67MR>F6CUP`AY:
MVLMY#>;<J"=&RLY%D@^$'C[95JYP5^%N*;A[8?'Y4&C-O"X8.RKGR7LP2U3>
M0];MTR/I6L[^@\Z9^<*2GG(ZUAR!\_M+*@3FU1.GKA(XEHO`4@2S"<7'(MDK
MU6WA:2".TAL8W*'+/8KZ(%Y)]WMX[0S0N$'/C2CD@B))</9AX&'4BHFT&7O)
M@.,OAGPG#L^%:23>A_@FQF1XD>PF8033?XYJXAK&_Y<;?4WA,SYW/'"]"&"D
MF\/C@2?[XN2;[*9X:RC.Z=8RXG@U?/LRA"D2\7M-'*=`$H,[1_P6U?1(^/*Y
MN?U4+U,022PSD&.,];GU>M+!T!)XD*_LDP$VWL`H&C=!9(P]W]<K[M_Q$GMJ
M+;P47H:!34$DZ+81D'F+Z*'1X..=Z,AN.`0P@)BQTSO>R>*\8R_67WI=;^0&
M>#L*8P*.*:X''P1XNU+B"<"`(+?;I8`8CF/R(MS56[K<!5@,B,)<^D8ZX@G+
MT.+`VV'V#MX-NX$*6@BC41BY>E8,X$GN-#1=%^\0<>LYNBB2?Z<R3B;&?JT#
MKOJI[^//0+2(!MB4H9<D?,7LCD8^R'*\[O3=<4U\`23S)6X!@3EF+T8N[#9"
MT[MU@Z[4,_>]P/4Q#FL4QA[#WB>(*;RH"(F.OG2FJV$,RD#,NL!:HD#>Q2:J
M8/\=!2N]YNOJB(%'2M,XCBTDT[5Y3_9EP/MD;R_>@X?\/:!G*EPB'844_"2]
M$2'6%>,(L1:(%%&4N%\I.@QCIR@XJQ",)/SQ!XR44V%G.GJ*D=:C,#,O3LS1
MS6]&`?&Z\$H*9RX>N+`)&*&&=_'^'2P6(\R\0/)S\!;2%>YB3)?\1#\^Q[!T
MS-[V/17#16C0&\&17EUUEYK"AG(L';YK7NPR::K32[LQA6AB"E>+T\Y?@"!-
MDKX')*C"!O#,=G%+^".&*3!D:OW92,Q[5/0;BB&"`?DCD!B?&P5JCD/06_K\
M#6$O*)B!MI%(Z`B/.P;VP3:?!O;)PQ>/8&I<(?Y]"<>(0H'>W\$&`3PT#YYU
M]1#3`S!X6BC\JT#.G[+YA,WZ1\.<!^(,FR>A2#IP5'#TI(S#$61VKV_ONNSW
M.70%40V;])L;I&YT)SCBJ^E8@@]^S4NV>R)A&VE*\Y5FW8XE.#)SFM\;[U[S
M>2A\#,@:N&DL>Y)/:A'X&J1B<!S1(X)B^2\:AUH%X'/L]C@*,^X.9"]5!YB/
M.@;A`(G^EL+Q;[09$PRJ];!Z$FD9YXDUHRY>#3`+>[BVCD^%[Y,!/*7">3B6
MASAH;C8*8\TF$RK6%+9&<S*M3.3Y.F@T0!B%R)OSJ&QFE"/+9`RSG79&^`!8
MLC^O%)GX9U+M`F3I&-*,X<QXC#!D;&^_S3%C\33%S]8-D*Z(EA"H!_:O`*Z,
M6>9@Q)!@6TC98-K!E@3L?KO.06U*@)*01Q&]M5>G7W++HS"X!K^"E!@G&$')
M,=VY.$[Q*\E+";OI(:L&,$@!0+YC$`?Z1X2A?#C2Y"PH6T"ZNF,W(HDA.F'`
M,7QT4$*?8M3A?;T2C1FS.@[,221'![I^'+*^I>&(Y$T*T\$L@>Q[<&2C$#8I
M0!7`B&(`FV5A+`./0N7UJ9M0$*<?KN_XS&@Q,<NA:2FB,H?F(S#;H(NA]NK0
M6)94@3&T@`.%<UL?+;X:3YLWO\ZY#EZKV9YR\)J*?]P[>+.<NYS%5AW`S54$
M3URR,[1D\6+;+@C"8(?H(F&]'BRU)/(XH8:LE'1$!(H&K!>2/T-ZC&?OF]C>
M>RV&`,R`+#")9@`J3MN-`_.]I;=8>A$.DYVTGAQIJY&)!IZB..>^.:?JQ9JX
MOQJB%T.^9,^+FRB,8X0=K$":HL"LPW-,MF&,3Y&=D!K>8*F2VV3,:%MGY".6
M@>QN(G<(?X1@8Y`SPXTB-[@I9ABOM?-CPB*3W[IH'B?N-^QU&L9LTUU)MHUW
M#P\/-0Y.46M'._\2EY#BR#VYR;)DNOI/^ZW./6VWVN.8W0<Z,<RB&F7N#G!_
MD!+(S`[]C)_`=@`S0I++W%7C,/I*W@H@M8A-C0[Y>]*$MI),>.2N@]#O*?='
M1F+$H&%'8R+*>U,[])CP^L)+Q%"Z06S-[(>Q5)ZMO\).S&XMSCVPQ5<A=IQ[
M8$R<(.TTT*),/6&=QKSI!*O,22XOH?RZKHOY$_!C+Y7,(&Y#'\X2"@4`%4C#
MS*;X179FZ73\$H9HVKLQ)M+!"GNP$T&1_^&U,OCM]WW<.]AW#\6-GPZ!,M,A
M[-0M2%WTC%FGONO&`^RL"$=''3H8V4W8*;A]]-KV$9G'"CE93A&)Q/;[XG?Q
M.U0H[,=5\A]@!G-->IE'DE(48?5>/[]J,D+1AT2&J+$]>S5QI#PPKH]94O(>
M-[35"B/'GX.C(USL>P=!'$BV^G&/QO`N+BP%3#1W,S&`=']LR/U8G;2'=WA"
M0CMD^YHU/X7F!MYP7C*[)UI0KV%>HUW3">5:ZI-C)>Z@8W`H>W@_RTFYF*+K
MDZR(']E\I7X6ZIT30BL[M`8Y\507B')L(V9P\>CR[<J1R4,MU%UM-H'/'1/"
M']N[:):-P/V;8R_*I*,],U_/TW^D)-9^/1'__G+ZRZ<33'B_O#B_/+H^/3\3
MVRIA$E3:B\OSBU^/KD[$IZ/W5XXX/3NNO1:_7]7$;^>_GHGCFOCE_,/'RY,_
M'7%R+8X^,:Y2/<L;,]\*13=J9:S#H*4#XA*VM6NGUQG/9+->W]4$<$QN=C@0
M:`_`NQ>8OH>?WZ?=KS'^#"S'$1<R".([_]8-/!>(!LX42.7?PD%`N`E[_4C"
M4V?`Y.[0:2FS[_!HJ@_BJNLA3/3=!Z)9!_W0-2)\+_@K#=CY&8%F"08=F"!@
MWFCWVS&(_)V3D__O!'$;IR.+DO9W&?GY;X&^DLCM`0>(OKXK'#Z?KC_[!':^
M?JSLL2#MXR5"A`,.)1R^7EPT*:ZT$VD/+EVHI`EI!#[G?#N*F75]+#\0PNG^
M*^W=4(=BLRR#F.RK6Q=,A33.]#*MVJCK(9>TN#C&BTR\5U#F`:U\6,O&$>=I
M1$:KCPF:0LE4XA?(DO/J7M>DH9GW20!84XY!#9%`@F/,H%0)GTH+5V4-Z"(#
M(<EP*/-5%K(Z":,TBE.\K4S";$H70?2Z8D2I]-;W@54+EH2*@4!CRRI_H.XF
MK:60__Q5IN:]>FWCZ2KMQ'@;2<"P@Q^'(0\_OFBKA_`Y>S-#CD6G8?C5`.4J
M2U#?"7>0<E`%DWP?9,C'>C\W(>6QX@GUDC11^%:L`4PB%NC](H#^E[S?+BOG
M/0G2E+93&6$HD261NPVX2%EQ+G;,S'ZDS%&=F`!E-OZ$-D$D%6%;]):5BP"*
MX>.'^I%-3,3=9@6D)M[#>G_\P4*5L@L8[XP!1</F&D"=99L0Z>+'TJAR1&!M
MED53'[)SPVG(03RF>Z-D(*U#R64O\"B3@RE%V@-VX0US@UVC61-+^1751$EZ
M0L\=NC=27T32>S:+RB'>YD`YAGDK,X9)._Z_<7[S%+T`I)+*AZ"*.U+E>R8`
MS$!34\182R11]M+#9\:P)O9?P`81#FQK$@\,*O1DM)CCI?P/!H-\4XSZ;>:*
M*-X?$K(\"ZJ/,=]*YX\#73J3XA>3'-UJU^I9^8]LK#^R@UW`JO\WOZ_$LK5*
M-P1.DY@+XEOO)HQ@770WK@,!X$'R:N:&4"_`5L2D;JN3HH,"@CR56;!65U/)
MNXM([H`TXJ"/+A8`0`]N!EP8W(2`T2FG>0@O])3?)*(*-6`7#EU+N+/8'V-D
MB4\.70[?B%D4=M&UMC,,C94P^7I.@NL@*]&D>^/Z@:.V%E4]0`B&''3@D`H>
M,'YT1`J30-,:B^48"QD.$*!<.=,%(P>,,5PS!D_Y2*TW`W2VP&$Q;AE#[#2@
M=BOX&!VBRNS00'"&Z)[WJ=N_`HI;S)0+_NLHX;I%%*J!-9(B-)DYYB/6C%R[
MUTS=)GZ@ZZ+"`.MZR.OY\L>]-+;A'T?'OY[_?GH$7UU]N3PZ.SX15R>7OY\>
MGZC'J";,Q]/+JVOQY0Q'O?^@.,)J,7_R\Z6S*O-ZI"O^0,D#5'*5HK$8&TOP
M#U",PELP#4_1HTNNKBNE3RL+#[G81R^"9[\$2%OW'P29"\;AG7H>'C$%CRB2
MIMY^ALG*X2)@/:"_WY!YG,)JQGP,=#T:NG_KFIBH)`3^1%=JB8M(($/-A'29
M]:,<]<R*.E'X%<`>#T+1=SWE%P2IVI5:+Z`AT/Q`Q^`-^[73S&NE[GTHQBJS
MVCEBI@5:2N+YXF@4P7_WZ+M=H+3,7VT,RPFE206A`$3D6]<@97#S@I'!8^QI
M2GZN2(9]QQA\^LI(FRBT@"Q$D?0G_X[M(#6J#JU!U2,[4QV)#S&$_'X&!JHM
ML?2-FETT*O"F*/)4E!OKZ2YJ70,73T*FD!>^:]#,]TB,;?3BTMHF$;Y+@$Q^
MVP:44X`J.R/5&LDK*6_PK"@:0F7KGJ=!F15S6$=G;@Q"\6H4P7*GD`6,G:,)
M'1%I[9&B/H.)4KG\7B0^+]56PO(X%\<U`!PWL!;C[J)2CG\#PZ$[SWNTB-HZ
MJ^G&IC$'2D7@`L'H8VBBAO^7"QNR/1=S"%XLD\3/W-%J6%*[8M#(_![;EJ3"
M6;11>%*(0]#/C^/I`4W#4B2*M0XK\GQI&U,B#689)>KR:DV!SK+-T3;`?*?H
M/*^I<A+7"K;@!-L^B/'=MR(=`:]$EF<23,:`MW",SS$DMW%-_)+>B7]SO5Q'
M_((VA?ETU<7D#G%U!]H^$.4G%(,8'S?Y_?4'!X-Z?!D/7/$KL$G,DN"O_R5O
MX02\C\(;E[S'`2R)/(CZ,=YMF%F&$8C63VB9P:?(';A#>`\FPIN9"Q=CK[OB
M$GC!Q<"-AD#H*27[T3Q$7.3?_A!*RY*C+<W5*2Z3NC:Y?U,VR3(06XZJ(#E&
MIN2!:4J*GM&!YE.Y<MBQ]:\9`:L)ZQHCY^G17$%S0!4Y9O(/V%]L,A,FKS:S
M?`O,*,!*A#Y[>MQ$!21@+!L<C7",6FU6_<_'.K6UQD\ZP4BM_PIC$%3$^P1D
MP`.CGG&6;KMV!/:Q=J[<C[K6MXQH86>^/>W\\6*=@U&</N22=TOR10(=6*VA
M(8CF3@!8\JW'OB+BQ9QODT6FY\,4@*7[OKDWG1R4+DB57'%5K(:.M+'PSQ[+
ML*MR64!!08$7BM_20'*!1ZWF(19A#W+^5%W1]'Y>5TT4>V1`<NZ0)X8WQY))
MSK/-W]GJN6^8)/GERY]&6*#1B]7#_W5T^:\O(%8NS]^?7%Y38MR7#Q].?P4S
M]K=+8+V?X7?Q_LOEV<GUM?KTZ>3WD[/K7X\^J<\?P0S^ER,^G7\YO1(P^/&_
M3O`G8/"_'7T&L_AS]_C+^_>G9V1"%T@S<02FLS@[_WQZ=O1)?#CY>'+VX>CL
MNG0LV3[;:&H&[E#V.+HH"(><1::E"T4UL)5*QQ]8E'?+'O?,^<_^02#/C[(3
M47)(DU,B\/1:L5%:ZT0VF<L/FA+U;HOM1]G^!<AF.!;^:``*6N$=\?996!-8
M)1\LD?KA:YUJ9:XP\#H.<:$BK3(<Z*O1?,H;<1P#LF;[0`6%N92237NVQ6+C
M^3<7.#!\W^NEP/-5."T/T$N19S-;QXN3F&J"$V.!-\`H-0E;]D6*2L>B^POD
M2HK!P3ZQ)]Z+LW4S</RWU^]SNI3*=4&H`2'*34N^8KP\BF.5^@5F`#KOY4Z&
MQ8SQ*>\]WC]95[_91)@X2977*0'.8IB8#4BB,-2WP^HF26V8Y3+.C?B_L4[&
MS,LO=:?!,3*8.I:R__?^Y07>#P4]8L+W[C",5/62[\Y&/2*S'9E$!_;(R<4@
M60(\"_"PBMEKM.6VRLEKY!G-:B7%R_1!++VL#K^MVA5S@H(C_^,/-,9.'72;
M?77J[;&5:.6PK%C[DPH+B\]7*#Q78QQS&X?RVOVV#A7%`2O&/]=XA\+M_/.)
MN#[ZOT^O@;\(V"9.PPQ0+%9H(I<+`YU72`2-X<?$#;=5$/%K%3A$VEOB?I-9
M*"Y&=F"U&;)G*)=5Q]FJ2N6DQT;RR26[5U6=^W!WGNK<2ZO$_>0R(B]94[O!
MZZ.JWV:V$_0X9Q_U+4/V3:OA+'@]4^H.;0R>F[I,6F-I`)9B>?6-7E[]H?(X
MY2D)CG\?LU^@`-Z9<;;X`HC+FK9:4OF7M,S*<OKH<8>-PU%6$7Q/EP3_*.'\
M/UA/KD25T!NZ$OI\!?_6O/Z[6?7V[D-BY-'97Z_;<@^*BF4_8[G++0Q;).?$
M_1-([UZA65$*H;XI!3HKW%6XVY3"L&56@C:GZOB<TG2J"%WE$N:3D"\J%O%O
MC'[`R]MR8:TR3;[?);VLM?6(A;52SC%?3>A2<K]&??W7T'2:AXM8167;K$K'
MW&X^Y+N>0\M\R#[?-*3!J)59\W22VUL:R;V$@*PVD47PX4'%..;%6GN^!I@5
MR4UH&ZWVTHCN9560&3KB_/C##"\_'=^KZTCR;-9AK7\>YK'F:"OL-OLDI#V)
M>ZPY]H!Y[.XNK!/3RV@>WY^#HUK2.BSIY5I4\D',Q1WNU&L-##S,V^_\)8UW
M:H5%<LYPEV)H4THFS8(@.[(?8AT9UT]5$#%&0V(>Y>+W<+Z[Y"=)R67YAYX`
M^GR2:ND'Z"G(GUM:K,`@G4/=S8JDSD;NFVI"+,QH_3X-L$69K]^3R;]`H[5$
M(GD>EWHFD+,$AN^(`*H(F&=PG#EC!BN.<S-_Y&%)_>O?;]/HYW&,[]W1\TR6
M\7TZ%Y_+,V;WC:VJ-731UJPLU9D2[(.NYWNYLA]<;`\K#_<Y[,;*\30M(+(D
M4-W8QS3/I-X^\9-3.U>&_"K?L\KW7`<\5_F>F["\E\KW7-T5CQ+LDTM_WD05
M)*MVNDQF/UX9=2'"=E$[6FMX`".ES)0[;+:?,_W:908VG&9]P<F!95SQCS_D
MUMQJ+7B77_1NQ1PX4W`ED%1616OJ2BM?%+M:5(#V7*&6R[I#K%*V:#/FBWM=
M29S:'-[!"QF!'48M=3VP0",LRF55ABN%$O@R#M?=ZE+Q&=[JQFYUJ_@$K#GU
MW;UEX>UEHQ;NA?>TBN)[FNW[`3[3PWM>-+KG>:ELY0CS>5XJF]/:W81DMA>.
M^9D[([FLFDT5.?G]+JF*<"N78E#E93TEH=-IS9>-72GQ&Q/D]OVQ[&I)Z["D
MD@C6*GJSD@I5].;W%;WY4BG.&QI,5\5O5O&;WVG\YF)[^G4*MJ.C?UQI:ZM\
MEXZ1N0JSFBK9EV+/Z+=1!66N:;!@%93Y,GA>]Z#,'W^HPC+7J`W'P_9\%A3A
M84??M]^#HZ):TCHL:37NI"P5^%[TZF>)/:=183I!EH!-A(?%O6TFE)`2A#9F
M@8WSE13:E%X>SXKD7-M5SQ=O,_L*5A72-Y&G?ZZ;BOM>G]I2IU'YXF4V)QQT
M<U;RD.)6;CE%3UW*)(VHU;#;[4:IZW,38FIH?`?6FV/9]Z35E0O[FT-'F[.2
M[=W]^0_%RF.].9#&'7D)G`$_C&/1=:/H#D[#V(UZ(DT\W_LOA];@2'%*WJ+M
M!@.N/I9K(S:'I#9G)=OM@[*65J,#$`9)Y'52G9CO!;?`^</HSJ;Y9D7S+T$I
MC;U%4,KF[$9IDG^N!FXD=SIN+'MT%R*#F`6#KE*!*E2<8-_Y<,3U-F_`FDBX
MFY(Z-F*[]=@QVM1;_MWY+.AU\>Z^4+3F@B(DODODK6=3P76[YGC&??\,S&/3
M0Y67@+/-33-<"K)>++MPOG)@RP]TX!EVDG"D9C%.X/H\H0\*4H,.'&HAX1``
M6#%G5'#6:RV3*/G`!IJGL[1*;<<_ON-Z.U0TC!>36TQ$<A3)F&)BL"R9[2Y`
M;1`CB$=I-`ICR4$SQL$FNI;/0<:U15),+EQF1ZW7IJ/L_QQ+4U'58JFJN5BJ
MPG4A20&U($'U9"_M<K+7K>OYA',W%BXF!<?R[Q3CKW1UO>Z$8=_E2\?,P$<7
M\-\I@-/WT*P!$\?C70RC&S=0M%Q1Y[I19]9(J8@^6\^F3]]-`"M`._$L1G'?
M"]R@ZP']`F6'L-#@)F.+09@HDH8A[C'--`"6*N*T.S!&-486RF\RZGHPZ4))
M<S&B=BH!OGC$)I70I$J9L68(((%@T#O!4!XTF_5WL*.P*?BE%;]I?F^\$QV9
MC*7D+%.8%NMX@HK%F^6"]$HXI,'WW`Z(O\3#'B2/[3J^H,9CH:G&&THW3B,Y
MI(NG`&^G8"Z\DH4#F@QH1;X[CL6-=XOC14`#2(9A&@$1<>]J>DC#M<`HU"KB
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M5,C[SI%7]7&\U\>QH-@P7P7[/MXRXU4L]HDINHX=N+'HX%7R*`IO/;Q#AB_&
MDJYITX"N0I,0WDQD-/0"Z0@78,*P`X0#H!G09REN9*"+WF,[FC1)([KMIA%4
M_TCWQO6".$'FWAW06\%]C_&V=0]^=O[)NO5^G7,>QZ(;IGX/@!<IA3JX6&X?
MEB%['@4N`-CP>8CU]WWOJ_3O$-@`@QMJXEK-W37UFA&::6C\Z,4@@P1>M3GX
MWSJYM?'N1HP!6UL'AP=.O5YWQ%:CMBN&GN_3&/#,5C/[PA&1C$?<(]._JXEC
M%?BC`R<H(,!$5,#+L$I,5H#-QD_P<A+QRCBCP8OC5%W1`S'<>ECBB;:C([ON
M$'?/>@7^3'W\`R:,=+02A8M0'Z$??Q#=%$@C2`!-(_>.(YA@5@QABA#N,,"C
MBCL929=O^+,@J)V1Z_6`HG>TJS^?NAK7Q&E@'G=,R!.2H2KFR?$)O'I[\19V
M$A3B",/67JV581FVU]`UO0@_X,9WD1`4'3P`Z7@@>?,M6FOLOX,=2#A,2Q\!
M>":6%CAT0%2<1$T<8;07(]E1CTX.2(!A:`T`EX6)8:1$OP]'L:#):D:G$V>$
MSL%.=A#,UKDC.,;?O"$VB-IJ-6I[!D\4_J&:1)F0#P())O-@+1T)_"?@/<XH
MOEF'U8!F=C.`#S"@.#*H].]HI1'SBL>A!.K>:M9K]1Q(,?6R,@`1_3X.5>,@
M#]5*V2].V"D0!QW]X^H$`X5RX;GHA+?`K(&M#]S;6?8*MP:D\L"0#-WCJ6-+
M>P9G^M=P+$%!=ZS6OSJN0[2(4]8/:5+I2\V1NV$`8P]))"&E9W%(G.,.DB4)
M(U3YD9I%GW<<8/7"GI#,@Z[D*%&S`,]5H4:%H4VYURS8U'FUHC,)SK[G([)`
M>OEF3@:24O,I$FX@-5`4,RPQKF4"(A8,%!L%3Y]>7C$G]>-0S9#_S0[\B@<`
MNIZ:I[7#OC0$0/P215N0#&(%PCW,XX'!\#_?LV*U!FHS,((4>;*2TSDT`PWI
MW4&XIR,V-KR6ND:[K`_(A]#^,2=-ZXHD2<PP#[-E`G&,W3J*5M9F4"Z#'A*X
M1&N@CGC#=*AVJ`_&H^BEJ`P4AMZZ3.("34WZ/'VP@N.!,D0)-%[=Q%(4H3^\
ME(-=LQ1]E.SCQ:RP"*A,,L")AP\I"3M-##.3CX/O^FF,0S^,`85.!+K1X`UX
M0=1F//,?;])XY\9U1V^Y_O>U^^T#H!S>`ZJ]!F;YW@=-Z)\__O`__]`/GK@1
MBHOX0D:4'6J>HL!K^'`I^S^_.N:___/QSY/_M!H[0*,[J-V]^N?C/'H1DN+L
M_/I$-!IFZQIPMD^.+L].SWZY$A<GE^+JUZ/+DZ=*D?6W:-Z[L=<54FTET@5'
M->>,@Y.+JYQQ(+\!<?=@Z)[GIT:/]&+B@BG*GP[&TX*1HQ19,DEL10R^`9[*
MZO4@]'M8A:AS1X=L+-'(E;T=D)^1"R9#D!)3PP!^]18""%I.FL!!9M:G3ZAF
M&1\0,(`#(,<CYE,4,#T`4CI(D,<:V$D38@LG[,*)%UX?,`1_<#0O*LM4X)72
M"5P:*&23(+<,`-R.S<;WX`UTJY$M,+%H_-FV%!`V'--5)SWW+$%(JS;/FAU3
MH<VXJ.0NOW"2@TIQYM4G$448WZEQAS(9`/MB(Q&S+KJ@AZ/"C0^#-4<.0=%)
M,X:C4$]MV%@\9L^!/MR5DM5/,H<+#*S<IO4`Q?"/O6]7'JZ?=5T/`?&!M&T2
M>&Q01_1],+G8N(PUMES\QL=S\A78(K!`F`2M6-+17+!&(T\F=S@^[PFK9=)%
MM#"+5SDILC>G!KQ)4?5'%/T.&HKO&?<#87<$JD^7CC9L%(J<,.(=@IE#$$K\
MA7I:L0.2P13IKE4<@V+:^2EQZPXR']`!+4[E#L,4J&"]ZBJWRA/E#G\A)/H]
M_'LG!I;Q5AQ,\1'B(T98SGM;LY3IGA<AW-J=&;0GQMJ7!6//#5FN:$7E7,P"
MFDD8*!\.-ACE]9+B8'-1KA(KRH*#9_"XAQ2&BC1RR1,S0/8IC..2HF!#,4Y^
MF`KG+XIS=(Z4$P,;BO"*K51L9?-Q7K&5BJUL.,8KME*QE?4QUI:W]X4+>,KF
MKG(Q%7HJ])1IQ`H]%7IXQ!]_J!!4T4^%GA*-N$'H>;G\71.YH(N>'/XTNY[+
M<5YS:/^3E566OO_%!5UFF';K*;/E2]#LS3'==M/9G_V2<2$K?+UYF_:\:9^^
M>XU=YZ"Q7_*EKL\VOO39J]<:!]716Z\]:SGM^LQQ,-6FE8Y?-@_:)5_J^FSC
MR_/+YLMNW@8>O9?GEP>[S6K3UI1?-IW#O5;)E[H^V_CR_+)5*M/NI9ICSWUO
M1GE&WJV,WSZ&KA>DL!?E#B]Y=-;`#U9M2[4MU;:4$_IJ6TH)?;4MI82^VI92
M0E]M2RFAK[:EE-!OZ+:LX+;]66&PYURNXLT?JE3%K)A\PJ3/"W-Z8GWDI9#1
M$PLJSP+,SI-)^7ETL%'QY]7^5_M?%EBJ_:_VO]K_:O^K_:_VO]K_:O^K_:_V
MO]K_:O_7=/]+&^]1^4W7VF]:;4M)%[;>T%?;4DKHJVTI)?35MI02^FI;2@E]
MM2VEA+[:EE)"OZ';4H)X#[M5Z@PKLQJPS(K&9\ZX(`?++*UL9P%GYI2=I_>^
MG06,YY9I>.:FS)Q2]V*;_^,/+[+]2Z?&.>G@N04?7OQP5MQ@&=S@>84C-HX9
M?%=[_\P"%-7F;X@<>%8ABTH.;`0O>%Y!C(H5K//>/[.P1K7Y&R$'GEF@HY(#
M&\$+GE?H8[FL(.?T>D/M0[//F]Z0.M^WON%0]WIJ)LN]WWO*OU;0LMKC)L>Q
MB]VF8]&9UMH:&ZPGH6Y&BVW:N9>MW7-Y<AN5FY'(D`%U='/A?A@-J3<R]W4N
M:E!L-],^YEFNZ.F3OU/OUO4EIH;I1QKO7CMB3/VHN3\QMM=.O)V>*KDB9+\O
MNXD(>7IJ[6X65Q./(9";*U.SZFF@F+;)U%D7U[9[X+3VVXYHM0^=QL$!#==H
MM9S]PZ:#/9-'`!"`YM\YJILTC:^&@3GDG<-=K%63;.H??K^9=;9'W$F<VPQG
M^^5%8@(+M?M'::*?_=0V]=3,?A2-!F^O@**]OM<%-!\#68=#&<7F,?%MZ`?Q
M6WSPYU>#)!F]??-F/![7`%TWOKSKAC6`]0VBNM%L-5Y1FW!X]U+V?WYUS'__
MY^.?)_]I-78^R.X./OCJG[ECM;@^]\U<G_NKTU_.3C^>'A^=78OC+U?7YY]/
M+MDIW<DC:P7'O"3<YCR-L&]Y+\6V[L0;O#B)O`ZQF&00A>G-@)M:AREVI`Y[
MCABF/IS&,$U\["4.)#5TNW=T(KH#%RBZ%Z4WR`PBG(O[EX\'H2]C.%RJ+_;0
MA3,+@\(+`<R(7ZO)8%@Z$E\"#T&XPB[9<4U<REL9I)+[DD\_W7R\MAK[M;88
M>KX/I\>!C[O91WITJW%8.\@>L,]O3?SA^C>1E`%RAY$;W.68E_YQ@EO!USN?
MW2A!5D++/@VZM<D7Z8G\>\>_7XEC0#LV9H?YHE$8\9'/,<S?K^RW:`67@)V=
M(Z]'+^6>QE\$_))_I=M%3@8(1?RY(]CR;]X04.O?B<;^3XYH[.)_6C\Q8VO^
M1*WFTQRJ`4V\!QF*8FOE&BJ<^\'YFBV>CZ>J%TQ5MZ:"Q3O9?/1.-N5#JVKC
M+&TU2\O,$A424OVP)JZU+$%1!J0:(\_%_0?N+>#A(>RLZN$>2T77D4Q<SQ==
MS32!^65B2R`HD0<3N+U;^-$67`A*!P1O(''"D>1MY_7UO<`-NO@>L-*>AS_4
M*EZ5O/M#$H>*T\Y?B$7<'28`V(:N!-F-;>:[D024(>:P2Y1&:Q\&I1%WDG`'
M_T7]R,6G8OEW*N%9M;/X$`A+!S3<NR$,`/\FL(G,-I#OX9Z*48J<"S;T-O13
MA#M$L>V-1O"JB+L#V4N1?L9>,J"=-O1!5!;+2?"&[IWP@-D@;<#C(5"+Z_N@
M)HS".(U(^*MU15[\U1'20R5&P*\><RT$()`WKM9!2*]PD_SD-$T'$`A+!/*%
MMURB1S@_G3ODW<&-)-5'`GCAT.LB9[Q)?1=X&LT0TJR&*&.>PP(^0R"+@]#W
M87RWX_E><H<89H4JUAI-B@?<.CO#$:P/WR:U$I4<.F:Q.>JQO=4=UX=S(O&[
M$3!=29R@K7A8NT%'/@D3.$>`Z)XL?!7@UTWK18NE24-)DT9]4C)\=@/W1A)9
M=*3O`2=1*$!P@?G<>J1)(V>!K8D]G`DY"A)((-)`X8.^+UH0Z.\`Y]\IDA@.
M0KO'^TZ,2=-#31P]##;IKKX?CG&1-!2:C$D_];-YQW`"_@MB70G$EE.O3R[8
MUB8?UQ-)G=1*Y[]38-`2:.RC9F:G`=H)1/"9:CF_KKAPJR^O0+9R"N2_OQQ=
M7I]<?OI3G)Y]/+_\?'1]>GXFMK^<'7WY<'I]\N'U0I3)G05P:+V*"5:]>CWW
MF@Q$I$4ZUT3GZK3&<"3<M$=ZWM^:7BSIYV44,ZGV$=':"L,V<3S04>$'```,
M+`GP9>:48CROWZY6D,ZS38PK!9VJK'JX]],\<XJN]+&53!=P__.K.G]6OAO\
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MI[W^B]AU]A>[B%4K$O3B:=`-AU)LHW?\-5_RH$?9"U)T-F;7:J78@NV&4V_,
M)3ZL6*F5`W^X/S_YE`/TAM-HS"6[RGA^@7@.6HT%[$!)I"VJ_9Y]>LN"Y>J(
M5D=T78[H'*)UV?B:^U4[7GE)TU9+JI:T@B651,*^I^AOO">_%S&N]&5S._[V
M>]B6:DG5DLK-#Y9@*6.VIQ>LH[%<K]7WUU2;76?8GP1ZV13Q>JW1?$D]?"F"
MW#ZZF;6<8;)4=O,:4_PZPUZ=UN6*V>]/6:F65"VIW%KRDX3M_8`RCK+KR:[*
MN'LK8`X9^5X@>0@KNOQ[P'^UI&I)Y3[XR[Q(?B@*[>55HH;SE*N<DNEU#:?Q
MA-N0DBVB[33K:Q^#L^<T#A>Z$R7Q<)<P8JNQO_;7F+O[:W]J6\[>^E\GMYSV
M_N'&"=KU<D(WG/K>(GP3*P&^Z33;\\NN<@!_N+O^?BU4@-;?#;T&$5O5$:V.
MZ)H<T<KW7"VI6E+9EE02"5M%;%5+JI94@B55$5M/C*,X6%-=%F,0VFL*.Z!]
M[>\*%D4[5<16=5K+#7MU6J><UOG*_-.7RRUPFQ50GZV69:[\)564'X1^3T8Q
MUI5/[L["1'[PXJY/%3S-6R]6+5T4X9$7[Q<T;.B[0\^_>WMO4/K\[I7`A@ZF
M6(UOE]`\R)=@OSX__M>OYY\^8.5U_?W^.W'R[R^GUW^*H[,/_(@X/O]\<7)V
M114V:1,Z>NB"XO83)/(<C$P0T0M@"?_P"JC.,VM\H:4O=YG6$1"7R#QB<>&[
MP4;N[7D@LL)T!XYH'!["?[%\[_O0C7I8B/B#%\EN$D:QZ,FN#R9\3[A@Y]]Z
M`&(OJ[JO.G'D&E-<Z&K3"HW;TNT.0+N@MU/7QX+/KCEU5`(>GC.?X11:Q9A5
M@6BL$#SY1JZF/1;`I@*DJE%(;'$TA##"R+D>UC7.5MYLZZ53CPTL*AU)X))8
M#EI,H0>Q70B*.,*"[UAJV0:*B[33:UB^V(7?L8L&EU7'<M&?7:POC_60ZP>Y
MJO@?O2A.Q!&^,#DHUUQ/(RIN?7_(H_0&:$4T#ASN,&"/>H65LGO%PS*LDZMQ
M1`:WPS6C>[J*-&TKO2#@22^A$O1YU%N8AWTQ9<BYO/E`FI8%-%Z0TJY8C5W0
M=11C=7K>$OBZXP42VS%$7T%AO77]5`HL0.W3MH]#1?U)MA+Y349=+\8BOAY7
M3=_:;>?6BN5V@S#13Q(1I;`>GX;)47K/3:1IF.+Y/E8G5_U0?(]!=V&5'9_\
M8@%H\%TNOTWK<]$?%N.!B02J]R-ZOM_W?,]%[QGV!(CCL,N?^%E</8#8!9F,
M1Q`;!.1+^\.I3>($NU(`BG)X<_!)JJQM0X)3!G`8$]PR>!:(WK4JK&.%>=A*
M\N:-0(VX0\0.W:_8'B!!*HAP5/F-JZ_#:'V)/0IB+#4/`*C^,.$X`.@''JUP
M'IAY8PR;P;43?E4?@KZX\6YUO76;S%S1KO^$>\7U]56G'1K3DN*QZ*91A%C(
M$5"?5D2;3_7P4]A=4A]KXE3UN[G5J!-=-Q[X,K8(2ZV)J,FAPTE(YRV+\OM'
M;P(Q!`1O1P:R[U'MZ!S&K).!G-)>*!:OS[`?J&FY^GH@<\B<&&F6\TW=E?!\
MNU9Y>#BU<>H&U,"`27^*H&#8Y!"DG3G@9I@XAR<+`B1')B-JB@&'RJ8.Q0)4
M,XR<F#&5['N6J`*]=P@L`F&%L]EWO8AV!,\W*,.Z6#UM4LC]`<:XAQW3^ZB#
MU?OQ>,"T23R!0WK1@Z]MZ0(H["=T"K`P/G&JWBWR&D*"W8S#"VYA4*['[P9?
M\=&^%PT5U<MO(T]U4T$^,PU?$SL63\@S4,`/IO58*KTNEE<PUW`!6IF\+AR*
MN\HAB#P?["ZH'_OBG%J09>IF;N$;J'N:XK]-TK_VIZJ>U"+GEE1//O,6INXI
M8H1*PJ&EU1AI;:E?<-)!,VHSKU8J#;?DP1%OL`,<^:O[`D0TL`F[&U/&CVQ>
M5!-?2#0F>D<1#)A:M6T;(5-*J$-5R..;KG/P!3!,/[R3)+!!&>B2PAI97&V2
M!Z'<BCSN3``R"+;-O9'FL9QH,UWN-*M4C(6`J(FS$%D^:@*W2IXJP%1?H([,
M:47$Q$AZ@2H@[D#KB17ONS<VKH`:HCS\U)AZVW%C/VT>H"R,)^92ZS1-;ZA+
MBE$';T/:L%$X5CH8"!&P6;B1B<)`S5;H+<K*;1F2ALJC0;N`$*1WBG:2H(:W
M4K7=GC(*>FF$$-QO]`5HH&Y-&W2`7Y)+O]BBBAK4T`%&16H$)Y'['Y)(]^(X
MY99!<!A[W%L(R581"FGWKM65L9\FV!0IO<\B<KH5$39P"G.21T1983=%L5]3
MO`\#R.6M%Z8Q:.N:'-4MFU9[W%L7U'D\L99J*Y$'D*V%[:3`&D)^%[*VJT"W
M'5Y98YU)Q02V",PA7%P0*LW8=_EXYSB#T0'IR"M0BUL!Z2:7B.Q&Z\#9;]<S
M=%K:(#6H0N:'S?TFP1(PPPWI5#CQ;RFV;JLWFJ8K8"9UZ@U@_CTYDCQJ.E+V
M0IX[;A!U?X>*%7%?=F63Y)1!['Y?6A;ZEM@@J+."1;I+H0!\$%F6!A6G'>X_
MEV`S-FV#H*5$+@O4I\RXG;O\A##:$7`=D(Z[JO_7I`+W\);=<U4]#'3>594I
M#9F3J5B5RWK$H4T(G!X5QCAS,AW6Z]AY3+\]\H$3L9HX\0N[?)"II<D@C&!O
M6,?$,;'-F2-.>73-U[=[LD_J3$?ZX?@U,=DT4"`4"0_\WPV8A3>*;36R'J'&
MG3))2/?;(E_GQB2F*LE/:FOIH,/L*T/:%GGN&%1VTZ=O"/;U.S$`+>Q61J!=
MYXX3(9K:Z&BN7]=<']N)TL(;SN[N(3%_A4.K=2):S@C7R.KD1RK9%/3>HZX\
MMG,.5<0TC?40ND%RT1H*A%?#:<$_N/=*<D_L;-'F:42G@9;/Y``D,-B)04=J
M<A4GZK6"91"`N1Z1CNK]J;!)[7+1B<`GE=&>K9F/.=,R]@+]Y@U3ZI,]0=@=
MV:6&W3DEPZ`]6^O#YU/[R1@*%,.[&H>Z(7<&;A>']GU0'Y;)HA<GJLS5F&GT
MTHF$>&.NF<SVX0*R9C#>A@FA(W3FY8S7G#/6,GS9\8A48+[$'LR"W9B943RD
MHV<T9'89X$,2X/?4]0_ZK;VN-T*VJ%3P!VFQ!E\%Z,$FI9V$6._6B]'T1AC`
M]J2.\8!"=.O%QE-@#'+D0GX</A.(Q_K`CS/S$S@!M[\\/&C2F<&GJ#FF.CR3
M/=YM-P,WHB6']'VGZE2#Y!'@+TQ#4Y)>U!H4V/<0Z/3.6.VV<:.\!'T-\=L-
MHOL9U>U<P\39U\(H,#%<#5R+;K?8^FEY3127CIKBZ)SI78->'I9G]G"L+P;N
M/\&\SF#G#I#FHU9/LF]TA[6UP/4S>D]6]/GL3GT+`=MTN5LSY)4)EK)L9'T=
MD5<F6$JRD?7#]4'>?")`3`^6+PR*5YK27N.G//*MZ.7G+O3,N)BT*:OT]EGW
M8+(7V<N3;0;!LI#T=)CJ$T#9Z57//BEL6&T"FBKB>6GB4<;X)J"I(IZ7)IZ=
M]4/0LP4UIZ,NWHC[7<8<$"(C+WQ4ZJZ(J$I#W<NBZ%V.`U@;?)0`_1M)!ZV=
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M01*[RCYHU#$=P"JN,LBI#RJBWZX?$$\I./#>Q3PG2KC%U`/?&WJHDPP\>#E"
M%0OSH@!3G+TTE@)O<H><7(B)A=_H@W\G6BV3]]#<=UJ8"Y'/>-"5AO+:C)7@
M;]9G-<ZD3#8L9:1FZ5!R4U]ZG+EL$M]P@K',,,*I3`AZEZH\*!?\)%9T7KC*
MTJ:$9:PXDXRE#*C,!/RR!_^0@]`1`%8W]6GU::QUK_\W2P:+O>'(]_J>UM*X
M>-I0)H.05NIVL?(6I651YC2^?G5R+*X2M]\71UTJEH3COD]]7\)?HM&HUX1%
M-;-.%GLTB11<F8CQ<:NNX2GO`PZ"^TTD6%]-5?W1^5]=;P3[G9@B/WDZZD@X
M9H&J+45[1!GK*O\/LTT\><N)+!85`=FYHA?B`0D3G0N*&)=N#!N(>1<=-_9B
M)D7.?,,<&45M^:U\/+O%C>&#3O:+F<PT<>A]>\J!J9)BJJ28DD;I5DDQ975+
M5/2Y2/JLDF)*`TM9-K)*BMF,C:R28E[,97"B]6EE"($A\9U=TY;'D;1;VV]7
M(2AKL>[EDT);[&0>A[7!2PFV82/I82U]S`L*2=*#**_![M[B<Z#NW<%&7OQ5
M]",)?[G)HP)Q`L(J2:L0IO82D[0:M>;,E[#+Q]%/%<&4G6":M=FMQ8I@*H+Y
M+M-`5VN:?M#-1NX\Z:]/LNA2`G9+'$I<,DP]SDK+MS\5X:S`I'F44$J`_\J6
M76?Q^8`M^W)^W=O0=Q//]Y*[M:'W[XP1[K=K![L_B1VQ?U#;:Y8,;3_-@;?R
M;=OW24]@V^X3/>W7]EHKE[*5[[B2MR6)3RY;2-UZ+>IZ]EA)?#U?3[P@O)=B
M1JG]6RZ`>*O1W#<AQ%M[C0,NJ&X'$=?$"7:X+81`QQ-3OX:)-A6FB:AI/?+8
M>DQT<HP!M-$-=XH+1Y+[&\4BO%5-%6YSI:WN%8TW*W94,&[!6%N-5B-;^6[S
M_L(=*G%/&6$['8K8[MH5WS$X-HBEJ8.?-2&9MDX5]XP3JCX>^?5+-PHPPOJ:
M^H'@9@7A;/.;M;](C[4E-UK/'^>.6<:T-?6\V[4ZVL6MOYHM.(C-^AP1^WRD
MD504->&7A^T]Y_"@3MT8[A_(6?J..7OMPXS%Y-J;,'>Q6UC/WCWHP1YO#[=5
M(-+0G4/N?<C3!1##&E/&9*\(["B53DD)T)2!:11A,K`Z6W"'HF#'^F9:SYY<
M<PUN.$^I"[&8R'.E#M3`=+AU*+7?R^4";%-WCS"-80Q`G_S6E8#=+*464Q%>
M%P3RY_9KO43T<D/Y3;7-^BKB]G&=;\4!9F+S!JPB+G-F@^VEH7U2Y.;$8JQ(
MS@=".9^WLA?.!BC9?CTC7Z!D*UDOO"_KG.PM:V'/SDHH[0:L%[3K0R[/RWTH
M[0:L%[1K0R[/S+`HV09LE%@M'4`%WN$9-,@2`%XZ3)8.H')MK8["SA9PQ.'8
MZX?8T@%4KIU>9TR6#J!R;:U)I:C.[F9N\#ICLG0`E6MKU_SL;I09L$;FU]*\
MT,M:V!5=$6[F%JP7M&M",+J@?;;`"ZQLOYE[LE[0K@D%52RG+-"N"<%4+*>T
MT*X)!54LIRS0K@G!+(/EK)5)^,26]:W=^7*]G[?T<Q5L%Z9)G+@!HESL6-5X
MP_Y,72`FUO!@18&7/B]/2Z%?$90'<Q8=>!Z8#2RIO9%X_.XI<.9N%BLAO&;M
M<.:8@8KNUHGNUH;S[1XLN<9318$5Y[L/W4%M;[?,V*OH;L,Y7]-I[E6<;R,I
ML-R<;[^VOU=F[+V8%^"!2B[W>T<N:[6_J+Z/CVQ(:<Y3Z<C@::46GLF[F\NH
M<_52^%HY`"7&S<O34F..FJ4E1-C*`2@Q;EZ>F`X/GE%J:N7X6CD`)<;-*AC3
M4EK)5\2T>MR\/#$MHUQ514FKQTU%22]HL#YX;?UR)JN.**B,UNK@5"RXE*!5
ME%11TCI0TG:C-7-%E!=#V.N*AM:)AL!.K9P>%3$MBB$UVZ5#6,60UHJ&@"&5
M3ZB5\U95O&1X^;$;8#G+Q^W627C+%/O^M/R#4I#6TT!?-K\_V'\..;P<EA\5
M`A75E@CTI0<OK@G5SH_E<I/ONF&S/#2[W7#JK6<5**QX;<5K7YYN#VN[,UN$
MZ\8=*O(M`>A+9KM[[34AWXKIKA/HRXY1G]VGNQY,]V4N_S4.FK7VBV*A.'T=
MVWS/F;A>O)!5;]XC1X2`%+TP[?BRA*3W9.B7GO3>FKF1Y:H)_/FZ547)"TB8
M*A<!UV9/7:[H=Y/I=_TY\>RAWA4E;S(EKR<GGJ>,246_FTR_:\^)YRB'4E'R
M)E/R>G+B><JJK`O]+B,D9N4DOW(`2AL!M8J0L8U`V\H!*#%N*I*J2*HBJ3*`
MMG(`2HR;BJ0JDJI(J@R@K1R`$N.F(JDJ_F!*_,$-5],3;@"@I9V_9#<122CZ
M:9)&4MS*.`$H*V_5&D*_Y"#/]I/CZ<OJM:KH^/OQNLZ3`EW1[R;3[[KSX5;%
MA]>%$DJ&W5+1\3RU$RM"K@BYM(0\<ZFGBHHK*JZH>&V\.55(PCHY[RJ?9T52
M%4F5`VTK!Z#$N*E(JB*IBJ3*`-K*`2@Q;BJ2JDBJ(JG5@[;9(0FJ2X+;\:4C
MW*0JAE`.HBNIAZHU>T_.51/VYGE:-P6C+TBOWR^2RP-?Q7X7QW[WJDHT)8-O
M_3!:L=_OBFPK]KNX<)FJ[$'YX%L_C%8,N`Q>F1D:@*P*!T>WKN>C1P9>C3A9
M9%/.<"6-%B>--JZ"R?J0\:9@M!)%WQ795MQW8>`?-"I+H&3PK1]&*_;[79%M
MQ7X7!O[&A<JO#Q5O"D8KYKMH-\R;!)T6V>>1!FCH1C<>@%P??6-8WHI&'?C&
M)"3\A2-B&7E]M5HOZ$E\H5F`@K_2./'Z=P]@85%K'BUI5?5:VPN6N:CK@11I
M$,EN>!/`UT!@`S>2.QTWAK^[X7`D@]C%JB1"?L._I8BD[V)QDB04";P<3M0L
MZ:2)",*$JI3(GB.V]0/PO-O]._4B*0[;>\[A09WGBE^+L1L+=S2*PF_>$,;V
M[\16>[_IU.MU##GZ(+MRV)&1:#4<T:PW&C4!4,?9U%:)%%4;16Q[K^EO$=["
MBPAG`"@437RF3=%+@/!M#YX:N+=2N&*?O@1$1T/1!W31.ST`!J.=:&WT/+P`
M(`,N3%040NB*L40&@25;8#[W1HI1Y'7IW2VL:D"57+:]V]<T['SX]F+ZLZMP
MWL$=,&_3\HJF!UH**5)KEU=;6S[-;LRA:^XOEY'@F>N'OA^.D52)*0(-#P%T
M>"@67M`/HR$3@=L)4YPH!%TJ+.A.1!6"<K].D.:]PP-D&``5AFD,[P("Y+>N
M!/Q$<NAZ`0[I>WU)XP(-,77B.7!?OZTHZ,D+L"=2^YVM9K;Q&2S5=%R)A;'7
M2P9OQ7[[)U@S-@6/1VX7]O#G5W7^K-0$_#S';<A,EQ[4K@XX_3AR1S^_XG^7
MOV&S:4-EATW,TZ*N"SQ)1O?7`]("]SOX^56COIC%J?)CV1K/,TZ3?0F?LP]6
M>/#Z;M9\=X6%IV,1&[J0-5^ZP8W,%A[V[RV]$PGQ9B%SJ<V7X@*5G?A1`BC'
M@5SLV6LN9AEG*0GI)6Z6?99+OE$5G4Q=QA]:T3]2BOX2*>;2J(1+G.087HC<
M;I*ZOO@$FF?9B:.BS5+0IA8]&>I(!HD+>3\M:7&S7J$U]-@>E5AUF3?Y;`YW
MXCR+VZK7#AIB!UTCC4<+Y:WHA"UIZ<\#Y#$O]#R0-&>O4;AR7)0`]8:++IIK
M[M5F+K%7[<-BV="JC^`\Y157O/?+#*==UO:"=#E`*=.N-1YMJ[E9E%TB*=->
M&U24`/-+$S+U6K4/WZF0F87[E63OU].8:=>:=10S![5&X_NB[?*(F=;,P;8K
M1T4),+\T,=.H5?OPG8J96;A?2?9^'6T90&\3A<QAK?VHR;A9E%T>(;-;.<S*
M(&2:E9#Y7H7,+-RO)'O_LE4!&W,&?\^UZX!UOJUIU0Z>W`ZF\6".0GEN2U<J
MN>8!=*%>NID]!"])>`N*`RP1+,7W\HL6D+NSWRA5VUER'O*\1HXOP#J>+116
M36XK*!2CPK:;>S\M-<L@3%S_J3N3A[3QT\K.709!<=#TTQ-,7P3NYHH!?WY!
M7FL#2BL82D.M&X/#YB2LJSU-&X/7M>2DJ]!G2L(_09>>^>:\]$2Z_&3L6?+?
MJDS!%T_P3E`5%%Z01%X0>UUQZ_HI)2=/)(W*GNBE$4;\?_1B4'XQ8;1.N:#-
M>OT0T[0GP5$Z<"1[#&X^YGNK4=_G+.Z@-^>;S>8>ONG``S$F/WNWTK^CQ.](
MBC'^)PAG`9^3Q85[<Q/)&TSG+L`")HL7)->J!/%I:;=V4C:EFE->K13]-$DC
MJ3*^'Q[@D4Q=3(O?:K0/&1%;C69+(U-LM8K0LWRR7<ZY\R>"].50_Y7B'U>4
MX/P+)N%SDEEJUI<]N2'']3001Z/(8]IUB*".[:H`\&'H)8DDPL5?WX=N1(G^
M'[P(""&,5"F%6ZP&$`AW*(,>_)^J(WR.:N)?;O0U53F>!\W&_CL<)1!R./+#
M.WK0A:,B\2^'"B#TQ%%Z`VL4C4.'^<`VSJM':-;?'>DYS'>-=Z]Q/C^$DRH&
M'H`4!)CA$[N^&]V)SAW2=9VH>3N,D+2=-OR-&>=#P-C@-1XF^:T[P&Q&JG+J
M<A$&7"B0/!QA.GJ<^B[_3HF]J1.M"E.HN8#!I%U$74U<I%&<NHP*?,+`[4S!
MC((:BS/HX?!,]F0WDE2P@2I%;.VKI2#X7$4B%%M[]?R7CI#]/I]4\=F]$_J0
M)X,H%;^E/GS3IJ^:#KH4N@,L_(!0JHX[^"=5IX"_!_S3M%W#:AJX--FKB2/X
M6W2!_0"29-`U9&.MW;V/4<9U"D-P\0R2`R=_IUYRER?'"Q]HC/&/BU;["'-P
M:8]L1WF=1>O9;NS6VOQ0_)JY]11X$/=#MX<\'$D['0'ZX6M#&(V]AG/0TF5%
M'+LN2%=&B0NO*>:LRX0`8GH><6>'ZW@8F;#5.&@PMXTUM#P/'@F&\CY0]LE%
M+HUON<,P9?"(*!DM7ARGL#A\%^14-^6**EP$)&0QHBMY=/TP1E!-09$PC8@+
MP'/,&/%XX!N^"X>TC_2UW8;C%[DD:7KN78POAT26")47=/V4?L.W$!07"4,7
M.U&+,+56/L*;ECP%ZI1<-`5.9W3#\B^$?799RH',KVO$/5K;1(,^9<,16CU;
MKFA*X6"X:[!IS79QU1B8"+X>>[Z/-52*@?<T,1,YPID$30%4)Q\/2LQDH2A<
MEY7)ZF9HFE*E5R0+^MS)?@$!_6*":B.599"^:,0A,3B3!_I)HEA71<KDBVBT
M6LYA\T"S`G@\=YIG9;IPO$8NLWX\12@2;*6]$P9I#(<WC6"H:!A&DA9D3L6"
MU]0\<-K[C:6NJ:'79,U+0J_'I:6HC,WD*\A!;+1TW7C`X_!I5I(;9Y,NR%P2
MWX"G;"&3[+8ZPR5?U(0&;5.+'X<6R8#PQUL>M`C#!S8<J&1WEZ@$?NS)OHPB
M4JU[0-8CU^LQ3>4D$JB]-,/`&[+>8P,$TZ0^20I68XP`1@TF?XYF/#?*Q+45
MC7A2U<AI_T]3/#2S<(,[2TF.]40+5$/B`CUD@RAT4X_=HH7+<0JR>'`G0&#N
MU5M3A(LSLW0AW;Z'NN%6:Y^TN`EYTZ[_I*VK^V)G@[;J)>EO>0XC[=RD3<\(
M:-KVT^HZ&^8M.@_(E\#F1=TAV47'9!#Z<"@L5U`RQ?]*ERD,S3U<VJZ0Z;(G
MA\XCY/%#=)2,TF@4QN:H/S[]_'/G9B9W22APN1Y8XRCD/'([@$3K>#X.@#\#
MML">$^11&H41BVL&L2^9NV2T!`+ZGF6*%J%TB6NAX&?9.S_L&M"8S=+$>.D#
MK@25N5`FE6EZ?@CKZ$@MW"<XX'R`8'U1[<!ILCY<$\#-)]5HIK"Q-"RZL;?K
M[.^S/WIOW]EKMHWGQ?9*.X5*E<6,&WO-S*]]6+_OUW:(._?4JG*J5DT<%9CZ
M)'O0!P__;P!D]?8<R!Q->`G1265\0#,RF[7VQ!>(B!?BF\M=$^\X%SD4NH!0
M3&1WCO1BWS!LFJ"8='T;HK;TK)Q2SZIZD7^Y^%+`R6EL<#ZDIV\@V(ENO+0/
MG42;%VVU%2L`GDUW9/!#!'`#/S!;*K+-`GXZ'"7^G5U9=\!6#`DA,N_5$"_C
M=%4L0\U9X$C-W:[F$2C=*`"PV@UG;[?IB%;;J>^WZ=D&NJ5WIW!:BZMJ[*D_
MF+OR#>+D6P]X:M>6D6VBB94G()MT0"J#!D`G+I`)ZA9=*7O*Q]6RKHT;S?TI
M%%!X2Z0OUNU8`:N.>Z-59SL*Z;+9IFEF5P&F"EI\LG%XN*]YM?%Q6%?_A46O
M)7H5<I?_ZTJ^9@#ZLE5\39Y;&*BI87"C>'UWX/*F7>-%90KJ.*&<7LH>W*"C
M`?KJE1PEMOMAC%>-0%-$%$BT>!4,`HWKJAMI1E;"Y/R^3.#-'55.^ZW8J=<:
MILO*Q=6IN``B#Y()X^>+4<-S.F/1M`0>_@"?0'MFK?<A)^1`^CV\-W\BI'E3
M20NO+"K&@C'K7+"[>T#'&\X4^3BW8RG%60B/M\Q%[<1KZ%C,)'B]MM?.RLA/
M.XS_>)/&.S>N.WI+2U6F*ZO6.-L'.,\@C]-(7@/]O/?AF7_^^,/__$._=0'"
M"B`X"GJDQEV$0.$R`?Z$B'XO`]GWDKA@$&1X2)&7LO_SJV/^^S\?_SSY3ZNQ
M`R;%#I+1JW_FSD(1`8NG'9"\;GIV?GTB#DU01:/Q3GPX^7AZ=O)!')^?75^>
MOO]R?7I^)BX^'9U=36BH18=V:8!.-0QFAJ*(,3P#LC^DP!M8NMU'FKZ(P@OB
M?I_<#CQY&G3%;KVQ_?6UN')OX8BPPG]I"(2D"P9!](!.`E)_,$*LDS)5HX6,
MQP4/)&O#4L8U<9Y&N0=C+<3H!;0[\WIE+@A`C\,/YX=!X/(&[L-3Y>7=A$[)
MTG+KX$"I@H>6*MC8;4R+()LXE4\]7W1(_\_.#BB^81(@V[B2%(DC=G;H-]\+
MOK[MJQ\_P0?QC;Y*[D9`/#`,Q;"\4M]&(9+4($E&;]^\&8_'M6^=R*^%T<T;
M6&KK#?[\!A]\16._N3<X?/V/-_B.]Q;_"Q__?U!+`P04````"`!]56=`/+5?
MG=@'``!<7P``%0`<`'!R<&@M,C`Q,3$R,S%?8V%L+GAM;%54"0`#/H)73SZ"
M5T]U>`L``00E#@``!#D!``#M7-MNVS@0?>X"^P]:][6.+TF+QDBV<.PD:R"I
M#2<M^E8PTM@F*HLN*?G2K]^A++FQ)5%TZE14=H$":10.9^8<<F9(D3K[L)RZ
MUARXH,P[KS2.ZA4+/)LYU!N?5S[=7U7?5S[\_><?9W]5JU\NAC=6E]G!%#S?
MNL4V(PJ.M:#^Q+K\4?U,80'<8IYU'X!PR.J-=4NX/;'J[]Y8S7JC:=5/6\?O
M6R<-:W#[LY_/:]U6X^BD6CV8IK>M!OX[R=!T?%A-C=9),T-3\X":CI6:&@?5
MA/_>9O%47VMRJ??M@0BP<`1YXKPR\?U9JU9;+!9'RP?N'C$^KC7K]>-:W+"R
M;ME:"KK5>G$<MVW4OMS>W-D3F)(J]81///NGE.PF3:YQ>GI:"_^*305MB5#^
MAMG$#\=TKEU69@OY6S5N5I6/JHUF];AQM!1.!3%X=<:9"T,86:'^EK^:P7E%
MT.G,E7:'SR8<1N>5&9]-L(-&H]%<B[^^\XD/$MG^Z(IZZ"DE[H`)*HWNN$2(
MD+6*)35\&O:V_/@>T+$+*YL=V6Q:DRUJFMW50JMMXMJ!&^)S@S9N60]+'SQ'
M:EX_E;T?2+G4_>K,9?:60E<RQ?@V7I&^D(X1$0\A)X&HC@F9U22.-7!]$3\)
MD:W6&Q$UKZ/'7]M"@"\Z`>=H6ZS`)0_@AFJ_IK>K_78[.T1,VIXC?UPBO'/B
MHAVB[7<(YRN,Q)^)&X#"?CWYR*]'Y+?YMHL8!F(M^-\$\]N3(VI1$\%T&O96
MI3@(8OD19U,5R+%>]A1/+,8=X.>5)F:K0*"1;"8-(&[%6@`=3WS,9`70V+9M
M%J"Y0[`!37]PX2/X&J-/)58&TM1^1UR=F,55SYNC=8ROT%0%-UO-RL#%ME\1
M]N_,PG[`84:H<[F<@2<`IWO?GP#7#=8ZTF5@2@N%B,#W9A&X-O(?<)TKQN\P
M1NNFV!21,E"5[6_$3Z-N(D&Y=)@!OAKU7:@-R_E8[Z*/-W0.3L_#!<N88OI;
M6Z[.+#F"1C.3Y[29*7_`V0RXOQJXQ/,QWLH"<R97+6JBE&)&TZ1VV,S:X(:2
M!^KBRA$T2H&4QL55_0.RDJ6O?KV_(U#P4,H&/JO<WW78S`"-UO(`G"%;$5=O
M5&5)E(F@=)?-C,N1N;>$?P,?U_@=)K0V;51B9>,JPWDS8W2X4-DK4&=)E(:F
M3)?-7*#=^<S^-F$NVB9DUO=7"G)2&A>P!<JF4^:%IN3N=NXV+7@498.=V-U,
M.&EHSG0<NK9C0"B6^!TRHSYQ'YFOBLOYPJ4A3`<(,Y/J$'Q"/7`N"?<PK0C,
M,\%4@@U.%T;4IJIPK2%<&@IU@#`SS=YS("+@*ZV@F-*X-!2E.9J?5ZL%+T]Q
M0;U7FLT5-:<84KJVRYZB*M)):V5S-ZVE=@HXJ^V\>C_<(8*>9[,I/.6\0"3Y
M[$<#(CV_?<Y><R;$@+.1,N<];E5`P4Y<$$.8@Q>`>CMRMV7!TR@%W,2,V?7-
MS*)7KKS[HVO&G#`@`)]3&\0=SG3E6B13R'QB5![GA[1"\F]_!IS(?9+HM:GJ
M'5>R;0'S&ESL<XSP;G9X(FM44SQ;J.!!E0E_8LXK_#9S^E^#A[ZY:'';F5*/
M"E]Z.H=\NO(DR\)9+@*FKG0%R/.K:'<7DXS+PE=<^;2IY<I"6H[W9JYLUY7@
M#2:H*_2\PSST-$!G(Z^9)RY@Q#BLV]V3)8C+)8Y&](9ZA*]ZB)WXR/"OGH^P
MRDC3\WS@(-1GN9Y/:X&9\*=;.KGP4>N"A_AO&`2)7?PTS,Q,1[$K\;FP>'FG
M&-VI`O\]DK.0,S-[X8)(:P)OMRN8U52CDSP\(_6F3MK(E2C_7F!%I=YUR)(H
M#\$IWNJO'9]Q/TQ>(;ARV4+T/(=RL/VG;(TE.WGV7;*DRB)BDK1BP-F<HB,7
MJT]"'O3;9,^VC<N"<.=4';!T._D_ZNI.RCUIV9VQ.VZ;&42[,,-A3T-$\/\N
MA$#CHG3*N$]_A,\5E&F)EYY)/9#,+'FN"?7D`.Q[<F>X/]HZIKHYHZK:<-'K
MH/0DZP*5O\@O9*\V/)S<F\X(Y=+.SH3PL3)E9`B4GL<L(`P].X;FP05!)SML
M*@N[O(B;(5!ZVK*`./B=GV0=*Y^LWYMUJ5B?ML;@'OHB+^%?,7Y!G"X\I-[Q
MV4.XM!SM`U#,EZ+.V3,^9A"VN7LIS["$_F\,RJ)))5)N<I1@Q)28]GH1JV-Y
M%@FZL/[9\Y)WF]6K^7SQTM*Z'T@QQ:95)4GKXY&J7L^JY5X@J5NPQ&R:=AXO
M:79TK;H+(^`<TJ]7[T6S5H<OD'\](#=[",8/C)UK:T\*X['L"Z0[`4_,[,&V
MAS*KIA13DG>BLBLH/?'24K8?2#%KANWY).T/H\C&_>AB1=['6+0[*2W;3P$L
MYMRT4BL#!5E8B%]]CY#620&?%"`KN:,C[EG;_AY0#IE7[A4>[M&)F<-:06CB
MDP1[`);_>J*049UP8?<3&/M0G9!]>0PGX3'T;#$Z;0,XX7&%E`UWW=F\1R_E
M)WL?R,P\BY@!0O0=RU]+4FF=%#RNY>VE?@B\N%P"MZD`U?V&?%DSQ[""/N48
M3H?'S!?E<:2]8GP(LX#;$ZP3^Z/<BXAJN?+SJ8;%T.23_N'3`7#*G-VU@(+;
MO;HIF.JGN)QRHD5[H56"2ZG/"$EJ5M_C@,@+A"0UJ&A7*6EG%\\V'Q7'7_X%
M4$L#!!0````(`'U59T"^/P_7V0\``$SD```5`!P`<')P:"TR,#$Q,3(S,5]D
M968N>&UL550)``,^@E=//H)73W5X"P`!!"4.```$.0$``.U=;7/;-A+^W)NY
M_Z!SOU:6)2=IXDFNH]A63E,[]MANVOO$@4E(PI4"5("4K?[Z`TA1U@L!`A0I
M@!G/9,:*!(#[[`.`N]@%\/&7YVG8FD/*$,&?CKK')T<MB'T2(#S^=/3;PZ#]
M_NB7?__S'Q__U6[_\?GNJG5!_'@*<=2ZYF5&"`:M)Q1-6I=_M[\A^`1IB^#6
M0PQ9`!8_M:X!]2>MDW<_M7HGW5[KY,/9Z?NS-]W6[?5+.]_29[>ZQV_:[<J>
M]/:LR_^]D3SIM-HG=<_>]"1/ZE7XI%/ED[J5/HG_>ROCZ21]4HCPGX^`P1;O
M09A].II$T>RLTWEZ>CI^?J3A,:'C3N_DY+23%3Q*2YX],[11^NDT*]OM_'%]
M=>]/X!2T$681P/Y++=%,7KWNAP\?.LFOO"A#9RRI?T5\$"5]NE"NEK2$^%\[
M*]867[6[O?9I]_B9!2NY>)D@6CUFO8&WG?3'(ZZN'SYR'5,2PCLX:BT__G8W
MW*V'<-0)T+2S+-,!8<@?)80XBQ8S^.F(H>DLA-EW$PI'4HR9`$+TMT+H'T5K
MG7W$X9\A%AVA'<`1B,.H0N%VVZY*5#(%"-<C:=KT?H(F;;2G</H(:952;K2[
MEX@3+@WUXT?87D&O4-"\UO<2%Y.H7^FX63:8"I5)5-3ZC,XFO(ENM]M+YXP?
ML]FTCX-+'*%H,<0C0J?)3'74VH8GQ/HK1N,0+GQR[)-I)P&G;&1?">\C$$'1
M^LUH@#"?@!$(;PE#HO'S$#"6O$RT9=5L;E^I/X-0O"ON)Q!&[!90_L`)C)`/
M0FU)%4U4J-,AMZVFL(SZEC4KE.5^PE%.2!CP-_LE?WBTX#WJAJ.FYV0ZXS^)
MD3B'Y44V>T"%R,X!FPQ"\L2&.$`4^E$9Z7<;227D[R:$DPY\Q<79$!0^1Q`'
M8GBDWXHF]QK-XH$_?`R)O_&84-@VA.9.9<DT-@+L,9G+8M8>`S#K"$5U8!BQ
M[)M$=>V3[M*8^7'YM;?"S['!(?_(LJ>$X!&&R;,]>6'O)%62'9D?P.-+-U')
MFQ3TNIFL+XSVZ:;4_'V2M;=\M1@9;"-*IAHJRQY)"L1M$<J'TJ<C7B-F7!(R
M$S*+.2Y]79WY!$>\#UZ&234^<.!8?'CY/20,!I^.(AK#TD0QZ!^/R;P30)1R
MQ#]L4\._\M+>?`?'B$44X.@KF.:1(ROJ]>JA)]?8*D>40O2,JNX.5X=1^SF7
MG(*03UWP^5>X4.I]JZQWVB#%[\J>:;YW<,V?QU18#0/$N-'P7PCH)0XN.!B)
M\F7%O3>-T+]"_(R"4TN=?X!";F)P6<:$JKO^1DGO;2,4GR]YIO,W!]?Y`P5B
MM?!^,7TDH43;&V6\=XW0\[;,F8;?VIK2R71*\'U$_#\3PYK=Q)%8(A-"JN=W
M147OYT9PH04D(^C=P0G*;/@'WJR$BO4BWOM&*'U+Y$R]/Q]<O7TN12`D&81`
MUM4WRG@?&J'@;9DS#;^WUH%O(44D4-LMN66][DDC5"X5/M/]!VNZ3RVI5+`!
M_R[/\U:6][HU>;0U<9`+X,5QLDR$,&GU:5B5]KK-\%L5XJ\HL.6\_@[#\%=,
MGO`]!(Q@&`P9BU]`YQHYDCI>MTG>K`+$BI3#^[6I;-](&.,(T-3SD(V*W+)>
MMQDNK53XE?)M>;1+9_L.S@B-A%/"$4EG)E45K]LD)U>.8<7(X?W=5+3;^#%$
M_B`D(%+2L%;.ZS;#\<T5?*5PB?O[L;,9%ZDC5*(93'P-FKP&35P+FI0GJL\8
MC%C_4807_+RY)K]@`\(G4L&K#YZ45[^(`O=Q(/Z($/8<A!P4ZT?G@-(%?R5]
M`V&L&CY:]2V'7'8)R"=*%XMTR%D8/;Y/N#7'[J`/N<!\2O@*HZ59H1I+BFJ6
MXS.Z9!5`<&F,#?&<"T7H@DNH(&6]F.58C2X)6R)7'YLLK_1;"F<`!9?/,X@9
MS!)S4F#%`T2CMN4PCRY%>DBJ#VGN:Q'\!X;!@-![/@EKS&>2*I;#/]ISF5S\
MZN.>^Q*CRT:&P6XPR(R"%YFKCX:6U_M`J`U>H3D,AC@">(SXVRX56/U&45>T
M'$729:801/5QT7W>.F0&:;2X#4&:\LCMR)GP$]1$J:K9#CWIOVC4&*J/K^X[
MDQ5.8;8C3F:3UWIXJ;H0:WDE7R'PB$*N,ZCCWN>4;D*LJ4!\ERSBS&.Z!0OA
M+NE[B9L5;(><9)I6NXF[&-SRXFD,@SNR`*'`I45-7@W;D2AC;F0@7'+?EV)>
M`_HG%%&:<\*TK&!%-=MAJE(\29&X-,DEWNT:O&*>)#5L1[/,*%*`<,FU-R(F
M#XY=?]Z,DWSY77+H1<(IBJ;)*C<.S@D6HQMBGTNL6O*7U_*Z[J=^:L)P:=@D
M*<&;&PV+#6IY):_K?OZH'@K7!M,R>[LP:+95U.O9SBY5*ED^?K9!N&13!P%*
M'WX+4##$YV"&(A"N2:VRW0HK>SW;R:@E*-.#Y9+M?0<CK@T87`**^?3,N"D:
M3^.0SQ_!!5>[CU0S8'%EKV=[A:$$BWJP7#+*'R@$+*8+K<EQM[#7LYWD6H*E
M?!AN6Q5&UH37LYWU6H*5?!@NF1'K/@8.C#@JJNKUW$^.-<%2$*,[1,JFXE25
MUS3-US3-[RA-,PS)D^CJ`T(O2/P8C>)P-P5+8U74I)TF)7D:XG+)R-XP(&<4
M^B@YG8=_#F&B<ASTIV*'PM_)]])`KWHQO))'-.#PCAH@NV3+KSF+_'UW0Q.5
M!(F!>PMILF]=;^5#5KL!YX.8H7')YM\Y8J`?1Q-"T=\O9H^:M>U:#3A41`^%
M2S[`CJ3)/DDCAM(:#3B*I!B!2ZEX&UY]*J?N4D9:N@$'DJBE+\BV._`^N>79
MBJ^^UJNO]?WX6B(#G#L-<XACJ,X;W2K9(']I5W*7/"*1X7(S^D)(D*P^03I'
M/F3W)%2_@V65&N2U*$&XY(=\H80Q[C2-E"&@M5(-\BLVI7;)?[CA/BH0B1++
M_40ZF;W2.@WR'5087/(<[F'(VQSSH;O*UEM*K'J+2"M9]A^46I>\5U18'$I/
M^`(QQQ:*1:!@RC4K<$5H#HO9*JAIV<$H05DQ()=,@SO((->)V"A^P<V7D"2+
M=,6T*>M9WB17@K0B."Z9"COP3%Y6EG?)E:`F#X*3-D3JO%]Q6T>'D)?2MG?$
M[</))@J73(<A]XDI9%&V13R[%T/*3'X%VWOF2I`C!^+2TN-+SQEPT&F^<LQQ
M+@$3S#[#$:'+ZT8>P#-DE\\<.8>`,*"+Q,+]2K!8_.`*#9/.F`)7DES;4VUO
M[RO54VK5ADL[F5<0EMKYS*TTM:\MJ6%[OZ")FZ>`X-)4\!5&6N_.C7*V]P::
M\+`CN$LC(\N[S4*\GP%#OK"#41A'RBA=04W;NP)-&-*`XM*&_P)QD]?^!6)B
MX3^F6JM:)5NTO:VP0HY5$*LYAV#W$C3QC?<[1.,)%Z`_YV_=,5Q&CK=O3"@>
MEN4;L[T1<1]F-KG>3P?J!;4#QX+-KN-[#1F_AHR_HY!Q!BCM^*+#$YQL;7U&
M6OTLKUY=X63%9;L*6E=4%5`J0>+0VO^6A!<;MS?GF1IYY6M;YY?<*JU@1J9Q
MB54A0?/]$>1=K%_S72-1FS>5U\W4"I9#C&WDJEUO6$]%>7EI:<N13NF@R&<F
M'X!#?&SO42VD)+^"Y0P!0U:D&%R*7TKV@!<2I*QG.;?&D*<B*"[%+M?2H@LI
MVBEK.>_,D)8\\5V*6^Z[7[HY1^/D"N_2)*9S0:BT;`-N3U3)[M+L5#(08?NT
MF]*!B!/W)J1TF\Q%3'GO2.\:3/:?);_=)+*QRV?N;B.F#$T8MV4[SF\\GYF"
M<RDW0P(@G1XJHEK1F.U(?05<%Z"K)KHKB5>HNM_E<QB+5>DKY"?W,XPIA)*]
MU*7;:D($?B]PU42'S=A+.U1%]*D;:T+D?C]TU82*501^H0!'>=UJ.@O)0LBA
MQYU!.TT(YY<&5FN`5R;0LB/M3YFTH2:$Y\LCJ_X2\#U-&EFG2U`\`OYR%JL'
M?+I(DNN*;!JSUFS'\(V-&G-X-5PV7I<-N\QB,"/<K+4F'4Y<$EX-5YOOL]+\
MOYBE!RP_$,F::W[?O8-_Q8BA""[WGZ;@[Z!/QBEK16=(UOWH)IV@?`A=U'![
M>[W]3J3XCD;0CT0>M_'D4]$3[!_[7&TOTH1<PVWS]7:6559X>KPNQ/ZBMFYC
M]"S[AU!7VX&,P:^ZD@N+=+LG_O9]/H%2(3:+KF$T(:IE.9WJ]L^K+GE\D`+/
MBD,7=E;DG'F42:U+W68M^V=7[W7@TSJ,%5%N'/TDKND>A.2)#7'`1?2CUY3>
MUY3>[RBE5UQGSKOX+25SQ$?)Y\5O3-R`NMJUV/<C-->]7=&\L0:=)54*G$OI
M#.7"Z'9?+.64KA-E=^MJQG6S5;B^V$<AW!#X@50W3NMXG.7DO"H[2DWJ<6DN
MT#DK6M&!=*I;SJJMB\3\+J.I$(>FG"]<B4()-U@<DG@SVC@97.>P=;T&+&>\
M'[87:*O$I:D@N=9[.)T!1(5TY]PC&RL/+\JO8/E$L,,2+56!2VF3YM&N_!4P
MN_&LPQ(K54$U&9FR3`1Q3*W829U<Y,%?&PD6L>MJ0.AG$%S`QRAO1.I7MIR-
M?!@2C=113>*EA-`AGG.LA"[$BF1V\48JA8Q&117;J<P'9*]`"RX=C\/!BY5,
M>`'3OVMPEX$&#4],OQ';F="'G8?-].+2N3V[DN]>T&34(7:KVTZ4-B1'E^%\
MH`ZY3+LB9].5^BIS93W;:=,UD;F%T"6'9U?86PJY*2_NM864PF!Y+%MVKDMB
M[)OQJ].@[7SKFHC7A>Z2IR2?BV[!HO2$O:QK.T&[YMEZ#66M/E*N!#2&+R>P
MBX"_U$O2K&X[,WLOLDR!NK3W+`>XF"^VT:LOJM%OQ'9:=DV#4@77)=])/UI3
M2;39=DYVQ5%,`]0NO64ED@M+D565:J!HK$G9U.70N40V-PNR+,PTN:O,?;[Z
MC=A.<BY)6#[[9K`=<I!W!!_B".`QXO9AH1-56-=V&G*]%.>A=<EIYK!]"(/D
M1/J<X*;N@-9OQ782<K5TF^%V:2+7UT,E;VO;F<R5TFX&VZ5#7R22#Q`&V*_(
M5E,TYO7</XM@/W0ND;TQ.QD>\U)8U^O97?XJ28_&/"Y#ZZ!!-B#T#LYBZD\`
MXR^?PG/EE/6\GMTULFH9+4+JDA&FC[R2V=CKV5TDJY1H,]@N66!";&XABC^B
M6\ZY_2C6W9-MTMM+@`K>39KQ>LTYQ,`4ETNKWOFR]WE/I73!.V71"01:];U>
M<Q:^M`&YM)I]'\]FZ?8N$&;[!8=X1.@TR6#2L)`U6_!.F[.5WP"28^D[V9UZ
M8M.X.MBT7M([M;Q+WD#?TG#2-J!*3%E)0'?M(.;T"!IN@ND><*=3USNUO+>P
M-"%&$%VR3]>D[:IFN[5BWJGEG>M[#YMM-`6F8\[^]8\=T;`X&(?_Y_]02P,$
M%`````@`?55G0`Z&]MQ>)P``C#4"`!4`'`!P<G!H+3(P,3$Q,C,Q7VQA8BYX
M;6Q55`D``SZ"5T\^@E=/=7@+``$$)0X```0Y`0``Y5U[<]RXD?_[KNJ^`\Z7
MJO56C6S)6CMK9S>IL2QM5+$M1=)NDMJZVJ)(C`:W'')"<F1I/_WA07+X`@CP
MT8"2JDT\FND&N\%?-X!&H_'=GQXV(;K'24KBZ/MG1R\.GR$<^7%`HKOOG_UX
M<W;P[;,__?&__O.[_SXX^/O[JX_H0^SO-CC*T"=*LR(X0%](MD:GOQW\1/`7
MG*`X0C<[G`;>XP)]\A)_C0[?+-"KPZ-7Z/#MN^-OWWUSA"X_[=OY23P;';WX
MYN!@LB>]?G=$__M&\J3C:9]T].Z;5Y(GO9KP2<?*)QU-^B3ZWVO9>SH43PI)
M].NMEV)$$12EWS];9]GVW<N77[Y\>?%PFX0OXN3NY:O#P^.7!>$S0?GN(24U
MZB_'!>W1R[]_^GCMK_'&.R!1FGF1O^=BS73Q';U]^_8E_Y62IN1=ROD_QKZ7
M<4SWRH6D%.RO@X+L@'UU</3JX/CHQ4,:/*-]\!_?)7&(K_`*\>>_RQZW^/MG
M*=EL0R8W_VZ=X%6W$&&2O&3\+R-\YV4X8`_X]H`^0SS@?_*OGR%&]./5>=D*
M;V&7OMRE!W>>MQ6-A-XM#HNFGKV<1;JW3/VC-U7I/K+'MD5L]N7;6EN""4S&
M2YR0.#B-A@G;X`:6^CKSDFR$W!5^,,EOXLP+!\E<X023]C,>UK\E'UR_4A>,
MA_7KGG-2:;.VI,:=6>M%[L4^TN?7),,/&8X"Y@K%MXQ3X=B%/V0#`FN3-AK[
MM>9"-C;$25W3;;)=4VV.CHY>Y?Z7??-+,?XM(^H",I(]GD>K.-GPL65YFV:)
MYV=%0UQXWOPO^KPO<QD9;TW*!*?Q+O&QD=*B[^OB>+<&XK#1EG*RV1^.#GZ\
M?O;'<@;@10$2C*C"B7XN>/_W._'\*16B,]/;N`3]OXY>0?YP_BA8Q5ZTU5DF
M=0.AT\%")OJQ1Y^<XJ4?T]G:-CNH87"5Q!M3BRA$B4V[XJ6!N5>G4BLOO>7Z
M%!,JY@9>XC`KIUC<,1P<'A53L_SK7^CHFF$FUXUWNW>=%3\@(00Q>JF03<"4
M!.AG3F+!D*>4%0+-:@`4T.UY^Q9P2H=6?$X_ICI8W1/;P6M56`4.&!GB="X`
M=PJAK2"X!0TIBMNX,$5RBOT7=_']RP`3`6+ZH8E=^M4OPM=?X3O"7'R4??8V
M75Y62@J"6X6@30#DH_&>#C%">-3.(#($9OL@42"V%P_SXO6$VDCBA>=TR?+P
M%_RH!&R3%ABQ;5$E[S\G1)P245*;H)U2:EC<2J#1!JX,%W,A]V27)/219R3U
MO?`?V$M.H^`#]?<2\$K)P?"K$+@)AIP4"5K$B.FZ*$",W`Z,9Q,>"LU]<*D"
MNA<K\WKC,Q+BY(0^[RY.U+ZX3@GLB9MB2CP:)T,%G4TG/)'`L/ZW$PQM[]N-
MA+EP>I-X;+_U^G%S&[?Z/!>_3@.&S:9HS9><_XX$@1TXCI41"H&=K[F*O>YW
M//-<-=YLXN@ZB_U?K]<>?4,7NXQMO#)!U!-7%2/T+%:MA&QRR+D09UL@P8@J
MG%9GN$`:`<]^-<#6,1760=I<5E($GF]HLQ)[J)&`(;\AF'03@/UN!\GC)(1"
M9M<+KF*P\^W.A;8E?5+`GG86>C+W6Z<!PUM3M.;K+']'C,`.XL;*"(6YSM=<
M!5WW.Y[;QY69+HJ%?S<MN-=KBBIU+H+0\G)_>JFAO6,G-+K<9#<NYD:NB"V(
M9Y_1[[JVM]3TX`CN$EF*ASSXD\."D]M%\O320R-:"IDN5,OQ`H-L%C73Q_6>
MVA*JJ^+VH8('-)U!]%22VT%S"R9R++<Q,F^<X6\X#/\2Q5^B:^RE<82#\S3=
MX42"9S4/<'1!+KID&<X8#C@'*EB0X+$94IA5#=@X0@^8VB&$/B3-B_V?XG`7
M95XBPLHR']Y-"XSUMJ@2<)2$(L!OR7E/+C0LCB7`:.-7AHJ98\-BX^X*;^,D
M8X'IS,ND4Q`E"W0\6":X+&Z:[[&6#$AP6(T`SZ8#<,Q7":*.:*\:0?,B_G)W
M&Q+_+(R]KJ3^;CI@;-=%E(!!$"%.91/$$P@+B]8.`+0AVO7V+>3R7JS.2.1%
M/J$KTS@E/2=2C-CMY/NJ%9(GTUZL4,F("DZKYU(F4RTV5LU*[K`&%*79Q#HX
MA+.N99KB+-6PHP8AJ,6TA&QM='`")TR@7];KZ].;:[M`[G[K3<A*7CD<.$^\
M=+V,`O;/Z3]WY-X+J?VDR^S$2Y)'.E?ZR0MWJE-(>OR@4-95J94621GX`3?^
MH<*Z0,L,%=R(L]L#_VCM?/8![UG1\\]QAM&KKV?0*:L<VX9\7U[S?2T0/P<^
M@XK;UIEZP%='];S%=R2*F*)T8'_$WAP!P6VCV@&LAIA^+]4-TJ4;^<JFIS=S
ME("S$]^/=U22*^QC*M5MB#_C+%\QJ^8J*C;8F8M:@=;<("='>_H%HAR+(MQA
M<5XS4).DHDF$^0S?"\/X"ZMU@U9Q@H)X=YNM=B'R"A9*\AM.8FYSOSLZ7M`V
MTBWV,W*/PT?K(\+4KU3J_4$GA!J&UIH>ZE@9G*\XC^[I@^/DD4JA\`TU,E!?
MT!"P"93R9PX/>X:N*Z9U0S3J3R>LK`NB3:OJQ"><%5TF>.N1X/1ABZ,4TSG!
M1;;&B5@)]@^\.MR@-J>G3A,Z.1?*V?A`Q!F1X'1@.!ZG&!9L*=<LYIKY^7Z*
MQYNP:R<&(&R:CPD"H:-L?\9A<!8GUW1VK3&'E;%8B+QU"BZ)P3':`TI\P*@=
M,!1S#=:4EL],4THM1KD4O>*F\HV]6>?<:L"''^7FT!V(5-@"M"7KFJ]%F^W#
MAS.F*1>4S]AZ!R9(^QLK*[R1:5F6/7,Z(Q')\$>ZL@_.HXQV**'+2"&4>AG7
MPPAJ<+U*-,$B&`XX!]JSE+-+J^L_8VTJ"G#<+U!(?#;["E"&_744A_%=L5H\
MMC:`SO&2G%A4ZIE0T_`U[0=RX1EO<9(]7M*7P,L>_G-'MFR_7.T'E&S`2TVE
M`NVEF"!?(,X@BE<6+)9=P&!5MJ4J>*]*$?7U_=UF%[+RO"C`VP3[1!0>I;_]
M[GCQYO!;$?`]7AQ_^[8SYFMO]OWOU"$&>X:30WZ!WI<[AN^]D.T1V-PQG$&_
M4WZ,7ZX<;)BEW^6VXRL:_A9Z.=:[#K.Q`).NO&PON!1+PKGR$`R66`;=!K^:
M4B^C+.#_(_%N24@R@G5R^+JH02VC6]SF^ZY0.9'2IRGU^?+]^<?SF_/3:[3\
M_`%=WUR<_.7/%Q\_G%Y=?X5.__KC^<T_[&)8`98FH%5(@4__N/0>V?:R?N)'
M@\%*RD=+:&EF0$[I0D3.6/:MH+2=C#&\LYU8PZN!+DN\D*`<U#Z3'0ZNXD<O
M9*Y"RT`[.:`M5")V!VH8)2I)W;!10^F3@I2O2-AV4(K\>+,A*;OAK,BQ?6U[
M4T@-I@XC4"()W`H^><FOF)W@.XE3K1TB%9L->Y`I((-528\X@SNF8:J(%]#V
M,Y(R5?8)$666HNV5AP:\),:AQA:<A?`<C,J4LM\X9!R@=B$7NXDDD1Q4(77`
M&$RE+_8NPSV+K5G=+*)#VFP/X)OFVH=V*_&$?B.U;9]:"''+*+5$KN<2.&"/
M4TMM*>C18X5.&"`K_DNR#3]^$P4G<<2&;QSY5"B%):JX8(\W*L5OG:S:4XNS
M<E5ZBZ<8S92X^/3I_.;3Z><;$?<[N?A\<_[YA]//)RP2*-96O[>\MM)`5>M(
MF`:D((M`Q/ZOZS@,<)*R+:?L4:OT@Y0)N."#0OAV+80],1+4:)EE";G=92S:
M@VYB=.EQ'^M";-Q,-^="XOVX:M=QZ`45[&B1EXKO/0O?)`4?%QJ"=@T&^V+^
M^<%H7K<NL#L4Z,F="KE_]^+P\/`UVGH)NF<,?T#>+EO'"?D-!^CUX8+^RO[W
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MM<_/#]?SK=`SPG?LD?8L#G*DTG?MS9'*P*_#C50W"?;27?*H%3OI(`8=B3J%
M;5_[*8AJ"SU[XXR9S'GTQ,N0'Z?9`KU>'!^_61R^/A;GU1=OOA%_0<=$#/SV
M\)?DF%<>HX@K/O>)HZ^N[(W.O,@)C2$')+D';PY`"O=M<P?+:.?*]H[5J)TJ
ME[:G.A29S^=JK6BT9!39%6F%]"M^I#3KN&(><M2SW,':@]HX.>UN2>IO15H^
M@18%1EZNE]7:V32)(JJ#:FS<[/"(3J2:3:'/5[E"E@^)0FMEZWR>RI14A_64
M=J3C%;;)=LUM_>A5;NGLFU]RUWB]QI@=/&*C^AIGQ/="12*.+B>(G>NK(1D6
MD.!"-3:K23A/4:4@OY:3E[H`T^F%'<LV-)W"L$WM!G#?NS@4<Q8G'_+"W>TZ
MT!J'GXS:@=T--U2Q%;DMJYO3!E#1`NJL`VX]'WTZ9;M+N3\G$?TV#+TDM1R>
MFU93K=?J6%S/2@\XM=D^Q'FU]MT'>2[0TZC[W95]42GZ.<3\KK$H6&[859._
M\>^E]7Q4SGNJ1T"?<IVJ8U2;==6V%ZALG:\\JNTO4*-<U*)>+\KJ*5J(CJJ5
M/)MYG-"M)?&4`.)$LL*3ZS.W1N2GUGM.C>83#W0=9^BG'>6L'`NA"\>+A-\]
M&O"=KTN<7+,]/<7PKL-MZ_"(0AUUVCME1!<)$JQBMQI19L2YG3A?,EBU\JQ)
M=11%%(QB]]:!HX>:6%3D^?<"T8IQ<1'297G`1\^H6ERVC*E#?#72!`/:<SAA
M.,9JB*2&RL$L9RQ$!BB%94C19-$BQ.$B$VO(.>Q:0BFVCA4X=3;12/X<_F0N
M\4W/$8[H?">V[7K@WVN[#>Q;RH$5LBALMHO:7A9L*6Y?8J(@="0/ME_JM&JC
M#B6T&O:W8POM<:JXM.I5V*PR[;%AL)#7LOKQ!O.I.UL-:Y3MD'$`7]8J$[M]
M_0VC1"6I$V4Y9A(?]K)4)7#:]Z:J40.8Z<L*K%[A>QSML/KRFB8E;(YO2\Q6
M@B^O%)N36+Z2IE]:^FU>V[9VU^&1O0N*A_2P$S-:"8);^:<2^$*N/-/L8O5#
M'`<\\PTG]\3'Z74<JA>?4B;@]:="^/8J*,W0Q0IQ<I'&F#,@QF%S%6JJ1;RJ
MVJG%"\1G$1UVY=D'__;BLQ?[<-;[0Q*GZ642KY1E`:I4H/99%Z^)!_XK$C_;
MLSX=&;=SR:AE9&,DA+2E#C`VC:<+B8!%M.EJUV-%&/.[S74N_)'SP!;25HC>
MJNA<T**"V(D%U3`5<$[\SG(YZC[HM`I2]^(&<#F%0]KF'1VNRG+VN52JE96<
M"7:1I1*^M1H0Q'QVM[]<(:>WN/0RTH%/CY@&FX+8VO)KLKYW8U'6:P>M]5F_
M$0!.]G!$?4K(LF:"#8D(\R?L/'F_+?=QPDX*>]5H37$$A\BVJO'8-VUS;>IT
MUB:5,[P%)XQ<TTI:,U--$X&L!)=BJON:BO0!W^,PYKEP_<:NY@.N_Z96H5V8
M2M!SC%4X[)OY*$V"BB:V(S8`BL#6U-(PDG8Y+1T+L;@N-5F/6EZ':JT_'5IT
M=FU:\\(@<7/):>WJIBE%MKI&UEX;V[0YL>OY,4ZUK*Y";<?N:N+*+2_?DW[.
M""V62M43FWV-&)X*1,>1O8O3QG2T$Q-@!;*EAM@!:\C\E@S3]\F.?/!KW(0P
M"FN4,`!GMTB$;F>'"$(^@1*7[0E:FZDMIK*3N236LLGIY(7-OE'!NIU\H\0T
M=+89<P5G5"5Q:]6.NHB+TC6_QZLXP8+NQGO`Z>D#72S'24`B+WD\S_`F_4R[
MB'+2[@JY=Q&Z*4UZOJ=:R'J;J_LDJ6=B]$'LB6C_2+1_)A(/+48K_M@%JCT8
M\2<O4/W9J'BX[40\J![MFHN@6]%[&6O;GA-TO!O@,QMG=5+=V9'S>BAH+T^E
MS)=@[W&$U4DD,@X+WK5+;(EGI*1%%`(]SZDMKH>,Y:>VAI[?YG+G,;>C0VO1
MPT'RXZ+_=?2`]R)2(^CV`'(+@+/>SSC3"EO4Z4`MM2EB5ZYQ??;B6N%C'0U"
M^I,M6[0AGUD)^9$8R.08@/02G<;6]`W=E@;G$8J;08I3_>^]E/AL?X.$NTQY
MD+B/$]1K]*O1Q%!YA4U9BF*!.)?80Q1\]IR(N4)[X0-&P[;70Y[A652CT*Y1
M`>.&S#64.R9(L]:TF*:AZYJ+,Z;/HTD?2.K3+M\E6CFO0UMTR54HU-9V(8L\
M7EMIQHE,VNE4_QLF=VM6SL>CC_;N,/+SJYA%@8-XEZ69Q\_N6LZ_'0ER0RON
M1?B(,N!%ER]%C^>U#'A_7^R[NW_\'M$87+'PH<I*<9HW5-Y'*G!::<N%P7]2
MU1OS`=H';/P7!@H^Z,^KF:U:Z5,I=+/&I2.-=IM;.G2PXV[58C%<W8I;1=G:
MRQ";U>U2S*_<];W09S7SV(^%-V;E!]!M"PBGE]<+%.`,)QM^G2.EH/]/&:C[
M0AG9L":H`.S)O.AP11A!(ZH_V*SL/LH;UHJ]CW.%D+=8Y>?K+U;M>R8T)F=Z
M_,!W7>FIU+[^JJB8<+'JNOG%B<G6>.7B5>>%*<Z4B3!"9/L&)1,X6C`S(0EU
M!]LXHG^FRP>B"IFJ^>R8E40%*>(6!<+V+!1LE,D%,YI3&2M6HP*8U%J4Z+)2
M=_`39A,6A66T:6W5&BQ%516Z0S\+,LLPD?:PHJA=HWL!;SX(`L(FREYXZ9'@
M/#KQMH2N!GJAH>:#O:.@1X7V::R"'C&&@_,(Y2R.`$CKG;0J;VN]$,BS3/4+
MS'L1)6$`/KTD$;I]1D80HC*2Z`9TU+W>=\F\-;#4JN[U(J6+VEY132E&ZI41
M'0&(HJ>5I1"M0:.UGE?-Y%NTL+/W#E%;D]R\/&:%RN(,74/@XH+`>4.0)I<G
M.R:TSCW*4XD,NMJ1&5YKA2.U.N"+XD5-Z`^[A,IPR=\-O_:`_W:QY0F;IP\X
M\4FJ3(\P;PO^FGE#53MOH<_+@2/1"A+-+,0U'XM\T,K;0F5CEF^E'ZGW91+[
M&`=YGC/.*7F4G*L;;R4GT6###`.QW'G5^2`@6S=<X5,FLEQ58RZ8KEK9SAG$
MP7N^\<.B23A*Q75PRR2A="(`_?X15>DNO4?^]?*+EU`3SY^R*,TZ1701+(1Q
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M)U"YG)@9*VW=`PTPW[;S&6*[,_B=W..-=SSRANQ['I62)JZGF&&Y[WM,-![J
M?&;>"1KEB$ST;TV5GK@OZC5I+6?4;\_``6V9P^2"\IS]:N2V+Z)MV!I\2-M8
M70-'MM^0DL2]+0>L1^O>[])8/&@?YE=,J,#CUL-PWAFX'@AR5W:J\B.%9H9M
MV)I#>U4R=>?<K.((J>Q4\:O_V#F2LSA989*Q8YNN[E[I]M=@9_!4-K24=F*V
MHZ4V$L@4ZO_;I1E[">E-+$G#[?9B5_B?.Y*2#.=WR@GUKK`?WT6\%>X!%5YD
M]D<#)W+/WI'M7/#RD:P`42,U'.U3P^7SCP4JGUY<+UFLP2H"V'-,%GI5=)4X
MFUIS5TX4+8>RUW:&/I"QNN7Z6/6TU0K[&2NB:#Q/FNH)SCDRO6X9X:\JY1#S
MLG6B6JQ[ZZCYNHLIGY<@=#OG;V)#&N)Z3*S(+0]35FG\0%^T3W#D/\[F:\R>
MY9S7,>TJ18U5-OQ$/@E)/@LZX=NTS`71MG&24/?"R)9IBJGQL1$J7_F%8?R%
MI;J[[7#&]E3%]2!/KK)K3F:0+0UQ-\,,R=*1-#Z_6OIT%I8PP=+L$\[6L2H5
M68O=WJ$UN4(]I]C$5FC!B?@%[X+7GCF/U4S,`[94NK7'BA;S%)MO+8=13/"G
M/+G7!SY+)B6".(5<NI;4X+)G0"WQ>^PFWXXM&!PQ%GTM)#;B3MA1`UQ*,Y$@
MRTJ5J!,O79_1*8-.Y4XEFZV:4%T**$M!,0;$.5RK`&6F2JRMBJ5R3U)H*:H\
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ME::S-'0J@.MCUK7GFZU'$B;!R=I+[K"J;+F$`7:-*A.ZM3ABA&A/B7)2BZM"
M7=$K0ON<R/)Z3(F3UHI*#1+@,IY&!R0<R*@9?<S!<FE/?=%-<G5AANM!"M3S
MLB7C,'@13?WS#N.37V1'JMDXSJXWBW?LZH$HX!&4E+9^%B?OO>`#OLVZ!AL#
M9L"CTYK*M)#")S,E(U\"EJSL%!&BS(ASVSHB/4JSH*;9MM1L136[I9H%,VFF
M=_IYH&K+N[N$SWM%W'2OXQVYQQ$+G[)Y*GTZNS"$:7H7QT&*TCCD!63\79K%
M&W;!$/L->TGXB+;B@!F?UWI^WERPPR_0,DQC1"(_W`6L2+.W8;\Q,O8,?Y>P
MJXGS*[3*.\[%I(#.C>_HU#+-BA@N/[+&V.+5BLU]OJR)OT:$RHTC2A!2.:AX
MC*#,#N0B!O'N-EOMPKUD[%M^==<NV<8B<SG!P<YG86*Z\,?DGMV=3)\F!&=?
M1W%&\;#_<9$?"\\5$C>0;2E"'LC&8Z2T?9+PZ'2"O9#\QF]CON>Y7L^YC(*1
MZ>QGHC3/+;LZ,@SYWU]WG"V?>[ECSV#@3LV;>.WZ27DCESUB8#F/J!52XL<R
MP;=\DFPX4;'`#2)JP=MYSSEU)9&YI+<T6`S5X+[48#NC!EJ#@ID*;$=2>%ON
MV5GJ*?6%57_/_%K"PJ&IV(:CGHN[2JYMX<:])'GD6VRE=R=EW^2N=I>1,(^<
MLM^WU.$G*+ZE#\$I]=-EOU&GNW?G7N,F^Y*>7\28H(V7_,HTB".1$)W:<IJS
M`@?,.6IXGII+U'$[<.OA\\AGV8?X`Q;_5O8P\P1YC20'@T9`U\U&RG4<,>%,
MZ'G!_C4[5+)/+R@O:W(@MV"4IN+$#+^:M;+Q+\[+L`E)2+Q;ZH<<2`(P1VMS
M:3L`JC:-<9E/OJ_**;21&7:P6S;`3H4T3:_@17MFERQ.2[52AV06'<QV:.;4
MP:Y;D-M-OT-0&(U-5U#,&XAR-T;-9]GXZRIH6GV%R25K[],EG^39"EM/T?FD
MUOG6]Y,G?`=VG5.')?=[I2XSMNF.+NGZUB-!<<;Z5$0AEU%P01>NB3AM;>2G
MM!JT[,`TE=;T;'EK*&^&S[5Y0_EA=9?<W4#-"Q7S(+583\1<Q^FS<,:Z$S@=
M[?H?$]/M=TQ&=NO"6NK2>QR\D"IX'5E%[54Q74+EG"ZYF'ZE2NFWLTD_<'(U
M[(60]@MQ(EM`VW;T%U--PQFUU=/QD&2'@T\\L,TB.7$JSR+098?<`M)52-_*
M&3LJ^7E]#%O)!,/5*_3P`OJ<C*0\+KD?7(O]:FNY!,,UR[>06*&B0%29YCOK
M8D>?B)S7_;Z0;C\@+ZNV@Z/`9JUU0SMM;)*8&:G5#1/V%II19/J"S39,9(W8
MWC"1*Z>[8<)!6CF5N=]8^+C?6.!%E%V:C1@H+C3LVSI9L+06=V8L(U\LL?9B
MQZ[RW'^Q=0UO9G^_H]2TO/W7XWLUMO_Z'*^+M4440XM!(X[6$I%,EPR/_#^%
MPB&RB:'9P7Q;8XI]/=TLDR+S/0,LT[KO8;L.Z51UC52-N>"+U,H:^J2R,=?*
MD$RB?+.N$2FU=:9@R'!$:QJN#ISA##B_K885NA6U`VLG2I=1H'/4W:`14(,U
M4JZU/U,<LV"%Z@5[>6AZ(4Y-+_ADUX%3[Z,4+1(2^494,-M%1%J3@VG>6*;[
MQJPG)P"\.$CG:>Y-FDYS@"NQZ"S/HXR^$'(;XM[,A7Y>NZZQ0Q4=C[AGLYY]
M,$0E3IF2_4F)F!VW**YB=\@O.*R+5J0)0B&KGD[F"GH=G-0/`/JU)/8Q#E)^
M@T&[KHCN+-"@%5A?9Z1>.T]'<.?7#S4J'SDW$YQ&5[XZ*RKHN%("R8YNH%[%
MW!!;_F6`%;H8+YHD3N1J?&B:N-!3"`:I8K@B$-0=R>V*##D6L0;7ULTPV/CP
MESM^Z(Q$7N1/%+=6->:"7U(K:^B?RL:>2-S:3/EFW'I5:NMZW%H#T9J&JP-G
M2TL6=@%.?L_Z:7Y!INI*IGY>>\L3B2H]BQ)^NU'.ADH^1U8AIBJ5\W.#RTXM
M+$`&J>7H_:W:UJ1<;2A-"3Y*>Q8G5[BX\NMBQ98]V:-&A+:;STIT5J:"-#++
MJL#M.5B@0O#8C\IJJU+(SNK=U*YOLQ^-=5D'HRCL'(K8B+XJ35P6>57;MXMK
MD$G6'JZN.:99:SR%!89Y/EO7.L.Q*`B@GFXNI\8OHRSX'B;9,@K8/\S_W7LA
M\XR7_`!0,]E9X7V,F@'U/X8*=B[XV98._U!I88%$&ZCC=(,]'S126V:=I-0G
MJ)[6\(N.X!_POG%;;L@)52$]T1!3;?JB078*6%U_M]V&_+96+RQN:SV/5G&R
MX><H=:X1UFP!MOZ^MEJM^KX5SOV-O*C"[$1L=2(%61WC,$Y9^AI;:)2[)=0H
MR[8L1U<-$=JJC&\(3]!SJ?$&WW@/.+WTB"IJVJ2$/F':$+/CM"&[ZY.3($9C
M]52HGK`9%W8[C["Z!SS'BPI\EJ\+KQT']CK!.J)^Q$F\V<01#W*>I^D.!V=Q
M\E&DHBWO$HPEV5'ZO'"5(S15:4V*.5N^VR`8><`Q9T4EKZ6*$>/4$N%X(M3*
M8G2YCM/MVKO#$?%3JN.&L)L#MKLDW;$+T]B-!,V41.3-V`-*>_XWT%^KM,;@
M+HA2NDA/\O+@K"Q77DV#C=%\4I)W$KOB1MQIT=+99M$,$^=4JYAAY)D`5P1[
M@8Y4T_XJ&>S<OBY@:W[+?A:V=&1Q?JX6LL/PV2TL%-EX5TS$%\A+BQMG\@MG
M>$T9?]YKPO3NV+*E'NC*H\,26LN++C.`,]:+Y,Z+\OLFF">-0Q)X^2V^E^(R
M"_[GQ2H/?GKA-?V&^Q:=_*IIV@=U#U-U2:OF1J7=!:JUG-\'MF^;[?Z6K:-]
M\TZ$#ISHH'A`!T':_J2&U70:TUK5$_$V'\I0TPU^R-Y3,7^=R_%T/>KI^*#N
MCIK%'>T?A7YF#T/\:4_5-\W0<3(WI=UQ3\9G*<QS4O>ELDW`.[-%D5,2W5U2
MZ7V]9',%$^S=V2KA)15XV09_0>W$+&16)4"OU>Z%4NMJ[7X<`2[WR5U$5L1G
M!]1:<NF,U)H-P(8(=)5J!0_VC*@3=$Z,DI;4`UU[&\&RM2HWPR3DGA\[@L4'
MPG,V7"Z#>UX'^"9>KE8D).Q*W6M_C8,=.SY:H=:ZTV]LV\#[BN.[HNL"F9R*
M%;)ET[FB65XYHVQX@8JFV=RXRN;"V#AWUY!&UV22KHGUNP9V(W(B(VIO74YE
M04_`H^B,[1,T_C1\BFK0G,*I.#%MF+UWAOH59V8=TQG39*[%YFQ%6KY"8S;2
MSPM]TK-7E8[S@]5",_4Z,TY,%&"U`CX6J0>]CF.1FKASP([,8N)&S;AA77HA
M634DG0M2NZ&M$]9H$#4>A-X128.7=$B-LBMRMZ;S\RBXPB$[JWD5/WIA]L@2
M%$CORGI8.W#)A`-4;!]?9DT@T0:'8MX*RIM!E7:LCGGN:0R68C84RK5TL\$X
M!K!!U>@WL"'WK%`Y)IB!TNHP^*^IM%:.ZQ1:W[#R*E'&*OCN3]_PM-:MZ(]D
MWQ])WA])WA_^_A$V4UX'F_4@AV1S!<SO&JK<C;6?J^@DS_4SPV:EZ"C3?=54
MA:LV0W5@#0RK%6@^AS;X6AD:^LASP9:T$L(TN!VQ)F7VD1)X3BQOP15SPZ;Z
MTYX,$`A83J(R<X^"DYAO=>/(-QVLS-J!+2AAJ&+7:81B%LD+2U1;<&TX<T)9
MT"(+0P#<JK(P"+V.6:G.,&C8D'MVJAI#]+'KQ$#IBK[.66OO4#H0Q<"'(-=Q
M&.`D%57J/L>9SC#:PPA_4%*E1.?1R9PAKUZ)&(L3`^,H;;[25@?\@&$ORCJ/
M'/9#S+:QF(UK^FTX8$)ZWEUJ3<X-9%-I^=4P->V;G,'090Y4T%EF>72:1U19
ME+F^Q:JW$M1N!7I^::!>QV2KY,XW&PI^!]>`=A4%GE&:@K9C.FF,6,#L'RJ:
M$(Q'D"YC*DDIX7L<X14Q/1T[N$G8K*#ABK>V"D53',XBTEAO#17-N3>XNMT+
MH%E$(PVAE5$TU@HLU/HS&HE57'9J`&H-0/MZ@*X-K'/K8:4<G_XXJ8,GJS:A
M=R9%P6;;*M0G)3KAY,0@!:"*9=O0.*&A@2LXZSCUDHA$=ZQ2]#6K?*<Q7$A9
M0*U"(7@31@4I*^R..+$3HX2!!FX/$7T8:II`+X#LP5]G9)#S6#4`E2/ML@`G
M!H19E;!I`[WC0#^*1B1$5PH3G.S2C/J.I/<`@I('+LVY1W15J8F2WOX!@MFU
M`$O"U8%2+=]6"T<38[LWL5_-9!?=NI54*L"PGYC_)!312K8WU42>6)]6=/2+
MIFPFT&N92J_QVER>_'7G)1E.PL>RQ%OE4@VC()=I2Z!S.7,UFZ@L6Z@4$JQ>
M)N-8A,P9A2'GB`/!W)PY#D6R(U:KL\32;,`=&U4-&'U(=6,E9DD]9^RO=\%F
MB$G`&`9/#V&;TW'$-J/CC4=:LYWJ4K63'C9V(1&YM>07>3XE(?I9D-J,6$PO
M.FB<0@665HQ"CI1<BX^4[8_T,_WGUDLQ_>7_`5!+`P04````"`!]56=`QD8O
M,]H4``"N0@$`%0`<`'!R<&@M,C`Q,3$R,S%?<')E+GAM;%54"0`#/H)73SZ"
M5T]U>`L``00E#@``!#D!``#M76USX[81_MS.]#^HSM?Z;,EW27QSUXQ?KYKZ
MSHKLI.TG#D1!$AJ*4`#2MO+KNR!%F9(($"`I@60]DYF[Z+#@[CZ+MWT!/OWT
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M?WSC!R18]OT)9?.(Z:..Z/>787^#^]]#,O7PTJ7O7#H_$2U.E)V<E.3P(4`!
M%KW?3VZ)#U@0Y`TH)Z+S*P]Q'MF5-J^:W97E^A)YPFP>9A@'?(`8?'"&`^(B
M3YM311<5ZK0/T^P<%U'?BK)"7AYF(.6,>F,8Y#?P\6`)%G4/4K,K.E_`/V&?
MDR=<G&6S#U0HV17BLUN//O.^/R8,NT$1[G<[*<OA/9LBG_P1#530Q&7(B8\Y
MUV9.1E]:<^%\CM@2`"-3'P:DBV!R<5T:PNSB3P?4(R[!^FQJ=E>6Z[[_A'D@
ML.K[@UDHUJD[-*(,!91!_W>>J\VQ1E=EN1TPNL`L6`X\%,_<P,9"?%&;27D/
MI7D#F_>#(9G.`@X=#[$'/XR'=(F\8`E#=4XBW>A;@':'I4=4-)F$3,S6=P2-
MB`<KBX&IRNC+\I62$?ECET:6#UML$]Y4?92?*ZG[V_;,'/TH9F:8ELUV))K=
ME>7Z&D]@PAM?@2H8&86B3S$8]%4J[:#\7"26L$?T8H!OFJ;L]V\0\\$Z^!WE
M?(!9M/!J,Y))7-K"7N?^JY`'("DS6$&RB,MR]'.(6("95VC/G4ELQE'6@<-C
M+.[?QU,Q18KCQKDX;G2_CWA>_0R+$9;L9--GE_.-OF*B@_$(ED,H'$B*,;M%
M?6"N8=?'@A)\I^@/QODC#9!7B.<4Y<&X_8:+Z7=-=SB]PER#B^GUE;)2;H-=
M3HV5N:%%.'IQV%9$D]@=L+'!('Z!O=M8'/'C7T4'I3P2XI-_^N11=^,SGG#5
M4)8W:8M?'%7W%R,>,"1.>'%'GI`SZM[1IG5.8\5H<KG21:3G">*C2-DA/YXB
MM#@1W)]@+^#)+Y$\QZ?=E0?IN]7/SOJD^8A&KP:18C^[H=-->$VC>,$V^4;,
M37J$O^Y`N.GP6K4X641.CV-W1KPU^A-&Y^;:3'BA.9)T*(,MX^<CH`@YL$@7
MHB/AM`'A)ABVY?%ZH&`^XOP)LQ'=&'MVH(3!A/OP5ZX#Y[JQT[,$J1R7'/S2
MK-<*0X[==U/Z=#+&)(8/_K*-&OSDQ,8[Q%,B;-8/OJ%YUA"4-77.ZH+8!A*;
MJ"F8EV)V&+U?`>,,>7U89E[^B9=*Q6^U==XW2O.[W">J[QY<]RLWQRWA+O+^
M@Q&#W?8U""-1OZRY\Z$A""@$2$#H61H`M\3#[`IXF5*F-O^-EL[W#5%]-N^)
MUL\.KO5'AD1L^V$Y'U%/HN^--LX/#='T-M>)CM_;FMKI?$[]R/47^9'X?1B(
MD*Y@4CW/*PB='QN"AI8H"40?#@Y1LGM_A&XE8*2;..<-4?L6TXF"OS^X@B^`
MB['@Y-9#,G/?:.-T3QNBXQVV$RW_8,V,USY#Q2XFLZW3M76(+FK9.^PGVO_1
MFO;C?57,V"W\EG7F5;9WNK4Y]VJBD"E"@L2Y923$#E<?AW5KI]N4LZQ"@-=#
ME:5MS[^PY_W3I\_^`T:<^GC<YSS$3+GCD=`XW68=<15BK&$Y_&$WYNU7ZH6@
M/Q8?160C([.MTVW*.5?*_EK]MHZYJQ/X$"\H$\D+0B+I_*0B<;K-.OG*I5AC
M<OA#<,S:(!QYQ+WU*,H*F62V<[I-.0UGLKY6N>1,_.ED.QZVGR"99BJLO>A%
M!E^*Z)H)^5N`K8BQJQ7Z%F-[B[$U#,,+SG'`->:4S8:-B+9)66\)=B(;_L(?
MBS]$AN<3\D`?_"*X0HPM88OS*_)"U22K16\]NK>+7C;*NM*T!/Q5]CX?8A>#
ML#"!?</!:I.K&L8*,NMA1%VH<X20QW.;!;$H@?"A[R5(IX`TW<QZ.%(7PBVF
MY='?9D$V8'B!R/CF1638XZ2T*E9*_N#4H+8>!=4%6$\6>?RY6;C'<OT#>^-;
MRAY@Z=&8B24DUB.KVK.P7`!YR+N)L.IBF<AO.T9K!N`KU_(HN"%JP58V^T$Q
M@P,Z"?`=><+C/NC>GQ+8'\2BJM=1-:']L+`NK/ERR*/QS1J>TO)+-=`J,OMQ
M:/T%5BV%/!F@62#'^LB=?.V'KLVFW72<>C=CH$D3;JI(5\./E-&Z&?'N'`':
M<NA,SM8#M!0':WV/PB:!_9"Y#">U2V%7BO;XBUB8%/R#3K2`S:*P'X4W1E8F
M1HO&K!#Q*V*_81';OJ)<Z]2B(+,?WB^$LE26MCB8(B]*2C7Y*$LH[&<0F`&L
M$*,M3B0C6+-48=MS9(9HM@25N8ZL[HE3%\6(F-3F93/R@)R<RNG:]BJ9[)%S
M!&G+9)QQQXY.<HZ,R.G9=C&98*R6HRUS<JIP*#><OM74Z=EV)>5`)!^[VV*T
MY0PT'I.8\0$BX[Y_A18$%HF4Q*K=<BZQT[/M@BH$N)Y@;3DK#7&`Q(5CR0U;
M<'`(YV%T&9ZXBLPEJKD[G]CIV?=E%;`!/<':LFX_,HQXR)9:T_IN8Z=GV[=5
M".-L0<HOU-(KSBSOQ8SV8$[/ME>K$*;9@K3C#)4^3:ZNKM3%-X_4Z=GV;A6-
M.,BDV1ODARK%4-SU7?ZV,GGG>7>5Y5.^%5+HWE2FI4OI1/=60_%60U%/#"\\
MCSX+R[ZE[)J&HV`2>KLIRAKQ&)-^FE6!82A96PPC?8H"SET2@01_]_#JP8"+
MN2A'C=\/4-Q'KXKA5?()ZV4>1N94G=!M<6NDO#6PLMZS2)WCZ)3W>OFXCNM2
M1FV].,0T_I`O3UO<&3N76UV$P8PR\L?K#ER-^3:5]2J2@EAGR-'".$0L972E
MAQ&^,87U`I)2V*YE:$N%P893+I91UQ<9M[9>+F*"9S;_E=4=[&)IX2*)U=-9
M%JH%Q7?7C&A$HB44;PX-`^N7Z_#-D?'FR&@:ALC#<!Y_PGZ(U24T6RT;Y8S8
MY;TE\(F<U_O)%TK'49P`LR?B8OY`/?4V44;4*)>`4HRV'/*_,/$<&*,399)"
MJE6C#NV;?%=V.+<:P[Q?8(9$\N.J#EZG0DI*TZACN4J*MAS*'[`'?4YAPEG7
M':RD52V=4B+K1W,E9I+%5"5-2];5+]@'O7C"JSR>$S]ZMR4@3S@?ZQQ*ZV?W
M`H#GB]26U78(D(`ZQ:52U[!;]&@4,\@'74EG_7*(`I#G"=06/_J.:DP6:?OW
M0Q1`-E.*RE;G>NR\8@^->$A7!\[7UO9O@B@#Z*8<;?&6]_T``Q9!<IW4RM>J
M<G%F$=B_*Z(`M')1]N@_M^#!%C9["PJ+J\9"T-%*6=3GEWA"&4Z]TGWS`EH#
M\8F/V#(ZD7RCOGB7'>3QHF$0*RW7"[Z7K]J_V**0G>U5'Y7=/61U=5D+O]+K
M)>R*U5X9"87]>S),#O4*(=JRQ'S#@=:.8:.=_3LQ3%#<8;T=%[\EM4M)AL\E
MXL059Q;BA8$R52*'TOY=&";H:@C3EOO?<D2-MDG7A+L>Y2'3\KT6[-'^91H5
M6HA*2/N7RDDJ//Z%R70&S%]`QVB*5XE#VT\]YD\)Q3NS?_U&&5PW+:6<%O;G
M]K60SA,)O%F6MSJ`@4+@PS/8!Y$G;"OK)\UIL=LH-.C?,H**S,0Y&LW++VEK
M?E"L"#%XJ(_%!3$O1"M5*(NN>5E#$BE:`G(J7_<KGH\R7UN4MJU/$I$,)%GJ
MR:X@5>'IU>NFE%Q0E73U22@R`SA/J,H"GK;0WK[](Q?F;(+Z9!N9X2N5IK+`
MIBU@-_+M<U'-:%V?E",S2+-%J2RR:0O/+25<TSD8KLJ=D=7>>II104QEPE3F
M>;:%:MG4>=M^AQ*I\^W)%BI[_Y#MO*!L<&1`9K!?U99W@1FA8V"'!=:PW'9R
MJ:#<;FL_$<@(RBSV*QN3-<"R8#RO-EXD#0QW6&]+0EXTS\0EO]<A`^,<1/84
MU?%'_W8?R<5O7C!S"5?&^(S[LI\D9#PEFXK7FCS\;.'CN:TB0U%T9C_-IP)+
MR9'/?GJ')/"G,OR;%R\4P9D[XD:/4$X9QI+[=`KW5<L$GAWP2XEG/[_0#/O8
ME"L"7]U9+1-_C-#/E\]^MH@*_B\,^4&60<\7'EU&-?E:R!OT4\M\(`7HAJ+5
M-L=#)LS*A,L#+NVHEOD]9H@K9:OL(<(Z;`1EYAYI8(1@0R-\B##-11CF[03-
M>K.?!&2\%307,+&6\S98BW0GO,J@,K,6L]YJ^:A/P8.#5,!79U+#S>5B_-^0
MQX\:/5))3#A[T`SQ[R'A),"K>REBQ0VQ2Z=^U$O>&P3[_G0M7QZ2&N(AM+&V
MVJ;')724)0HZ)A/L!J+BQWCBJ^@+=7@NJ5H;U!1Z;6I-=]?JZ&1=010_*X-]
M=[DWHS/Z5AT>;ZK6_(S%7QMBT_W!NR_=7+@P\3,A,@^^XF!&51Y@'?(ZO/.D
M;RZZ$JTMH.E5?!D7C282ZP*_256'-Y\*XKTKR!KFIE>,M^#1IU)9%ZFWGKJE
MW;-QL/[&M_>$5ZFTBSH^Z620=I%ZPZE;VO.:!:6%VJDKQ&>W'GWF?9"1P4;8
M:GW4FANSLJ@=LK=JJ&+54%F*E$YU+2^"NBN6Z5F;(\K_\27)WW`@+'G`Z!.!
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MTTCYNHVRRX?$(/K^$RB*LJ4(1R;/],8BR,Q`06*_8.^`X.?HH7RY1CUV#*`X
M$<;$USC^,Z6J58:#WAN'FIW8K_<[[!IBIAG[12#[,JK==^B-S&F7W'XYH"&T
MNO:1+6KI8VY=9YMDFB7*8XJ2SGYQX)Y,84O&MAQ2=P4=,`R'+]A/Q4*L[CU/
MK@"-CF=FUJ'3H?VJPCV9C:[PY4^W=;6G9`X=H&7AI69%:[\,<<_K3$K.VIYK
M,[EG(7Y]#D]D6$I/MIKD]NL/2T%M*JK]RP;V=H(1\]RVYM1/+>MW8K_X<$\3
M@DK@MIQV]2.BE:23V"\]K#C3P$#N=CPM+)%9[,QY57E(BLYJ63)HFHB4(U];
M4@!@(Y64"L55`!O11MA^ZX1Q]3NQ7\E7$.YLVS$3O"7ND!VA^X"B/R6P'\\]
M].;2VJ^UVZ^!9,G;%A<)J,S%>!P]#IB1NJ`[F>CW8K_2KEIC,9.\+7%^?1U6
MLDNQ7ZY7J=&8"=Z.!YPE,M\2'_EN1?M;16>UK`TTW=_FR->6R65C3C6\[C.7
MUGYA84%P-=8?F;PM25U--F:WE`WQ(F3N#'%8<',KA95T3L^V+[9:>\B3M2T;
M5WVM5;*..#W;SMA*S<1,\'9XV(3`L!\7?XCA\`2[=1&5BFJKMYW4"ILQZ<;I
MV7;+FNPZ3"5KQ\8T6^H+&!^,+6$HY%WFID7OG#7)O:HM4F61O1J\+'$@.[#M
M2]V#'521HUJ;2TO"Q<*+](.\Y(:#OC^A;!X#I7'7A%X/SIEMIZF))1@(U:+4
MTOB^-<S%/6SJD'ZZI7-FV\-I@I8T:+\MDO5#I"1E)_5>:WR;+1Q]=!\)T*%U
MSFS['HO#:21D6\*C*4F[JGDZU<PYL^X=+#UDM^79HS?P4'=/W;,I\E<5V+`/
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M/1','](E\H*E\!B1>,HQ&8L2!YWNIQ1CK5`_AN.N)/>JT52L(VOCJ:BVLYR/
M1:1N_NB**MRN0L:BZ`H:P:(>6#E61HRD.'B=SG2\4KG$=EQ.4K:TO$CYU-87
M,BW%R[P^6O(U?XBEY@[DCUT:':BQ;\=[DYX/_?%5FAFC$6?4CY7!I\6ASC@T
MZ\CZD#1%1I9182IU\P?J[CLW('GTX\85D35X;.@;#70&J9K0TG,B62R9#4CM
M/JR/Q5P`5!%230F;/^[$,X$^CN881D9A=*\@G&[MK([K<1Z=`0+"\.;A6F]M
MU.W%CL<%F(M9B[9@`PJ\K'F\Q#[`81KQ+-JE]1%JAI7,)U-<^N:/WE0"EHUH
M2?+4J,D`55!9BG#L\*,7NY"361]8:AU+XPU*B9H_6&X0\V$?S<65J@/,HNNT
M#S]J$BX2#C2&C(S$RGC99D9GL$AIK(\4A6HEPT0E2_/'2"H!X2KD`4P(K`KG
M?E:W>8Y\%4TU3ONL+^0ZZ)5$=IWQ.1K+<KSG2=-\B_XY1"S`S%NF\F0//^NO
MN5@GT:78,=H_&?9D98U0\JBS8.AU8'WU,,="LJAHRWO@\?CI1+`[0AS#__P/
M4$L#!!0````(`'U59T#]=GU1(`D``!T_```1`!P`<')P:"TR,#$Q,3(S,2YX
M<V155`D``SZ"5T\^@E=/=7@+``$$)0X```0Y`0``[5MM<^(X$OX\5W7_0<>7
MVZL:XI"WG:22V3)@$M<9S!B8G;FKJRUA*Z`:([.2G(3]]=N2[4#`=LR0J<W<
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M)C;.S\\-/9J1,C+!D@2%DY\;/`J)D9)E7+&H3S">/W+=8C'6'.D`<#8:]<-&
M_;BQQE+'4A:SP2"GXU@2D;'Y4<PD7SQUJ"#^P22Z,]+!'&E^S#E$C2*^=#2'
M,2`TGP<&<LC)@S_-IU<C.0R4W1$A\UF2L1PFAJDO\GGT4`Z+H'X^`PSDHR,7
M<R)RH=$C>3+DG!<(@9$<!DYN"Q?:F0&C2Q3FG/C/+$P($7IMWF)?ULG#/,0,
MRX@O.O#[T7,18_$L?Y)`<D.99@!1':@(I_YR6\CGM\12RO,BLNDEYA,B>WA&
MQ!S[Y`G;[S&=A&3A1P=^--/N:QPMG3?G\VD5<HB$;RXQ8Y'$$L+C^TL\GU-V
M&ZG[;]Y<JLU_H0P8@EY(78P\NV1>;6L6<TT66$Q2N;!A0C[3`FJ(`DJE%(GH
M5'9`;BFC6C4(N*B^#.APZ;9&7:LW1&:OC>#;'GY&=J_C>EUS:+N]2V-]AM6)
M8T$"E[W7U[!\!$RIQ:M(FG*F)$5<RXFK\_@X]..P3%!Z*_/Y+C@,P")]N+FW
M'<H@Y%,<]B.A56Z%6(CTC%.(5*0MQN8(`'F<!*Y;;F_@.G;;'%IMU#0=L]>R
MT.#&LH:#'QZ8)@[5`3R8$B)%'\/I(J=$4M`A`:-DO!B`X^H`H/\^F?1_/SP@
M*ZO?ANIA1C8V17J[V/TG9>X?#.%+A:H!<CO([5N>CE#[G;#BX<$4UN0T"@-(
MU"T@E0LX'5Q8H[P5S<#\*6&"WI$"?+;C+H;QM#J,@Z';^O>-Z[0M;_!/9'T8
MP?FS!W0)20N+:2>,[H7-`@H)FMP`;9.B&)BSZL"TS,$-ZCCNK_O]Y?()9O0/
M+0TV1#,6E!$A$B2*!HM!^%EE753X821B3N"'ZUV;/?L_.IKI-*PY&M@]:[#W
M_"">S3!?0&2B$P;)DX\AW?5U#4K9I!^%U*<D!:(B;3$N[]9Q&8RZ7=/[K,.4
M?=VS.W;+5(ERJ^6.(%'N7:,^;)Z6;>V!LG4=K:**S?K36#TD<O`XXJHZ!*\[
MH9^`5(&N&*#S=8#LWD=K,-35B]U#_1O8-K"#'+/I0FK@>@#,6^0XK8,?'IX^
MC^:$RT4_Q$F]"#1SA4*"2O%P(1B-PW4P^IY*R8:?WZ*^8V;U))SG?87/'@$X
M=)GTZ&0J!7C8(Z%ZU.)%"QS*!617,ZIW11K+*E,7X]/8P`=.=X#%LZ]OX(17
MZ'B6HP]^S_UL.E#VM]QNU];;:1_0DJQ7/[24#L5C&H*VV5%3-%B,QM'&F3^\
ML3S4&GF>`L6QS:;MV,/]44*,E>6-6>!'^O@F;'G0EQ$4(W"\CL#*:M>[`7)A
M=:9;O?V!KDN0R/^R7@KJFZH4A#IPY4%D1=IB;$XV,J^<JE"#I`<4='VK-]@_
MH-0/BI6")&C!/M`O<D"H.L?3S5(X6HS&Z3H:;:L#Y4BR0SR[.=)UBCKD]]LD
M>10RQ`]9<%J]4>SBL\U,%M:TA8;FIWWL,2S,&81TX41"]`G73Z42[^:.%+MY
MH]*V3*\',7Z`(%-%@QO3LWYX9Z]4RZU82%B\/"NH\T:*G;U9/J_4S*T11.XN
M1/,?WM\?8LPEX>'F^[S<D6)_;U3#'T:F-[0\Y\G[._33J&>.VC;D^?_ZO_.]
M^J,Z03QRBW2+Q85Z\WM5$W0V#U5KAKXWU>_`U;O<>O;&]C<P\.!A%F8D:O*2
M9@\-W+I/4L'9%.FK\?(6$)A$5]J0JAJ9\C7C94P"[V]KTE/`7IM!(1YO:Q"P
MD/`UV@++?%M;UG;&"UMT:60]"G"U[%Q0C0Q@3,0E8KD-$T5=4$DCF!/Y>IX2
M%O6KGO'5U:UZXZA^W#AX$$&BVS8*/%JUI0(9WY8*Y/>6512=,2B9IU6DE;9X
M%0C5`G,9#1)*D=VI+Z>J;'=)SU29,CELZ?4N2N3UH5718I4O^[&3'GE];944
M665\_+6+*AOM;U74>&325[N(WVR+JR)_R95<[J+!>I]=%?D9C[K82?9Z^UTE
MX1F3OMI2_'-MHU6B4LCY$RX5FLY5.&R<[:1"Q:"X(E[N++J\-[&J.JNS6,M)
MMM2NM(VURLK(>-3%+NMBLQNRBB/6N7;!)K_E<SLM(M8K4R3M/M>:E+=%FF,A
M.<Z:*%2*]ELU\B3/TTWA%W"/LHDMR4S5(S6$4ZJKFN2QR@(U%>1=-`J&FB^(
M>5KG,1I"CJKRMH16Q,!,I7XN=\VC>)X)H3!]KGG%;6TYQE4A?CVF_4K4"R\2
MF'>$XPE1S_DCII_Q"#>6*F-4_Y'2Q!"J`:TV#6.9=5YJ:[^2_XD#-'6>`VYQ
M*+ZY!_1#<UN(F`3M6$'1UX(^XC`FUD,8J^XKA_J$"6).."'+5[C:`5_'OFH_
M.(Q(S!=+#Y0;4>J/#>>M.RAA'B>+]*KF<Q)0N8UC$G"_WC//\9<MC6_HF$(/
M7'/,9!ZX4']&"QW&BHS?BK5\26RU*?(Q?JF]DF-5BNE7>:2$]S5%"1P2H1[]
MJ?)%]0?T>71'52]-)^)-'+3).&LD2*RM1O\]@*[ZAYA*R-3:U<(>;5DQN)3J
M^S`3YL*"M$GR;3/3]V&NH(OY%Z+>=[<B\03CRAS?SOR`C%_&^O3@7H9L6*8E
ML;T:^7=@=]6NGYQ$;WO6UY/V5=5]2!YD,P24O\+N%=[$\.2_U"YD=O^O"^8Y
M;]ER`"XG>SU@YNF9!]PS='\Q2)=&4J#"Y9]02P$"'@,4````"`!]56=`VA%.
MDVN2``!(P04`$0`8```````!````I($`````<')P:"TR,#$Q,3(S,2YX;6Q5
M5`4``SZ"5T]U>`L``00E#@``!#D!``!02P$"'@,4````"`!]56=`/+5?G=@'
M``!<7P``%0`8```````!````I(&VD@``<')P:"TR,#$Q,3(S,5]C86PN>&UL
M550%``,^@E=/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`?55G0+X_#]?9
M#P``3.0``!4`&````````0```*2!W9H``'!R<&@M,C`Q,3$R,S%?9&5F+GAM
M;%54!0`#/H)73W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`'U59T`.AO;<
M7B<``(PU`@`5`!@```````$```"D@06K``!P<G!H+3(P,3$Q,C,Q7VQA8BYX
M;6Q55`4``SZ"5T]U>`L``00E#@``!#D!``!02P$"'@,4````"`!]56=`QD8O
M,]H4``"N0@$`%0`8```````!````I(&RT@``<')P:"TR,#$Q,3(S,5]P<F4N
M>&UL550%``,^@E=/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`?55G0/UV
M?5$@"0``'3\``!$`&````````0```*2!V^<``'!R<&@M,C`Q,3$R,S$N>'-D
M550%``,^@E=/=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``$;Q````
!````
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
